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Research is to see what everybody else has seen, and  
to think what nobody else has thought.  
Albert Szent-Györgi 
 
 
 
All truths are easy to understand once they are discovered;  
the point is to discover them. 
Galileo Galilei 
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Cenix BioScience, Dresden, Germany.  
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The financial support was provided by the portuguese Fundação para a Ciência e 
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This thesis is structured in 5 chapters, which are preceded by a summary, both in 
Portuguese and in English.  
Chapter 1 comprises a general introduction to malaria and its current world situation, 
followed by an overview on the Plasmodium life cycle, the state of the art on the liver 
stage biology and the objectives of this thesis.  
Chapters 2 to 4 consist of the results obtained throughout the research project, which 
are presented in a publication format. Each results chapter includes an abstract, an 
introduction, the results and discussion, as well as the methods, acknowledgments 
and references.  
Chapter 5 encloses a general discussion and the future perspectives of the work 
develop.  
In Appendix are supplied my Curriculum Vitae and the publications in which I have 
participated until the date of printing this thesis.  
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Malaria remains the most important parasitic infection in humans and one of the most 
prevalent infectious diseases worldwide. It is estimated that 350–500 million people 
become infected and one million of children under the age of five years die every 
year. This disease is caused by a protozoan parasite of the genus Plasmodium and is 
transmitted by mosquitoes of the genus Anopheles. During a malaria infection, the 
parasite undergoes intracellular development within two different host cells, 
hepatocytes and erythrocytes. The first stage of a malaria infection, the liver stage, is 
asymptomatic while the second phase, the blood stage, is responsible for all the 
disease-associated symptoms. Although clinically silent, the liver stage is an 
obligatory and extremely important step in Plasmodium life cycle. Therefore, 
understanding the parasite’s requirements during this period is crucial for the 
development of any form of early intervention. Despite this awareness, the strategies 
developed by Plasmodium to allow its survival and development inside host liver cells 
remain poorly understood. We have sought to disclose some of these strategies 
through the identification of host factors which are important for hepatocyte infection 
by Plasmodium. For this purpose, RNA interference (RNAi) was extensively applied to 
an in vitro model of Plasmodium infection. The infection outcome of the rodent P. 
berghei parasite was addressed in the context of individual gene loss of function of a 
total of 830 different genes.  
In chapter 2 of this thesis, it was studied the functional relevance of a selection of 50 
genes differentially expressed by hepatocytes throughout Plasmodium infection, 
revealed by a microarray approach. Two host transcription factors, the Activating 
Transcription Factor 3 (Atf3) and the Myelocytomatosis oncogene (c-Myc), were 
recognized as important for sporozoite infection. It was observed that their individual 
silencing led, respectively, to an increase and to a decrease in P. berghei hepatocyte 
infection levels. In addition, Atf3’s functional relevance was confirmed in vivo.  
In chapter 3, the role of host kinases and kinase-interacting proteins was explored.  
From the 727 genes investigated at least six host kinases, namely the Met proto-
oncogene (MET), Protein Kinase C iota (PKCι), Protein Kinase C zeta (PKCζ), WNK 
lysine deficient protein kinase 1 (PRKWNK1), Serum/Glucocorticoid Regulated 
Kinase 2 (SGK2) and Serine/Threonine Kinase 35 (STK35) were identified as playing 
important roles during Plasmodium sporozoite infection. Moreover, the importance of 
one of these kinases, PKCζ, was further demonstrated for in vivo P. berghei infection, 
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and also for human primary hepatocytes infection by P. falciparum, the deadliest of the 
human malaria parasites. 
Finally, in chapter 4, the function of 53 host lipoprotein pathway genes was 
investigated and the Scavenger Receptor Class B member 1 (SR-BI) was identified as 
being crucially required for hepatocyte infection by P. berghei. In addition, SR-BI’s 
importance in Plasmodium infection was also observed in vivo for P. berghei and ex vivo 
for P. falciparum. Further detailed analyses revealed that SR-BI is required for both 
sporozoite invasion and development within the hepatocyte.  
Altogether, the work presented in this thesis reveals different host factors that play 
important roles during hepatocyte infection by Plasmodium sporozoites and, therefore, 
offers new insights into the processes underlying Plasmodium liver infection. 
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Malaria, Plasmodium, liver stage, host factors, RNA interference. 
 
 Resumo 
 
 
A malária é uma das doenças infecciosas em humanos com maior prevalência em 
todo o mundo, sendo a mais importante de todas as doenças parasitárias. Esta doença 
afecta cerca de 40% da população mundial e estima-se que, todos os anos, entre 250 a 
500 milhões de pessoas ficam infectadas e que morrem aproximadamente um milhão 
de crianças com menos de cinco anos. O parasita responsável por esta doença é um 
protozoário que pertence ao género Plasmodium e é transmitido por mosquitos do 
género Anopheles. O parasita humano P. falciparum provoca as formas mais severas da 
doença e é responsável pela maior parte das mortes por malária. 
O parasita Plasmodium, no estadio de esporozoíto, após ter sido transmitido ao 
hospedeiro mamífero através da picada de um mosquito infectado, migra até ao 
fígado onde infecta hepatócitos. No interior dos hepatócitos, cada parasita replica-se e 
diferencia-se no estadio seguinte, em merozoítos. Estes são libertados na corrente 
sanguínea e infectam eritrócitos. Assim sendo, uma infecção de malária caracteriza-se 
pelo desenvolvimento intracelular do parasita em dois tipos de células hospedeiras, 
hepatócitos e eritrócitos. A primeira fase de uma infeccção de malária, a fase hepática, 
é assintomática, enquanto que a segunda, a fase sanguínea, é responsável pelos 
sintomas associados à doença. Apesar do desenvolvimento de esporozoítos de 
Plasmodium em hepatócitos decorrer sem qualquer sintoma associado, a fase hepática 
é um passo importante devido à sua obrigatoriedade para o estabelecimento da 
infecção. Como tal, a compreensão das necessidades do parasita durante este período 
é fundamental para o desenvolvimento de qualquer tipo de intervenção precoce. 
Apesar disso, as estratégias que o parasita Plasmodium desenvolveu para conseguir 
sobreviver e desenvolver-se no interior dos hepatócitos são ainda desconhecidas. O 
presente trabalho teve como objectivo revelar algumas destas estratégias através da 
identificação de factores do hospedeiro importantes para a infecção de hepatócitos 
pelo parasita Plasmodium. Para tal, recorreu-se a utilização da técnica conhecida por 
RNA de interferência (RNAi). Esta técnica baseia-se no mecanismo celular em que 
moléculas de RNA na forma de dupla cadeia silenciam o gene alvo através da 
degradação específica do seu RNA mensageiro. Deste modo, através da inserção em 
células de duplas cadeias de RNA é possível induzir especificamente o silenciamento 
do gene desejado e analisar o seu papel funcional ao nível de um determinado 
fenótipo. No presente trabalho aplicou-se a técnica RNAi a um modelo in vitro de 
infecção com Plasmodium e avaliou-se qual o efeito do silenciamento de genes 
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específicos em termos de infecção do parasita de ratinhos, P. berghei. Ao todo foram 
analisados 830 genes, de diferentes categorias, nomeadamente genes expressos ao 
longo de uma infecção por Plasmodium, genes que codificam cinases e proteínas 
associadas e ainda genes associados ao metabolismo de lipoproteínas. Estes estudos 
são apresentados como parte integrante da presente tese em três capítulos distintos de 
resultados.  
No capítulo 2, foi estudada a relevância funcional de 50 genes que são expressos 
diferencialmente por hepatócitos ao longo de uma infecção por Plasmodium, genes que 
foram seleccionados a partir de um estudo anterior em que se utilizaram microarrays. 
Através da utilização de RNAi procedeu-se ao silenciamento individual de cada um 
dos 50 genes seleccionados e, após diferentes passos experimentais de confirmação, os 
factores de transcrição, Activating Transcription Factor 3 (Atf3) e Myelocytomatosis 
oncogene (c-Myc), foram reconhecidos como sendo importantes para a infecção 
hepática por esporozoítos, dado que quando silenciados, a infecção com P. berghei 
aumenta e diminui, respectivamente. Adicionalmente, foi confirmada in vivo a 
relevância funcional para o factor de transcrição Atf3. Em ratinhos da estirpe BALB/c 
observou-se cinco horas depois da infecção com esporozoítos de P. berghei um 
aumento na quantidade de RNA mensageiro do gene Atf3 ao nível do fígado. E 
ratinhos Atf3 knock-out quando infectados com esporozoítos de P. berghei apresentam 
um nível de infecção mais elevado que ratinhos controlo, sem qualquer deficiência ao 
nível da expressão do gene Atf3.  
No capítulo 3, foi explorado o papel de um total de 727 cinases do hospedeiro ou 
proteínas que interagem com cinases. A relevância de cada gene foi estudada através 
do seu silenciamento individual com três small interfering RNAs (siRNAs), tendo sido 
realizadas três experiências de rastreio em que os genes candidatos foram 
seleccionados progressivamente de acordo com os resultados obtidos. Na última 
experiência, confirmou-se ainda o nível de silenciamento atingido, através da 
quantificação do nível de RNA mensageiro específico para uma das cinases 
identificadas como sendo potencialmente importante(s) para a infecção da linha 
celular de hepatócitos humanos (Huh7) por esporozoítos de P. berghei. No final, foram 
seis os genes de cinases para os quais se observou uma correlação entre o nível de 
silenciamento e um fenótipo em termos da infecção, mais especificamente Met proto-
oncogene (MET), Protein Kinase C iota (PKCι), Protein Kinase C zeta (PKCζ), WNK lysine 
deficient protein kinase 1 (PRKWNK1), Serum/Glucocorticoid Regulated Kinase 2 (SGK2) e 
Serine/Threonine Kinase 35 (STK35). Para as cinases MET, PKCζ, SGK2, PRKWNK1 e 
STK35 observou-se que o seu silenciamento está associado a uma redução ao nível de 
 x 
 células infectadas com P. berghei, enquanto que para a cinase PKCι observou-se que o 
seu silenciamento leva a um aumento do nível de células infectadas com P. berghei.  
A importância de uma destas cinases, PKCζ, foi ainda explorada através da realização 
de experiências adicionais. O tratamento de células Huh7 in vitro com um inibidor 
para a cinase PKCζ, que funciona como um pseudo-substracto, teve como resultado 
uma redução no nível de infecção. Este resultado foi também observado ex vivo em 
hepatócitos primários de ratinhos da estirpe C57BL/6 e em hepatócitos primários 
humanos sujeitos ao tratamento com o inibidor da PKCζ, e que foram posteriormente 
infectados com esporozoítos do parasita P. berghei ou P. falciparum, respectivamente. 
Através da realização de RNAi in vivo para a cinase PKCζ, em que se induziu uma 
redução da expressão desta cinase ao nível do fígado, foi demonstrado que esta cinase 
também desempenha um papel na infecção de malária in vivo, já que se observou uma 
significativa diminuição no nível de parasita no fígado. Todos estes resultados 
adicionais para a cinase PKCζ apoiam de certo modo a validade dos genes candidatos 
identificados através da utilização de RNAi, e demonstram também  que esta cinase 
específica é importante para a infecção de Plasmodium.  
Finalmente, no capítulo 4, foi investigada a função de 53 genes associados a vias 
metabólicas que envolvem lipoproteínas, e o receptor Scavenger Receptor Class B 
member 1 (SR-BI) foi identificado como sendo fundamental para a infecção de 
hepatócitos por P. berghei. A relevância deste receptor para a infecção in vitro de P. 
berghei foi demonstrada através da realização de diferentes experiências em que se 
recorreu ao tratamento da linha celular Huh7 com diversos reagentes que permitiram 
silenciar o gene SR-BI ou bloquear a actividade do receptor SR-BI. O silenciamento do 
gene SR-BI foi realizado através da utilização de três siRNAs diferentes, e o nível de 
silenciamento obtido foi comprovado ao nível de RNA mensageiro e também ao nível 
da quantidade de proteína. Para bloquear a actividade de SR-BI recorreu-se a um 
anticorpo contra este receptor e a compostos que bloqueiam a actividade de 
transporte de lípidos (BLTs de blocker lipid transport) pelo receptor SR-BI. Em todas as 
experiências realizadas observou-se que o silenciamento ou bloqueio de SR-BI conduz 
a uma redução ao nível da infecção por P. berghei. O papel deste receptor na infecção 
de P. berghei foi confirmado em hepatócitos primários de ratinhos C57BL/6 sujeitos ao 
silenciamento de SR-BI ou ao bloqueio da sua actividade através do tratamento com o 
composto BLT-1 e ainda em experiências in vivo, em que ratinhos C57Bl/6 foram 
tratados por RNAi para induzir o silenciamento do gene SR-BI. Em todas estas 
experiências observou-se uma redução na infecção de P. berghei. A importância de SR-
BI foi também observada em experiências ex vivo para o parasita P. falciparum. Uma 
análise extensiva revelou que o receptor SR-BI é necessário não só para a invasão dos 
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esporozoítos, mas também para o seu desenvolvimento no interior dos hepatócitos. O 
papel exacto que cada um dos factores do hospedeiro identificados desempenha na 
infecção de hepatócitos por Plasmodium tem ainda de ser determinado.  
O trabalho apresentado nesta tese identifica já diferentes factores do hospedeiro que 
desempenham papéis importantes durante a infecção de hepatócitos por esporozoítos 
de Plasmodium, oferecendo assim uma nova perspectiva acerca dos processos que 
decorrem durante a fase hepática de uma infecção de malária. 
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General Introduction 
 
1.1. Malaria: from ancient times to modern scientific discoveries 
Malaria is one of the most important infectious diseases in the world, and its history 
dates back to ancient times. The characteristic periodic fevers of malaria are recorded 
from every civilized society from China in 2700 BC through the writings of Greek, 
Roman, Assyrian, Indian, Arabic, and European physicians up to the 19th century 
(Cox, 2002). The earliest detailed accounts are those of Hippocrates in his Book of 
Epidemics in the 5th century BC, and thereafter there are increasing numbers of 
references to the disease in Greece and Italy and throughout the Roman Empire 
(Sherman, 1998). Over this period, it became clear that malaria was associated with 
marshes, and there were many ingenious explanations to enlighten the disease in 
terms of the miasmas rising from the swamps (Cox, 2002). In fact the disease was 
initially called ague or marsh fever due to its association with swamps and only later, 
in 1740, was the term malaria coined from the italian “mala aria” meaning "bad air" 
(Bruce-Chuvatt, 1981).  
Malaria scientific studies made their advance in the 19th century. The German 
Heinrich Meckel, in 1847, noted the presence of a brown pigment in the organs of 
people who died of fever and proposed that the pigment was the malaria cause 
(Bruce-Chuvatt, 1981). However, in 1880, it was the French Charles Louis Alphonse 
Laveran who associated malaria to a living organism when he observed the malaria 
parasite in a fresh blood specimen from patients with fever episodes. Laveran named 
these parasites Oscillaria malariae (Bruce-Chuvatt, 1981; Sherman, 1998). In 1907 
Laveran was awarded the Nobel Prize for Physiology or Medicine for these 
discoveries [see http://nobelprize.org/nobel_prizes/medicine/laureates/ and 
(Nobel, 1967)]. In 1884, the Italians Ettore Marchiafava and Angelo Celli, with the help 
of microscopes with oil immersion lenses, were also able to observe the parasite 
development within the red blood cell, confirming Laveran's theory of a parasite. 
However, since the parasite they observed had no resemblance to the one described 
by Laveran, they named it as Plasmodium malariae (Sherman, 1998). The genus name 
Plasmodium of Marchiafava and Celli became the one chosen for the malaria parasite. 
The Italian Camillo Golgi, in 1886, established that there were at least two forms of the 
disease, one with tertian periodicity (fever every other day) and one with quartan 
periodicity (fever every third day). Golgi also noticed that the fever coincided with 
the rupture and release of new parasites into the blood stream (Sherman, 1998).  
The malaria transmission mystery was solved independently by the British Ronald 
Ross and the Italians Giovanni Battista Grassi, Amico Bignami, and Giuseppe 
Bastianelli. In 1897, when studying malaria in birds, Ronald Ross described oocysts of 
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the malarial parasite in the walls of the stomach of an unclassified mosquito. Giovanni 
Battista Grassi and colleagues confirmed experimentally that the human malaria 
parasites go through the same stages as the bird parasites and are transmitted by 
mosquito bite. However, by the time the Italians began working in human malaria 
transmission, Ross’s proof was complete and parts had already been published 
(Sherman, 1998; Capanna, 2006). Ross received the 1902 Nobel Prize in Medicine for 
his achievements [see http://nobelprize.org/nobel_prizes/medicine/laureates/ and 
(Nobel, 1967)]. For nearly 50 years, the life cycle in humans remained poorly 
understood as it was not known where the parasites, which could not be seen in the 
blood in the first days after infection, developed during this period. Finally, in 1947, 
Henry Shortt and Cyril Garnham showed that a phase of division in the liver 
preceded the development of parasites in the blood (Shortt and Garnham, 1948).  
 
1.2. The malaria burden reality 
The malaria burden is not evenly distributed since the global pattern of malarial 
transmission suggests a disease centered in the tropics, but with a reach into 
subtropical regions in five continents. As of 2004, 107 countries and territories were 
reported as exposed to malaria transmission (Figure 1.1) with 40% of the world total 
population at risk (WHO and UNICEF, 2005). Current estimates are that around 350–
500 million clinical disease episodes occur annually, with about 90% of these 
occurring in sub-Saharan Africa. This inequality is due to the fact that the majority of 
infections in Africa are caused by Plasmodium falciparum, the most deadly of the 
human malaria parasites, and also because the Anopheles gambiae mosquito, the most 
effective malaria vector and difficult to control, is largely widespread in this 
continent. Malaria is thought to kill between 1.1 and 2.7 million people worldwide 
each year, about 1 million of which are children under the age of 5 years (WHO and 
UNICEF, 2000). These estimates render malaria the most pre-eminent tropical 
parasitic disease and one of the top three killers among communicable diseases. 
Moreover, malaria has also a major economic and social burden in endemic areas. 
Malaria endemic countries are not only poorer than non-malarious countries, but they 
also have lower rates of economic growth (Sachs and Malaney, 2002). The malaria 
burden falls disproportionately on poor and vulnerable individuals (Barat et al., 2004). 
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Figure 1.1 | Global distribution of malaria incidence in 2003.  
Malaria is found in tropical regions throughout sub-Saharan Africa, Southeast Asia, the 
Pacific Islands, India, and Central and South America [adapted from (Todryk and Hill, 2007), 
with original data taken from World Malaria Report, WHO and UNICEF, 2005]. 
 
During the 20th century, the Global Malaria Eradication Programme attempted to 
reduce the malaria spread through vector control combined with improved access to 
treatment. The Programme’s effort was able to reduce or eliminate malaria 
transmission but only in areas where transmission occurred at low intensity, such as 
the Americas, Asia, Europe and Transcaucasia. Recent evidence shows that the 
burden of malaria increased in several areas in terms of proportions of population at 
risk, of the severity of infections and of the number of deaths. Factors contributing to 
malaria increase consist of parasite resistance to the common used antimalarial drugs, 
breakdown of control programmes, complex emergencies, collapse of local primary 
health services and resistance of mosquito vectors to insecticides (WHO and UNICEF, 
2005).  
As consequence of the present malaria reality, a wide-ranging coalition of interests 
has been gathering to fight this disease, namely: the World Health Organization’s 
“Roll Back Malaria” campaign, which aims at halving the burden of disease by 2010 in 
the participating countries through interventions that are adapted to local needs and 
by reinforcement of the health sector; pharmaceutical industry support; research 
coordination, with the main funding agencies coming together in the Multilateral 
Initiative on Malaria; and philanthropy, most notably the Malaria Vaccine Initiative 
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supported by the Bill and Melinda Gates Foundation (Nabarro and Tayler, 1998; 
WHO and UNICEF, 2000; Remme et al., 2001; Carucci, 2004).  
 
1.3. Overview of the Plasmodium life cycle  
Plasmodium, the causative agent of malaria belongs to the Apicomplexa phylum. The 
Apicomplexa are named after their distinctive organelle, the apical complex, which 
plays a central role in cell invasion. Several other intracellular animal parasites belong 
to this phylum, for example Cryptosporidium, Eimeria, Leishmania, Theileria, and 
Toxoplasma. 
The Plasmodium genus includes more than 100 species that infect a wide range of 
vertebrate hosts such as reptiles, birds, rodents, non-human primates and humans. 
Under natural conditions only four Plasmodium (P.) species can infect humans: P. 
falciparum, P. vivax, P. ovale and P. malariae. The first two species are responsible for 
most infections worldwide.  
P. falciparum, most prevalent in Africa south of the Sahara and in certain areas of 
South-East Asia and the Western Pacific, is the agent of severe, potentially fatal 
malaria, causing around 1.1 - 2.7 million deaths annually, most of them in young 
children in Africa. The second most common species, P. vivax, found in Asia, Latin 
America and in some parts of Africa, can cause symptoms that are incapacitating and 
only exceptionally leads to death (often due to rupture of an enlarged spleen). P. vivax 
contributes substantially to malaria social and economic burden. P. ovale is found in 
West Africa and the islands of the western Pacific. P. vivax and P. ovale form resting 
stages in the liver, called "hypnozoites", which can reactivate leading to a clinical 
relapse several months or years after the infecting mosquito bite. P. malariae, found 
worldwide, produces long-lasting infections and if untreated can persist 
asymptomatically in the human host for lifetime [reviewed in (Despommier et al., 
2000)].  
The Plasmodium life cycle comprises two different hosts, a mammalian and a female 
anopheline mosquito. The life cycle is rather complex and begins when a Plasmodium 
infected mosquito probes for a blood source under the skin of the mammalian host. 
During this process sporozoites, the parasite’s designation at this stage, are deposited 
in the skin together with anticoagulant saliva that ensures an even flowing meal 
(Ponnudurai et al., 1991; Matsuoka et al., 2002). These sporozoites reach the circulatory 
system and are transported to the liver (Sidjanski and Vanderberg, 1997; Vanderberg 
and Frevert, 2004; Amino et al., 2006). Once in the liver, sporozoites migrate through 
several hepatocytes by breaching their plasma membranes until they infect a final one 
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with the formation of a parasitophorous vacuole (PV) (Mota et al., 2001a; Frevert et al., 
2005). After several days of development inside a hepatocyte, between 2 and 16 days 
depending on the Plasmodium species (spp.), 10000 to 30000 merozoites per invading 
sporozoite are released via budding of parasite-filled vesicles (merosomes) into the 
blood stream [reviewed in (Prudêncio et al., 2006)]. Each released merozoite invades 
an erythrocyte, again with the formation of a PV, and undergoes a replication cycle 
that ends with the release of new 16 to 32 merozoites from the mature infected 
erythrocyte (schizont), which go on to infect other erythrocytes [reviewed in (Sturm 
and Heussler, 2007)]. This cyclic blood stage infection occurs with a periodicity of 48 
to 72 hours, depending on the Plasmodium spp.. Malaria associated symptoms only 
occur during the blood stage of infection. Furthermore, some merozoites develop into 
sexual parasite stages, the male and female gametocytes (micro- and macro-
gametocytes, respectively), which can be taken up when another female mosquito 
feeds off an infected mammalian host. The Plasmodium life cycle continues in the 
mosquito midgut, where the exflagellation of microgametocytes occurs and the 
macrogametocytes are fertilized. The resulting ookinete migrates through the 
mosquito midgut into the hemocele and develops into an oocyst, where sporozoites 
are formed. When the oocyst is fully matured it bursts and the released sporozoites 
migrate into the mosquito’s salivary glands, where they become more infective and, 
therefore, ready for the next transmission step [reviewed in (Barillas-Mury and 
Kumar, 2005; Matuschewski, 2006; Vlachou et al., 2006)] (Figure 1.2).  
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Figure 1.2 | Plasmodium life cycle in the human and mosquito hosts.  
(a.) The parasite's life cycle in the human host begins when sporozoites are inoculated into 
the host's skin through the bite of an infected female Anopheles mosquito. The sporozoites are 
rapidly transported to the liver as soon as they reach the blood stream. (b.) In the liver 
sporozoites migrate through several hepatocytes before infection of a final host cell with the 
formation of a parasitophorous vacuole. (c.) The liver schizonts, named exoerythrocytic 
forms (EEFs), proliferate and differentiate into thousands of merozoites that will ultimately 
be released through merosomes into the blood stream. (d.) Each merozoite will recognize, 
bind to, and invade an erythrocyte, initiating a replication cycle that ends with the release of 
new merozoites. (e.) Some merozoites develop sexual parasite morphologies (male and 
female gametocytes), which can be ingested by a mosquito during a blood meal. (f.) Once in 
the mosquito midgut, the parasite undergoes a series of transformations, culminating in the 
development of new sporozoites that invade the salivary glands and (g.) consequently can be 
inoculated into another host . 
 
1.4. A glimpse at the malaria clinical features and pathogenesis  
Malaria infection manifestations include a wide variety of symptoms, ranging from 
absent or very mild symptoms to severe disease and even death. Symptoms and signs 
of uncomplicated malaria comprise sensation of cold, shivering, fever, headaches, 
vomiting, sweats and tiredness. Severe malaria manifestations include metabolic 
acidosis which leads to respiratory distress, severe anemia, thrombocytopenia (blood 
platelets decrease), organ failure, cerebral malaria (impairment of consciousness, 
seizures, coma, or other neurological abnormalities) and placental malaria in pregnant 
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women. Overall patterns of disease depend markedly on the age and the previous 
immunological experience of the host [reviewed in (Greenwood et al., 2005; Schofield 
and Grau, 2005)]. The multiplicity of severe malaria syndromes has confounded the 
identification of unifying mechanisms of the disease. Research studies support the 
idea that these several syndromes arise from the intersection of a few basic processes: 
rapid expansion of infected erythrocytic mass; destruction of both infected and 
uninfected erythrocytes; adhesion and sequestration of infected erythrocytes in the 
vasculature; release of bioactive parasite products in host tissues molecules; local and 
systemic production of cytokines and chemokines by the innate and adaptive immune 
systems in response; and activation, recruitment and infiltration of inflammatory cells 
(Table 1.1) [reviewed in (Malaguarnera and Musumeci, 2002; Clark and Cowden, 
2003; Rasti et al., 2004; Hisaeda et al., 2005; Schofield and Grau, 2005; Boutlis et al., 
2006)]. Over the last few years, significant progress has been made towards the 
identification of both parasite and host molecules that actively participate in these 
processes. This is particularly important because understanding the biology 
associated with the malaria disease is an essential key for the development of 
successful tools for intervention.  
 
 
 
Table 1.1 | Severe malaria clinical features and underlying mechanisms.  
Severe malaria comprises a variety of diverse syndromes that present singular and distinguishing 
clinical features. The comprehension of the mechanisms that lead to the development of each 
syndrome constitutes a leading area of malaria research. A remarkable knowledge has been achieved, 
however there is still a great deal to be understood [adapted from (Schofield and Grau, 2005)]. 
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1.5. The fight against malaria: available tools  
 
1.5.1. Anti-malarial tools: the present 
Currently, the fight against malaria is focused on mosquito eradication, reduction of 
human–vector contact and disease prevention and treatment using antimalarial 
drugs. A viable vaccine is not yet available, despite the significant efforts that have 
been made to develop one.  
Mosquito eradication is mainly achieved through indoor residual spraying and 
environmental management to eliminate breeding sites. Global control efforts from 
the 1950s to the 1970s, mainly through the use of the insecticide Dichloro-Diphenyl-
Trichloroethane (DDT), virtually eliminated malaria transmission in the subtropics 
(Greenwood et al., 2005). However, the programme was abandoned due to the 
negative impact of the use of high concentrations of DDT, namely resistence 
developed by mosquitoes and toxic effects to humans (Turusov et al., 2002). A deeper 
reason for abandoning the campaign might have been geopolitical (Sachs, 2002). 
Despite attempts to ban DDT completely, the use of small amounts of DDT (allowed 
under the Stockholm Convention on persistent organic pollutants) still plays a major 
role in malaria control (Schapira, 2004; Greenwood et al., 2005). A new and alternative 
approach, the deployment of mosquito-killing fungi, has been recently shown as 
possible (Blanford et al., 2005; Scholte et al., 2005) and has been extensively discussed 
[see (Michalakis and Renaud, 2005; Kanzok and Jacobs-Lorena, 2006; Thomas and 
Read, 2007)]. Although vector control strategy is very effective in reducing malaria in 
some regions of Africa, it is also expensive, logistically demanding and has been 
undermined by problems of insecticide resistance, environmental contamination and 
risks to human health.  
Reduction of human–vector contact is achieved through insecticide-treated bed nets 
(ITNs) and is more appropriate for malaria control in Africa (Klausner and Alonso, 
2004). Randomized trials of the ITNs in diverse settings have established their 
effectiveness at cutting malaria-related morbidity and mortality (Lengeler, 2000). 
Nonetheless, though ITNs are inexpensive and effective, fewer than 2% of Africans 
sleep under them, which means that considerable campaigns to increase their use are 
urgently required (Monasch et al., 2004). Furthermore, the regular ITN re-treatment 
with insecticide has proved difficult to sustain on a large scale. However, this might 
be overcome by the development of long lasting insecticidal ITNs and in fact different 
prototypes are being produced and two have already been approved by the WHO 
and are undergoing large-scale production (WHO and UNICEF, 2004).  
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Antimalarial drugs have been quite essential in the combat against malaria, but 
parasite resistance problems are arising. The used antimalarials are quinolines 
(amodiaquine, piperaquine, primaquine, quinine, mefloquine and chloroquine), 
antifolate drugs (pyrimethamine, chloroguanide, sulfadoxine, sulfalene and dapsone), 
artemisinins and derivatives (artemether, arteether, artesunate and 
dihydroartemisinin), atoquavone, and antibiotics (such as, tetracycline, doxycycline, 
and clindamycin) [reviewed in (Cunha-Rodrigues et al., 2006b; Schlitzer, 2007; 
Vangapandu et al., 2007)]. The choice of the drug to use is usually driven by what 
drugs the parasites in the area are resistant to, as well as their side-effects. To 
counteract the rapid development of resistance some drugs are used in fixed 
combinations [reviewed in (Fidock et al., 2004)].  
The increasingly serious problem of malaria parasite resistance to the currently used 
antimalarials discloses the urgent need to develop new and effective antimalarial 
molecules. This goal can be achieved in two ways: either by focusing on validated 
targets in order to generate new drug candidates or by identifying new potential 
targets for malaria chemotherapy [see (Jana and Paliwal, 2007)].  
 
1.5.2. Anti-malarial tools: the future 
Sadly, the available tools against malaria mentioned above provide no strategy to 
sustainably reduce or eliminate the burden of malarial disease. A vaccine against 
malaria could lead the way given that this has been the most cost-effective health 
intervention for a range of other infectious diseases. However, despite the extensive 
research that is developed in this area, there is still no vaccine available. Malaria 
vaccine research has focused on different approaches: an anti-infection vaccine aimed 
at protecting malaria-naive travelers or residents of low endemic areas from becoming 
infected; an anti-disease/anti-mortality vaccine aimed at children, pregnant women 
and migrants living in endemic areas; and an anti-mosquito-stage vaccine aimed at 
preventing the transmission of malaria from one person to another. Different pre-
erythrocytic, blood stage, and transmission-blocking vaccines are the focus of ongoing 
research [reviewed in (Richie and Saul, 2002; Moorthy et al., 2004; Todryk and Hill, 
2007)].  The currently most advanced malaria vaccine candidate in development is the 
pre-erythrocytic RTS,S/AS02A [state of the art addressed in (Alonso, 2006; Hill, 
2006)]. RTS,S/AS02A comprises a hybrid molecule in which the circumsporozoite 
protein of P. falciparum is expressed with hepatitis B surface antigen in yeast (Stoute et 
al., 1997). This is the only vaccine candidate shown in field trials to prevent malaria 
and, in one instance, to limit disease severity. RTS,S/AS02A has provided substantial, 
short-lived protection in volunteers, exposed experimentally to bites by infected 
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mosquitoes (Kester et al., 2001), and substantial (71%) but only short-term protection 
in naturally exposed, semi-immune adults from The Gambia (Bojang et al., 2001). In a 
subsequent trial in Mozambican children, RTS,S/AS02A gave 30% protection against 
the first clinical episode of malaria and 58% protection against severe malaria (Alonso 
et al., 2004). 
Another approach for malaria control focuses on the development of transgenic or 
genetically modified genetic mosquitoes in order to convert them into inefficient 
parasite vectors (Moreira et al., 2002; Marrelli et al., 2006; Marrelli et al., 2007).  
In addition, the availability of genome sequences, such as the ones from the three 
most relevant organisms to malaria, Homo sapiens (Nature, 2001; Science, 2001), 
Anopheles gambiae (Holt et al., 2002) and Plasmodium falciparum (Gardner et al., 2002), 
together with bioinformatics tools and high-throughput technologies (microarrays, 
RNA interference, proteomics) will ultimately provide an integrated picture of the 
parasite biology and malaria pathogenesis and hopefully facilitate the development of 
the existing and new approaches [see (Hoffman et al., 2002; Ghosh et al., 2003; Carucci, 
2004; Johnson et al., 2004)].  
 
1.6. A close look at the pre-erythrocytic stage 
Although the clinical symptoms only appear during the erythrocytic stage of 
Plasmodium’s life cycle it should not be disregarded that the asymptomatically                
pre-erythrocytic stage (also referred to as liver stage) is essential for the malaria 
infection outcome. During this stage Plasmodium develops inside hepatocytes and 
there is an amazing parasite multiplication. Still, relatively little knowledge exists on 
Plasmodium-hepatocytes interactions, which is due to the fact that the blood stage, 
being the pathogenic stage of the parasite’s life cycle, has soon attracted much more 
attention than the asymptomatic liver stage. Also, large and detailed studies of liver 
stage development are difficult because of the prerequisite of freshly extracted 
infectious sporozoites (breeding of infectious mosquitoes is a necessity) and to the low 
infection rates obtained in vitro (Prudêncio et al., 2007) and in vivo (Heussler et al., 
2006). Despite these restrictions, malaria researchers have been working towards an 
understanding of the biology behind the malaria liver stage and, during this journey, 
huge steps have been made to disclose the processes involved in this stage.  
 
1.6.1. Plasmodium models for liver stage research 
Liver stage research of human malaria is not feasible in vivo, therefore, several studies 
have successfully accessed the complete development of hepatic stages of human 
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Plasmodium sps. in human primary hepatocytes (Mazier et al., 1984; Smith et al., 1984; 
Mazier et al., 1985; Mazier et al., 1987). Still, these are technically challenging because 
they do not grow continuously in culture and, consequently, their availability is 
dependent on often scarce and unpredictable material. Thus, several studies have 
focused on the development of model systems using human hepatocyte cell lines (Uni 
et al., 1985; Calvo-Calle et al., 1994; Karnasuta et al., 1995; Sattabongkot et al., 2006). 
Initially, P. vivax and P. falciparum development in vitro was shown to be possible, 
although in different cell lines. Complete liver stage development for P. vivax was 
shown in HepG2-A16 cells (Uni et al., 1985) while P. falciparum liver stage growth was 
achieved in Huh1 cells (Calvo-Calle et al., 1994) as well as HHS-102 cells (Karnasuta et 
al., 1995). Only recently has a human hepatocyte cell line, HC-04, been shown to 
support the complete liver stage development of both P. vivax and P. falciparum 
(Sattabongkot et al., 2006). The main advantage of this cell line over the ones 
previously mentioned is the fact that it allows the development of the two most 
prevalent human malaria parasites with greatly improved infection rates. In addition, 
mouse models with humanized livers have been shown to represent a promising new 
tool for P. falciparum in vivo studies (Morosan et al., 2006; Sacci et al., 2006). These 
recent developments are extremely important because they might finally bring new 
avenues to human malaria liver stage research. Nevertheless, it should not be 
disregarded that human malaria research also requires the production and handling 
of human malaria parasite infectious mosquitoes, which involves very controlled 
conditions. 
As a result of the difficulties mentioned above, liver stage malaria research progress 
has been achieved through the use of rodent Plasmodium spp., in particular P. berghei 
and P. yoelii. These parasites are established as well-suited models for Plasmodium pre-
erythrocytic stage biology, immunology and vaccine development (Hafalla et al., 2006; 
Prudêncio et al., 2006). P. berghei and P. yoelii share more than 90% genome identity 
(Kooij et al., 2005). Although the P. yoelii model is generally thought to reflect human 
malaria better than the P. berghei model (Calvo-Calle et al., 1994; Doolan and Hoffman, 
2000; Mota et al., 2001b), the latter is the most widely used because the technologies to 
enable its transfection were developed earlier (van Dijk et al., 1996) than for P. yoelii 
(Mota et al., 2001b; Jongco et al., 2006). Moreover, green or red fluorescent protein-
tagged parasites have been developed first for P. berghei (Natarajan et al., 2001; 
Franke-Fayard et al., 2004; Frevert et al., 2005) and these have already allowed 
extensive in vivo studies focused in sporozoite transmission by mosquito bite 
(Frischknecht et al., 2004), its subsequent journey from the skin to the liver 
(Vanderberg and Frevert, 2004; Frevert et al., 2005; Amino et al., 2006) and liver stage 
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development (Sturm et al., 2006). Only recently were GFP-tagged P. yoelii parasites 
developed (Tarun et al., 2006; Ono et al., 2007) and used for in vivo liver stage studies 
(Tarun et al., 2006).  
Both P. berghei and P. yoelii are able to infect primary mouse hepatocytes (Meis et al., 
1984; Millet et al., 1985; Davies et al., 1989; Long et al., 1989) and these cells have often 
been used in liver stage research. However, since primary cells have to be freshly 
prepared and can only be maintained in culture for a short period of time, established 
cell lines have been more widely used. Cell lines, easily maintained in culture through 
several passages, constitute an extremely important tool that provides useful 
information to be subsequently tested ex vivo and/or in vivo.  
The hepatoma cell lines that present a relatively high level of infectivity for P. berghei 
and P. yoelii and, therefore, are widely used in in vitro studies are the human 
hepatoma cell lines, HepG2 and Huh7 (Aikawa et al., 1984; Calvo-Calle et al., 1994) 
and the murine hepatoma cell line, Hepa1-6 (Mota and Rodriguez, 2000). P. berghei is 
known to be more promiscuous than P. yoelii, since the former is able to efficiently 
infect both the human and the murine hepatoma cell lines (Aikawa et al., 1984; Calvo-
Calle et al., 1994; Mota and Rodriguez, 2000) whereas the latter only infects the murine 
Hepa1-6 cells efficiently (Mota and Rodriguez, 2000). P. berghei sporozoite invasion 
and exoerythrocytic forms (EEFs) development has also been observed in some non-
hepatic cell lines, namely the human lung cell line WI38 (Hollingdale et al., 1981; 
Hollingdale et al., 1983) and the human epithelial cells HeLa (Calvo-Calle et al., 1994). 
Additionally, it has been shown that P. berghei and P. yoelii sporozoites incubated, 
without any host cells, at 37º C in the presence of serum develop into early EEFs 
(Kaiser et al., 2003; Wang et al., 2004). Although at the morphological level axenically 
cultured EEFs are indistinguishable from those that develop within hepatocytes, 
intracellular residence is essential for parasite’s further growth.  
P. berghei and P. yoelii display different infection efficiencies in vitro and in vivo. There 
is an inverse relationship between the two species in their in vitro and in vivo infection 
rates. P. yoelii infection rate is high in vivo but low in vitro, whereas P. berghei stands in 
the opposite situation with the highest infection rate of malaria models in vitro, both 
in primary hepatocytes and hepatoma cell lines, and comparatively low in vivo 
success in mice (Khan and Vanderberg, 1991; Briones et al., 1996; Druilhe et al., 1998). 
Moreover, P. berghei and P. yoelii infectivity differences in vivo not only depend on the 
parasite but also on the clone and the genetic background of the rodent host (Jaffe et 
al., 1990; Scheller et al., 1994; Belmonte et al., 2003). All these aspects should be 
considered while extrapolating results obtained with the different experimental 
models. 
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1.6.2. Introducing the Plasmodium sporozoite 
The invasive Plasmodium stage that is transmitted by mosquitoes and is responsible 
for initiating the infection in the vertebrate host is called sporozoite and it is 
distinguished by specific features. Sporozoites are small unicellular organisms, about 
10 μm long and 1 μm wide. At the anterior cell pole, they possess the apical polar 
ring, which serves as a microtubule-organizing center, and a unique set of secretory 
organelles, termed micronemes and rhoptries, that belong to the apical complex. 
Micronemes are small vesicles of varying electron density while rhoptries are large, 
usually paired, pear-shaped organelles. Both these organelles discharge at the anterior 
pole and their contents are involved in the three basic types of tissue interaction in the 
mammalian host cell environment: gliding motility (a substrate-dependent form of 
locomotion), migration through cells by membrane rupture wounding and invasion 
of the host cell with the formation of a PV. The micronemes, rhoptries and also dense 
granules (microspheres of approximately 200 nm in diameter) are characteristic 
organelles of other invasive forms of apicomplexa parasites. Interestingly, dense 
granules have not yet been observed for the sporozoite invasive form. Another unique 
organelle of the sporozoite is the inner membrane complex, a flattened vesicle 
underneath the cell membrane that is associated with a set of subpellicular 
microtubules. An actin-myosin motor essential for sporozoite motility and invasion is 
located in the narrow space between the plasma membrane and the outer membrane 
of the inner membrane complex [reviewed in (Kappe et al., 2004)] (Figure 1.3). The 
Plasmodium sporozoite’s features outlined above are essential for sporozoite 
expedition to the liver’s host cell. 
 
 15
Chapter 1  
 
 
Figure 1.3 | The Plasmodium sporozoite. 
Schematic representation of a Plasmodium sporozoite, showing some of its organelles and 
subcellular structures. At the anterior cell pole is positioned the apical complex which is 
formed by the apical polar ring and the secretory organelles, micronemes and rhoptries. 
Underneath the sporozoite’s cell membrane is the inner membrane complex with an actin-
myosin motor and associated to subpellicular microtubules [adapted from (Kappe et al., 
2004)]. 
 
1.6.3. The sporozoite journey from the skin to the liver  
Malaria transmission takes place when an infected mosquito bites a mammalian host 
while probing for a blood source under the skin (Matsuoka et al., 2002). During the 
mosquito bite saliva containing sporozoites, vasodilators and anticoagulants is 
released (Griffiths and Gordon, 1952). Although mosquitoes can harbor thousands of 
sporozoites in their salivary glands, the number of sporozoites delivered in each bite 
rarely exceeds 200 and most estimates from experimental infections record numbers 
around 20 (Vanderberg, 1977; Rosenberg et al., 1990; Ponnudurai et al., 1991; 
Rosenberg, 1992). Recently, 2 different studies (Frischknecht et al., 2004; Medica and 
Sinnis, 2005) report higher numbers (sporozoite means 114 and 123, respectively). 
Nevertheless, considering the total number of sporozoites present in the salivary 
glands the number of sporozoites injected is quite low.  
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Sporozoites are deposited into the skin (Sidjanski and Vanderberg, 1997; Amino et al., 
2006), where they migrate for at least 30 min (Vanderberg and Frevert, 2004; Amino et 
al., 2006). Recently, a study using quantitative Real-Time Polimerase Chain Reaction 
(qRT-PCR) has determined the kinetics with which P. yoelii sporozoites leave the 
injection site and arrive in the liver and has shown that the majority of infective 
sporozoites can remain in the skin for hours (Yamauchi et al., 2007). A sporozoite 
surface phospholipase (PL) was shown to be required for host cell membrane 
breaching during migration in the skin (Bhanot et al., 2005). Sporozoites migrate 
extensively through the avascular dermis until they reach a vessel and enter the 
circulatory system, which transports them into the liver. It has been proposed that 
sporozoites may also travel using the lymphatic system (Vaughan et al., 1999; Krettli 
and Dantas, 2000). Intravital microscopy observations have showed that within 1 hour 
after P. berghei injection a proportion of sporozoites invades blood vessels and gets 
carried away by the blood flow, whereas others actively enter lymph vessels or 
remain in the skin after exhaustion of their motility (Amino et al., 2006) (Figure 1.4). 
 
 
 
Figure 1.4 | Plasmodium sporozoites are deposited in the skin and enter the circulatory 
and lymphatic systems.  
Sporozoites (in green) are placed under the skin of the mammalian host while an infected 
female Anopheles mosquito probes for a blood meal. Sporozoites migrate in the skin until they 
come into contact with a blood vessel (in red) and enter the circulatory system, being then 
transported into the liver. A small proportion of sporozoites can enter the lymphatic system 
(in yellow). Adapted from the Plasmodium‘s life cycle presented on Figure 1.2. 
 
Most of the sporozoites that enter the lymphatic vessels do not reach the circulatory 
system; instead, they are trapped in the lymph nodes. Some of these sporozoites 
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partially develop into small-sized EEFs before eventually being degraded (Amino et 
al., 2006). The relevance of presence of parasites in such an important organ of the 
immune system has been under investigation by Chakravaraty and Zavala. It has 
been observed a sporozoite-specific cytotoxic T-cell (CTL) response in the draining 
lymph node just 2 days after intradermal immunization with irradiated sporozoites. 
When the draining lymph node was surgically ablated to prevent early local priming, 
the number of sporozoite-specific CTLs in the liver was significantly reduced, 
highlighting the importance of skin-draining lymph nodes in the initiation of the 
immune response to sporozoites during natural infection [Chakravaraty and Zavala, 
unpublished data referenced in (Sinnis and Coppi, 2007)].  
 
1.6.4. Sporozoite arrest in the liver  
Once in the circulatory system, sporozoites are rapidly arrested in the liver. 
Sporozoites are found in hepatocytes within 2 minutes after intravenous injection into 
rats (Shin et al., 1982). The speed and selectivity of this process suggests specific 
interactions between parasite surface protein(s) and host molecule(s).  
The major surface protein of Plasmodium sporozoites, the circumsporozoite protein 
(CSP), appears to have an essential role by interacting with the heparan sulphate 
proteoglycans (HSPGs) of liver cells. It has been reported that recombinant CSP binds 
specifically to HSPGs from the basolateral cell surface of hepatocytes in the Disse 
space (region that separates the sinusoidal endothelium from hepatocytes) and that 
this interaction occurs between the CSP’s conserved I and II-plus regions and heparin-
like oligosaccharides and/or heparan sulfate (Cerami et al., 1992; Pancake et al., 1992; 
Frevert et al., 1993; Cerami et al., 1994; Sinnis et al., 1994; Rathore et al., 2002; Ancsin 
and Kisilevsky, 2004). Although HSPGs are present in most tissues, liver HSPGs are 
known to be more highly sulphated than those in other tissues (Lyon et al., 1994). This 
feature has been proposed to be responsible for the selective recognition of 
recombinant CSP and Plasmodium sporozoites in the liver (Ying et al., 1997; Pinzon-
Ortiz et al., 2001).  
Between the blood and hepatocytes there is a layer of liver endothelial cells that have 
open fenestrations which allow direct contact between the circulation and the space of 
Disse (Wisse et al., 1985). Lipoproteins, because of their small size (90 nm of diameter),  
are able to freely diffuse through the endothelial fenestrations and access directly the 
space of Disse while sporozoites cannot due to their larger size (1µm). It has been 
proposed that hepatocyte HSPGs may extend through endothelial fenestrations to the 
lumen of blood vessels where they would sequester sporozoites (Sinnis et al., 1996). 
More recently, it has been shown that CSP and another parasite protein, 
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thrombospondin-related anonymous protein (TRAP), recognize HSPGs, not only on 
hepatocytes, but also on Kupffer cells (resident macrophages of the liver) and stellate 
cells (highly branched fat-storing cells that embrace the sinusoids from within the 
Disse space) (Pradel et al., 2002). Stellate cells synthesize eight times more sulphated 
HSPGs than hepatocytes and incorporate twice the amount of sulphate into heparan 
sulphate (Gressner and Schafer, 1989). Therefore, it has been suggested that 
Plasmodium sporozoites initial arrest in the liver sinusoids (blood vessels in the 
periphery of the liver lobules) is mediated by matrix HSPGs that are produced by 
stellate cells and protrude through the endothelial fenestrations (Pradel et al., 2002, , 
2004) (Figure 1.5). 
 
 
 
Figure 1.5 | Plasmodium sporozoite arrest in the liver. 
Sporozoites (in green) reach the liver sinusoids, where they are arrested due to interactions 
with heparan sulphate proteoglycans (HSPGs) from hepatocyte and stellate cells [adapted 
from (Prudêncio et al., 2006)]. 
 
In addition, it has also been proposed that the highly selective sporozoite arrest in the 
liver involves at least two different cell surface receptors, a highly sulfated HSPG that 
associates with CSP region I-plus together with another receptor that would bound to 
CSP region II-plus (Ancsin and Kisilevsky, 2004). A similar co-receptor strategy is 
employed by the fibroblast growth factor (HSPG + tyrosine kinase receptor) 
(Rapraeger et al., 1991; Yayon et al., 1991) and Apolipoprotein E (ApoE) containing 
lipoproteins [HSPG + low density lipoprotein receptor (LDLR) or low density 
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lipoprotein receptor-related protein (LRP)] (Willnow et al., 1994; Rohlmann et al., 
1998). In fact, malarial sporozoites may be using an existing host lipoprotein clearance 
pathway since lipoproteins (such as chylomicrons, very low lipoprotein and low 
density lipoprotein) are removed from circulation by binding to liver-specific HSPG 
in the space of Disse (Herz et al., 1995; Ji et al., 1995) and recombinant P. falciparum 
CSP can compete with lipoproteins for binding and clearance (Sinnis et al., 1996). High 
affinity binding between CSP and LRP has been reported and shown to be inhibited 
using a LRP specific blocker (Shakibaei and Frevert, 1996). However, when another 
study demonstrated that LRP-deficient hepatocytes in vivo and LRP-null cells in vitro 
showed an infection efficiency equal to controls (Marshall et al., 2000) it was 
considered that LRP and HSPGs may not function in a coordinated fashion during 
sporozoite entry, as in remnant lipoprotein metabolism, but instead may be used as 
alternate binding sites during sporozoite passage to the liver.  
The identity of the liver HSPG receptor remains elusive. Possible candidates are 
members of the syndecan family, a major class of vertebrate membrane-bound 
proteoglycans (Couchman, 2003). The multi-functional cell surface co-receptors 
Syndecans-1, -2, -3 and -4 (Syn-1, -2, -3 and -4) are type 1 transmembrane proteins 
expressed in a wide variety of tissues. Syn-1 and -2 are considered as possible 
candidates for the HSPG receptor for Plasmodium sporozoites since they are expressed 
in the liver (Bernfield et al., 1999). Syn-1 seems not an important sporozoite receptor 
because P. yoelii infection in Syn-1 deficient mice showed that these mice are as 
susceptible to sporozoite infection as the wild-type controls (Bhanot and 
Nussenzweig, 2002). It is possible that Syn-1 function as a hepatic HSPG receptor for 
Plasmodium is redundant, and that in its absence its role is fulfilled by another 
molecule. Syn-2 is probably the CSP receptor since it is an unusual member of the 
family of HSPGs, with a large proportion of heparin like, highly sulfated structures at 
the distal end of the glycosaminoglycans chains (Lyon and Gallagher, 1991; Pierce et 
al., 1992). Notably, among glycosaminoglycans, heparin is the most efficient inhibitor 
of CSP binding to HepG2 cells. A well-defined decasaccharide isolated from heparin, 
which has a structure commonly found in liver Syn-2, blocks the interaction between 
CSP and HepG2 cells (Rathore et al., 2001). The same decasaccharide binds specifically 
to apolipoprotein E (Dong et al., 2001), providing additional support for the view that 
sporozoites and chylomicron remnants compete for the same liver sites. Syn-2’s role 
in this process can be clarified when Syn-2 deficient mice become available. 
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1.6.5. Hepatocyte infection 
 
 1.6.5.1. Reaching hepatocytes 
After sporozoites are arrested in the liver sinusoid, they must reach and invade the 
hepatocytes. The liver sinusoid is composed of a single cell layer of fenestrated 
endothelial cells along with interspersed Kupffer cells, the liver resident 
macrophages. Although liver endothelial cells have fenestrations, these are too small 
(about one tenth of the diameter of a sporozoite) to allow sporozoite passage. 
Research in this matter has provided strong evidence that sporozoites cross the 
sinusoidal layer primarily through Kupffer cells [reviewed in (Frevert et al., 2006)] 
(Figure 1.6). 
 
 
 
Figure 1.6 | Plasmodium sporozoite’s arrival at hepatocytes through Kupffer cells. 
Liver sinusoids (S) are lined by fenestrated endothelia (EC) and interspersed Kupffer cells 
(KC). Stellate cells (SC) are located inside the narrow Disse space (D), which is formed by 
sinusoidal cell layer and hepatocytes (H). Sporozoites (represented by the red dotted line) are 
transported through liver sinusoids, until they encounter a Kupffer cell. Then, sporozoites 
reach hepatocytes by traversing the Kupffer cell [adapted from (Baer et al., 2007)].  
 
In vitro observations of the interaction between sporozoites and sinusoidal cells found 
that sporozoites preferentially invaded Kupffer cells (Pradel and Frevert, 2001). More 
recently, Baer et al. (2007) provided strong evidence that Kupffer cells represent the 
sporozoite’s doorway to hepatocytes. In vivo, Plasmodium infection of homozygous 
op/op mice, known to have fewer Kupffer cells than their wild-type counterparts 
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[because they lack macrophage colony stimulating factor 1 due to a mutation in the 
osteopetrosis (op) gene], led to the observation that infection in homozygous mice 
was decreased by 84% when compared with their heterozygous siblings, which have 
normal Kupffer cell numbers (Baer et al., 2007).  
The Kupffer cell invasion process was observed to occur with the formation of a PV, 
which allows sporozoites to go through Kupffer cells avoiding lysosomal fusion 
(Pradel and Frevert, 2001). Intravital microscopy provided evidence that sporozoites 
arrested in the liver sinusoids were found to move towards the hepatocytes through 
Kupffer cells at a lower speed than the normal speed measured when sporozoites 
traverse cells using plasma membrane disruption (Frevert et al., 2005). Furthermore, it 
was shown that Plasmodium sporozoites are able to survive the Kupffer cell passage 
unharmed through the suppression of the respiratory burst in these cells (Usynin et 
al., 2007). Sporozoites exploit the overall macrophage deactivating and anti-
inflammatory properties of cyclic adenosyl monophosphate (cAMP) to suppress 
reactive oxygen species production in Kupffer cells. cAMP concentration in Kupffer 
cells was previously shown to be increased by the high-affinity interaction between 
CSP and the scavenger receptor LRP (Shakibaei and Frevert, 1996), which suggests 
that HSPGs might also contribute to the induction of the signaling cascade by 
facilitating CSP binding to LRP (Usynin et al., 2007). 
Nevertheless, it has been also been suggested that crossing of the sinusoidal layer 
might occur by the disruption of cell plasma membranes since P. berghei parasites 
deficient in the SPECT1 (sporozoite microneme protein essential for cell traversal) and 
SPECT2 (also called Plasmodium perforin-like protein 1, PPLP1) proteins, known to 
confer a defect in the ability to traverse cells, have low infectivity in vivo (Ishino et al., 
2004; Ishino et al., 2005a). More studies are needed to reconcile these results with the 
previously described ones. 
 
1.6.5.2. Migration through hepatocytes 
Sporozoites migrate through several hepatocytes before finally engaging the 
mechanism to enter hepatocytes with formation of a PV. It has been shown both in 
vitro and in vivo that during migration through cells, Plasmodium sporozoites breach 
the plasma membranes of several hepatocytes and these can rapidly be repaired 
(Mota et al., 2001a; Frevert et al., 2005) (Figure 1.7). 
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Figure 1.7 | Plasmodium sporozoite migration through hepatocytes. 
Sporozoites (in green) migrate through several hepatocytes until infection of a final one. The 
migration process involves hepatocyte plasma membrane breaching while hepatocyte 
infection occurs with the formation of a parasitophorous vacuole [adapted from (Prudêncio 
et al., 2006)]. 
 
Migration through host cells induces exocytosis from sporozoite apical organelles and 
parasite molecules, such as TRAP, are released (Mota et al., 2002). Sporozoites usually 
present a faint TRAP surface staining pattern but, after incubation with host cells, 
high concentrations of TRAP are observed forming an apical “cap” on the sporozoite 
surface (Gantt et al., 2000). Elevated cytosolic concentrations of Ca2+ in sporozoites 
induce exocytosis  (Gantt et al., 2000; Mota et al., 2002), which suggests that signaling 
cascades might be activated in the parasite during migration through cells. In 
addition, the host cell wounding by sporozoite migration was also shown to induce 
the secretion of a host factor, hepatocyte growth factor (HGF), which renders 
surrounding hepatocytes more susceptible to infection (Carrolo et al., 2003). By 
activating its receptor, MET, HGF induces important rearrangements in host cell 
cytoskeleton (Carrolo et al., 2003) and protects the host cell(s) from apoptosis (Leirião 
et al., 2005a).  
Although a full understanding of the molecular mechanisms associated with cell 
migration is still far, four P. berghei proteins involved in this process have been 
identified. These are SPECT1, SPECT2, PL and CelTOS (cell traversal protein for 
ookinete and sporozoite) (Ishino et al., 2004; Bhanot et al., 2005; Ishino et al., 2005a; 
Kariu et al., 2006). Sporozoites in which either one of the SPECT proteins or CelTOS 
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were deleted show similar phenotypes: in vitro they lack the ability to traverse cells 
but when placed directly on hepatocytes they invade and develop normally. In vivo it 
was observed that these mutants lack infectivity for the mammalian host when 
injected intravenously and this phenotype was inverted in mice whose liver Kupffer 
cells were depleted because sporozoites access hepatocytes directly through gaps in 
the sinusoidal barrier (Ishino et al., 2004; Ishino et al., 2005a; Kariu et al., 2006). These 
proteins may also be required for sporozoite exit from the dermis and in fact this has 
been demonstrated by intravital microscopy for the SPECT1 mutant [Amino and 
Menard, unpublished data referenced in (Sinnis and Coppi, 2007)]. Altogether, the 
SPECT and CelTOS mutant data suggest that, although migration through cells is 
necessary to reach the hepatic parenchyma, migration through hepatocytes may not 
be necessary for infection. This is in disagreement with the notion that migration is a 
prerequisite to enable sporozoites to invade the appropriate host cell and therefore, 
these different perceptions need further attention to be reconciled. 
Mutant sporozoites in which PL is deleted or its catalytic site altered also show a 
reduced cell traversal activity. Although, these mutants are impaired in reaching the 
liver when injected intradermally, they present a normal infectivity when injected 
intravenously (Bhanot et al., 2005). Therefore, PL appears to be required only for 
crossing cell barriers in the skin suggesting that the migration mechanism in the skin 
might differ from the one in the liver.  
 
1.6.5.3. Hepatocyte invasion 
Following migration through cells, Plasmodium sporozoites engage in a final invasion, 
with the formation of a parasitophorous vacuole, which is essential for further 
differentiation of the parasite. The parasite and host molecules involved in hepatocyte 
invasion process have been under investigation. Several parasite proteins were shown 
to be involved in this process and these are described below.  
CSP has been extensively shown to be essential for sporozoite localization to the liver 
but the role of CSP–hepatocyte interactions during the invasion process itself is still 
under investigation. Recently, it was found that CSP is proteolytically cleaved by a 
parasite cysteine protease upon contact with hepatocytes and this cleavage process 
seems to be specifically associated with productive sporozoite invasion (Coppi et al., 
2005). In addition, CSP intracytoplasmic deposition was shown to take place during 
sporozoite attachment to the host cell, reaching its peak 4 to 6 hours after invasion. 
CSP interacts initially with cytosolic as well as endoplasmic reticulum-associated 
ribosomes and throughout parasite development CSP binding becomes restricted to 
ribosomes lining in the outer membrane of the host cell nuclear envelope (Hugel et al., 
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1996). Moreover, it was shown that CSP leads to the inhibition of protein synthesis in 
host cells (Frevert et al., 1998). 
TRAP, normally present in small amounts on the sporozoite surface, is released in 
large amounts onto the sporozoite surface upon parasite contact with hepatocytes or 
during the migration process (Gantt et al., 2000; Mota et al., 2002). TRAP is a 
transmembrane protein whose extracellular portion has two cell-adhesive sequences, 
an A-domain (or I-domain of integrins) and a type I thrombospondin motif (TSR) 
[reviewed in (Menard, 2000)]. TRAP’s role in hepatocyte invasion has been elucidated 
thanks to the generation TRAP mutants in these domains (Wengelnik et al., 1999; 
Matuschewski et al., 2002). Mutations in only one of the adhesive domains were 
shown to significantly decrease infectivity for hepatocytes while mutations in both 
domains completely abolished infection.  
The apical membrane antigen 1 protein (AMA-1), known to be involved in 
Plasmodium merozoite invasion of erythrocytes, was also shown to be expressed in 
sporozoites (Florens et al., 2002; Silvie et al., 2004) and to have a role in hepatocyte 
invasion by P. falciparum parasites in vitro (Silvie et al., 2004).  This protein is initially 
found intracellularly and is secreted onto the sporozoite surface in the presence of 
hepatocytes. 
P. berghei P36p and Pb36 proteins, members of a small family of Plasmodium proteins 
that have 6 conserved cysteine residues, were also shown to be important for 
sporozoites to recognize hepatocytes and commit to infection (Ishino et al., 2005b).  
The Py235 rhoptry protein, first described in P. yoelii but with clear homologues in 
other rodent and human malaria species (Gruner et al., 2004), was also involved in 
sporozoite invasion of hepatocytes (Preiser et al., 2002).  
A role in hepatocyte invasion has been suggested for other proteins, namely the 
secreted protein with altered thrombospondin repeat (SPATR) (Chattopadhyay et al., 
2003), the erythrocyte-binding antigen 175 (EBA 175) (Gruner et al., 2001b), the 
sporozoite-threonine-asparagine-rich protein (STARP) (Pasquetto et al., 1997) and the 
Plasmodium falciparum erythrocyte membrane protein 3 (PfEMP3) (Gruner et al., 
2001a), due either to their localization in the sporozoite or to the fact that antibodies 
directed against them can decrease sporozoite infectivity.  
More recently, a new parasite protein called thrombospondin related sporozoite 
protein (TRSP) initially described in P. yoelii (Kaiser et al., 2004) was shown to 
facilitate host cell entry (Labaied et al., 2007a).  
Regarding the host cell molecules that the parasite exploits, so far only a few have 
been described and these are presented below.  
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The HSPGs already mentioned to be involved in sporozoite arrest in the liver may 
also be involved in invasion [see (Sinnis and Coppi, 2007)]. More recently, an 
interaction between fetuin-A glycoprotein on hepatocyte membranes and the 
extracellular region of TRAP has been shown to enhance the parasite’s aptitude to 
invade hepatocytes (Jethwaney et al., 2005).  
Another host molecule identified as essential for sporozoites invasion is the 
tetraspanin CD81 (Silvie et al., 2003). This membrane protein is expressed on the 
surface of hepatocytes and has been previously shown to be a putative receptor for 
hepatitis C virus (Pileri et al., 1998). CD81 appears to have an important role in the 
invasion of mouse hepatocytes by P. yoelii and human hepatocytes by P. falciparum 
(Silvie et al., 2003), which has been proposed to be linked with CD81 being localized in 
tetraspanin-enriched microdomains (Silvie et al., 2006a). On the other hand, P. berghei 
was shown to use both CD81-dependent and -independent pathways to enter the 
hepatocyte (Silvie et al., 2006b; Silvie et al., 2007). 
To date, the precise role of CD81 remains elusive, as attempts to identify a sporozoite 
ligand for CD81 have not yet allowed the identification of a binding partner (Silvie et 
al., 2003). Therefore CD81 may not function as a receptor but, instead, might regulate 
the activity of another host molecule that has an essential role in sporozoite invasion. 
This hypothesis is in agreement with the reported ability of tetraspanins to associate 
with, and regulate the function of, molecular partners. Another possibility is that 
CD81 functions during the early stages of PV formation, which is suggested by the 
finding that the small proportion of P. yoelii sporozoites that invade CD81-negative 
cells are found developing in the nucleus without a PV (Silvie et al., 2006b). 
Research focused on the identification of host receptors essential for sporozoite 
infection has also revealed host molecules that seem not to play a role in this process. 
Plasmodium in vivo infection was accessed in mice deficient in molecules such as 
ICAM-1 and ICAM-2 (intercellular adhesion molecule 1 and 2, respectively, expressed 
in endothelial and epithelial cells) (Sultan et al., 1997), CD36 (scavenger receptor 
found on many cells including Kupffer and endothelial cells) (Sinnis and Febbraio, 
2002), Syn-1 (HSPG expressed by many cell types, including hepatocytes) (Bhanot and 
Nussenzweig, 2002), SR-AI and SR-AII (scavenger receptors class A, member 1 and 2 
expressed by Kupffer and liver endothelial cells) (Cunha-Rodrigues et al., 2006a). In 
these studies it was observed that mice deficient in these proteins showed levels of 
Plasmodium infection similar to those of wild-type mice. However, it is possible that 
Plasmodium can invade host cells using multiple, alternative pathways, with 
significant redundancy. Therefore, it remains to be elucidated whether any of the 
receptors mentioned above plays (a) specific role(s) in malaria infection.  
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As mentioned above, sporozoite hepatocyte invasion is characterized by the 
formation of a PV. The processe(s) involved in PV formation is (are) unknown. Three 
different models have been proposed to explain PV formation in apicomplexan 
parasites: (i) de novo PV formation through the discharge of proteins and membranous 
material from the parasite rhoptries; (ii) PV formation by direct invagination of the 
host cell membrane and (iii) PV formation through the discharge of material from the 
rhoptries along with cell membrane invagination [reviewed in (Mota and Rodriguez, 
2002)]. If any of these model(s) applies to the PV formation at the time of hepatocyte 
infection still has to be determined. 
 
1.6.5.4. Development within the hepatocyte  
After invasion, the sporozoite resides inside the PV and differentiates into an EEF, 
which grows (trophozoite stage), multiplies (schizont stage) and, within a few days 
(only 2 days for the murine Plasmodium models), generates thousands of erythrocyte-
infectious merozoites. The initial phase of sporozoite differentiation into an EEF 
probably occurs without nutrient acquisition from the host cell but, afterwards, in 
order to develop and multiply, the parasite must establish an extensive system to 
remodel and exploit the host hepatocyte [reviewed in (Mikolajczak and Kappe, 2006)]. 
During EEF development within the hepatocyte the parasite notably outgrows the 
normal host cell limits (Figure 1.8). During this phase there is certainly a huge 
membrane and nucleic acid synthesis and an important question that remains 
unanswered is how the parasite acquires the nutrients required for this process. The 
hepatocytes’ unique properties of metabolic “superachievers” (e.g. for major lipids 
and purines) and “storehouses” (e.g. for glycogen) could be one reason why 
mammalian species have acquired the ability to infect hepatocytes, whereas the 
evolutionarily older avian and reptilian species develop in the sinusoidal cells 
(Frevert, 2004; Bano et al., 2007). A recent study shows that, during its development, 
the EEF is found in the juxtanuclear cell region where optimal replication occurs and 
their PV is associated with the host endoplasmic reticulum. The PV membrane was 
shown to be cholesterol-enriched and the lipids are likely to be derived from the host 
plasma membrane. Moreover, Plasmodium transforms its vacuole into a highly 
permeable compartment by creating channels within the PV membrane, which allow 
the trafficking of a wide range of small metabolites from the host cytosol to the PV 
(Bano et al., 2007).  
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a. b.
 
 
Figure 1.8 | Plasmodium development within the hepatocyte. 
(a.) Plasmodium EEF development within the hepatocyte occurs indoors the parasitophorous 
vacuole. (b.) Infected hepatocytes are enormously increased in cell volume when compared 
to a non-infected cell [adapted from (Sturm et al., 2006)]. 
 
The molecular mechanisms that occur in the parasite or the hepatocyte to establish the 
intrahepatocytic niche are still poorly understood.  
To date only a few sporozoite proteins, namely UIS3, UIS4  and Pb36p (Mueller et al., 
2005a; Mueller et al., 2005b; van Dijk et al., 2005; Tarun et al., 2007), have been shown 
to be essential for parasite development within the hepatocytes.  
UIS3 and UIS4 (UIS for upregulated in infective sporozoites) knock-out (KO) P. 
berghei and P. yoelii sporozoites were shown to successfully invade hepatocytes with 
the formation of a PV and transform into EEFs but, subsequently, to present a severe 
growth defect (Mueller et al., 2005a; Mueller et al., 2005b; Tarun et al., 2007).  
For P. berghei P36p KO sporozoites, while one study shows that these invade 
hepatocytes but are not able to maintain the PV and consequently their early 
development is arrested (van Dijk et al., 2005), a different study shows that P36p KO 
sporozoites are able to infect cells with the formation of the PV, although with 
reduced efficiency (Ishino et al., 2005b). In the latter study a significant increase in cell 
traversal activity of KO parasites was also observed and it was proposed that these 
fail to switch to the “infection mode” and keep on traversing host cells. A  recent 
study, shows that a P. yoelii P36p and P36 double mutant can enter and traverse host 
cells normally (no increase in traversal activity was observed) but cannot establish a 
PV early in hepatocyte infection (Labaied et al., 2007b). Thus, although P36p-deficient 
sporozoites might be impaired in both invasion and intracellular development within 
the host cells, it is likely that P36p plays a critical role in the pathway that leads to the 
formation of the PV membrane. 
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Even if the exact role of all of these proteins in EEF development remains to be 
elucidated, a remarkable application of these genetically attenuated sporozoites (GAS) 
is their use as live attenuated vaccines, similarly to radiation attenuated sporozoites 
(RAS), which also present a deficient growth within hepatocytes (Sigler et al., 1984). 
Immunization with RAS was shown to induce protection against challenge with 
infectious sporozoites (Nussenzweig et al., 1967) and this model has allowed an 
understanding of the basic immune mechanisms that mediate sterile protection 
against infection (Doolan and Hoffman, 2000; Doolan and Martinez-Alier, 2006; 
Hafalla et al., 2006). Immunization with GAS was also shown to confer full protection 
against a subsequent challenge with fully infective sporozoites (Mueller et al., 2005a; 
Mueller et al., 2005b; van Dijk et al., 2005; Douradinha et al., 2007; Labaied et al., 2007b; 
Tarun et al., 2007), which has already been shown to occur through the induction of 
protective immune responses for the UIS-deficient parasites (Jobe et al., 2007; Mueller 
et al., 2007; Tarun et al., 2007).  
Barely any host factors important for EEF development in the host cell are known. As 
mentioned before, HGF is secreted by hepatocytes damaged during sporozoite 
migration (Carrolo et al., 2003). Through HGF/MET signaling, this host factor induces 
rearrangements of the host cell actin cytoskeleton that might play a role during the 
early development of the parasites within the hepatocyte (Carrolo et al., 2003). 
Moreover, it was also shown that HGF/MET activity on infection is also due to 
apoptosis prevention in infected host cells, a crucial requirement for the full parasite 
development (Leirião et al., 2005a).  
Studies focused on the role of the UIS4 and UIS3 parasite proteins, essential for EEF 
development, have revealed that they seem to interact with the host proteins ApoA1 
(apolipoprotein A-I) and L-FABP (liver-fatty acid binding protein), respectively.  
ApoA1 and UIS4 were observed to co-localize in the PV 24 hours after sporozoite 
infection and ApoA1 relevance in Plasmodium infection was confirmed in vitro and in 
vivo [Mueller and Matuschewski, unpublished data referenced in (Prudêncio et al., 
2006)]. ApoA1 is a major protein component of high density lipoprotein (HDL) and 
therefore it is speculated that its role in Plasmodium intrahepatocytic development 
might be related with the synthesis of large amounts of additional membrane 
essential for the considerable PV expansion that must occur to allow intra-vacuolar 
replication of malaria sporozoites [reviewed in (Prudêncio et al., 2006)].  
UIS3 was shown to interact directly with L-FABP, using a two-hybrid system 
(Mikolajczak et al., 2007). L-FABP expression down-regulation in hepatocytes severely 
impairs parasite growth and L-FABP overexpression promotes growth. As the main 
cytoplasmic carrier of fatty acids in hepatocytes, L-FABP acts as a shuttle of fatty acids 
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for import, storage, export and delivery to intracellular destinations. Even though 
whether a direct interaction of UIS3 and L-FABP takes place in infected hepatocytes 
remains to be demonstrated, the authors suggest a major pathway for fatty acid 
acquisition by Plasmodium from the host hepatocyte via docking of L-FABP to UIS3 
(Mikolajczak et al., 2007). Further studies are needed to prove the speculated roles for 
ApoA1 and L-FABP. 
During schizogony the parasite grows considerably in size and infected hepatocytes 
become several times larger than non-infected ones. Although this enormous growth 
is certainly an important stress factor for the host cell, and stress normally induces 
apoptosis, infected cells surprisingly do not exhibit signs of cell death [reviewed in 
(Sturm and Heussler, 2007)]. In fact there is accumulating evidence for parasite-
dependent survival of the host cell during liver stage development. A recent study 
suggests that irradiated dying parasites induce apoptosis of the host cell confirming 
that viable parasites are required to constantly stimulate host cell survival pathways 
(Leirião et al., 2005b). Moreover, it was shown that dendritic cells (DCs) phagocytose 
apoptotic cells containing the remains of intracellular parasites (Leirião et al., 2005b). It 
is possible to extrapolate that apoptotic infected cells may play a role in the protective 
immune response since it has previously been demonstrated that DCs mediate the 
protective immune response induced by irradiated sporozoites (Hafalla et al., 2003). 
Another piece of evidence that parasite death results in host cell apoptosis arises from 
the observation that host cell apoptosis occurs upon parasite death (van de Sand et al., 
2005). Moreover, P. berghei infected hepatocyte analysis revealed that the presence of 
the parasite protects the host cell from apoptosis induced in vitro by peroxide 
treatment or serum deprivation and in vivo by TNF-α. This parasite-dependent 
inhibition of apoptosis although more pronounced at 48 h post infection (p.i.) is 
already detectable at 24 h p.i.  
 
1.6.6. The parasite breaks away from the hepatocyte 
Ultimately Plasmodium intrahepatocytic development comes to an end and the 
thousands of newly formed merozoites must be released into the blood stream, where 
they will invade erythrocytes, initiating the blood stage of malaria infection. These 
merozoites must leave the PV membrane and the host cell membrane, cross the space 
of Disse and penetrate endothelial cells to enter blood vessels and finally infect 
erythrocytes. For many years it has been assumed that merozoites would be liberated 
by rupture of the host cell membrane, but this does not explain how they can cross the 
extracellular matrix-filled space and the endothelium of the blood vessels, being also 
able to escape the host immune system. Recently, it was proposed that P. berghei liver 
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stage parasite manipulates their host cells to guarantee the safe delivery of merozoites 
into the blood stream (Sturm et al., 2006). Parasites induce the death and the 
detachment of their host hepatocytes, followed by the budding of parasite-filled 
vesicles, named merosomes (Figure 1.9).  
 
a. b.
 
 
Figure 1.9 | Plasmodium exit from the liver into the blood stream. 
(a. and b.) Plasmodium merozoites are released from the liver via merosomes, merozoite-filled 
vesicles, that bud off from infected hepatocytes into the sinusoidal lumen [adapted from 
(Sturm et al., 2006)]. 
 
Merosomes, which can contain from just a few to several thousand merozoites, bulge 
into liver sinusoids and appear to act as shuttles that ensure the release of living 
merozoites directly into the circulation. Interestingly, although merosomes present 
apoptotic features they are able to act as protective shields against phagocytosis due 
to the lack of the phosphatidylserine signature of a dying cell. This mechanism of cell 
death and cell movement of the host cell seems to be controlled by cysteine proteases 
as well as factors that mediate Ca2+ accumulation (Sturm et al., 2006). Merosome-like 
structures have also been reported for P. yoelii (Tarun et al., 2006).    
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1.7. Objectives 
The biological events that take place throughout the liver stage of Plasmodium 
infection are obligatory during the establishment of a natural malaria infection and 
therefore constitute an ideal target for potential anti-malarial vaccines and 
prophylactic drugs. Although there have been recent significant advances in our 
understanding of the mechanisms by which Plasmodium sporozoites establish 
infection in the mammalian host, there is still insufficient information on the host and 
parasite molecules involved in Plasmodium invasion and development within 
hepatocytes.  
The overall goal of the research proposal that led to the work presented in this thesis 
was to identify host factors playing a role on Plasmodium liver stage infection. To this 
end, we sought to apply an RNA interference (RNAi) approach, which allows 
selective down-regulation of gene expression. RNAi is an evolutionarily conserved 
mechanism by which double stranded RNA molecules (dsRNA) silence a target gene 
through the specific destruction of its messenger RNA (mRNA) [reviewed in (Meister 
and Tuschl, 2004)]. In mammalian cells small interfering RNA (siRNA) molecules 
(with 21 to 23 nucleotides) are capable of specifically silence gene expression without 
induction of the interferon response pathway [see (Echeverri and Perrimon, 2006)]. 
RNAi’s ability to induce the destruction of individual targeted mRNAs with high 
efficacy and specificity enables the generation of direct relationships between a gene’s 
expression level and its functional role in any biological process being studied (Sachse 
et al., 2005). Basically, we used an in vitro assay in which Plasmodium infection was 
accessed in host cells treated with siRNAs to specifically silence the genes under 
investigation.  
Initially, we tested the feasibility of a high throughput RNAi procedure in our in vitro 
P. berghei infection system by performing a small screen in which a total of 96 genes 
expressed in liver cells and involved in different processes (such as cytoskeleton, 
signaling, apoptosis and others) were targeted. This initial screen allowed the 
optimization and the standardization of all experimental conditions. More, regarding 
the RNAi screen system itself, it allow us to realize the crucial importance of: (i) use of 
at least three different siRNAs to target each gene to avoid false-negative results; (ii) 
confirmation rounds in order to achieve reproducible results for a specific gene with 
at least two different siRNAs; and (iii) a final confirmation step in which the observed 
phenotypic effect in infection is correlated with gene knock-down. Concerning the in 
vitro Plasmodium infection system it was understood that the widely used human 
HepG2 hepatoma cell line was not appropriate for the high-throughput type of 
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reading used. HepG2 cells in culture show a high aggregation level, which makes the 
automated acquisition of images at different focusing levels rather difficult. All these 
conclusions allowed us to better plan the different steps of the RNAi screen(s). 
Subsequently, three different sets of genes were screened: 
(i) host hepatocyte genes differentially expressed throughout Plasmodium 
infection, which were identified using microarray technology; 
(ii) host genes encoding kinases and kinase-interacting proteins and 
(iii) host lipoprotein pathway genes. 
Why were these genes chosen? The explanation for the first screen involves previous 
work performed in our laboratory, namely the identification of host genes that are 
differentially expressed as a result of Plasmodium infection. Briefly, a microarray 
approach was used to compare gene expression of infected cells to the one of non-
infected cells. Although this study has disclosed valuable information regarding the 
host genes specifically modulated throughout Plasmodium infection, by itself it did not 
supply evidence on their functional relevance. In order to achieve this some candidate 
genes were selected from the microarray analysis and their function was further 
studied by gene silencing using RNAi.  
The second RNAi screen sought to determine host kinases and kinases-interacting 
proteins role in Plasmodium infection. It is known that these proteins are important 
intracellular signaling players and tightly control numerous cellular processes 
(Manning et al., 2002). Therefore, it seemed likely that kinases and kinases-interacting 
proteins modulate the cell’s behaviour during the infection process by an intracellular 
pathogen.  
Finally, in a follow-up work from previous reports, in which a link between host 
lipoprotein clearance pathways and Plasmodium sporozoite infection of the liver was 
suggested (Shakibaei and Frevert, 1996; Sinnis et al., 1996), we observed a lipoprotein-
mediated inhibition of Plasmodium hepatocyte invasion. To better understand this 
observation the role of lipoprotein pathway genes in the liver stage of Plasmodium 
infection was accessed by RNAi. 
Data from these three studies has revealed several host factors that seem important 
for the establishment and development of Plasmodium infection. Other approaches 
have been employed to further validate their role. The choice of the different 
approaches used was made according with the question to address and the tools 
available such as antibodies, inhibitory compounds and transgenic mice among 
others. The data obtained for the host factors studied provides strong evidence of 
their role in liver stage Plasmodium infection.  
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Plasmodium liver stage infection represents the most appealing stage for prophylaxis 
and vaccine strategies and effective intervention will only become realistically 
attainable by understanding the crucial host-parasite interactions. Therefore, the 
knowledge of important host factors for liver stage Plasmodium infection might 
provide new targets for drug and vaccine development. 
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Results 
 
 
After entering their mammalian host via the bite of an Anopheles mosquito, 
Plasmodium sporozoites are arrested in the liver. There, they traverse several 
hepatocytes before invading the one in which they develop and multiply into 
thousands of merozoites (Mota et al., 2001). Plasmodium strategies that enable its 
survival and development inside host liver cells remain a poorly understood, yet 
essential step in malaria infection (Prudêncio et al., 2006). A molecular analysis of 
this process was initiated using a post-genomics approach that comprises host cell 
transcriptional profiling of P. berghei-infected hepatoma cells followed by 
functional testing of identified genes using RNA interference (RNAi). The data 
revealed differential expression patterns for 611 host genes, with the largest 
proportion correlating specifically with the early stages of the infection process. Of 
these genes, RNAi-induced loss of functions implicated two transcription factors, 
Atf3 and c-Myc, whose silencing leads, respectively, to a significant increase and 
decrease in Plasmodium hepatocyte infection levels. The in vitro result was 
confirmed in vivo by our finding that Atf3-deficient mice have significantly higher 
liver parasite loads than wild-type mice.  
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The pre-eminent tropical malaria disease is one of the top three communicable 
diseases in the world today. Forty percent of the world’s population is at risk of 
infection, with 500 million clinical cases every year and up to three million deaths, 
mostly of children, being attributable to this disease (Sachs and Malaney, 2002). 
Malaria infection is initiated when Plasmodium sporozoites are injected into a 
mammalian host during the bite of an infected female Anopheles mosquito while 
probing for a blood meal. These sporozoites rapidly reach the liver, where inside 
hepatocytes they develop into thousands of merozoites within 2 to 16 days, 
depending on the Plasmodium species [reviewed in (Prudêncio et al., 2006)]. When 
released into the blood stream each merozoite rapidly invades an erythrocyte, thus 
initiating the erythrocytic stage of infection, responsible for all the malaria symptoms 
and associated pathology. Although clinically silent, the pre-erythrocytic stage is 
critical for malaria infection establishment and constitutes an ideal target for potential 
anti-malarial vaccines or prophylactic treatments [reviewed in (Cunha-Rodrigues et 
al., 2006)]. However, the host factors that constitute an adequate environment for 
sporozoite development within hepatocytes remain largely unknown and 
consequently their identification along with the underlying molecular mechanisms in 
which they participate are extremely important. With the aim of identifying such 
factors, we have used an established in vitro malaria model, infection of mouse 
hepatoma Hepa1-6 cells with P. berghei sporozoites (Mota and Rodriguez, 2000), to 
identify host factors involved in Plasmodium-host cell interactions. Initially, a genome-
wide microarray technology was employed to define the temporal host cell 
transcriptional response to Plasmodium sporozoite infection. The transcriptome of 
infected cells was compared with that of non-infected cells using Affymetrix 
oligonucleotide chips. 
Plasmodium sporozoite infection in vitro is characterized by a very low efficiency, with 
an average of only 2.7 ± 0.7 % infected cells (n=8) in our chosen model. Therefore, P. 
berghei sporozoites expressing Green Fluorescent Protein (GFP) (Franke-Fayard et al., 
2004) during all stages of parasite development (including the stages within 
hepatocytes) were used in cell infection and the GFP-positive (GFP+) population, i.e. 
Plasmodium infected cells, were isolated from the total cell population by Fluorescence 
Activated Cell Sorting (FACS). In order to obtain an overview of the host cell response 
to parasite development until it reaches a fully replicating schizont, infected samples 
were collected at four different time points post-infection (p.i.), namely 6 h (early 
infection), 12 h (intermediate development), 18 h (early parasite replication) and 24 h 
(late parasite replication and differentiation). In vitro Hepa1-6 infection with GFP-
expressing P. berghei always yielded infection levels lower than 4% and the proportion 
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of infected cells decreased throughout the infection period (Figure 1a, b), which can 
be explained by the fact that infected cells might not cope with parasite development 
and/or by cell proliferation through time and, therefore, dilution of the infected cell 
population. After selection by FACS, the infected cell population adhered 
successfully, did not show any morphological defect and was able to support parasite 
development (Figure 1c). In parallel, control non-infected samples were prepared by 
incubating cells with salivary glands material obtained from uninfected mosquitoes.  
For each selected time point, two replicate samples were analyzed in two independent 
experiments. RNA obtained from an average of 7x104 cells per sample was processed 
to obtain labeled cRNA, which was then hybridized to the oligonucleotide GeneChip® 
Mouse Genome 430 2.0 Array (Affymetrix), which represents the whole mouse 
transcriptome. Comparison between non-infected and infected samples was carried 
out using a Fold Change (FC) ratio threshold of 1.4 (putative up-regulation or down-
regulation). To exclude false positives due to cross-hybridization of parasite RNA 
with the mouse probes, P. berghei sporozoites were cultured axenically (without 
intracellular residence in host hepatocytes) (Kaiser et al., 2003) and samples were 
collected at the same time points as those used when the parasites were incubated 
with cells. cRNA from axenic cultures of P. berghei sporozoites was pooled and 
hybridized with the same GeneChip type used for the cell samples. No match was 
found between the genes differentially expressed in the array incubated with P. 
berghei infected cells and the genes expressed in the array incubated with parasite 
cRNA, indicating that the parasite RNA did not interfere with the mouse expression 
profiles obtained in the infected samples. 
The comparison of the transcriptome of infected cells with that of non-infected cells at 
the four time points post-infection assessed in this study, reveals a total of 611 genes 
differentially expressed during infection of Hepa1-6 cells by GFP-expressing P. berghei 
sporozoites (Figure 2a and Supplementary Table 1a,b). A hierarchical clustering 
analysis shows a clear segregation between non-infected (n=8) and infected cell 
samples (n=8) (Figure 2a). These results suggest that Plasmodium parasites induce host 
cell responses during their development within the host cell. Interestingly, we find 
that the number of differentially expressed host genes decreases, from 330 at 6h to 115 
at 24 hours post-infection (Figure 2b). This suggests that the initial invasion of 
hepatocytes by Plasmodium leads to more profound changes in the host cell gene 
expression than the subsequent intracellular parasite development occurring within 
the study’s timeframe. Indeed, these early effects may reflect host cell responses to the 
known traversal of sporozoites through several hepatocytes, which precedes the final 
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productive infection event (Mota et al., 2001; Frevert et al., 2005) and leads to changes 
at the microenvironment level (Carrolo et al., 2003). 
In order to determine which of these host cell changes modulate the infection process, 
we sought to manipulate the expression levels of a selection of these genes prior to 
and during infection. To this end, we used RNA interference (RNAi) to silence the 
expression of 50 genes deemed of highest priority based on our transcriptional 
profiling results. Of these, 46 genes were among those differentially expressed during 
infection (a FC ratio threshold of 1.2 was applied) (Figure 2c and Supplementary 
Table 2). Moreover, 4 additional genes were chosen based on gene network analysis 
with the Ingenuity Pathway Software (Ingenuity Systems, USA; www.ingenuity.com). 
This software was used to perform a dynamic computational analyses of the 
microarray results in terms of gene networks formed by the genes differentially 
expressed throughout infection and also other associated genes, for which molecular 
interaction information was obtained from the Ingenuity Pathway Knowledge Base. 
The biological networks included information such as the gene molecular interactions, 
functions and pathways and revealed recurrent genes that, although not differentially 
expressed during infection, are tightly associated to the later (Supplementary Figure 
1a-d and Supplementary Table 3). These genes, referred to as “central genes”, are 
mostly kinases or transcription factors, which are regulated at the phosphorilation 
level and therefore did not appear as modulated at the transcriptional level.     
Each of the 50 selected genes was targeted with three different small interfering RNAs 
(siRNAs) individually and in triplicate samples, following the experimental workflow 
summarized in Figure 3a. Briefly, each siRNA was transfected into Hepa1-6 cells 
which were seeded 24 hours earlier in 96-well plates. Forty-eight hours later cells 
were infected with P. berghei sporozoites freshly extracted from the salivary glands of 
Anopheles stephensi mosquitoes. Infected samples were fixed 24 hours after sporozoite 
addition, immuno-stained for nuclear DNA, host cell actin and Plasmodium EEF-
specific antigen. Infection rates were then quantified with fluorescence microscopy 
and automated image analysis. Basically, the number of stained EEFs that developed 
inside Hepa1-6 cells was determined and normalized to the cell confluency, 
quantified through the host cell actin staining, to account for potential differences in 
the total cell surface available for infection in each well. As controls, untransfected 
samples and cells transfected with a negative control siRNA not targeting any 
annotated genes in the mouse genome were used. In order to compare the data 
between the different experimental plates the infection rate in each experimental well 
was calculated as a percentage of the negative control infection rate, which was 
considered as 100%. To account for cell proliferation or toxicity effects, the infection 
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data obtained through the described analysis was plotted against the number of cell 
nuclei in the same experimental well, calculated as a percentage of the average 
number of nuclei within each experimental plate. 
The first screening pass includes data from two independent runs for all the tested 
siRNAs. The genes for which treatment with at least one siRNA yielded a statistically 
significant infection rate increase or decrease greater or smaller than one standard 
deviation (s.d.) of the average of all the experimental sample data were selected to 
undergo a second confirmation pass (Figure 3b). A total of 11 out of the 50 initial 
genes, corresponding to 22% of the screened genes, were chosen for the second 
screening pass (Figure 3b and Supplementary Table 4 and 7). From these 11 genes 
there are: (i) two genes, Fos and c-Myc, for which two distinct siRNAs lead to an 
increase and decrease in infection, respectively; (ii) six genes, Atf3, Bst1, Cebpb, Kif5c, 
Slc7a11 and Zbtb20, for which one siRNAs leads to an increase and (iii) three genes, 
A130090K04RIK, Ldlr and Src, for which one siRNA leads to a decrease in infection 
rate (see Supplementary Table 4 and 7). In this confirmation round each gene was re-
assayed with a set of three independent siRNAs, i.e., the siRNAs from the first 
screening pass were re-assayed and one or two additional siRNAs, depending on the 
gene, were designed and included in the experiment (Figure 3c). The experimental 
procedure and data analysis performed in the second screening pass was the same as 
the one used in the first screening pass, already described above. To ensure that the 
observed infection phenotype is due to the siRNA specific-gene silencing and not to 
siRNA sequence-dependent off-target effects [see (Echeverri and Perrimon, 2006)] in 
this second pass only the genes for which at least two distinct siRNAs reproducibly 
yield the same Plasmodium infection outcome were considered as candidate genes. 
Two genes, Atf3 and c-Myc yielded a statistically significant (P < 0.05) infection 
phenotype with two distinct siRNAs (Figure 3c and Supplementary Table 5 and 7). 
These genes underwent a final confirmation pass in which the levels of specific-gene 
silencing were determined in parallel with the infection phenotype. Briefly, as 
described previously, siRNAs were transfected individually into Hepa1-6 cells and, 
48h later, cells were either infected with P. berghei sporozoites or lysed for quantitative 
RT-PCR (qRT-PCR) analysis of the target mRNA remaining level at the time of 
sporozoite addition. Analysis of the infection phenotype plotted against cell nuclei 
revealed an effect on the infection outcome greater or smaller than 1 s.d. of the 
untreated and negative control samples for both genes with at least two distinct 
siRNAs (Figure 4a). Actually, Atf3 silencing with all the six siRNAs tested led to a 
statistically significant (P < 0,05) increase in infection which correlated well with Atf3 
mRNA remaining levels (Figure 4b and Supplementary Table 6 and 7). On the other 
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hand, c-Myc silencing effect at the time of infection was only statistically significant 
with two out of the four independent siRNAs tested (Figure 4b and Supplementary 
Table 6 and 7).  
The combination of the microarray and RNAi approaches allowed the identification 
of two host genes Atf3 and c-Myc, which likely play a role during infection of host 
hepatocytes by Plasmodium. Nevertheless, it should not be disregarded that from all 
the genes differentially expressed throughout infection only about of 8% were 
selected to undergo a functional confirmation by RNAi and, moreover, the present 
RNAi screen data does not completely rule out the possible involvement of other 
genes among those tested since negative results in RNAi screens are generally 
inconclusive [see (Echeverri et al., 2006)]. Therefore, future follow-up studies will be 
extremely valuable to elucidate the potential participation of other host genes and 
also to characterize the function(s) of the two genes already implicated in Plasmodium 
infection in the present study.  
The c-Myc protein, encoded by the myelocytomatosis oncogene, is a basic region 
helix–loop–helix leucine zipper transcription factor and is involved in the regulation 
of cellular proliferation, apoptosis and cell growth [reviewed in (Dang, 1999; Levens, 
2002)]. In particular, c-Myc was shown to regulate the size and ploidy of hepatocytes, 
being involved in liver regeneration (Baena et al., 2005). c-Myc expression promotes 
the transition from G0/G1 to S phase of the cell cycle in multiple cell types, including 
hepatocytes, by regulating cyclin/cyclin-dependent kinase complexes (Obaya et al., 
1999) while the absence of sufficient c-Myc turns hepatocytes susceptible to TNF-
induced apoptosis and necrosis (Liu et al., 2000).  
In the present work we observed that, although not differentially expressed 
throughout Plasmodium infection, this gene appeared as a central gene in the 
microarray analysis and, moreover, when silenced by RNAi a decrease in infection 
was observed. Therefore, c-Myc seems to play a role in Plasmodium infection which 
might be associated with c-Myc regulation of apoptosis since it has been showed that 
an active inhibition of apoptosis in host cell during infection by Plasmodium is 
required for a successful infection (Leirião et al., 2005; van de Sand et al., 2005). In 
addition, since c-Myc is a transcription factor, it is possible that this modulates 
other(s) target and/or modulator gene(s) that mediate(s) the host cell response to 
Plasmodium infection. In fact, recently several studies have revealed that candidate c-
Myc target genes fall into a broad spectrum of diverse functional categories, ranging 
from metabolic enzymes, biosynthesis of macromolecules such as RNA, protein and 
DNA, transcription, and cell signaling (Menssen and Hermeking, 2002; O'Connell et 
al., 2003; Remondini et al., 2005). Therefore, it is possible that c-Myc role in Plasmodium 
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infection is related with the latter pathways, a possibility that remains to be 
elucidated.  
The activating transcription factor 3 gene (Atf3) encodes a member of the ATF/CREB 
(cAMP-response-element-binding protein) family of basic region leucine zipper 
transcription factors. Atf3 can act as a transcriptional repressor or activator depending 
on whether it forms homodimers with Atf3 or heterodimers with other proteins, such 
as c-Jun, Atf2, JunB, and gadd153/CHOP10 [reviewed in (Hai and Hartman, 2001)]. 
Atf3 is a stress-inducible transcription factor, expressed at low levels in quiescent cells 
and rapidly and highly induced in different cell types by multiple and diverse 
extracellular signals, such as mitogens (serum, epidermal growth factor and 
hepatocyte growth factor) (Weir et al., 1994; Allan et al., 2001), cytokines (interferon-γ 
and interleukin-4) (Drysdale et al., 1996) and genotoxic agents (ionizing radiation and 
UV light) [reviewed in (Hai et al., 1999)].  
The early stress response, important for the maintenance of cell homoeostasis under 
adverse conditions, activates cascades of phosphorylation events. These, in many 
cases, increase the expression of the immediate early genes that encode transcription 
factors, which regulate downstream genes and initiate a network of transcriptional 
regulation. Atf3 has already been involved in diverse cellular functions, i.e., stress 
response, regulation of the cell cycle and apoptosis (Hartman et al., 2004; Yan et al., 
2005; Lu et al., 2006; Lu et al., 2007). Moreover, Atf3 has been shown to be regulated 
upon diverse microbe infections [reviewed in (Jenner and Young, 2005)]. In fact an 
Atf3 increase was observed in response to bacteria and viral infections, such as spiral 
Helicobacter pylori (Liu et al., 2006), hepatitis B virus (Tarn et al., 1999) and adenovirus 
(Zhao et al., 2003; Granberg et al., 2006). 
The microarray data presented here (see Figure 2c and Supplementary Table 2) also 
shows an increase in Atf3 in response to hepatocyte infection by Plasmodium. 
Moreover, although Atf3 increase is observed throughout all the infection time points 
accessed, the highest expression level occurs in the earliest infection time point 
assessed, namely at 6h post-infection. This is in agreement with the kinetics of Atf3 
induction being immediate and transient [reviewed in (Hai and Hartman, 2001)]. The 
early and transient nature of Atf3 induction suggests the existence of a mechanism 
that turns off Atf3 gene expression after its induction, and in fact, Atf3 itself can 
repress the activity of its own promoter (Wolfgang et al., 2000).  
The functional genomics data from the RNAi screen reveals atf3 as a promising gene 
candidate to have a role in Plasmodium infection since a statistically significant 
increase on infection was observed with treatment with 6 distinct siRNAs in the third 
confirmation pass. In order to determine the physiological relevance of the in vitro 
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results for Atf3, BALB/c mice were infected with different amounts of Plasmodium 
sporozoites (2x104 or 10x104) and the Atf3 mRNA levels, quantified by qRT-PCR at 
different time points post-infection, were compared to the levels present in non-
infected mice (Figure 4c and Supplementary Figure 2). Atf3 mRNA level was found to 
be upregulated 5 h after sporozoite infection, which is in agreement with the 
microarray data since it was in the 6 h time point post-infection that Atf3 was found 
to be more up-regulated (see Supplementary Table 2).  
Furthermore, Plasmodium in vivo infection was accessed in Atf3 deficient mice. 
Basically, Atf3 deficient mice were infected with 2x104 P. berghei sporozoites and the 
liver infection load was compared with that of wild-type littermate mice (Figure 4d). 
Forty-hours post-infection, i.e., immediately prior to parasite passage into the blood 
stream, livers were dissected and the infection load was determined by qRT-PCR. The 
results show that infection is higher in Atf3 deficient mice and are in agreement with 
those of the RNAi functional screen whilst lending further support to the notion that 
the absence of Atf3 leads to a significant increase of liver infection by P. berghei. All 
the data taken together suggest that hepatocytes may respond to P. berghei infection 
by increasing expression of Atf3, which, in turn, plays a role in countering infection. 
Therefore, the results yielded by the in vitro approach employed in this study are of 
significance to Plasmodium berghei in vivo infection.  
In conclusion, the genomics approach employed to identify host molecules that may 
play relevant roles during the liver stage of malaria unequivocally showed that at 
least 2 host cell factors, c-Myc and Atf3, play a relevant role during Plasmodium 
infection of hepatocytes, which can readily be rendered rate-limiting even with partial 
RNAi-induced gene expression silencing. The fact that the two host cell factors 
identified in the present study are transcription factors is consistent with the notion 
that the primary response to the stress induced by the intracellular parasite must 
include the activation of transcription factors which will subsequently control the 
second wave of the host cell response. Moreover, several microarray studies 
demonstrate that the genes regulated by diverse microbe infections converge towards 
a common set of alert genes, from which Atf3 identified here as important for 
Plasmodium liver stage infection belongs to [reviewed in (Jenner and Young, 2005)]. 
The study of the mechanism(s) by which these host molecules, c-Myc and Atf3, 
modulate Plasmodium infection of hepatocytes will be of considerable interest since 
this knowledge might shed light into the host cell response not only to Plasmodium  
but also other microorganisms infections.   
Previous genomic studies on malaria pre-erythrocytic stage have focused exclusively 
on the parasite (Kappe et al., 2001; Le Roch et al., 2003; Kaiser et al., 2004; Le Roch et al., 
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2004; Wang et al., 2004; Sacci et al., 2005). The present study constitutes, to our 
knowledge, the first genomic study aimed at identifying the host liver molecules that 
influence infection by Plasmodium through the use of microarray and/or RNAi 
technologies. Moreover, the success of this initial targeted application of RNAi 
technology suggests that larger scale and more systematic approaches hold an 
enormous potential for further advances in the malaria liver stage field. 
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Methods 
 
Cells and parasites 
Hepa1-6 (murine hepatoma cell line) cells were cultured in Dulbecco’s MEM medium 
(DMEM) supplemented with 10% fetal calf serum (FCS, Gibco/Invitrogen), 1% 
penicillin/streptomycin (pen/strep, Gibco/Invitrogen) and 1 mM glutamine 
(Gibco/Invitrogen) and maintained at 37 °C with 5% CO2. Cells were routinely 
screened and found to be negative for mycoplasma.  
Green fluorescent protein (GFP) expressing Plasmodium berghei (parasite line 259cl2) 
sporozoites (Franke-Fayard et al., 2004) were obtained from dissection of infected 
female Anopheles stephensi mosquito salivary glands. 
 
Sample preparation and collection for microarrays  
Hepa1-6 cells were seeded (2x105 cells per well) in 24-well plates twenty-four hours 
before infection. At the infection time the cell confluency was approximately of 80% 
and 2x105 GFP-expressing P. berghei sporozoites were added per well (referred to as 
infected samples). Salivary glands from non-infected mosquitoes were extracted and 
the same volume of the extraction solution was added to control samples (referred to 
as non-infected samples). All plates were then spun down at 1800xg for 7 min and 
incubated at 37°C with 5% CO2.  
Infected samples were collected at 6, 12, 18 and 24 hours after sporozoite addition and 
fluorescence activated cell-sorting (FACS) was used to select and collect infected cells 
among the total cell population within each well. Briefly, cells were collected using 
Trypsin (Gibco), washed with 10% FCS in PBS and resuspended in 2% FCS in PBS. 
Infected hepatocytes were separated from non-infected cells using the high speed cell 
sorter Dako-Cytomation (Mo-Flo MLS, 1999). Only infected samples with 
approximately 90% purity (confirmed in the FACSCalibur 4 Color Analyser; Becton 
Dickinson, FACSCalibur, 1998) were selected. Two replicates from independent 
experiments were prepared and for further processing, only replicates with similar 
infection and parasite development rates were used. In parallel non-infected samples 
were collected at the same time points and passed through the cell sorter.  
Sorted cells were collected in cell lysis buffer (RLT, Qiagen) and total RNA was 
extracted with the Rneasy Micro Kit (Qiagen), according to the manufacturer’s 
instructions. RNA concentration and quality of all replicates was evaluated with the 
NanoDrop ND-1000 UV-Vis Spectrophotometer (NanoDrop Technologies) and 
Bioanalyser 2100 (Agilent). The extracted RNA was used as template to synthesize 
double-stranded cDNA and processed for usage on Affymetrix GeneChip® Mouse 
 62 
Results 
Genome 430 2.0 Array, according to the manufacturer’s small sample labeling 
protocol version II. Data were filtered to include only those spots for which the ratio 
of Fold Change (FC) was ≥ 1.4 (putative up-regulation or down-regulation) in at least 
one time point post-infection but in both replicates for each time point. For P. berghei 
cross-hybridization RNA control experiments, P. berghei sporozoites were cultivated 
as previously described (Kaiser et al., 2003), and collected 6, 12, 18 and 24 hours post-
incubation. Total parasite RNA was pooled and further sample processing was 
performed as described above.  
 
Microarray replicates infection quantification  
Replicate infection and parasite development data were obtained at the same time 
points by processing parallel infected samples for immunofluorescence. Briefly, cells 
were washed with PBS, fixed with 4% paraformaldehyde (PFA) and permeabilized 
with 0.1% saponin in blocking solution (3% bovine serum albumin, 100mM glycine 
and 10% FCS). Exoerythrocytic forms (EEFs) were detected using the mouse 
monoclonal antibody 2E6 against the parasite heat shock protein 70 (Hsp70) (Tsuji et 
al., 1994) and an AlexaFluor555 labeled goat anti-mouse secondary antibody 
(Molecular Probes/Invitrogen). Cell nuclei were stained with 4'6-diamidino-2-
phenylindole (DAPI, Sigma) and host cell actin with AlexaFluor488 Phalloidin 
(Molecular Probes/Invitrogen). Infection was assessed by manual quantification of 
the number of EEFs per sample.  
 
Microarrays accession codes 
The array data files are available online on http://www.ebi.ac.uk/arrayexpress/ 
under the accession number E-MEXP-667. 
 
siRNA design, siRNA library and screening controls 
All siRNAs were purchased from Ambion’s Silencer genome wide library 
(Ambion/Applied Biosystems, Austin USA). The siRNA library screened included a 
total of 50 genes selected from the microarray study analysis. Each gene was initially 
targeted with 3 distinct siRNAs used individually in all cases and in the following 
confirmation steps more siRNAs per gene were tested. Each siRNA was transfected in 
triplicate. Negative control samples included untransfected cells and cells transfected 
with a negative control siRNA not targeting any annotated genes in the human 
genome. A full list of gene names and siRNA ID numbers are shown in 
Supplementary Table 7. 
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High-throughput siRNA screening of Plasmodium infection 
Hepa1-6 cells (4,5x103 per well) were seeded in 100 µl of complete DMEM medium in 
optical 96-well plates (Costar) and incubated at 37°C and 5% CO2. Twenty-four hours 
later, growth medium in each well was replaced by 80 μl of serum-free medium and 
cells were transfected with 1 μl of 10 μM siRNA diluted in 16 μl of Opti-Mem 
(Invitrogen) complexed with 0.4 μl Oligofectamine (Invitrogen) diluted in 2.6 μl 
OptiMem. Transfection was performed following the recommended manufacturer 
instructions. Four hours after cell transfection, 50 μl of fresh DMEM medium 
supplemented with 30% FCS, 3% pen/strep and 3% glutamine were added to the 
cells. Two days later, cells were infected with 20x105 P. berghei sporozoites per well. 
Twenty-four hours after infection, cells were fixed with 4% PFA in PBS and 
permeabilized with 0.2% saponin in PBS. Cell nuclei and actin were stained with 
Hoeschst-33342 (Molecular Probes/Invitrogen) and Phalloidin AlexaFluor 488 
(Molecular Probes/Invitrogen), respectively. EEFs were detected with the mouse 
monoclonal 2E6 antibody (Tsuji et al., 1994) and an AlexaFluor555 goat anti-mouse 
secondary antibody (Molecular Probes/Invitrogen). 
 
Automated image acquisition and analysis 
Images were acquired with a Discovery1 automated fluorescence microscope 
(Molecular Devices Corporation, CA, USA) using a 10x lens. In each well, cell nuclei, 
actin and EEFs were imaged in 9 fields covering a total area of 2.7 x 2.0 mm. Image 
data was analyzed using a custom MetaMorph (Molecular Devices Corporation, CA, 
USA) based algorithm extracting the following values for each imaged field: cell 
proliferation as measured by the number of nuclei per imaged field (Hoechst 
staining), cell confluency as measured by the percentage of the imaged field covered 
by actin staining and number of EEFs as number of compact, high contrast objects in a 
size range from 16 to 150 pixels. Within each field, the number of EEFs was 
normalized to the cell confluency. Normalized EEF numbers and number of nuclei 
were averaged between the 9 imaged fields within each well. Mean and standard 
deviations were calculated for each experimental triplicate. Final readouts included 
number of EEFs shown as a percentage of the negative control and number of nuclei 
as a percentage of the plate mean.  
 
Gene-specific expression and infection quantification by qRT-PCR 
For gene-specific expression in vitro, total RNA was isolated from Hepa1-6 cells 48 h 
after cell transfection (Invitek Invisorb 96-well plate kit) and converted into cDNA 
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(ABI’s HighCapacity cDNA reagents) with random hexamers, following the 
manufacturer recommendations. qRT-PCR used the SybrGreen method with 
Quantace qPCR mastermix at 11 μl total reaction volume, containing 500 nM of the 
target-specific primers, and primers that were designed to specifically target the 
selected genes. Real-time PCR reactions were performed on an ABI Prism 7900HT 
system. Relative amounts of remaining mRNA levels of RNAi targets were calculated 
against the level of the housekeeping gene 18S rRNA. Remaining mRNA levels of 
RNAi-treated samples were compared with those of samples transfected with 
Negative siRNA, which were considered as 100% expression of the specific gene 
under study. 18S rRNA-specific primer sequences were: 5’- CGG CTT AAT TTG ACT 
CAA CAC G -3’ and 5’- TTA GCA TGC CAG AGT CTC GTT C -3’. 
The determination of liver parasite load in vivo, was performed according to the 
method developed for P. yoelii infections (Bruna-Romero et al., 2001). Livers were 
collected and homogenized in denaturing solution (4 M guanidine thiocyanate; 25 
mM sodium citrate pH 7, 0.5 % sarcosyl and 0.7 % β-Mercaptoethanol in DEPC-
treated water), at different time points after sporozoite injection depending on the 
experiment. Total RNA was extracted using Qiagen’s RNeasy Mini kit, following the 
manufacturer’s instructions. RNA for infection measurements was converted into 
cDNA using Roche’s Transcriptor First Strand cDNA Synthesis kit, according to the 
manufacturer’s protocol. The qRT-PCR reactions used Applied Biosystems’ Power 
SYBR Green PCR Master Mix and were performed according to the maunufacturer’s 
instructions on an ABI Prism 7000 system (Applied Biosystems). Amplification 
reactions were carried out in a total reaction volume of 25 µl, containing 0,8 
pmoles/µl or 0,16 pmoles/µl  of the Atf3-, PbA- or housekeeping gene-specific 
primers, respectively. Relative amounts of Atf3 and PbA mRNA were calculated 
against the Hypoxanthine Guanine Phosphoribosyltransferase (HPRT) housekeeping 
gene. Atf3-specific primer sequences were 5’- CCA GGT CTC TGC CTC AGA AG -3’ 
and 5’- TCC AGG GGT CTG TTG TTG AC -3’. For PbA 18S the primers used were 5’- 
AAG CAT TAA ATA AAG CGA ATA CAT CCT TAC -3’ and 5’- GGA GAT TGG TTT 
TGA CGT TTA TGT G -3’. For HPRT the specific primer sequences were 5’- TGC TCG 
AGA TGT GAT GAA GG -3´ and 5’- TCC CCT GTT GAC TGG TCA TT -3’, 
respectively. 
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Plasmodium berghei in vivo infection  
BALB/c mice were bred and housed in the pathogen-free facilities of the Instituto 
Gulbenkian de Ciência and Instituto de Medicina Molecular, respectively. All 
protocols were approved by the Animal Care Committee of both Institutes.  
BALB/c mice (male, 6-8 weeks) were infected with 2 or 10 × 104 P. berghei sporozoites 
by intra-venous (i.v.) injection. At different time points post-infection, namely 5, 10, 20 
and 40 h after sporozoite injection, the Atf3 mRNA level (determined by qRT-PCR) 
was compared to the level in non-infected mice (considered as 100%).  
Atf3 knock-out mice and wild-type littermates (male, 6-8 weeks) were infected i.v. 
with 2 × 104 P. berghei sporozoites and PbA infection level, determined 40 h after 
sporozoite injection by qRT-PCR, was compared between the two experimental 
groups. 
 
Statistical analysis 
Statistical analysis was performed using unpaired Student t or ANOVA parametric 
tests. P < 0.05 was considered significant. 
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Figure 1 | Isolation of GFP-expressing P. berghei
 
infected cells using FACS at 
different time points post-infection (p.i.). 
(a) Pre-sorting fluorescence images of infected cell populations (top panels, bar = 60 
μm) or isolated infected cells (bottom panels, bar = 10 μm) at the 6, 12, 18 and 24 h 
p.i.. Nuclei labeled by DAPI (in blue), host cell actin by Phalloidin
 
(in red) and P. 
berghei EEFs by anti-PbHSP70 antibody (in green).
 
(b) FACS plot of sorting 
experiments performed at the respective time point’s p.i. with the selected infected-
 
population and their correspondent infection level (GFP+ population gated and 
highlighted in green). Infection level for each time point was determined as the 
average ±
 
s.d. from 3 or more independent samples.
 
(c) Post-sorting imaging of 
infected cells at the different time points p.i.. Infected cells are shown with green 
EEFs inside (transmitted light and fluorescence pictures merged,
 
bar = 60 μm).
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Figure 2 | Microarray analysis identifies host genes differentially expressed 
throughout P. berghei
 
infection of Hepa1-6 cells. 
(a) Heat map and cluster analysis of genes differentially expressed in P. berghei
 
infected Hepa1-6 cells at different time points p.i. (6, 12, 18 and 24h p.i.) compared to 
non-infected samples. Gene and sample clustering branches are represented on the 
left and top of the map, respectively. Gene expression values vary within the [-3 to 3] 
scale with -3 corresponding to the brighter green (lower expression level), zero to 
black (median expression level) and 3 to the brighter red (higher expression level).
 
(b) Venn diagram representing the distribution of host differential gene expression 
between and at distinct time points post-infection. Each area is proportional to the 
number of genes represented and the darker areas represent the common genes 
between the respective time points.
 
(c) Expression profile of the selected 46 genes 
differentially expressed in P. berghei infected Hepa1-6 cells when compared to non-
 
infected cells at the different p.i. time points. Gene expression values above or below 
a Fold Change of 1.2 are represented by the [-3 to 10] scale with -3 corresponding to 
the brighter green (lower expression level), zero to black (median expression level) 
and 10 to the brighter red (higher expression level). 
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Figure 3 | RNAi screens validate the functional relevance of host genes that
 
 
influence P. berghei
 
sporozoite infection of Hepa1-6 cells. 
(a) Schematic representation of the RNAi screen experimental workflow used to 
identify host factors that influence P. berghei
 
sporozoite infection of Hepa1-6 cells 
among those selected from the microarray study. Each siRNA
 
was used to transfect 
Hepa1-6 cells seeded 24 h earlier in 96-well plates. Fourty-eight h after transfection, 
cells were infected with 2x104 P. berghei
 
sporozoites and 24 h p.i. the number of 
Plasmodium
 
EEFs, cell nuclei and confluency
 
were determined. The candidate genes 
underwent three screening passes.
 
(b) Plot of two independent runs of the first pass 
of the RNAi screen representing the effect of 150 siRNAs targeting 50 mouse genes 
on Hepa1-6 cell infection by P. berghei
 
sporozoites and cell nuclei count. Infection 
rates for each experimental condition were normalized against cell confluency
 
and 
calculated as a percentage of the infection rate of the negative
 
control. The horizontal 
lines represent 100% ±
 
1.0 s.d. of the average of all data in the assay. Each circle 
represents one siRNA
 
(mean of triplicate values). Negative controls appear as blue 
and green circles, corresponding to untreated cells and cells transfected
 
with a non-
 
specific control siRNA, respectively. Red circles highlight the siRNAs targeting the 
11 candidate genes selected to undergo a second screening pass.
 
(c) Plot of two 
independent runs of the second pass of the RNAi screen representing the effect of 33 
siRNAs targeting a total of 11 genes on Hepa1-6 cells infection by P. berghei
 
sporozoites and cell nuclei count. Experimental conditions, normalization criteria as 
well as colour
 
attributions are the same as in panel
 
(b),
 
with red circles representing 
the siRNAs targeting the 2 genes selected to undergo a third screening pass. The 
horizontal lines represent 100% ±
 
1.0 s.d. of the average of the average of all data in 
the assay. 
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Figure 4 | Atf3 and c-Myc
 
host genes influence P. berghei
 
sporozoite infection. 
(a) Plot of the third pass of the RNAi screen representing the effect of 10 siRNAs 
targeting 2 mouse genes on Hepa1-6 cell infection by P. berghei
 
sporozoites and cell 
nuclei count. The horizontal lines represent 100% ±
 
1.0 s.d. of the average of all the 
negative controls in the assay. Each circle represents one siRNA
 
(mean of triplicate 
values). Untreated controls appear as blue circles and negative controls as green 
circles. Atf3 silencing leads to an increase in infection with all the 6 distinct siRNAs 
tested (in red) while for c-Myc
 
(4 siRNAs used, all in grey) a decrease in infection is 
only observed with 2 siRNAs (in darker grey).
 
(b) Effect of each siRNA
 
on infection 
rate versus
 
the remaining mRNA level for the specific gene determined in the third 
pass RNAi screen. Colour attributions are the same as in (a). Each circle represents 
one siRNA
 
(mean of triplicate values).
 
(c) Atf3 mRNA level in P. berghei in vivo 
infections. BALB/c mice were infected with 2x104
 
P. berghei
 
sporozoites and the Atf3 
mRNA level was determined by qRT-PCR at different time points, namely 5, 10, 20 
and 40h p.i. (3 mice per experimental group). An increase on the Atf3 mRNA level is 
observed 5h after sporozoite injection when comparing to non-infected control mice 
(NI).
 
(d) P. berghei in vivo infection in Atf3 knock-out (Atf3-/-
 
or KO) and wild-type 
(WT) mice. Liver infection load in the two experimental groups (each with 5 mice) 
was determined 40 h after sporozoite i.v. injection (2x104) by qRT-PCR. Atf3 KO mice 
showed an increase in P. berghei infection when compared to that of WT mice.
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Supplementary Figure 1 | Microarray data analysis with Ingenuity
 
Pathway 
Software revealed recurrent genes that were included in the RNAi
 
screen.
(a-d) Microarray analysis of the genes differentially expressed throughout
 
 
Plasmodium-hepatocyte infection (6, 12, 18 and 24 h p.i.) in terms of gene networks 
with the Ingenuity Pathway Software. Representative gene networks for the
 
recurrent genes, that although not modulated during infection, were selected to be 
studied in the RNAi screen due to their frequent appearance in gene networks 
constituted by the genes differentially expressed. The latter are represented by
 
 
symbols filled in red/pink if up-regulated, green in down-regulated and in yellow if 
modulated in more than one infection time point whereas the recurrent genes, i.e., 
Fos, c-Myc, Tnf
 
and Src
 
are respectively highlighted by orange, red, blue and green 
boxes.
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Supplementary Figure 2 | Atf3 mRNA level
 
is up-regulated 5 h after Plasmodium 
berghei
 
sporozoite infection in vivo. 
BALB/c mice were infected with 10x104
 
P. berghei
 
sporozoites and the Atf3 mRNA 
level was determined by qRT-PCR at different time points, namely 5, 10, 20 and 40h 
p.i. (3 mice per experimental group). An increase on the Atf3 mRNA level is 
observed 5h after sporozoite injection when comparing to non-infected control mice 
(NI).
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Albuquerque et al. , Supplementary Table 1a
Gene information
Microarray Fold Change ratio at
different time points          
post-infection1
Gene Official Full Name Gene Official Symbol NCBI Gene Accession Number 6h 12h 18h 24h
chemokine (C-X-C motif) ligand 2 Cxcl2 20310 10,35 3,2 2,06 1,08
ChaC, cation transport regulator-like 1 (E. coli) Chac 1/ 1810008K03Rik 69065 8,88 4,44 2,32 2,27
chemokine (C-X-C motif) ligand 1 Cxcl1 14825 6,33 2,51 1,49 0,88
nuclear protein 1 Nupr1 56312 6,21 3,91 2,56 2,08
tribbles homolog 3 (Drosophila) Trib3 / Ifld2 228775 4,79 3,71 2,79 2,54
DNA-damage inducible transcript 3 Ddit3 13198 4,65 3,23 1,41 1,48
chemokine (C-C motif) ligand 2 Ccl2 20296 4,61 1,55 1,22 1,08
chemokine (C-X-C motif) ligand 5 Cxcl5 20311 3,93 1,72 -0,79 -0,96
1200016E24Rik RIKEN cDNA 1200016E24 gene 1200016E24Rik 319202 3,26 1,01 0,77 -0,6
solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 Slc7a2 11988 3,24 1,87 0,92 0,79
solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 Slc7a2 11988 3,17 1,77 0,69 0,87
growth arrest and DNA-damage-inducible 45 beta Gadd45b 17873 3,15 2,64 1,71 1,35
CCAAT/enhancer binding protein (C/EBP), delta Cebpd 12609 3,08 1,07 0,88 0,85
activating transcription factor 3 Atf3 11910 2,99 1,82 1,48 1,58
G protein-coupled receptor 137B Gpr137b 83924 2,99 3,76 3,19 1,73
vascular cell adhesion molecule 1 Vcam1 22329 2,93 -1,19 -0,99 -1,05
solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 Slc7a11 26570 2,9 2,01 2,12 1,46
Tnf receptor-associated factor 1 Traf1 22029 2,88 0,85 0,88 0,96
interleukin 1 receptor antagonist Il1rn 16181 2,87 3,2 1,66 0,96
chloride channel calcium activated 1 Clca1 12722 2,81 0,94 -0,67 -0,83
tumor necrosis factor, alpha-induced protein 2 Tnfaip2 21928 2,7 1,08 -0,79 -0,92
expressed sequence AI845619 AI845619 103846 2,66 1,83 1,37 1,28
carbonic anhydrase 2 Car2 12349 2,62 2,32 1,35 0,86
chloride channel calcium activated 1  /// Clca2 chloride channel calcium activated 2 Clca1 /// Clca2 12722 /// 80797 2,59 0,83 -0,42 -1,01
neuropilin 2 Nrp2 18187 2,55 2,2 1,43 1,31
ankyrin repeat and BTB (POZ) domain containing 2 Abtb2 99382 2,43 1,37 1,1 1
chemokine (C-X-C motif) ligand 16 Cxcl16 66102 2,39 1,6 1,01 1,37
myeloid differentiation primary response gene 116 Myd116 17872 2,3 3,46 1,71 1,52
caspase 4, apoptosis-related cysteine peptidase Casp4 12363 2,24 1,15 -1,03 0,87
G protein-coupled receptor, family C, group 5, member B Gprc5b 64297 2,24 0,6 -0,43 0,81
3110004L20Rik RIKEN cDNA 3110004L20 gene 3110004L20Rik 73102 2,21 1,33 1,2 0,98
macrophage activation 2 like [ Mpa2l 100702 2,17 -1,2 -0,88 -0,89
growth differentiation factor 15 Gdf15 23886 2,15 2,07 1,32 1,29
chemokine (C-X-C motif) ligand 10 Cxcl10 15945 2,14 -0,85 1,03 0,9
#probe design_01 2,09 1,44 1,41 1,16
a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 1 Adamts1 11504 2,08 1,55 0,86 1,09
interferon-related developmental regulator 1 Ifrd1 15982 2,05 1,46 0,93 1,02
BCL2-like 11 (apoptosis facilitator) Bcl2l11 12125 2,04 1,41 1,14 1,12
serine (or cysteine) peptidase inhibitor, clade B, member 2 Serpinb2 18788 2,03 1,16 0,64 -0,9
Nuclear receptor subfamily 4, group A, member 2 Nr4a2 18227 2,01 1,34 1,64 0,97
 
 Gene information
Microarray Fold Change ratio at
different time points          
post-infection1
Gene Official Full Name Gene Official Symbol NCBI Gene Accession Number 6h 12h 18h 24h
chemokine (C-C motif) ligand 20 Ccl20 20297 2 -0,88 -0,86 -1,09
#probe design_02 1,97 2,59 1,37 0,46
nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, beta Nfkbib 18036 1,97 1,41 1,06 1,11
solute carrier family 30 (zinc transporter), member 1 Slc30a1 22782 1,97 1,58 1,1 0,85
solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 Slc7a11 26570 1,97 2,37 1,7 1,27
2310005L22Rik RIKEN cDNA 2310005L22 gene 2310005L22Rik 69471 1,95 1,7 1,27 0,93
5430416N02Rik RIKEN cDNA 5430416N02 gene 5430416N02Rik 71426 1,95 1,92 1,02 0,84
methylenetetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cyclohydrolase Mthfd2 17768 1,94 1,57 1,37 1,1
#probe design_03 1,93 1,9 1,01 1
syndecan binding protein (syntenin) 2 Sdcbp2 228765 1,93 1,95 1,48 1,17
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 Herpud1 64209 1,91 1,16 -0,82 0,73
growth arrest and DNA-damage-inducible 45 gamma Gadd45g 23882 1,9 1,9 1,46 1,02
solute carrier family 20, member 1 Slc20a1 20515 1,9 1,72 1,09 1,37
integrin beta 6 Itgb6 16420 1,86 1,18 0,91 0,88
tumor necrosis factor, alpha-induced protein 3 Tnfaip3 21929 1,86 1,09 0,95 0,91
small nucleolar RNA, C/D box 22 Snord22 83673 1,83 1,73 0,87 1,11
solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 Slc11a2 18174 1,83 -0,92 -0,85 0,71
a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 4 Adamts4 240913 1,8 1,09 -0,9 0,86
Aars alanyl-tRNA synthetase Aars 234734 1,8 1,67 1,58 1,43
zinc finger, AN1-type domain 2A Zfand2a 100494 1,78 1,72 1,16 1,04
mannosidase 1, alpha Man1a 17155 1,77 1,2 -0,87 -0,87
metallothionein 2 Mt2 17750 1,77 2,95 1,31 1,15
apolipoprotein B editing complex 1 Apobec1 11810 1,74 1,28 1,04 -0,96
chloride channel calcium activated 4 Clca4 229927 1,74 1,61 -0,57 -0,54
A kinase (PRKA) anchor protein 2 Akap2 11641 1,73 1,2 1,22 1,12
activating transcription factor 4 Atf4 11911 1,73 1,78 1,23 0,92
B-cell leukemia/lymphoma 6 Bcl6 12053 1,71 1,12 1,02 0,88
SKI-like Skil 20482 1,71 1,62 1,05 0,93
solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 Slc7a5 20539 1,71 1,21 1,27 0,95
leukemia inhibitory factor Lif 16878 1,7 1,25 1,01 0,88
aldehyde dehydrogenase 18 family, member A1 Aldh18a1 56454 1,7 1,53 1,28 1,02
activating transcription factor 5 Atf5 107503 1,69 1,39 1,63 1,45
proviral integration site 1 Pim1 18712 1,69 1,13 1,28 0,79
activating transcription factor 2 Atf2 11909 1,68 1,06 -0,94 -0,83
#probe design_04 1,68 1,16 -0,53 0,94
RIKEN cDNA 2410187C16 gene 2410187C16Rik 76773 1,68 1,1 -0,82 -0,94
transformed mouse 3T3 cell double minute 2 Mdm2 17246 1,67 1,59 1,28 0,93
solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 Slc1a4 55963 1,66 1,01 1,27 0,96
RIKEN cDNA 2610034E01 gene 2610034E01Rik 69236 1,65 1,08 1,01 0,7
solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 Slc3a2 17254 1,65 1,82 1,17 1,28
fos-like antigen 1 Fosl1 14283 1,64 1,44 1,66 0,89
#probe design_05 1,64 0,72 0,96 0,99
 
 Gene information
Microarray Fold Change ratio at
different time points          
post-infection1
Gene Official Full Name Gene Official Symbol NCBI Gene Accession Number 6h 12h 18h 24h
expressed sequence AI597479 AI597479 98404 1,63 1,27 1,19 1,05
torsin family 3, member A Tor3a 30935 1,63 1,21 -0,88 1,02
#probe design_06 1,62 -0,93 -0,94 -1,07
F-box only protein 33 Fbxo33 70611 1,61 1,5 1,15 1,17
colony stimulating factor 1 (macrophage) Csf1 12977 1,61 1,03 1,35 0,84
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 Pfkfb3 170768 1,6 1,13 1,16 0,91
inhibitor of kappaB kinase epsilon Ikbke 56489 1,6 -0,87 -0,6 0,97
syntaxin 11 Stx11 74732 1,6 -0,86 -1,06 -1,11
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein K (avian) Mafk 17135 1,6 1,25 1,39 1,28
arrestin domain containing 4 Arrdc4 66412 1,59 1,29 1,22 1,01
CDC42 effector protein (Rho GTPase binding) 3 Cdc42ep3 260409 1,59 1,25 1,21 1,01
sequestosome 1 Sqstm1 18412 1,59 1,71 1,46 1,09
*cDNA sequence_01 1,58 1,54 1,05 -0,88
keratin associated protein 6-1 Krtap6-1 16700 1,58 -0,82 -1,07 -0,97
serine (or cysteine) peptidase inhibitor, clade B, member 9g Serpinb9g 93806 1,57 1,6 2,13 0,76
LON peptidase N-terminal domain and ring finger 1 similar to CG32369-PB, isoform B LOC631639 631639 1,57 1,45 1,1 1,19
purine rich element binding protein B Purb 19291 1,57 1,15 1,13 -0,82
schlafen 2 Slfn2 20556 1,57 0,95 1,09 0,94
transformation related protein 53 inducible nuclear protein 1 Trp53inp1 60599 1,57 1,35 1,69 0,93
#probe design_07 1,56 -0,86 -0,76 -1,12
Sequestosome 1 Sqstm1 18412 1,56 1,65 -0,7 1,24
RIKEN cDNA 2410018M08 gene 2410018M08Rik 71970 1,56 0,92 1,31 1,14
zinc fingers and homeoboxes protein 2 Zhx2 387609 1,56 0,89 0,91 1,1
phorbol-12-myristate-13-acetate-induced protein 1 Pmaip1 58801 1,55 1,31 1,45 0,56
zinc finger protein 423 zfp423 94187 1,55 1,47 1,39 0,83
poly (ADP-ribose) polymerase family, member 8 Parp8 52552 1,54 2,04 0,25 1,94
Rho family GTPase 1 Rnd1 223881 1,54 -1,01 0,91 0,78
melanoregulin Mreg 381269 1,54 1,37 1,26 0,68
leucine-rich repeat-containing 5 Lrrc8d 231549 1,53 1,24 1,22 1,04
solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 Slc7a1 11987 1,53 1,34 1,02 0,89
RIKEN cDNA 2700007P21 gene 2700007P21Rik 212772 1,52 1,24 1,15 0,94
TruB pseudouridine (psi) synthase homolog 2 (E. coli) Trub2 227682 1,52 1,09 1,14 0,99
zinc finger CCCH type containing 8 Zc3h8 57432 1,52 1,16 1,2 0,89
ADP-ribosylation factor related protein 1 Arfrp1 76688 1,51 1,11 1,24 0,99
colony stimulating factor 1 (macrophage) Csf1 12977 1,51 1,31 0,84 0,73
CCAAT/enhancer binding protein (C/EBP), beta Cebpb 12608 1,51 1,42 1,49 1,25
immediate early response 5 Ier5 15939 1,51 1,37 1,28 1,06
repetin Rptn 20129 1,51 -0,83 -0,69 -0,72
B-cell linker Blnk 17060 1,5 1,84 1,81 1,45
cDNA sequence BC010981 BC010981 407830 1,5 1,17 1,09 0,68
gene model 129, (NCBI) Gm129 229599 1,5 1,1 0,95 1
leucine-rich repeats and immunoglobulin-like domains 1 Lrig1 16206 1,5 0,91 -1 -1,02
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RIKEN cDNA A830080D01 gene A830080D01Rik 382252 1,5 1,24 0,97 0,9
trinucleotide repeat containing 15 Tnrc15 227331 1,5 1,09 0,7 1
RIKEN cDNA 6720458F09 gene 6720458F09Rik 328162 1,49 1,35 1,53 0,98
HECT, UBA and WWE domain containing 1 Huwe1 59026 1,49 0,93 0,85 -0,96
aldehyde dehydrogenase 1 family, member L2 Aldh1l2 216188 1,49 1,55 1,33 1,02
RIKEN cDNA D730035F11 gene D730035F11Rik 320010 1,49 1,22 0,92 -0,78
serine/threonine kinase 17b (apoptosis-inducing) Stk17b 98267 1,49 1,29 1,11 1,13
*cDNA sequence_02 1,48 1,17 1,02 0,94
nuclear receptor subfamily 4, group A, member 2 Nr4a2 18227 1,48 1,22 1,11 0,76
protein tyrosine phosphatase, non-receptor type 14 Ptpn14 19250 1,48 1,51 1,25 1,13
centrosome and spindle pole associated protein 1 Cspp1 211660 1,48 0,8 1,06 -0,56
cysteine rich protein 61 Cyr61 16007 1,47 0,62 0 1,32
dipeptidylpeptidase 7 Dpp7 83768 1,47 1,53 1,39 1,83
intercellular adhesion molecule Icam1 15894 1,47 -0,96 -1,05 -0,92
sema domain, immunoglobulin domain (Ig), and GPI membrane anchor, (semaphorin) 7A Sema7a 20361 1,47 0,96 -1,06 -0,93
TAP binding protein-like Tapbpl 213233 1,47 0,98 -1,04 -1,03
ornithine decarboxylase, structural 1 Odc1 18263 1,46 1,15 -0,94 0,92
STE20-like kinase (yeast) Slk 20874 1,46 1,26 0,79 0,98
zinc finger protein 346 Zfp346 26919 1,46 1,25 1,02 0,87
BH3 interacting domain death agonist Bid 12122 1,45 1,3 1,28 1,2
vacuolar protein sorting 37B (yeast) Vps37b 330192 1,45 1,31 1 0,94
dual specificity phosphatase 4 Dusp4 319520 1,45 1,68 0,96 0,97
lymphotoxin B Ltb 16994 1,45 0,86 -1,46 -1,38
protein phosphatase 1 (formerly 2C)-like Ppm1l 242083 1,45 1,07 1,2 0,88
RIKEN cDNA 1110054O05 gene 1110054O05Rik 66209 1,45 1,31 1,46 1,04
oxidative stress induced growth inhibitor 1 Osgin1 71839 1,45 1,13 0,97 0,82
RIKEN cDNA 2610207I05 gene 2610207I05Rik 233789 1,45 1,26 0,87 0,82
choline kinase alpha Chka 12660 1,44 1,45 -0,63 0,94
cryptochrome 1 (photolyase-like) Cry1 12952 1,44 1,21 0,96 1,12
RAB32, member RAS oncogene family Rab32 67844 1,44 0,94 0,9 0,89
neuron-glia-CAM-related cell adhesion molecule Nrcam 319504 1,44 1,35 0,8 -0,9
WD repeat domain 37 Wdr37 207615 1,44 0,94 0,98 -0,86
apoptosis inhibitor 5 Api5 11800 1,43 1,1 1,21 1,04
Kruppel-like factor 4 (gut) Klf4 16600 1,43 1,35 1,26 1,57
ESF1, nucleolar pre-rRNA processing protein, homolog (S. cerevisiae) Esf1 66580 1,43 1,21 1,04 0,73
CD83 antigen Cd83 12522 1,42 -1,02 -0,93 -1,03
interferon stimulated exonuclease gene 20-like 1 Isg20l1 68048 1,42 1,14 1,3 0,91
sestrin 2 Sesn2 230784 1,42 1,59 1,52 1,18
zinc finger protein 296 Zfp296 63872 1,42 1,35 1,49 1,3
zinc finger protein 566 Zfp566 72556 1,42 1,41 1,15 0,92
cDNA sequence BC022687
Growth factor receptor bound protein 2-associated protein 2
BC022687
Gab2
217887
14389
1,41
1,41
1,22
1,5
1,27
1,18
1,18
0,66
Esterase D/formylglutathione hydrolase Esd 13885 1,2 1,75 0,86 0,89
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#probe design_08 1,41 1,4 1,18 1,05
expressed sequence AW112010 AW112010 107350 1,41 1,06 -1,01 -0,93
gephyrin Gphn 268566 1,41 -0,91 0,96 0,81
meningioma expressed antigen 5 (hyaluronidase) Mgea5 76055 1,41 1,06 0,96 0,84
prostaglandin-endoperoxide synthase 1 Ptgs1 19224 1,41 0,69 1 0,58
SFT2 domain containing 2 Sft2d2 108735 1,41 1,35 1,03 1,13
trans-golgi network protein Tgoln1 22134 1,41 1,24 0,86 1,2
translocase of inner mitochondrial membrane 10 homolog (yeast) Timm10 30059 1,41 1,41 1,32 1,24
Nfkbiz nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta
#
Nfkbiz 80859 1,4 0,94 -0,79 0,85
probe design_09 1,4 0,77 0,75 -1,02
RIKEN cDNA 5031425E22 gene 5031425E22Rik 75977 1,4 1,24 1,07 1,07
cytochrome b5 reductase 1 Cyb5r1 72017 1,39 1,78 1,36 1,36
cache domain containing 1 Cachd1 320508 1,39 1,74 1,32 1,2
small proline-rich protein 1B Sprr1b 20754 1,39 2,21 2,27 2,31
spermidine/spermine N1-acetyl transferase 1 Sat1 20229 1,39 1,4 1,12 1,07
fibronectin leucine rich transmembrane protein 3 Flrt3 71436 1,37 1,44 1,25 1,37
ATPase, Na+/K+ transporting, beta 1 polypeptide
#
Atp1b1 11931 1,35 1,49 1 0,83
probe design_10 1,34 1,53 1,77 1,82
RIKEN cDNA 3110023B02 gene 3110023B02Rik 67291 1,33 1,41 1,25 0,9
expressed sequence AI117581 AI117581 103629 1,32 1,4 0,79 0,93
RIKEN cDNA 2610200G18 gene 2610200G18Rik 67149 1,32 1,42 1,1 1,02
TATA box binding protein (Tbp)-associated factor, RNA polymerase I, A Taf1a 21339 1,32 1,45 1,09 0,84
heme oxygenase (decycling) 1 Hmox1 15368 1,31 0,54 1,84 1,16
acyl-CoA thioesterase 2 Acot2 171210 1,31 1,66 1,47 0,98
solute carrier family 25, member 33 Slc25a33 70556 1,31 1,5 1,15 1,16
ataxin 2 binding protein 1 A2bp1 268859 1,3 -1,12 -0,99 -1,42
phosphoserine phosphatase Psph 100678 1,3 1,8 1,36 1,1
pyrroline-5-carboxylate reductase 1 Pycr1 209027 1,3 1,61 1,37 0,98
ribonuclease P 40 subunit (human) Rpp40 208366 1,29 1,28 1,47 1,14
ATPase, H+ transporting, lysosomal V0 subunit B Atp6v0b 114143 1,28 1,36 1,34 1,45
thioredoxin reductase 1
#
Txnrd1 50493 1,28 0,33 1,5 1,19
probe design_11 1,27 1,41 0,96 0,99
Serine hydroxymethyltransferase 2 (mitochondrial) Shmt2 108037 1,25 1,48 1,16 1,35
ectonucleotide pyrophosphatase/phosphodiesterase 2 Enpp2 18606 1,24 1,07 -1,42 -1,44
DEP domain containing 7 Depdc7 211896 1,24 1,22 1,49 1,24
metallothionein 1 Mt1 17748 1,24 1,92 0,88 0,85
ceroid lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeyer-Vogt disease) Cln3 12752 1,23 1,21 1,33 1,4
DPH2 homolog (S. cerevisiae) Dph2 67728 1,23 1,26 1,44 1,32
Nur77 downstream gene 2 Ndg2 103172 1,23 1,97 2,67 2,39
4-hydroxyphenylpyruvate dioxygenase-like Hpdl 242642 1,22 1,16 1,67 1,31
receptor accessory protein 6 Reep6 70335 1,22 1,55 1,79 1,49
kit ligand Kitl 17311 0,94 1,57 1,61 1
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phosphomannomutase 1 Pmm1 29858 1,19 1,66 1,63 1,3
serine (or cysteine) proteinase inhibitor, clade E, member 2 Serpine2 20720 1,19 1,62 1,09 0,6
zinc finger protein 142 Zfp142 77264 1,17 1,42 1,02 0,86
C-type lectin domain family 4, member d Clec4d 17474 1,16 2,26 1,42 0,91
nucleolar and coiled-body phosphoprotein 1 Nolc1 70769 1,15 0,71 0,97 1,42
ribosomal protein S15a Rps15a 267019 1,15 1,46 0,58 0,9
transmembrane and tetratricopeptide repeat containing 2 Tmtc2 278279 1,15 -0,86 -1,54 -1,42
Capping protein (actin filament), gelsolin-like Capg 12332 1,14 1,49 1,02 0,75
psoriasis susceptibility 1 candidate 2 (human) Psors1c2 57390 1,14 -1 -1,37 -1,78
calcium/calmodulin-dependent protein kinase kinase 2, beta
#
Camkk2 207565 1,13 0,95 1,44 0,84
probe design_12 1,12 1,71 0,8 1,13
laminin, gamma 2 Lamc2 16782 1,12 1,51 1,69 1,32
RIKEN cDNA A830021K08 gene A830021K08Rik 320427 1,1 1,5 1,17 1,12
target of myb1 homolog (chicken) Tom1 21968 1,1 1,44 1,21 1,19
*cDNA sequence_03 1,08 1,13 1,43 1,04
serine (or cysteine) proteinase inhibitor, clade B, member 9b Serpinb9b 20706 1,08 1,41 1,21 1,23
glycoprotein (transmembrane) nmb Gpnmb 93695 1,07 1,27 1,52 1,35
heat shock protein 1A Hspa1a 193740 1,06 1,77 -0,8 0,66
RIKEN cDNA 4932425I24 gene 4932425I24Rik 320214 1,06 0,93 1,42 1,09
arginase type II
#
Arg2 11847 1,05 0,82 -1,44 -0,81
probe design_13 1,05 -1,46 -1,28 -1,22
RIKEN cDNA 2700078E11 gene 2700078E11Rik 78832 1,05 1,01 1,42 1,12
RIKEN cDNA 2310047B19 gene 2310047B19Rik 66962 1,04 1 0,98 1,48
claudin 4 Cldn4 12740 1,03 1,23 1,21 1,45
glucosamine-6-phosphate deaminase 1 Gnpda1 26384 1,03 1,01 1,6 1,21
DNA segment, Chr 5, ERATO Doi 593, expressed D5Ertd593e 52331 1,01 1,4 0,94 1,01
spermatogenesis associated 17
#
Spata17 74717 1,01 1,69 -0,71 -0,74
probe design_14 1,01 1,07 0,72 1,85
RIKEN cDNA C230093N12 gene C230093N12Rik 98952 1,01 1,1 1,4 0,98
cDNA sequence AY036118
#
AY036118 170798 1 0,88 0,97 1,52
probe design_15
#
1 1,58 0,85 1,29
probe design_16 1 0,8 1,45 1,16
protocadherin 9 Pcdh9 211712 1 1,43 -0,9 -1,12
carboxypeptidase M Cpm 70574 1 -1,23 -1,07 -1,48
glycoprotein (transmembrane) nmb Gpnmb 93695 0,99 1,61 1,37 1,34
monoamine oxidase A Maoa 17161 0,99 1,33 1,44 1,09
Apolipoprotein H Apoh 11818 1,47 -0,77 0,67
heat shock protein 1B Hspa1b 15511 0,97 2,63 1,09 0,93
epiplakin 1 Eppk1 223650 0,95 0,98 1,62 0,99
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon Nfkbie 18037 0,95 -1,42 -0,96 -1
gelsolin Gsn 227753 0,94 1,29 2,12 1,69
Nuclear factor of activated T-cells 5 Nfat5 54446 0,45 -1,47 -0,62 -1,04
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stannin Snn 20621 0,94 1,23 1,44 0,98
basic helix-loop-helix domain containing, class B5 Bhlhb5 59058 0,93 -1,26 -1,34 -1,56
heat shock protein 1A /// heat shock protein 1B Hspa1a /// Hspa1b 193740 /// 15511 0,93 2,68 1,21 0,54
RIKEN cDNA 2610528E23 gene 2610528E23Rik 66497 0,93 1,22 1,53 1,19
abhydrolase domain containing 5 Abhd5 67469 0,92 1,04 1,39 1,41
cytoplasmic polyadenylation element binding protein 2 Cpeb2 231207 0,91 -0,53 1,75 0,59
Cathepsin A Ctsa 19025 0,91 1,13 0,85 1,46
nucleotide binding protein 2 Nubp2 26426 0,91 0,99 1,44 1,26
transmembrane protein 69 Tmem69 230657 0,91 -0,93 1,47 1,09
ets homologous factor Ehf 13661 0,9 -1,18 -0,99 -1,53
pappalysin 2 Pappa2 23850 0,9 1,51 1,26 1,45
vomeronasal 1 receptor, C6 V1rc6 113863 0,9 1,53 -0,78 -0,64
*cDNA sequence_04 0,89 -1,01 -1,3 -1,4
insulin induced gene 1 Insig1 231070 0,89 -1,5 -0,95 -1,06
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Ppargc1a 19017 0,88 0,99 1,34 1,47
adenosine deaminase Ada 11486 0,87 1,08 1,46 0,9
protein tyrosine phosphatase, receptor type, E Ptpre 19267 0,87 -1,06 -1,35 -1,43
gene model 440, (NCBI) Gm440 242819 0,85 -1,13 -1,29 -1,43
methionine adenosyltransferase II, alpha Mat2a 232087 0,85 -1,48 0,92 0,76
chromodomain helicase DNA binding protein 9 Chd9 109151 0,84 -0,96 -1,4 -0,99
coagulation factor II (thrombin) receptor F2r 14062 0,84 1,47 0,85 0,8
tubulin, beta 2c Tubb2c 227613 0,84 -1,46 -0,69 0,69
#probe design_17 0,83 1,41 -0,89 0,83
RIKEN cDNA 1700034I23 gene 1700034I23Rik 73297 0,82 0,96 0,48 2,06
inhibitor of kappaB kinase gamma Ikbkg 16151 0,8 1,19 1,56 1,22
centaurin, delta 1 Centd1 212285 0,79 -0,83 1,43 0,84
Sorbin and SH3 domain containing 1 Sorbs1 20411 0,79 -1,5 -0,72 -0,7
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide Adh7 11529 0,78 1,77 1,5 1,24
*cDNA sequence_05 0,77 -0,99 -1,07 -1,57
Peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Ppargc1a 19017 0,73 0,96 1,52 1,05
Baculoviral IAP repeat-containing 4 Birc4 11798 0,66 -1,42 -0,81 0,55
Ataxia telangiectasia and Rad3 related Atr 245000 0,66 -1,42 -0,82 -0,85
*cDNA sequence_06 0,65 -1,34 -1,03 -1,56
ubiquitin specific protease 15 Usp15 14479 0,57 -1,57 1,26 0,84
Membrane associated guanylate kinase, WW and PDZ domain containing 1 Magi1 14924 0,53 -1,54 -0,39 -0,8
Myeloid ecotropic viral integration site-related gene 1 Mrg1 17536 0,52 -1,56 -0,5 -1,04
Rho-associated coiled-coil containing protein kinase 1 Rock1 19877 0,51 -1,49 -0,26 0,77
glutathione S-transferase, alpha 3 Gsta3 14859 0,51 1,31 2,28 1,39
*cDNA sequence_07 0,49 -1,61 -0,58 -0,88
RIKEN cDNA 3110047M12 gene 3110047M12Rik 73184 0,49 -1,68 -0,3 -0,66
Annexin A4 Anxa4 11746 0,47 -1,55 -0,21 -0,99
RIKEN cDNA D230012E17 gene D230012E17Rik 241062 -0,9 -1,01 -1,38 -1,52
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RIKEN cDNA 5230400M03 gene 5230400M03Rik 329406 0,45 -1,44 -0,49 -0,96
DENN/MADD domain containing 1B Dennd1b 329260 0,44 -1,44 -0,75 -0,88
*cDNA sequence_08 0,42 -1,41 -0,69 -1,13
*cDNA sequence_09 0,41 -1,53 -0,44 -1,09
RIKEN cDNA 5930427L02 gene 5930427L02Rik 402754 0,4 -1,52 -0,76 -0,83
ADP-ribosylation factor guanine nucleotide-exchange factor 1(brefeldin A-inhibited) Arfgef1 211673 0,38 -1,43 -0,29 -0,88
DNA segment, Chr 3, ERATO Doi 452, expressed D3Ertd452e 51898 0,37 -1,45 -0,95 -1,34
Nipped-B homolog (Drosophila) Nipbl 71175 0,35 -1,4 -0,31 -0,8
*cDNA sequence_10 0,34 -1,5 -0,64 -0,71
RIKEN cDNA 9630019E01 gene 9630019E01Rik 319967 0,33 -1,33 -0,37 -1,42
*cDNA sequence_11 0,32 -1,49 -0,65 -0,91
*cDNA sequence_12 0,19 -1,57 -0,1 -0,66
Ubiquitin-conjugating enzyme E2H Ube2h 22214 0,17 -1,42 -0,86 -0,53
*cDNA sequence_13 0 -2,08 -0,16 -0,9
solute carrier family 12, member 2 Slc12a2 20496 0 1,42 -0,54 0,41
RAS, guanyl releasing protein 2 Rasgrp2 19395 -0,32 -0,7 -1,44 -0,76
RIKEN cDNA 2610024D14 gene 2610024D14Rik 70410 -0,51 -1,42 0,97 0,59
cysteine-rich secretory protein 1 Crisp1 11571 -0,57 -0,98 -1,59 -0,93
chemokine (C-C motif) ligand 28 Ccl28 56838 -0,59 0,74 -0,8 1,58
histone cluster 1, H2bc Hist1h2bc 68024 -0,59 0,86 1,48 -0,67
collectin sub-family member 11 Colec11 71693 -0,69 0,68 1,19 1,52
PDZ and LIM domain 5 Pdlim5 56376 -0,69 -1,42 -1,2 -1,32
#probe design_18 -0,7 -1,43 -1,31 0,62
LUC7-like 2 (S. cerevisiae) Luc7l2 192196 -0,72 -1,23 -0,93 -1,44
UDP-glucose ceramide glucosyltransferase Ugcg 22234 -0,73 -1,62 -0,23 0,86
Praja 2, RING-H2 motif containing Pja2 224938 -0,74 -0,63 -1,9 -0,1
preimplantation protein 4 Prei4 74182 -0,77 -1,45 -0,73 -0,99
zinc finger and BTB domain containing 20 Zbtb20 56490 -0,79 -1,54 -0,85 -0,75
transmembrane protein 16A Tmem16a 101772 -0,81 1,14 1,51 1,37
#probe design_19 -0,83 -1,14 -1,5 -1,36
Interferon gamma receptor 1 Ifngr1 15979 -0,84 -1 -1,56 -1,1
CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase like 2 Ctdspl2 329506 -0,86 -1,49 -0,91 -0,86
interleukin 13 receptor, alpha 1 Il13ra1 16164 -0,86 -1,35 -1,71 -1,22
ubiquitin specific protease 53 Usp53 99526 -0,86 -1,68 -0,69 -1,52
ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 Atp8a1 11980 -0,87 -1,28 -1,6 -1,5
latent transforming growth factor beta binding protein 3 Ltbp3 16998 -0,87 -1,05 -1,21 -1,42
transcription factor 7-like 2, T-cell specific, HMG-box Tcf7l2 21416 -0,87 -1,44 -0,84 -0,95
leucine rich repeat containing 28 Lrrc28 67867 -0,88 -0,83 1,49 1,07
*cDNA sequence_14 -0,89 -1,47 -0,8 -0,65
Sterol-C4-methyl oxidase-like Sc4mol 66234 -0,89 -1,32 -1,53 -1,01
activated leukocyte cell adhesion molecule Alcam 11658 -0,9 -1,12 -1,42 -1,13
hydroxyacid oxidase 1, liver Hao1 15112 -1,06 -1,01 -1,18 -1,45
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adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 2 Appl2 216190 -0,92 -0,97 -1,66 -1,24
Wilms tumor homolog Wt1 22431 -0,92 -1,27 -1,26 -1,41
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3G Sema3g 218877 -0,93 -0,95 -1,74 -1,51
dedicator of cytokinesis 4 Dock4 238130 -0,93 -1,17 -1,38 -1,41
glutamate-cysteine ligase , modifier subunit Gclm 14630 -0,93 1,64 1,66 1,46
zinc finger protein 654 Zfp654 72020 -0,93 -1,43 -1,21 -1,17
serum response factor Srf 20807 -0,93 1,44 1,09 0,92
bromodomain and WD repeat domain containing 3 Brwd3 382236 -0,94 -0,98 -1 -1,66
#probe design_20 -0,94 -1,58 -0,78 -1,34
potassium channel tetramerisation domain containing 12 Kctd12 239217 -0,94 -1,41 -1,71 -1,54
cyclin T2 Ccnt2 72949 -0,95 -1,16 -1,49 -1,3
fibrinogen, B beta polypeptide Fgb 110135 -0,95 -1,17 -1,68 -1,18
mitogen activated protein kinase kinase kinase 12 Map3k12 26404 -0,95 -1,48 -0,86 0,87
forkhead-associated (FHA) phosphopeptide binding domain 1 Fhad1 329977 -0,95 -1,16 -1,49 -1,19
bone marrow stromal cell antigen 1 Bst1 12182 -0,96 -1,42 -1,9 -0,79
ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 Atp8a1 11980 -0,96 -0,88 -1,62 -1,79
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 Hmgcs1 208715 -0,97 -1,64 -2,4 -1,31
complement component factor i Cfi 12630 -0,97 -1,07 -1,02 -1,41
fibrinogen-like protein 1 Fgl1 234199 -0,97 -1,13 -1,24 -1,41
#probe design_21 -0,97 1,51 1,25 0,96
ERO1-like (S. cerevisiae) Ero1l 50527 -0,98 -1,01 -1,53 -1,4
apolipoprotein C-IV Apoc4 11425 -0,99 -1,15 -1,58 -1,07
hepatic nuclear factor 4, alpha Hnf4a 15378 -0,99 -1,43 -0,93 -0,84
coiled-coil-helix-coiled-coil-helix domain containing 6 Chchd6 66098 -0,99 1,03 1,15 1,44
SLIT and NTRK-like family, member 6 Slitrk6 239250 -0,99 -1,29 -1,49 -1,27
carbonic anhydrase 8 Car8 12319 -1 -1,02 -1,49 -1,34
RIKEN cDNA 4930431B09 gene 4930431B09Rik 74645 -1 -1,44 -1,4 -1,4
histocompatibility 2, Q region locus 1 H2-Q1 15006 -1 -2,14 -0,53 -1,7
protein kinase, cGMP-dependent, type II Prkg2 19092 -1 -1,07 -1,43 -1,39
cingulin-like 1 Cgnl1 68178 -1 -1,26 -1,41 -1,43
asparagine-linked glycosylation 6 homolog (yeast, alpha-1,3,-glucosyltransferase) Alg6 320438 -1,01 -1,38 -1,42 -1,01
RIKEN cDNA 0610037L13 gene 0610037L13Rik 74098 -1,01 -1,22 -1,83 -1,13
vesicle-associated membrane protein 4 Vamp4 53330 -1,01 -1,07 -1,41 -1,21
isopentenyl-diphosphate delta isomerase Idi1 319554 -1,02 -1,42 -1,45 -0,91
solute carrier family 36 (proton/amino acid symporter), member 4 Slc36a4 234967 -1,03 -1,11 -1,27 -1,52
myeloid/lymphoid or mixed lineage-leukemia translocation to 3 homolog (Drosophila) Mllt3 70122 -1,04 -1,47 -0,8 -0,76
phosphomevalonate kinase Pmvk 68603 -1,04 -1,39 -1,45 -1,09
DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 Ddx58 230073 -1,05 -1,32 -1,4 -1,45
glutathione S-transferase, alpha 4 Gsta4 14860 -1,05 1,33 1,61 1,37
mal, T-cell differentiation protein 2 Mal2 105853 -1,05 -1,45 -1,21 -1,19
fatty acid desaturase 2 Fads2 56473 -1,06 -1,65 -1,39 -1
serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 10 Serpina10 217847 -1,2 -1,54 -1,35 -1,07
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RIKEN cDNA 5730469M10 gene 5730469M10Rik 70564 -1,06 -1,41 -1,32 -1,17
butyrylcholinesterase Bche 12038 -1,07 -1,46 -1,56 -0,91
DNA segment, Chr 11, ERATO Doi 461, expressed Ccdc69 52570 -1,07 -1,42 -0,82 0,96
solute carrier organic anion transporter family, member 2a1 Slco2a1 24059 -1,07 -1,71 -1,13 -1,19
cytochrome P450, 51 Cyp51 13121 -1,08 -1,37 -1,62 -1
nudix (nucleoside diphosphate linked moiety X)-type motif 13 Nudt13 67725 -1,08 -0,95 -1,12 -1,42
transcription elongation factor A (SII)-like 6 Tceal6 66104 -1,08 -1,6 -0,7 -0,88
WD repeat domain 26 Wdr26 226757 -1,08 0,94 -1,05 -1,6
annexin A4 Anxa4 11746 -1,09 -1,17 -1,05 -1,43
RIKEN cDNA 1810023F06 gene 1810023F06Rik 217845 -1,09 -1,22 -1,44 -1,27
cDNA sequence BC011467 Spns2 216892 -1,1 -1,32 -1,41 -1,67
Calcium/calmodulin-dependent protein kinase II, beta Camk2b 12323 -1,1 -1,3 -1,62 -1,52
glutamine fructose-6-phosphate transaminase 2 Gfpt2 14584 -1,1 -1,3 -1,43 -1,23
#probe design_22 -1,11 -1,39 -1,43 -1,6
phosphofructokinase, liver, B-type Pfkl 18641 -1,11 -1,42 -1,01 -0,89
procollagen, type VIII, alpha 1 Col8a1 12837 -1,11 -1,31 -1,5 -1,45
phosphodiesterase 4D interacting protein (myomegalin) Pde4dip 83679 -1,11 -1,11 -1,38 -1,41
heparan sulfate (glucosamine) 3-O-sulfotransferase 1 Hs3st1 15476 -1,13 -1,08 -1,43 -1,24
dedicator of cytokinesis 9 Dock9 105445 -1,14 -1,12 -1,18 -1,43
protein phosphatase 1, regulatory (inhibitor) subunit 9A Ppp1r9a 243725 -1,14 -1,21 -1,5 -1,24
24-dehydrocholesterol reductase Dhcr24 74754 -1,15 -1,41 -0,74 -0,67
caspase 12 Casp12 12364 -1,15 -1,38 -1,45 -1,36
zinc finger, MIZ-type containing 1 Zmiz1 328365 -1,15 -1,28 -1,35 -1,45
fibroblast growth factor receptor 4 Fgfr4 14186 -1,15 -1,43 -1,23 -1,2
inter-alpha (globulin) inhibitor H5 Itih5 209378 -1,15 -1,34 -1,51 -1,16
V-set and immunoglobulin domain containing 1 Vsig1 78789 -1,15 -1,41 -1,24 -1,04
sialyltransferase 4A (beta-galactoside alpha-2,3-sialytransferase) St3gal1 20442 -1,15 -0,96 -1,45 -1,03
stearoyl-Coenzyme A desaturase 1 Scd1 20249 -1,16 -1,44 -1,24 -1,01
cAMP responsive element binding protein 3-like 2 Creb3l2 208647 -1,17 -1,42 -1,22 -1,42
DNA segment, Chr 7, ERATO Doi 413, expressed D7Ertd413e 52325 -1,17 -1,6 -0,95 -0,53
muscleblind-like 3 (Drosophila) Mbnl3 171170 -1,17 -1,4 -0,92 -0,79
myosin, light polypeptide kinase Mylk 107589 -1,17 -1,32 -1,45 -1,48
phospholipase C, beta 1 Plcb1 18795 -1,17 -1,39 -1,28 -1,5
proline-rich coiled-coil 1 Prrc1 73137 -1,17 -1,08 -1,06 -1,4
sestrin 3 Sesn3 75747 -1,17 -1,23 -1,2 -1,47
insulin-like growth factor binding protein 3 Igfbp3 16009 -1,18 -1,3 -1,61 -1,45
guanine nucleotide binding protein (G protein), gamma 2 subunit Gng2 14702 -1,19 -0,8 -1,47 -1,33
SH3-domain GRB2-like (endophilin) interacting protein 1 Sgip1 73094 -1,19 -1,56 -1,51 -1,41
wingless-related MMTV integration site 5A Wnt5a 22418 -1,19 -1,54 -1,03 -0,96
protein kinase, cGMP-dependent, type II Prkg2 19092 -1,2 -1,32 -1,49 -1,47
ATP/GTP binding protein-like 3 Agbl3 76223 -1,2 -1,47 -1,17 -1,02
interferon activated gene 203 Ifi203 15950 -1,4 -1,53 -1,04 -0,92
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myeloid/lymphoid or mixed lineage-leukemia translocation to 3 homolog (Drosophila) Mllt3 70122 -1,21 -1,42 -0,83 -0,93
RIKEN cDNA C030045D06 gene C030045D06Rik 109294 -1,21 -1,28 -1,69 -1,39
ATP-binding cassette, sub-family A (ABC1), member 5 Abca5 217265 -1,22 -1,37 -1,45 -1,51
BCL2/adenovirus E1B 19kDa-interacting protein 3-like Bnip3l 12177 -1,22 -1,45 -1,22 -1,13
solute carrier family 2 (facilitated glucose transporter), member 1 Slc2a1 20525 -1,22 -1,09 -1,51 -1
mitogen activated protein kinase kinase kinase 1 Map3k1 26401 -1,23 -1,56 -1,23 -0,97
3-hydroxybutyrate dehydrogenase (heart, mitochondrial) Bdh1 71911 -1,24 -1,5 -1,32 -0,95
chemokine (C-X-C motif) ligand 15 Cxcl15 20309 -1,24 -1,62 -1,15 -1,15
Janus kinase 2 Jak2 16452 -1,24 -1,4 -1,44 -1,19
low density lipoprotein receptor Ldlr 16835 -1,24 -1,35 -1,69 -1,12
platelet-derived growth factor,  C polypeptide Pdgfc 54635 -1,24 0,89 1,41 1,27
early growth response 2 Egr2 13654 -1,25 -1,81 -2,44 -2,54
T-cell leukemia translocation altered gene Tcta 102791 -1,25 -1,41 -1,08 -1,1
*cDNA sequence_15 -1,26 -1,13 -1 -1,45
smoothelin-like 2 Smtnl2 276829 -1,26 -0,95 -1,4 -1,2
aquaporin 11 Aqp11 66333 -1,27 -1,22 -1,41 -1,25
*cDNA sequence_16 -1,27 -2,43 -1,84 -1,47
insulin-like growth factor binding protein 1 Igfbp1 16006 -1,27 -1,3 -1,45 -1,06
killer cell lectin-like receptor, subfamily A, member 2 Klra2 16633 -1,27 -1,29 -1,4 -1,18
phosphofructokinase, platelet Pfkp 56421 -1,27 -1,29 -1,47 -1,05
phosphoglucomutase 2 Pgm2 72157 -1,27 -1,4 -1,15 -0,92
potassium channel, subfamily K, member 2 Kcnk2 16526 -1,27 -1,19 -1,42 -1,5
ATPase, class V, type 10A Atp10a 11982 -1,28 -1,4 -1,34 -1,14
butyrylcholinesterase Bche 12038 -1,28 -1,45 -1,61 -1,21
Inositol polyphosphate-4-phosphatase, type II Inpp4b 234515 -1,3 -1,21 -0,75 -1,43
StAR-related lipid transfer (START) domain containing 4 Stard4 170459 -1,3 -1,77 -1,48 -1,21
chemokine (C-X-C motif) ligand 15 Cxcl15 20309 -1,32 -1,92 -1,33 -1,46
TBC1 domain family, member 8B Tbc1d8b 245638 -1,32 -1,39 -1,56 -1,63
ankyrin repeat and sterile alpha motif domain containing 1B Anks1b 77531 -1,32 -1,21 -1,43 -1,2
RIKEN cDNA D630039A03 gene D630039A03Rik 242484 -1,32 -1,44 -1,14 -1,18
histone 2, H2bb Hist2h2bb 319189 -1,33 -1,21 -1,34 -1,45
calcium/calmodulin-dependent protein kinase II inhibitor 1 Camk2n1 66259 -1,33 -1,38 -1,18 -1,41
farnesyl diphosphate synthetase Fdps 110196 -1,34 -1,42 -1,24 -0,7
spastic paraplegia 3A homolog (human) Spg3a 73991 -1,35 -1,15 -1,51 -1,16
DNA segment, Chr 7, ERATO Doi 743, expressed Tmem41b 233724 -1,37 -1,28 -1,44 -1,06
erythrocyte protein band 4.1-like 2 Epb4.1l2 13822 -1,38 -1,57 -1,28 -1,08
platelet derived growth factor receptor, alpha polypeptide Pdgfra 18595 -1,38 -0,94 -1,66 -1,39
protein C Proc 19123 -1,38 -1,52 -1,35 -1,52
protein phosphatase 1K (PP2C domain containing) Ppm1k 243382 -1,38 -1,05 -1,54 -1,42
coatomer protein complex, subunit zeta 2 Copz2 56358 -1,39 -1,46 -1,28 -1,2
general transcription factor II E, polypeptide 2 (beta subunit) Gtf2e2 68153 -1,4 -1,09 -1,16 -1,2
odd-skipped related 1 (Drosophila) Osr1 23967 -1,45 0,92 -0,83 0,94
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glutathione S-transferase, mu 7 Gstm7 68312 -1,4 -1,31 -1,02 -1,25
arylsulfatase G Arsg 74008 -1,4 -1,63 -1,49 -1,58
t-complex 11 (mouse) like 2 Tcp11l2 216198 -1,4 -0,78 -1,2 -1,26
ubiquitin specific protease 18 Usp18 24110 -1,4 -0,92 0,93 0,95
amylo-1,6-glucosidase, 4-alpha-glucanotransferase Agl 77559 -1,41 -1,14 -1,07 -1,46
fibroblast growth factor 1 Fgf1 14164 -1,41 -1,22 -1,14 -0,79
KH domain containing, RNA binding, signal transduction associated 3 Khdrbs3 13992 -1,41 -1,35 -0,95 -1,17
peptidyl arginine deiminase, type III Padi3 18601 -1,41 -1,13 -0,58 -0,7
PX domain containing serine/threonine kinase Pxk 218699 -1,41 -1,09 -1,05 -1,01
2,3-bisphosphoglycerate mutase Bpgm 12183 -1,42 0,9 0,89 0,88
calponin 2 Cnn2 12798 -1,42 -1,04 -0,92 0,94
integrin alpha FG-GAP repeat containing 1 Itfg1 71927 -1,42 -1,28 -1,06 -1,05
GH regulated TBC protein 1 Grtp1 66790 -1,42 -1,59 -1,1 -0,88
membrane bound O-acyltransferase domain containing 5 Mboat5 14792 -1,42 -1,39 -1,22 -1,11
kinesin family member 5C Kif5c 16574 -1,42 -1,48 -1,46 -1,37
mitochondrial tumor suppressor 1 Mtus1 102103 -1,42 -1,13 -1,56 -1,35
protein kinase C, alpha Prkca 18750 -1,42 -1,03 -1,01 -1,74
RIKEN cDNA 1200009F10 gene 1200009F10Rik 67454 -1,42 -1,15 -1,38 -1,25
MON2 homolog (yeast) Mon2 67074 -1,42 -0,87 -1,1 -1,2
RIKEN cDNA 6720489N17 gene 6720489N17Rik 211378 -1,42 -1,16 -0,82 -1,01
sphingomyelin phosphodiesterase 1, acid lysosomal Smpd1 20597 -1,42 -1,02 -1,08 -0,92
CD38 antigen Cd38 12494 -1,43 -1,15 -1,17 -1,29
lanosterol synthase Lss 16987 -1,43 -1,63 -1,54 -1,11
thyroid hormone receptor interactor 12 Trip12 14897 -1,43 -1,17 -1,26 -1,32
proline rich 16 Prr16 71373 -1,43 -1,27 -1,19 -1,13
centaurin, beta 2 Centb2 78618 -1,43 -1,21 -0,99 -1,13
HEAT repeat containing 5B Heatr5b 320473 -1,43 -1,01 -1,04 -1,15
stromal antigen 2 Stag2 20843 -1,43 -1,15 -1,1 -1,16
abhydrolase domain containing 3 Abhd3 106861 -1,44 -0,89 -0,91 -0,81
estrogen receptor 1 (alpha) Esr1 13982 -1,44 -1,22 -0,98 -1,03
FK506 binding protein 14 Fkbp14 231997 -1,44 -1,3 -1,75 -1,23
glycerol-3-phosphate acyltransferase, mitochondrial Gpam 14732 -1,44 -1,42 -1,41 -1,16
interferon consensus sequence binding protein 1 Irf8 15900 -1,44 -1,6 -1,09 -0,92
RIKEN cDNA 2510009E07 gene 2510009E07Rik 72190 -1,44 -1,23 -0,92 -1,31
solute carrier family 40 (iron-regulated transporter), member 1 Slc40a1 53945 -1,44 0,76 -1,03 -0,99
tripartite motif protein 2 Trim2 80890 -1,44 -1,09 0,79 -1,21
villin 1 Vil1 22349 -1,44 -1,19 -1,22 -1,04
C-terminal binding protein 2 Ctbp2 13017 -1,45 -1,43 0,83 -0,99
exocyst complex component 7 Exoc7 53413 -1,45 -1,08 -0,87 -0,89
F-box only protein 6b
microtubule-associated protein, RP/EB family, member 2
Fbxo6
Mapre2
50762
212307
-1,45
-1,45
-1,21
-1,19
-1,01
0,76
-0,76
0,8
cysteinyl leukotriene receptor 1 Cysltr1 58861 -1,54 -1,09 -0,81 -0,98
methionine sulfoxide reductase B Msrb2 76467 -1,54 -1,11 -1,08 -1,25
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palmdelphin Palmd 114301 -1,45 -1,23 -1,25 -1,14
arginine/serine-rich coiled-coil 1 Rsrc1 66880 -1,45 -1 0,85 -0,81
serine (or cysteine) proteinase inhibitor, clade B, member 7 Serpinb7 116872 -1,45 -1,32 -0,88 -0,83
ATP-binding cassette, sub-family A (ABC1), member 6 Abca6 76184 -1,46 -1,36 -0,94 -0,66
B lymphoma Mo-MLV insertion region 1 Bmi1 12151 -1,46 -1,21 -0,98 -1,02
NIMA (never in mitosis gene a)-related expressed kinase 1 Nek1 18004 -1,46 -1,16 -1,01 -1,03
phosphofructokinase, muscle Pfkm 18642 -1,46 -1,4 -1,21 -1,13
RAS p21 protein activator 3 Rasa3 19414 -1,46 -1,19 -1,07 -1,01
retinitis pigmentosa 2 homolog (human) Rp2h 19889 -1,46 -1,11 -0,8 -0,9
acid phosphatase-like 2 Acpl2 235534 -1,46 -1,02 -1,03 -0,98
dystrophin, muscular dystrophy Dmd 13405 -1,47 -1,37 -1,18 -1,22
sphingomyelin synthase 1 Sgms1 208449 -1,47 -1,23 -1,36 -1,34
peptidylglycine alpha-amidating monooxygenase COOH-terminal interactor Pamci 237504 -1,47 -1,24 -1,07 -1,21
purinergic receptor P2Y, G-protein coupled, 14 P2ry14 140795 -1,47 -1,27 -1,43 -1,01
RAS, guanyl releasing protein 3 Rasgrp3 240168 -1,47 -1,6 -1 -1,09
RIKEN cDNA 4631426J05 gene 4631426J05Rik 77590 -1,47 -1,04 -1,14 -1,08
ferrochelatase Fech 14151 -1,48 -1,07 -1,21 -1,03
Endothelial PAS domain protein 1 Epas1 13819 -1,48 -1,78 -1,58 -1,66
growth factor receptor bound protein 14 Grb14 50915 -1,48 -1,33 -1,2 -0,95
MAD homolog 6 (Drosophila) Smad6 17130 -1,48 -1,07 -0,9 -0,59
methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) Mccc1 72039 -1,48 -1,31 -1,56 -1,21
potassium channel tetramerisation domain containing 11 Kctd11 216858 -1,48 -1,49 -1,11 -1,2
RIKEN cDNA C730027H18 gene C730027H18Rik 319572 -1,48 -1,44 -1,19 -1,37
7-dehydrocholesterol reductase Dhcr7 13360 -1,49 -1,37 -1,4 -0,78
potassium inwardly-rectifying channel, subfamily J, member 8 Kcnj8 16523 -1,49 -1,05 -1,04 -1,13
RIKEN cDNA 2610027C15 gene 2610027C15Rik 230752 -1,49 -1,33 -1,23 -0,97
RIKEN cDNA 5730494M16 gene 5730494M16Rik 66648 -1,49 -0,98 -0,91 -0,78
bicaudal C homolog 1 (Drosophila) Bicc1 83675 -1,5 -1,24 -1,11 -1,01
centrosomal protein 290 Cep290 216274 -1,5 -1,54 -1,1 -0,87
grancalcin Gca 227960 -1,5 -1,49 -1,07 -0,95
zinc finger protein 467 Zfp467 68910 -1,5 -1,15 -1,17 -0,96
UDP glucuronosyltransferase 2 family, polypeptide B34 Ugt2b34 100727 -1,51 -1,38 -1,03 -1,08
kinesin family member 16B Kif16b 16558 -1,51 -0,96 0,96 -0,99
RIKEN cDNA 1700011H14 gene 1700011H14Rik 67082 -1,51 -1,24 -0,8 -0,79
RIKEN cDNA 2900024C23 gene 2900024C23Rik 67266 -1,51 -1,08 -1,09 -1,07
RIKEN cDNA 9230111E07 gene 9230111E07Rik 77748 -1,52 -1,11 -0,94 -0,94
hypothetical protein 4832420M10 Kif26b 269152 -1,52 -1,28 -0,86 -1,36
flavin containing monooxygenase 2 Fmo2 55990 -1,53 -1,53 -1,29 -1,15
sulfide quinone reductase-like (yeast) Sqrdl 59010 -1,53 -1,17 -0,86 -1,03
ankyrin repeat and SOCS box-containing protein 1 Asb1 65247 -1,54 -1,16 -1,13 -1,11
mannan-binding lectin serine protease 1 Masp1 17174 -1,73 -1,32 -0,91 -1,15
odd Oz/ten-m homolog 4 (Drosophila) Odz4 23966 -1,73 -1,24 -0,86 -0,76
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nebulin-related anchoring protein Nrap 18175 -1,54 -1,13 -1,1 -1,08
olfactomedin-like 2B Olfml2b 320078 -1,54 -1 -0,99 0,82
tetratricopeptide repeat domain 8 Ttc8 76260 -1,54 -1,21 -1,2 -1,1
acetyl-Coenzyme A synthetase 2 (ADP forming) Acss2 60525 -1,55 -1,55 -1,3 -1,18
N-glycanase 1 Ngly1 59007 -1,55 -1,01 -1,2 -1,16
PDZ and LIM domain 5 Pdlim5 56376 -1,55 -0,94 0,85 -0,7
RIKEN cDNA 1810074P20 gene 1810074P20Rik 67490 -1,55 -1,17 -1,27 -1,09
protein tyrosine phosphatase-like A domain containing 2 Ptplad2 66775 -1,55 -1,17 -1,23 -1,13
tribbles homolog 2 (Drosophila) Trib2 217410 -1,55 -1,3 -1,1 -1,18
SUMO1/sentrin specific peptidase 7 Senp7 66315 -1,56 -1,07 -1,15 -1,16
sphingomyelin synthase 1 Sgms1 208449 -1,56 -1,09 -1,16 -0,93
erythrocyte protein band 4.1-like 4b Epb4.1l4b 54357 -1,57 -1,65 -0,93 -1,14
thymidine kinase 1 Tk1 21877 -1,58 -1,25 -0,99 0,97
arginine vasopressin receptor 1A Avpr1a 54140 -1,59 -1,37 -1,12 -1,23
neuritin 1 Nrn1 68404 -1,59 -1,22 -1,47 -1,16
RAD50 homolog (S. cerevisiae) Rad50 19360 -1,6 1,11 -0,72 -0,71
RIKEN cDNA 9130213B05 gene 9130213B05Rik 231440 -1,6 -1,02 -1,27 -1,23
solute carrier family 16 (monocarboxylic acid transporters), member 4 Slc16a4 229699 -1,6 -1,43 -1,46 -1,27
troponin T2, cardiac Tnnt2 21956 -1,6 -1,44 -1,23 -1,36
protein kinase, cAMP dependent regulatory, type I beta Prkar1b 19085 -1,61 -1,05 -1,01 -1,05
RIKEN cDNA 1190002N15 gene 1190002N15Rik 68861 -1,61 -1,25 -1,89 -1,43
RIKEN cDNA 1110020G09 gene 1110020G09Rik 68646 -1,62 -1,43 -1,43 -1,15
RIKEN cDNA 9130005N14 gene 9130005N14Rik 68303 -1,62 -1,42 -1,28 -1,18
gene model 640, (NCBI) Gm640 270174 -1,63 -1,33 -1,21 -1,18
*cDNA sequence_17 -1,63 -1,53 -1,12 -0,79
expressed sequence AL024069 5033414K04Rik 98496 -1,64 -2,03 -1,29 -1,2
naked cuticle 1 homolog (Drosophila) Nkd1 93960 -1,64 -1,6 -1,21 -1,3
methionine sulfoxide reductase B3 Msrb3 320183 -1,64 -1,33 -1,17 -1,18
thiamin pyrophosphokinase Tpk1 29807 -1,64 -1,25 -0,97 -0,89
immunity-related GTPase family, M Irgm 15944 -1,66 -1,12 -0,79 -1,12
selenium binding protein 1 Selenbp1 20341 -1,66 -1,63 -1,9 -1,29
secernin 3 Scrn3 74616 -1,68 -0,93 -0,88 -0,99
aldolase 3, C isoform Aldoc 11676 -1,69 -1,82 -1,9 -1,28
G protein-coupled receptor 155 Gpr155 68526 -1,69 -1,46 -1,54 -1,51
solute carrier family 38, member 4 Slc38a4 69354 -1,69 -1,35 -1,3 -1,02
UDP-glucose pyrophosphorylase 2 Ugp2 216558 -1,7 -1,37 -1,22 -1,03
acyl-CoA synthetase long-chain family member 1 Acsl1 14081 -1,71 -1,41 -1,3 -1,22
UDP glucuronosyltransferase 2 family, polypeptide B35 Ugt2b35 243085 -1,72 -1,39 -1,15 -1,21
ATP-binding cassette, sub-family A (ABC1), member 8b Abca8b 27404 -1,73 -1,5 -1,53 -1,24
Aquaporin 11 Aqp11 66333 -1,73 -1,51 -1,45 -1,1
RIKEN cDNA A130090K04 gene A130090K04Rik 320495 -2,55 -2,33 -1,55 -1,76
-2,73 -2,43 -2,59 -2,4
 
#probe design_numbered: Affymetrix probe design information/ target description (see Supp. Table 1b); *cDNA sequence_numbered: gene transcript description (see Supp. Table 1b).
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solute carrier family 39 (metal ion transporter), member 8 Slc39a8 67547 -1,74 -1,34 -1,3 -1,34
cortactin binding protein 2 Cttnbp2 30785 -1,76 -2,22 -1,68 -1,04
pleckstrin homology domain containing, family C (with FERM domain) member 1 Plekhc1 218952 -1,76 -1,1 -1,2 -0,93
RasGEF domain family, member 1B Rasgef1b 320292 -1,76 -1,62 -1,21 -1,11
DEP domain containing 6 Depdc6 97998 -1,77 -1,87 -1,29 -1,38
dopa decarboxylase Ddc 13195 -1,8 -1,27 0,82 -0,72
cytochrome P450, family 2, subfamily s, polypeptide 1 Cyp2s1 74134 -1,85 -1,44 -1,32 -1,17
neuronal pentraxin 1 Nptx1 18164 -1,89 -1,41 -0,86 -0,94
Lrp2 binding protein Lrp2bp 67620 -1,9 -1,94 -1,35 -1,12
#probe design_23 -1,95 -1,83 -1,44 -1,16
purinergic receptor P2Y, G-protein coupled 12 P2ry12 70839 -1,96 -1,53 -1,11 -1,52
UDP-glucose pyrophosphorylase 2 Ugp2 216558 -1,97 -1,56 -1,16 -1,07
transmembrane protein 71 Tmem71 213068 -1,99 -1,55 -1,45 -1,36
cytochrome P450, family 1, subfamily a, polypeptide 1 Cyp1a1 13076 -2,03 -0,93 -0,86 -0,64
hydroxyprostaglandin dehydrogenase 15 (NAD) Hpgd 15446 -2,04 -0,75 1,15 0,9
sorbin and SH3 domain containing 2 Sorbs2 234214 -2,11 -1,52 -1,11 -0,82
angiopoietin 1 Angpt1 11600 -2,13 -1,77 -1,62 -1,01
avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog Maf 17132 -2,16 -1,79 -1,56 -1,72
DNA segment, human D4S114 D0H4S114 27528 -2,16 -1,16 0,9 0,82
avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog Maf 17132 -2,18 -1,7 -1,31 -1,56
avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog Maf 17132 -2,23 -1,38 -1,18 -1
RIKEN cDNA 1110059G02 gene 1110059G02Rik 68786 -2,27 -1,67 -0,72 -1,13
stearoyl-Coenzyme A desaturase 2 Scd2 20250 -2,51 -1,88 -1,67 -1,22
ATP-binding cassette, sub-family D (ALD), member 2 Abcd2 26874
1Microarray Fold Change ratio at different time points post-infection: positive and negative values represent genes up- and down-regulated, respectively.                                                                                    
Notes:

Albuquerque et al. , Supplementary Table 1b
#probe 
design Affymetrix probe design information/ target description
1 gb:AW741388 /DB_XREF=gi:7653171 /DB_XREF=ur54c07.x1 /CLONE=IMAGE:3154092 /FEA=EST /CNT=6 /TID=Mm.148901.1 /TIER=ConsEnd /STK=2 /UG=Mm.148901 /UG_TITLE=ESTs
2 gb:BQ176966 /DB_XREF=gi:20352458 /DB_XREF=UI-M-DJ2-bwa-o-19-0-UI.s1 /CLONE=UI-M-DJ2-bwa-o-19-0-UI /FEA=EST /CNT=3 /TID=Mm.117588.1 /TIER=ConsEnd /STK=2 /UG=Mm.117588 /UG_TITLE=ESTs
3 gb:BB748708 /DB_XREF=gi:16152944 /DB_XREF=BB748708 /CLONE=G030001K12 /FEA=EST /CNT=3 /TID=Mm.215937.1 /TIER=ConsEnd /STK=2 /UG=Mm.215937 /UG_TITLE=ESTs
4 gb:AW552076 /DB_XREF=gi:7197499 /DB_XREF=L0208A04-3 /CLONE=L0208A04 /FEA=EST /CNT=5 /TID=Mm.182691.1 /TIER=ConsEnd /STK=4 /UG=Mm.182691 /UG_TITLE=ESTs
5 gb:BE631223 /DB_XREF=gi:9913911 /DB_XREF=uu05g03.x1 /CLONE=IMAGE:3371092 /FEA=EST /CNT=24 /TID=Mm.2322.3 /TIER=Stack /STK=12 /UG=Mm.2322 /LL=18712 /UG_GENE=Pim1 /UG_TITLE=proviral integration site 1
6 gb:AI451554 /DB_XREF=gi:4304812 /DB_XREF=mu47b11.x1 /CLONE=IMAGE:642525 /FEA=EST /CNT=2 /TID=Mm.32490.1 /TIER=ConsEnd /STK=2 /UG=Mm.32490 /UG_TITLE=ESTs
7 gb:BB560961 /DB_XREF=gi:9647327 /DB_XREF=BB560961 /CLONE=E530118N19 /FEA=EST /CNT=7 /TID=Mm.86981.1 /TIER=ConsEnd /STK=5 /UG=Mm.86981 /UG_TITLE=ESTs
8 gb:BB447409 /DB_XREF=gi:16425180 /DB_XREF=BB447409 /CLONE=D030060G22 /FEA=EST /CNT=16 /TID=Mm.6358.1 /TIER=Stack /STK=9 /UG=Mm.6358 /UG_TITLE=ESTs
9 gb:BQ032894 /DB_XREF=gi:19768173 /DB_XREF=UI-1-CF0-axl-e-01-0-UI.s1 /CLONE=UI-1-CF0-axl-e-01-0-UI /FEA=EST /CNT=2 /TID=Mm.117583.1 /TIER=ConsEnd /STK=2 /UG=Mm.117583 /UG_TITLE=ESTs
10 gb:AW489857 /DB_XREF=gi:7060127 /DB_XREF=UI-M-BH3-aso-c-06-0-UI.s1 /CLONE=UI-M-BH3-aso-c-06-0-UI /FEA=EST /CNT=5 /TID=Mm.57956.1 /TIER=ConsEnd /STK=4 /UG=Mm.57956 /UG_TITLE=ESTs
11 gb:BE627361 /DB_XREF=gi:9907781 /DB_XREF=ut87f07.x1 /CLONE=IMAGE:3369445 /FEA=EST /CNT=30 /TID=Mm.10336.1 /TIER=Stack /STK=28 /UG=Mm.10336 /UG_TITLE=ESTs
12 gb:BB710847 /DB_XREF=gi:16064016 /DB_XREF=BB710847 /CLONE=B020018M09 /FEA=EST /CNT=3 /TID=Mm.212452.1 /TIER=ConsEnd /STK=3 /UG=Mm.212452 /UG_TITLE=ESTs
13 gb:BG069809 /DB_XREF=gi:12552378 /DB_XREF=H3080D04-3 /CLONE=H3080D04 /FEA=EST /CNT=14 /TID=Mm.24295.1 /TIER=Stack /STK=9 /UG=Mm.24295 /UG_TITLE=ESTs
14 gb:BB324785 /DB_XREF=gi:16403528 /DB_XREF=BB324785 /CLONE=B430111L14 /FEA=EST /CNT=4 /TID=Mm.210179.1 /TIER=ConsEnd /STK=2 /UG=Mm.210179 /UG_TITLE=ESTs
15 gb:AI464196 /DB_XREF=gi:4318226 /DB_XREF=vc88h09.x1 /CLONE=IMAGE:790145 /FEA=EST /CNT=2 /TID=Mm.220190.1 /TIER=ConsEnd /STK=2 /UG=Mm.220190 /LL=99653 /UG_GENE=AI464196 /UG_TITLE=expressed sequence AI464196
16 gb:BB048406 /DB_XREF=gi:8455554 /DB_XREF=BB048406 /CLONE=6430584J18 /FEA=EST /CNT=2 /TID=Mm.161167.2 /TIER=ConsEnd /STK=2 /UG=Mm.161167 /UG_TITLE=ESTs
17 gb:BG074824 /DB_XREF=gi:12557393 /DB_XREF=H3139G06-3 /CLONE=H3139G06 /FEA=EST /CNT=2 /TID=Mm.182743.1 /TIER=ConsEnd /STK=2 /UG=Mm.182743 /UG_TITLE=ESTs
18 gb:AI662750 /DB_XREF=gi:4766333 /DB_XREF=vb21d10.x1 /CLONE=IMAGE:749587 /FEA=EST /CNT=2 /TID=Mm.150125.1 /TIER=ConsEnd /STK=2 /UG=Mm.150125 /UG_TITLE=ESTs
19 gb:BB471757 /DB_XREF=gi:16427963 /DB_XREF=BB471757 /CLONE=D230040H21 /FEA=EST /CNT=2 /TID=Mm.209394.1 /TIER=ConsEnd /STK=2 /UG=Mm.209394 /UG_TITLE=ESTs
20 gb:BE949437 /DB_XREF=gi:10527196 /DB_XREF=UI-M-BH3-avi-h-07-0-UI.s1 /CLONE=UI-M-BH3-avi-h-07-0-UI /FEA=EST /CNT=8 /TID=Mm.205708.1 /TIER=ConsEnd /STK=3 /UG=Mm.205708 /UG_TITLE=ESTs
21 gb:BB258019 /DB_XREF=gi:8950852 /DB_XREF=BB258019 /CLONE=A730082I06 /FEA=EST /CNT=33 /TID=Mm.45298.1 /TIER=Stack /STK=8 /UG=Mm.45298 /LL=99692 /UG_GENE=AI649393 /UG_TITLE=expressed sequence AI649393
22 gb:AV164956 /DB_XREF=gi:15404628 /DB_XREF=AV164956 /CLONE=3110030K23 /FEA=EST /CNT=17 /TID=Mm.82292.1 /TIER=Stack /STK=15 /UG=Mm.82292 /UG_TITLE=ESTs
23 gb:BB535327 /DB_XREF=gi:16446530 /DB_XREF=BB535327 /CLONE=E030042O04 /FEA=EST /CNT=6 /TID=Mm.187844.1 /TIER=ConsEnd /STK=5 /UG=Mm.187844 /UG_TITLE=ESTs
*cDNA 
sequence Gene transcript description
1 Adult male corpus striatum cDNA, RIKEN full-length enriched library, clone:C030047F10 product:unknown EST, full insert sequence
2 7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730046J11 product:unclassifiable, full insert sequence
3 Adult male testis cDNA, RIKEN full-length enriched library, clone:4930525M22 product:unclassifiable, full insert sequence
4 0 day neonate skin cDNA, RIKEN full-length enriched library, clone:4632424N07 product:unknown EST, full insert sequence
5 Adult male epididymis cDNA, RIKEN full-length enriched library, clone:9230106H08 product:unclassifiable, full insert sequence
6 Adult male aorta and vein cDNA, RIKEN full-length enriched library, clone:A530047H08 product:unknown EST, full insert sequence
7 Adult female vagina cDNA, RIKEN full-length enriched library, clone:9930108O06 product:hypothetical protein, full insert sequence
8 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630054P20 product:unknown EST, full insert sequence
9 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130031H03 product:unclassifiable, full insert sequence
10 12 days embryo male wolffian duct includes surrounding region cDNA, RIKEN full-length enriched library, clone:6720461E04 product:unknown EST, full insert sequence
11 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630020J17 product:unknown EST, full insert sequence
12 Adult male aorta and vein cDNA, RIKEN full-length enriched library, clone:A530021B03 product:unknown EST, full insert sequence
13 10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:B930004G13 product:unknown EST, full insert sequence
14 0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130202F10 product:hypothetical protein, full insert sequence
15 10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:B930049N01 product:unclassifiable, full insert sequence
16 Adult male olfactory brain cDNA, RIKEN full-length enriched library, clone:6430531K17 product:unclassifiable, full insert sequence
17 Transcribed locus, moderately similar to XP_001066067.1 hypothetical protein [Rattus norvegicus]
Gene information

Supplementary Table 1 | Microarray data analysis reveals a total
 
of 611 genes 
differentially expressed throughout P. berghei
 
infection of Hepa1-6 cells.
List of the 611 genes differentially expressed during infection of Hepa1-6 cells by 
GFP-expressing P. berghei
 
sporozoites. For each gene is indicated the microarray fold 
change ratio at the different infection time points (6, 12, 18 and 24 h p.i.). The fold 
change positive and negative values represent genes up-
 
and down-regulated, 
respectively. In addition, detailed gene information is provided, i.e. the gene official 
full name, the official symbol and the National Center for Biotechnology Information 
(NCBI) gene accession number (http://www.ncbi.nlm.nih.gov/sites/entrez
 
for
 
 
Entrez
 
Gene Database). For some cases the gene specific sequence is not assigned and 
therefore the information is provided either through the labeling of “probe design”
 
or 
“cDNA
 
sequence”, which correspond to the Affymetrix
 
probe design 
information/target description or Affymetrix
 
gene transcript description,
 
 
respectively. The different “probe design”
 
or “cDNA
 
sequence”
 
were sequentially 
numbered in Supplementary Table 1a and their corresponding key is provided in 
Supplementary Table 1b.
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Gene Official Full Name Gene Official Symbol
NCBI Gene 
Accession 
Number
6h 12h 18h 24h
ChaC, cation transport regulator-like 1 (E. coli) Chac 1 69065 8,88 4,44 2,32 2,27
nuclear protein 1 Nupr1 56312 6,21 3,91 2,56 2,08
tribbles homolog 3 (Drosophila) Trib3 228775 4,79 3,71 2,79 2,54
DNA-damage inducible transcript 3 Ddit3 13198 4,65 3,23 1,41 1,48
growth arrest and DNA-damage-inducible 45 beta Gadd45b 17873 3,15 2,64 1,71 1,35
G protein-coupled receptor 137B Gpr137b 83924 2,99 3,76 3,19 1,73
activating transcription factor 3 Atf3 11910 2,99 1,82 1,48 1,58
neuropilin 2 Nrp2 18187 2,55 2,2 1,43 1,31
myeloid differentiation primary response gene 116 Myd116 17872 2,3 3,46 1,71 1,52
solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 Slc7a11 26570 1,97 2,37 1,7 1,27
activating transcription factor 5 Atf5 107503 1,69 1,39 1,63 1,45
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein K (avian) Mafk 17135 1,6 1,25 1,39 1,28
CCAAT/enhancer binding protein (C/EBP), beta Cebpb 12608 1,51 1,42 1,49 1,25
B-cell linker Blnk 17060 1,5 1,84 1,81 1,45
Kruppel-like factor 4 (gut) Klf4 16600 1,43 1,35 1,26 1,57
zinc finger protein 296 Zfp296 63872 1,42 1,35 1,49 1,3
translocase of inner mitochondrial membrane 10 homolog (yeast) Timm10 30059 1,41 1,41 1,32 1,24
small proline-rich protein 1B Sprr1b 20754 1,39 2,21 2,27 2,31
ATPase, H+ transporting, lysosomal V0 subunit B Atp6v0b 114143 1,28 1,36 1,34 1,45
Nur77 downstream gene 2 Ndg2 103172 1,23 1,97 2,67 2,39
gelsolin Gsn 227753 0 1,29 2,12 1,69
heme oxygenase (decycling) 1 Hmox1 15368 1,31 0 1,84 0
C-type lectin domain family 4, member d Clec4d 17474 0 2,26 1,42 0
CCAAT/enhancer binding protein (C/EBP), delta Cebpd 12609 3,08 0 0 0
Tnf receptor-associated factor 1 Traf1 22029 2,88 0 0 0
Gene information
Microarray Fold Change ratio at 
different time points p.i. (FC 
threshold 1.2)
Gene Official Full Name Gene Official Symbol
NCBI Gene 
Accession 
Number
6h 12h 18h 24h
vascular cell adhesion molecule 1 Vcam1 22329 2,93 0 0 0
caspase 4, apoptosis-related cysteine peptidase Casp4 12363 2,24 0 0 0
CDC42 effector protein (Rho GTPase binding) 3 Cdc42ep3 260409 1,59 1,25 1,21 0
zinc fingers and homeoboxes protein 2 Zhx2 387609 1,56 0 0 0
zinc finger protein 423 zfp423 94187 1,55 1,47 1,39 0
zinc finger CCCH type containing 8 Zc3h8 57432 1,52 0 0 0
zinc finger and BTB domain containing 20 Zbtb20 56490 0 -1,54 0 0
hydroxyprostaglandin dehydrogenase 15 (NAD) Hpgd 15446 -2,04 0 0 0
low density lipoprotein receptor Ldlr 16835 -1,24 -1,35 -1,69 0
bone marrow stromal cell antigen 1 Bst1 12182 0 -1,42 -1,9 0
early growth response 2 Egr2 13654 -1,25 -1,81 -2,44 -2,54
chemokine (C-X-C motif) ligand 15 Cxcl15 20309 -1,32 -1,92 -1,33 -1,46
kinesin family member 5C Kif5c 16574 -1,42 -1,48 -1,46 -1,37
solute carrier family 16 (monocarboxylic acid transporters), member 4 Slc16a4 229699 -1,6 -1,43 -1,46 -1,27
selenium binding protein 1 Selenbp1 20341 -1,66 -1,63 -1,9 -1,29
aldolase 3, C isoform Aldoc 11676 -1,69 -1,82 -1,9 -1,28
acyl-CoA synthetase long-chain family member 1 Acsl1 14081 -1,71 -1,41 -1,3 -1,22
avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog Maf 17132 -2,16 -1,79 -1,56 -1,72
stearoyl-Coenzyme A desaturase 2 Scd2 20250 -2,51 -1,88 -1,67 -1,22
RIKEN cDNA A130090K04 gene A130090K04Rik 320495 -2,55 -2,33 -1,55 -1,76
ATP-binding cassette, sub-family D (ALD), member 2 Abcd2 26874 -2,73 -2,43 -2,59 -2,4
Gene information
Microarray Fold Change ratio at 
different time points p.i. (FC 
threshold 1.2)
Supplementary Table 2 | Genes selected from the microarray data and included in 
the RNAi screen to access their functional role in Plasmodium infection.  
List of the 46 genes differentially expressed throughout Plasmodium
 
infection and for 
which their functional relevance in infection was addressed by RNAi. For each gene 
is provided the relevant gene information together with the microarray fold change 
ratio at the different infection time points (6, 12, 18 and 24 h
 
p.i.). The different values 
reflect the expression levels, with positive and negative values
 
corresponding to         
up-
 
and down-regulated genes, respectively. A fold change threshold of at least 1.2 
(FC_1.2) was applied for this selection. Zero represents that the gene did not 
assemble the FC_1.2 criteria and therefore was considered as not
 
differentially 
expressed. 
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Gene information Gene emergence (in %) in IPA networks*
Gene Official Full Name
Gene 
Official 
Symbol
NCBI 
Gene 
Acc. Nb.
Infected 
samples 
Non-infected 
samples 
FBJ osteosarcoma
 
oncogene Fos 14281 6,7 2,4
myelocytomatosis
 
oncogene c-Myc 17869 8,9 3,5
tumor necrosis factor Tnf 21926 13,3 2,4
Rous
 
sarcoma oncogene Src 20779 4,4 0
transformation related protein 53# Tp53 22059 8,9 8,2
Notes: 
*Central genes emergence in Ingenuity Pathway (IPA ) networks analysed
 
in the dataset 
of infected samples and non-infected samples datasets. The non-infected sample dataset 
is considered as the control condition. All values are expressed
 
in percentage (%).         
#Tp53  gene was considered as a positive control since it emerged
 
equally in the infected 
as well as in the non-infected dataset.
Supplementary Table 3 | Central genes percentage of recurrence in gene networks 
composed by the genes modulated throughout Plasmodium
 
infection and also other 
associated genes. 
List of the central genes included in the RNAi screen
 
and selected based on gene network 
analyses with the Ingenuity Pathway Software (IPA). The central genes emergence in
 
IPA 
networks was analyzed in the dataset of infected and non-infected samples and their 
frequency is expressed as a percentage (%). The non-infected dataset is considered as the 
control condition and the Tp53 gene as a positive control, meaning that is not 
considerably associated with Plasmodium infection, since it emerged equally in the 
infected as well as in the non-infected dataset.
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Gene
Official
Symbol
NCBI 
Gene
Accession
Nb
NCBI  
Accession ID 
for Targeted
Transcripts 
siRNA
ID from 
Supplier 
Infection
Rate
Cell
Proliferation
Atf3 11910 NM_007498 60299 134,47 94,83
Atf3 11910 NM_007498 60299 140,74 122,51
Bst1 12182 NM_009763 214981 152,88 101,17
Bst1 12182 NM_009763 214981 158,14 99,77
Cebpb 12608 NM_009883 214962 145,75 120,13
Cebpb 12608 NM_009883 214962 134,44 119,09
Fos 14281 NM_010234 158593 129,65 83,16
Fos 14281 NM_010234 158595 129,35 105,72
Kif5c 16574 NM_008449 215005 144,14 106,55
Kif5c 16574 NM_008449 215005 152,25 106,87
Slc7a11 26570 NM_011990 188174 143,09 99,53
Zbtb20 56490 NM_019778 214992 133,53 100,87
A130090K04Rik 320495 NM_001033391 215038 66,54 111,00
A130090K04Rik 320495 NM_001033391 215038 79,56 115,37
Ldlr 16835 NM_010700 67892 34,12 85,97
Ldlr 16835 NM_010700 67892 67,39 111,89
c-Myc 17869 NM_010849 68392 50,84 79,89
c-Myc 17869 NM_010849 68392 66,09 86,42
c-Myc 17869 NM_010849 156407 79,93 75,55
c-Myc 17869 NM_010849 156407 71,66 82,23
Src 20779 NM_009271 150978 80,27 99,24
Supplementary Table 4 | Genes identified from the first RNAi screening pass as 
candidates to influence P. berghei
 
sporozoite infection of Hepa1-6 cells. 
List of 11 genes selected from the first RNAi pass to undergo into the second confirmation 
round. For each gene is provided the relevant information, namely the gene official symbol, 
the NCBI gene accession number (Nb), the NCBI accession ID for targeted transcripts, the 
siRNA
 
ID from the supplier (Ambion, Applied Biosystems) for which a phenotype was 
observed and the observed infection rate (corresponding to the number of EEFs normalized 
to confluency, shown as the percentage of plate-specific negative controls) and cell 
proliferation (number of cell nuclei expressed as % of plate mean).
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Gene 
Official
Symbol
NCBI
Gene
Accession
Nb
NCBI 
Accession ID
for Targeted
Transcripts 
siRNA
ID from
Supplier
Infection
Rate
Cell
Proliferation
Atf3 11910 NM_007498 60299 142,98 94,48
Atf3 11910 NM_007498 240520 158,85 145,68
Atf3 11910 NM_007498 240520 136,05 120,47
c-Myc 17869 NM_010849 68392 69,17 76,59
c-Myc 17869 NM_010849 156407 62,16 65,52
Supplementary Table 5 | Genes confirmed in the second RNAi screening pass as 
candidates to influence P. berghei
 
sporozoite infection of Hepa1-6 cells. 
The 2 genes selected from the second RNAi pass to undergo to the
 
third confirmation 
round. Gene information is the same as in Supplementary Table 4.
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Gene 
Official 
Symbol
NCBI 
Gene 
Acc. Nb
NCBI  
Accession ID 
for Targeted 
Transcripts 
siRNA
 
ID
Infection 
Rate
Cell 
Proliferation Remaining mRNA
Atf3 11910 NM_007498 48555 172,65 88,94 39,43
Atf3 11910 NM_007498 48642 204,52 115,86 9,88
Atf3 11910 NM_007498 60393 165,17 122,19 35,97
Atf3 11910 NM_007498 159756 178,00 120,19 45,00
Atf3 11910 NM_007498 240519 170,96 118,93 64,28
Atf3 11910 NM_007498 240520 166,50 125,67 43,27
c-Myc 17869 NM_010849 47943 91,41 99,23 44,48
c-Myc 17869 NM_010849 68392 77,20 80,45 70,60
c-Myc 17869 NM_010849 156407 78,02 74,35 54,17
c-Myc 17869 NM_010849 240550 99,20 107,49 79,22
Supplementary Table 6 | Atf3 and c-Myc
 
silencing data obtained in the third RNAi 
confirmation round. 
Atf3 and c-Myc
 
silencing was performed through the treatment with 6 and 4 distinct 
siRNAs, respectively. The infection phenotype outcome was once again accessed and in 
addition was also determined the specific-gene mRNA level (shown as % relative to the 
negative control). For both genes the relevant information is provided for all the siRNAs 
used, following the same criteria as explained previously in Supplementary Table 4 and 5. 
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Gene Official 
Symbol
NCBI 
Gene Acc. 
Nb.
siRNA1 siRNA2 siRNA3 siRNA1 siRNA2 siRNA3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA6
A130090K04Rik 320495 215037 215038 215039 215038 215039 240571
Abcd2 26874 214995 214996 214997
Acsl1 14081 215016 215017 215018
Aldoc 11676 215034 215035 215036
Atf3 11910 60299 60393 159756 60299 240519 240520 49555 48642 60393 159756 240519 240520
Atf5 107503 84801 172161 172163
Atp6v0b 114143 214986 214987 214988 214963 214964 214986
Blnk 17060 62728 62899 155208
Bst1 12182 214980 214981 214982 65854 214981 240537
Casp4 12363 60483 60674 160000
Cdc42ep3 260409 214989 214990 214991 80897 214989 240564
Cebpb 12608 214960 214961 214962 66041 214962 288793
Cebpd 12609 215013 215014 215015
Chac1 69065 81375 81464 180675
Clec4d  17474 68179 68275 68370
Cxcl15 20309 69078 69263 151595
Ddit3 13198 61044 61140 61228 288790 288791 288792
Egr2 13654 66675 158361 158362
Fos 14281 67034 158593 158595 66846 158593 158595
Gadd45b 17873 214977 214978 214979
Gpr137b 83924 215007 215008 215009
Gsn 227753  90697 90887 170256
Hmox1 15368 67540 158978 158979
Hpgd 15446 214983 214984 214985
Kif5c 16574 215004 215005 215006 155043 155044 215005
Gene information siRNA ID from Supplier (Ambion, Applied Biosystem)Pass 3Pass 1 Pass 2
Gene Official 
Symbol
NCBI 
Gene Acc. 
Nb.
siRNA1 siRNA2 siRNA3 siRNA1 siRNA2 siRNA3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA6
Klf4 16600 215025 215026 215027 67853 215027 240545
Ldlr 16835 67892 156096 156097 67988 67892 156096
Maf 17132 215031 215032 215033
Mafk 17135 68032 68126 156226 67937 156224 156226
Myc 17869 68203 68392 156407 47943 68392 156407 47943 68392 156407 240550
Myd116 17872 63095 63187 155481 63003 63187 155481
Ndg2 103172 214974 214975 214976
Nrp2 18187 215010 215011 215012 166858 215010 215012
Nupr1 56312 74306 185512 185513 74124 74306 185513
Scd2 20250 215019 215021
Selenbp1 20341 214957 214958 214959
Slc16a4 229699 90710 170275 170277 90806 90900 170275
Slc7a11 26570 70494 70588 188174 70588 188172 188174
Sprr1b 20754 101439 101530 101606
Src 20779 64804 150978 150979 150978 240568 240567
Timm10 30059 71849 71944 184165
Tnf 21926 71316 188363 188364
Traf1 22029 215022 215023 215024
Trib3 228775 215001 215002 215003
Vcam1 22329 214998 214999 215000
Zbtb20 56490 214992 214993 214994
Zc3h8 57432 75183 165931 165932
Zfp296 63872 76296 76487 182288
Zfp423 94187 85277 85372 166171
Zhx2 387609 215028 215029 215030
Gene information siRNA ID from Supplier (Ambion, Applied Biosystem)Pass 1 Pass 2 Pass 3
Supplementary Table 7 | siRNAs used to access the functional role of the
 
 
corresponding target gene in Plasmodium infection throughout the three
 
 
confirmation phases of the RNAi approach.
The list of the RNAi screened genes together with the number and
 
siRNAs ID used in 
the different confirmation phases is supplied. The siRNAs for which an increase or 
decrease in infection was observed are highlighted in red and green, respectively.
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Kinome-wide RNAi screen identifies host PKCζ as a critical 
kinase for Plasmodium sporozoite infection 
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Results 
 
 
When sporozoites of Plasmodium, the causative agent of malaria, are injected into 
their vertebrate host through the bite of an infected Anopheles mosquito, they 
travel to the liver where they invade hepatocytes and develop into merozoites that 
are then released into the blood and give rise to the clinical phase of infection. 
Since the combined activities of kinases and phosphatases can tightly control 
numerous cellular processes, we sought to examine the role of host kinases in P. 
berghei sporozoites infection of hepatocytes using RNA interference. 
Quantification of infection of Huh7 cells following transfection with 2306 siRNAs 
identified at least 6 host kinases playing crucial roles during P. berghei sporozoite 
infection. This screen represents the first comprehensive identification of novel 
host factors involved in Plasmodium sporozoite infection. Moreover, in order to 
provide a final validation of the screen, we have studied one of these kinases for 
which available tools, such as a pseudo-subtrate inhibitor, exist and showed that 
the host aPKCς plays a role in P. berghei and P. falciparum sporozoite infection of 
hepatocytes. Moreover, down-modulation of aPKCς in vivo in the liver leads to a 
reduction of liver infection up to 90%.  
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Intracellular phosphorylation and dephosphorylation events are enzymatically 
catalysed by kinases and phosphatases, respectively, and constitute the most 
important signalling mechanisms known in eukaryotic cells (Hunter, 2000). The 
phosphorylation state of a protein can determine its activity and, thereby, regulate the 
pathway(s) in which it is involved.  
Malaria, caused by the protozoan parasite of the genus Plasmodium, is transmitted 
through the bite of an infected female Anopheles mosquito. Plasmodium sporozoites 
enter the mammalian host and travel to the liver. Once there, they cross several 
hepatocytes before invading a final one, with formation of a parasitophorous vacuole 
(Mota et al., 2001). Each invading parasite then replicates asexually into several 
thousand merozoites that constitute a so-called exoerythrocytic form (EEF) of 
Plasmodium. This asymptomatic stage of infection is followed by the release of 
merozoites into the blood stream, where they invade erythrocytes, initiating the 
blood-stage of infection, which is responsible for the malaria-associated symptoms. 
Plasmodium sporozoites display a marked tropism for hepatocytes, the only cells 
where they are able to undergo the huge replication process that results in the 
formation of thousands of merozoites from each invading parasite [reviewed in 
(Prudencio et al., 2006)]. In fact, in hepatocytes, Plasmodium achieves one of the fastest 
growth rates among eukaryotic cells. In addition, there is increasing evidence that the 
asymptomatic hepatic stage of infection, triggers an immune response in the 
vertebrate host (Waters et al., 2005; Renia et al., 2006). In conjunction, these facts 
constitute a clear indication that the host liver cells do not play a passive role during 
Plasmodium infection and that host factors that strongly influence its fate must exist. 
Since the combined activities of kinases and phosphatases can tightly control 
numerous cellular processes, it seems logical to assume that they can modulate the 
cell’s behaviour during the infection process by an intracellular pathogen. For this 
reason, we decided to use RNA interference (RNAi) to selectively silence the 
expression of 727 genes in the human genome, encoding all the known proteins with 
putative kinase activity, as well as several kinase-interacting proteins (Supplementary 
Table 1). The effect of gene knock-down on Plasmodium infection of Huh7 cells, a 
human hepatoma cell line, was monitored by high-throughput, high-content 
immuno-fluorescence microscopy.  
Short interfering RNA oligonucleotides (siRNAs) with sequences complementary to 
those of the genes of interest were designed and used to transfect Huh7 cells seeded 
24 h earlier in 96-well plates. Forty-eight h after transfection cells were infected with 
P. berghei sporozoites freshly extracted from the salivary glands of infected Anopheles 
stephensi mosquitoes. Cells were fixed and immuno-stained for parasite, host cell 
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nuclei and actin 24 h after infection. Following image acquisition, the number of EEFs, 
nuclei and cell confluency were automatically determined. Candidate genes 
underwent three screening passes with increasing stringency criteria (Figure 1a). 
Infection was quantified by normalizing the number of EEFs against the cell 
confluency in each well. In order to compare results across different plates, a second 
level of normalization was introduced by calculating the infection level in each 
experimental well as a percentage of the average infection of the whole plate. In order 
to account for proliferation or cell toxicity effects, infection data obtained in this way 
were plotted against the number of nuclei in the same experimental well, expressed as 
a percentage of the average number of nuclei within the plate. 
To validate the experimental procedure outlined above Huh7 cells were transfected 
with 2 siRNAs targeting the Met gene, whose knock-down is known to lead to a 
decrease in infection of HepG2 cells by Plasmodium (Carrolo et al., 2003). Met knock-
down was confirmed by quantitative Real-Time PCR (qRT-PCT) and a significant 
decrease in infection was observed relative to controls (data not shown). Two types of 
negative controls, untransfected cells and cells transfected with a negative control 
siRNA not targeting any annotated genes in the human genome, were included in 
every experimental plate and all experimental conditions were assayed in triplicate 
wells.  
The 727 selected genes were initially screened by targeting each of them with three 
independent siRNA oligonucleotides (Supplementary Table 1). This corresponds to a 
total of 2181 siRNAs in twenty-four 96-well plates that were used to transfect a total of 
72 experimental cell plates. Approximately 10% of these genes were selected to 
undergo a second screening pass. In order to minimize the number of false negative 
results, genes were selected for which the knock-down in expression with at least one 
siRNA led to a statistically significant effect on infection levels with a negligible effect 
on cell proliferation (Figure 1b).  
Seventy-four genes were selected to undergo a confirmation round of the screen. For 
most of these, an additional two siRNAs were designed and included in the assay 
(Supplementary Table 1). Infection increase or decrease was considered significant 
when it was greater or smaller than 2.0 standard deviations of the average of all the 
negative controls in the assay, respectively. To minimize the chances of false positive 
results at this stage, selection of candidate genes required that at least two 
independent siRNAs targeting the same gene met the selection criteria, leading to 
either a significant increase or decrease in infection (Figure 1c). All the siRNAs were 
assayed in triplicate and in two independent experiments yielding very consistent 
results, demonstrating the robustness of the experimental approach employed (Figure 
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1d). Only those siRNAs for which the selection criteria were met in both experiments 
were considered as candidates for the next confirmation round. 
The 19 genes selected for further verification were targeted with the siRNAs yielding 
the strongest infection increase or decrease phenotypes in the previous round of the 
screen. In order to increase the stringency of the selection, genes were selected for the 
final confirmation step only if at least two siRNAs targeting each of them led to an 
infection increase or decrease greater or smaller than 3.0 standard deviations of the 
average of all the negative controls in the assay, respectively (Figure 2a). 
The knock-down level attained for the eight genes that met these criteria was then 
assessed by qRT-PCR. A good correlation between the infection phenotypes observed 
when targeting these genes by RNAi and their corresponding mRNA levels at the 
time of sporozoite addition was observed for 6 of these genes (Figure 2b, Table 1). It 
can thus be concluded that MET, PKCι, PKCζ, PRKWNK1, SGK2 and STK35 are likely 
to play important roles during infection of host hepatocytes by Plasmodium. It should 
be noted that the present data does not fully rule out the possible involvement of 
other genes among those tested here, as negative results in RNAi screens are 
generally inconclusive (Echeverri et al., 2006). 
The protein kinase (PK) complement of the human genome was thoroughly analyzed 
in a seminal paper by Manning et al. (Manning et al., 2002) that divided the human 
kinome in ten major groups, based on sequence comparison of their catalytic 
domains, sequence similarities, domain structures and biological functions. In 
addition to these PKs, the present screen also included a number of additional genes 
that can be included in three additional classes: lipid kinases, other non-protein 
kinases (i.e., proteins that phosphorylate substrates other than proteins and lipids) 
and proteins without kinase activity but known or proposed to interact with kinases 
(such as kinase anchors or inhibitors). The relative representations of these groups 
throughout the screen were analysed (Figure 2c). The eight genes in Table 1 belong to 
4 different classes, with the “AGC” and “other” groups having the larger 
representations. An analysis of the selected genes in terms of their ontology (Figure 
2d) can be indicative of the cellular processes that are likely to be preferentially 
exploited or subverted by the parasite during infection. Agaisse et al. (Agaisse et al., 
2005) have used RNAi to identify host factors that influence infection of Drosophila 
cells by intracellular bacterial pathogens. They conclude that these factors span a wide 
range of cellular functions with particular emphasis for gene products involved in cell 
cycle, vesicular trafficking and cytoskeleton. The genes identified by the present 
screen have also been implicated in various cellular processes, suggesting a complex 
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response of the host to the invading parasite. The list includes genes involved in cell 
cycle control, cytoskeleton regulation and stress/immune response.  
MET encodes the hepatocyte growth factor (HGF) receptor and has previously been 
shown to influence Plasmodium infection of hepatocytes (Carrolo et al., 2003; Leiriao et 
al., 2005). It has been demonstrated that HGF/MET signaling facilitates infection, an 
effect that has been proposed to occur through inhibition of apoptosis (Leiriao et al., 
2005). MET was used to establish the validity of the screening method and, 
reassuringly, underwent all the steps in the screen emerging as one of the genes 
whose knock-down consistently led to a decrease in infection.  
Both SGK2 and PRKWNK1 are serine/threonine kinases that have been implicated in 
osmotic control through the regulation of Na+ and K+ transport channels (Gamper et 
al., 2002; Friedrich et al., 2003; Moriguchi et al., 2005; Anselmo et al., 2006). Down-
modulation of both of these osmotic and oxidative stress-responsive proteins led to a 
reduced infection in the present screen. Although their exact role in Plasmodium 
infection is not obvious, it is tempting to speculate that their function is exploited by 
the parasite in order to create an osmotic balance that favors infection.  
STK35 is a poorly characterized gene product, known to interact with CLP-36, a PDZ-
LIM protein, and re-localize from the nucleus to actin stress fibres. This suggested that 
STK35 may act as a regulator of the actinmyosin cytoskeleton in non-muscle cells 
(Vallenius and Makela, 2002). In the present screen, knock-down of STK35 led to a 
decrease in infection by Plasmodium. It has been suggested that host cell actin 
cytoskeleton reorganization processes may be important for Plasmodium infection 
(Carrolo et al., 2003). Thus, it is possible that recruitment of STK35 may be enhanced 
by the parasite in a way that favors cell infection. 
Protein kinase C (PKC) is a family of proteins that has been implicated in numerous 
cellular processes. PKC isotypes constitute a family of 10–15 members, divided in 4 
groups (Mellor and Parker, 1998). One of these groups, known as the atypical PKCs 
(aPKCs) (Moscat and Diaz-Meco, 2000), comprises the PKCζ (PKCzeta) (Ono et al., 
1989) and PKCλ/ι (PKCiota/lambda) (Akimoto et al., 1994) isoforms, both of which 
were targets in the present screen. The aPKCs have been implicated in numerous 
processes, including cell growth and survival, regulation of NF-κB activation and 
polarity (reviewed in (Moscat and Diaz-Meco, 2000; Moscat et al., 2006; Suzuki and 
Ohno, 2006)). In the present screen, the down-modulation of PKCλ/ι caused an 
increase in infection whereas the knock-down in the expression of PKCζ led to an 
infection decrease. This is particularly interesting since these two proteins that have a 
72% overall amino acid identity (Akimoto et al., 1994) were, for a long time, 
considered redundant. In fact, only recently has a distribution of functions between 
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the two aPKC isoforms begun to emerge (Suzuki et al., 2003; Soloff et al., 2004; 
Muscella et al., 2005), the exact details of which remain largely to be understood. The 
results presented here clearly suggest that these two proteins do indeed serve 
different purposes in the cell, in what may be viewed as a manifestation of the 
intricate relations that exist between molecular structure and function. 
In order to provide a final validation for the results of the RNAi screen, the aPKCζ 
was selected for further investigation, to ascertain whether it indeed plays a role in 
Plasmodium infection of hepatocytes. The screen results show that knock-down of 
PKCζ leads to a decrease in Huh7 cell infection by P. berghei sporozoites. This RNAi-
based identification of PKCζ was further validated by testing the effects on infection 
of a known PKCζ pseudo-substrate inhibitor (PKCζInh). Addition of the PKCζInh to 
cells 1 h prior to sporozoite addition led to a marked, dose-dependent decrease in 
infection rate as compared to control samples, measured by flow citometry 24 h after 
P. berghei sporozoite addition, in two different hepatoma cell lines (Figure 3a and 
Supplementary Figure 1). Importantly, infection rates were not affected by pre-
incubation of Plasmodium sporozoites with PKCζInh for 1 h prior to addition to cells, 
showing that PKCζInh has no effect on sporozoite viability (Figure 3b). The efect of 
PKCζInh on infection was further confirmed using a qRT-PCR-based assay that 
quantifies infection rates by measuring levels of Plasmodium 18S RNA found within 
Huh7 cell extracts harvested 24 h after P. berghei sporozoite addition (Prudêncio et al., 
2007) (Figure 3c). Our results show that a 20 μM concentration of PKCζInh leads to 
~50% reduction in Plasmodium infection rates. Interestingly, this is in agreement with 
the IC50 of 10-20 μM reported for this compound (Standaert et al., 1997). As the above 
experiments were all performed using hepatoma cell lines infected with the rodent 
malaria parasite P. berghei, we sought to validate the role of PKCζ in Plasmodium 
infection under more physiologically relevant conditions. To this end, we first 
confirmed that inhibition of PKCζ also leads to a reduction in P. berghei infection of 
primary mouse hepatocytes (Figure 3d). In addition, the role of PKCζ was also tested 
for P. falciparum infection, the most pathogenic Plasmodium spp. for humans, in 
primary human hepatocytes 72h after sporozoite addition, using a similar qRT-PCR-
based assay. Once again, PKCζInh treatment of human primary hepatocytes caused a 
significant and specific decrease of P. falciparum infection in these cells (Figure 3e,              
P < 0.05). 
Finally, we also confirmed the relevance of these findings in vivo, using systemically-
delivered, liposome-formulated siRNAs to silence PKCζ expression in adult mice and 
subjecting these to infection by P. berghei sporozoites. Here, the qRT-PCR-based assay 
was used to quantify infection rates by measuring levels of Plasmodium 18S RNA 
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found within extracts of liver samples harvested 40 h after intravenous (i.v.) 
sporozoite injection. In vivo RNAi treatments have previously yielded potent gene-
specific knock-downs in rodent livers using cholesterol-conjugated siRNAs or in non-
human primates after systemic administration of siRNAs encapsulated in stable lipid-
nanoparticles. In our experiments, PKCζ expression was also reduced successfully in 
adult mouse livers using 3 distinct PKCζ-specific siRNAs, each of which yielded ~56-
73% remaining PKCζ mRNA, as measured by qRT-PCR of tissue extracts taken 76 h 
after a single i.v. injection and normalization to PKCζ mRNA levels in the livers of 
adult mice treated with control siRNA (Fig 3f). When compared to control siRNA 
treatment, this administration of PKCζ-specific siRNAs resulted in a significant 
reduction of liver infection by P. berghei sporozoites, yielding ~9-40% of control 
infection loads, as measured by qRT-PCR of P. berghei 18S rRNA in samples taken 40h 
after sporozoite injection (Fig 3f, P < 0.01, black bars). In a parallel experiment, mice 
treated with one of the PKCζ siRNAs also showed a reduction in the number of 
parasites reaching the bloodstream, when compared to their controls (Figure 3g,              
P < 0.001). While by day 4 after sporozoite injection, all mice in the control group were 
positive for blood stages, none of the 6 mice in the group pre-treated with PKCζ-
specific siRNA were positive. In fact, by day 5 only 2 mice became positive in this last 
group.  
Although the dissection of the role of the aPKCs in the establishment of a malaria 
infection clearly merits further attention, these results clearly demonstrate that this 
approach constitutes a valid and important strategy for the identification of genes that 
clearly influence the infection of hepatocytes by Plasmodium under physiological 
conditions. 
The RNAi technology has been successfully employed to systematically address the 
role of specific groups of genes in various cellular processes using both Drosophila cell 
lines (Ramet et al., 2002; Lum et al., 2003; Boutros et al., 2004; Agaisse et al., 2005) and 
more recently mammalian cells (Berns et al., 2004; Fraser, 2004; Paddison et al., 2004; 
Pelkmans et al., 2005). However, the approach described here constitutes, to our 
knowledge, the first report of a kinome-wide RNAi screen of factors that influence the 
outcome of a parasitic infection in human cells. This RNAi approach enabled the 
unequivocal establishment of an important role for several genes in facilitating or 
hampering Plasmodium infection of a human hepatoma cell line, shedding light on the 
fundamental biology of this process and opening avenues for further investigation. 
Attention should be drawn to the fact that the list of potentially important genes 
should not be restricted to those outlined in Table 1. In fact, RNAi is an evolving field, 
with algorithms of increasing efficiency in designing siRNA oligonucleotides able of 
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effectively silencing the expression of their target genes constantly being developed. 
Moreover, depending on the specific turnover of the proteins encoded by each 
targeted gene and on the efficiency of the knock-down process itself, the down-
modulation of certain genes may be more prone to having a detectable effect with the 
phenotypic assessment method used. Due to the very stringent criteria employed 
throughout the screen, it is not unlikely that certain genes may not have reached the 
final screening stage despite their relevance for infection. Thus, all phenotype details 
for all siRNAs used are described (Supplementary Table 1). Altogether, these results 
contribute towards an understanding of host-pathogen interactions, which may help 
fostering the rational design of prophylactic and/or therapeutic strategies against 
infectious diseases in general and malaria in particular. 
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Methods 
 
Cells, mice and parasites  
Huh7 cells were maintained in RPMI medium (Gibco/Invitrogen) supplemented with 
10% fetal calf serum (FCS, Gibco/Invitrogen), 1% glutamine (Gibco/Invitrogen), 1% 
non-essential aminoacids (Gibco/Invitrogen) and 1% HEPES, pH 7.0 
(Gibco/Invitrogen) in the presence of penicillin/streptomycin (pen/strep, 
Gibco/Invitrogen) and grown at 37 ºC and 5% CO2.  
C57BL/6 mouse primary hepatocytes were isolated by perfusion of mouse liver 
lobules with liver perfusion medium and liver digest medium (Gibco/Invitrogen) and 
purified using a 1.12 g/ml; 1.08 g/ml and 1.06 g/ml Percoll gradient. Cells were 
cultured in William´s E medium containing 4% FCS, 1% pen/strep, 50 mg/ml 
epidermal growth factor (EGF), 10 µg/ml transferrin, 1 µg/ml insulin and 3.5 µM 
hydrocortisone in 24 well plates coated with 0,2% Gelatine in PBS. Cells were 
maintained in culture at 37°C and 5% CO2.   
Human primary hepatocytes were isolated from the healthy parts of liver biopsies 
from patients undergoing a partial hepatectomy with informed consent provided, as 
previously described (Mazier et al., 1985). Freshly isolated human primary 
hepatocytes were cultured in Williams Medium E supplemented with 10% FCS, 1% 
glutamine, 1% insuline/transferrine/selenium (Invitrogen), 10-7 M dexamethasone 
(Sigma), 1% sodium piruvate, 2% pen/strep in 48 well plates coated with rat tail 
collagen, type I. Cells were maintained in culture at 37ºC and 5% CO2. Medium was 
supplemented with 2% DMSO after complete cell adhesion (12-24h) and until 1 h 
before infection. 
C57BL/6 mice were bred and housed in the pathogen-free facilities of the Instituto 
Gulbenkian de Ciência and Instituto de Medicina Molecular, respectively. All 
protocols were approved by the Animal Care Committee of both Institutes.  
Green fluorescent protein (GFP)-expressing P. berghei (parasite line 259cl2) sporozoites 
(Franke-Fayard et al., 2004) or P. falciparum sporozoites (NF 54 strain) were obtained 
from dissection of infected female Anopheles stephensi mosquito salivary glands. 
 
siRNA design, siRNA library and screening controls 
Custom siRNA library sets were designed (Cenix Bioscience GmbH) and synthesized 
(Ambion/Applied Biosystems, Austin USA) with three siRNA duplexes for each gene 
target (Supplementary Table 1). For selected genes, two additional siRNAs were 
designed and synthesized. Negative control samples included untransfected cells and 
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cells transfected with a negative control siRNA not targeting any annotated genes in 
the human genome. A pre-validated siRNA targeting the met gene (see text), leading 
to a decrease in infection, was included as positive control in all plates. The siRNA 
duplexes were arrayed in a 96-well format.  
 
High-throughput siRNA screening of Plasmodium infection 
Huh7 cells (4500 per well) were seeded in 100 µl complete RPMI medium in optical 
96-well plates (Costar) and incubated at 37ºC in 5% CO2. Twenty-four h after seeding, 
cells were transfected with individual siRNAs in a final concentration of 100 nM per 
lipofection. Each siRNA was transfected in triplicate. Briefly, for each well, cell 
supernatant was replaced by 80 µl of serum-free culture medium without antibiotics. 
One µl of 10 µM siRNA diluted in 16 µl of Opti-MEM (Invitrogen.) was complexed 
with 0.4 µl Oligofectamine (Invitrogen) diluted with 2.6 µl Opti-MEM and added onto 
the cells following the manufacturer′s protocol.  Four h after addition of the complex, 
50 µl of fresh RPMI medium, supplemented with 30% FCS, 3% pen/strep, 3% non-
essential amino acid, 3% glutamine and 3% HEPES were added to the cells. Two days 
after siRNA transfection, cells were infected with 104 P. berghei sporozoites/well. 
Twenty-four h after infection, cells were fixed with 4% paraformaldehyde (PFA) in 
PBS and permeabilized with 0.2% saponin in PBS. Cell nuclei were stained with 
Hoechst-33342 (Molecular Probes/Invitrogen), filamentous actin was stained with 
Phalloidin AlexaFluor488 (Molecular Probes/Invitrogen), EEFs were detected using 
the mouse monoclonal antibody 2E6 (Tsuji et al., 1994) and an AlexaFluor555-labeled 
goat anti-mouse secondary antibody (Molecular Probes/Invitrogen).  
 
Automated image acquisition and analysis 
Plates were acquired with a Discovery1 automated fluorescence microscope 
(Molecular Devices Corporation, CA, USA) using a 10x lens. In each well, cell nuclei, 
actin and EEFs were imaged in 9 fields covering a total area of 2.7 x 2.0 mm. Image 
data was analyzed using a custom MetaMorph (Molecular Devices Corporation, CA, 
USA) based algorithm extracting the following values for each imaged field: cell 
proliferation as measured by the number of nuclei per imaged field (Hoechst 
staining), cell confluency as measured by the percentage of the imaged field covered 
by actin staining and number of EEFs as number of compact, high contrast objects in a 
size range from 16 to 150 pixels. Within each field, the number of EEFs was 
normalized to the cell confluency. Normalized EEF numbers and number of nuclei 
were averaged between the 9 imaged fields within each well. Mean and standard 
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deviations were calculated for each experimental triplicate. Final readouts included 
number of EEFs and number of nuclei, shown as a percentage of the plate mean.  
 
Gene-specific expression and infection quantification by qRT-PCR 
For gene-specific expression in vitro, total RNA was isolated from Huh7 cells 48 h 
post-transfection (Invitek Invisorb 96-well plate kit) and converted into cDNA (ABI’s 
HighCapacity cDNA reagents) with random hexamers, following the manufacturer 
recommendations. qRT-PCR used the SybrGreen method with Quantace qPCR 
mastermix at 11 µl total reaction volume, containing 500 nM of the target-specific 
primers, and primers that were designed to specifically amplify a fragment of the 
selected genes. Real-time PCR reactions were performed on an ABI Prism 7900HT 
system. Relative amounts of remaining mRNA levels of RNAi targets were calculated 
against the level of RPL13A or 18S rRNA, as housekeeping genes. Remaining mRNA 
levels of RNAi-treated samples were compared with those of samples transfected 
with Negative unspecific siRNA. RPL13A-specific primer sequences were: 5’-CCT 
GGA GGA GAA GAG GAA AGA GA-3’ and 5’-TTG AGG ACC TCT GTG TAT TTG 
TCA A-3’. 18S rRNA-specific primer sequences were: 5’-CGG CTT AAT TTG ACT 
CAA CAC G-3’ and 5’-TTA GCA TGC CAG AGT CTC GTT C-3’. 
For infection determination in vivo, in vitro or ex vivo, total RNA was isolated from 
livers, Huh7 cells or primary hepatocytes using Qiagen’s RNeasy Mini or Micro kits, 
respectively for livers and cells, following the manufacturer’s instructions. The 
determination of liver parasite load in vivo, was performed according to the method 
developed for P. yoelii infections (Bruna-Romero et al., 2001). Livers were collected 
and homogenized in denaturing solution (4 M guanidine thiocyanate; 25 mM sodium 
citrate pH 7, 0.5 % sarcosyl and 0.7 % β-Mercaptoethanol in DEPC-treated water), 40 h 
after sporozoite injection. Total RNA was extracted using Qiagen’s RNeasy Mini kit, 
following the manufacturer’s instructions. RNA for infection measurements was 
converted into cDNA using Roche’s Transcriptor First Strand cDNA Synthesis kit, 
according to the manufacturer’s protocol. The qRT-PCR reactions used Applied 
Biosystems’ Power SYBR Green PCR Master Mix and were performed according to 
the manufacturer’s instructions on an ABI Prism 7000 system (Applied Biosystems). 
Amplification reactions were carried out in a total reaction volume of 25 µl, containing 
0,8 pmoles/µl or 0,16 pmoles/µl of the Plasmodium- or housekeeping gene-specific 
primers, respectively. Relative amounts of Plasmodium mRNA were calculated against 
the Hypoxanthine Guanine Phosphoribosyltransferase (HPRT) housekeeping gene. 
18S PbA- and mouse HPRT-specific primer sequences were 5’- AAG CAT TAA ATA 
AAG CGA ATA CAT CCT TAC – 3’ and 5’ - GGA GAT TGG TTT TGA CGT TTA 
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TGT G – 3’and 5’ – GTA ATG ATC GTC GTC AAC GGG GGA – 3´ and 5’ – CCA 
GCA AGC TTG CAA CCT TAA CCA – 3’, respectively. 18S Pf- and human HPRT-
specific primer sequences were 5’- CTG GTT TGG GAA AAC CAA AT – 3’ and 5’ – 
CTC AAT CAT GAC TAC CCG TCT G – 3’and 5’ – TGC TCG AGA TGT GAT GAA 
GG – 3´ and 5’ – TCC CCT GTT GAC TGG TCA TT – 3’. For PKCζ mRNA level 
determination by qRT-PCT, mouse or human PKCζ-specific primers (from 
SuperArray, USA; catalog number PPM05103A and PPH02321B, respectively) were 
used according to the manufacturer’s protocol. 
 
PKCζ inhibition in Huh7 cells 
Freshly-prepared serial dilutions of PKCζ pseudo-substrate inhibitor, Myristoylated 
(PKCζInh, from Calbiochem/Merck KGaA, Germany) were added to Huh7 cells 1h 
before sporozoite addition. Infection level was determined 24 after sporozoite 
addition (1-3 × 104 per well, depending on the experiment) by FACS or qRT-PCR, 
depending on the experiment. As control, a dilution of PBS, matching that present in 
the most concentrated inhibitor preparation was used.  
Infection level determination by FACS was performed through the quantification of 
the percentage of parasite-containing cells (cell population GFP+). Cell samples for 
FACS analysis were washed with 1 ml PBS, incubated with 150 µl trypsin for 5 min at 
37 ºC and collected in 400 µl 10% FCS in PBS at the selected time-points post-
sporozoite addition. Cells were then centrifuged at 0.1 g for 3 min at 4 ºC and 
ressuspended in 150 µl 2% FCS in PBS. Cells were analysed on a Becton Dickinson 
FACScalibur with the appropriate settings for the fluorophores used. Data acquisition 
and analysis were carried out using the CELLQuest (version 3.2.1fl1, Becton 
Dickinson) and FlowJo (version 6.3.4, FlowJo) software packages, respectively. 
For infection measurement by qRT-PCR, as described above, cell samples were 
collected for RNA extraction in 150 µl of RLT buffer (Qiagen) containing 0.1% β-
mercaptoethanol. 
 
PKCζ inhibition in mouse and human primary hepatocytes  
C57BL/6 mouse primary hepatocytes (10 × 104 per well) were incubated with 20 µM 
PKCζInh one h prior to infection with 5 × 104 freshly extracted P. berghei sporozoites. 
Forty-eight h after infection, cells were collected in 150 µl of RLT buffer (Qiagen) 
containing 0.1% β-mercaptoethanol for RNA extraction and infection measurement by 
qRT-PCR. 
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Human primary hepatocytes (10 × 104 cells per well) were incubated with 20 µM 
PKCζInh one h prior to infection with 10 × 104 freshly extracted P. falciparum 
sporozoites. Three days after infection, cells were collected in 150 µl of RLT buffer 
(Qiagen) containing 0.1% β-mercaptoethanol for RNA extraction and infection 
measurement by qRT-PCR. 
 
In vivo RNAi 
C57BL/6 mice (male, 6-8 weeks) were treated with a single intravenous (i.v.) 
administration of 5 mg/kg of siRNA formulated in liposomal nanoparticles (Alnylam, 
Germany).  Three different modified siRNAs targeting PKCζ, were used. A modified 
siRNA targeting luciferase was used as control. Thirty-six h after siRNA 
administration mice were infected by i.v. injection of 2 × 104 P. berghei sporozoites. 
Remaining PKCζ mRNA levels and parasite load in the livers of infected mice were 
determined by qRT-PCR 40 h after sporozoite injection, 76 h after siRNA 
administration. Infection of mice treated with one PKCζ siRNA was allowed to 
proceed onto the blood stage and parasitemia (% of infected red blood cells) was 
measured daily.  
 
Statistical analysis 
Statistical analysis was performed using unpaired Student t or ANOVA parametric 
tests. P < 0.05 and P < 0.051 were considered statistically significant. 
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Figure 1 | A kinome-wide RNAi screen identifies candidate host genes that 
influence P. berghei
 
sporozoite infection of Huh7 cells. 
(a) Schematic illustration of the experimental workflow for the cell-based RNAi
 
 
screening approach used to explore the influence of known proteins with putative 
kinase
 
activity, as well as several kinase-interacting proteins in the outcome of P. 
berghei
 
sporozoite infection of Huh7 cells. The candidate genes underwent three 
screening passes with increasing stringency criteria. (b) Plot of pass 1 of the RNAi 
screen representing the effect of 2181 siRNAs targeting 727 human genes on Huh7 
cell infection by P. berghei
 
sporozoites and cell nuclei count. Infection rates for each 
experimental condition were normalized against cell confluency. The horizontal lines 
represent 100% ±
 
2.0 s.d. of the average of all data in the assay. Each circle represents 
one siRNA
 
(mean of triplicate values). Negative controls appear as blue and green 
circles, corresponding to untreated cells and cells transfected
 
with a non-specific 
control siRNA, respectively. Red circles highlight the siRNAs targeting the 74 
candidate genes selected to undergo a second screening pass.
 
(c) Plot of 2 
independent runs of pass 2 of the RNAi screen representing the effect of 229 siRNAs 
targeting 74 human genes on Huh7 cell infection by P. berghei
 
sporozoites and cell 
nuclei count. Experimental conditions, normalization criteria as
 
well as colour
 
attributions are the same as in panel
 
(b), with red circles representing the siRNAs 
targeting the 19 genes selected to undergo a third screening pass. The horizontal lines 
represent 100% ±
 
2.0 s.d. of the average of all the negative controls in the assay.
 
(d) 
Plot comparison of the 2 runs of pass 2 of the RNAi screen. Colour
 
attributions are 
the same as in panel (b).
 
The comparison reveals a high correlation (R = 0.88) 
between the duplicate pass 2 of the screen.
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Figure 2 | Identification and analysis of host kinases and related genes affecting 
infection by P. berghei
 
sporozoites. 
(a) Plot of pass 3 of the RNAi screen representing the effect of 43 siRNAs targeting 19 
human genes on Huh7 cell infection by P. berghei
 
sporozoites and cell nuclei count. 
Colour
 
attributions are the same as in Figure 1. Red circles highlight
 
genes selected 
for final confirmation. The horizontal lines represent 100% ±
 
3.0 s.d. of the average of 
all the negative controls in the assay.
 
(b) Effect of siRNA
 
on infection rates versus
 
remaining mRNA levels for genes selected on pass 3 of the screen. Each circle 
represents one siRNA
 
(mean of triplicate values) with the siRNAs targeting PKCι
 
in 
yellow, STK35 in light orange, WNK1 in orange, PKCζ
 
in red, SGK2 in dark grey and 
MET in black. For all genes except GUK1 and ULK1, represented in
 
light grey, a 
positive correlation between infection rate and remaining gene-specific mRNA levels 
is observed.
 
(c) Data analysis for the RNAi screen in terms of gene distribution 
through kinase
 
and kinase-related families and (d)
 
based on gene ontology and 
molecular function.
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Figure 3 | PKCζ
 
inhibition effect on infection confirms the physiological 
relevance of the RNAi screen results. 
(a) PKCζ
 
inhibition by a pseudo-substrate inhibitor (PKCζInh) decreases
 
P. berghei 
sporozoite infection of Huh7 cells in a dose-dependent manner. PKCζInh
 
was added 
to Huh7 cells 1 h before GFP-expressing P. berghei
 
sporozoite addition and infection 
rate was measured 24 h later, by flow cytometry.
 
(b) Infection load was not affected 
by pre-incubating P. berghei
 
sporozoites with PKCζInh
 
for 1 h prior to addition to 
cells. Results are expressed as the mean ±
 
s.d. of GFP+
 
cells (%) in 3 independent 
infections.
 
(c-e) PKCζInh
 
(20 μM) reduces P. berghei
 
load in Huh7 cells
 
(c) or mouse 
primary hepatocytes (d) and P. falciparum
 
load in human primary hepatocytes
 
(e). 
Parasite loads were measured by qRT-PCR 24 h, 48 h or 5 days after sporozoite 
addition, respectively. Results are expressed as the mean ±
 
s.d. of triplicate samples. 
“C”
 
indicates solvent-treated cells used as control and results were normalized to C 
levels (100%).
 
(f) Effect of siRNA-mediated in vivo
 
silencing of PKCζ
 
on mouse liver 
infection by P. berghei, measured by qRT-PCR analysis of liver extracts taken 40 h 
after sporozoite i.v. injection. Results are plotted as the percentage of the mean of 
negative control samples “C”. The remaining mRNA levels for PKCζ
 
were measured 
by qRT-PCR in the same liver samples. Each circle represents one siRNA
 
(mean of 5 
mice per group). Black circle represents the negative control (luciferase-targeting 
siRNA). Red circles highlight the 3 independent siRNAs targeting the PKCζ
 
gene.
 
(g) 
Knock-down of PKCζ
 
expression by RNAi delays the onset of blood stage infection, 
as measured by parasitemia
 
quantification (percentage of infected red blood cells, 
iRBC) using flow cytometry. Results are expressed as the mean ±
 
s.d. of 6 mice per 
group.
165

Prudêncio
 
et al., Supplementary Figure
 
1
167
Supplementary Figure 1 | PKCζ
 
inhibition effect on P. berghei
 
infection of     
Hepa1-6 cells. 
(a) PKCζ
 
inhibition by a pseudo-substrate inhibitor (PKCζInh) decreases
 
P. berghei 
sporozoite infection of Hepa1-6 cells in a dose-dependent manner. PKCζInh
 
was 
added to Hepa1-6 cells 1 h before GFP-expressing P. berghei
 
sporozoite addition and 
infection rate was measured 24 h later, by flow cytometry.
C
In
fe
ct
io
n 
R
at
e
(%
 o
f c
on
tro
l G
FP
+
ce
lls
[PKCζInh]( μM)
0
50
100
150
5 10 20

Prudêncio
 
et al., Table
 
1
Gene name Kinome
 
Group Main described functions
NCBI Gene 
Accession
 
Number
MET TK Cell growth and proliferation 4233
PRKCI AGC Cell growth and survival; cytoskeleton organisation 5584
PRKCZ AGC Cell growth and survival; cytoskeleton organisation 5590
SGK2 AGC Regulation of transport; apoptosis 10110
PRKWNK1 Other Group Regulation of salt transport; cell growth 65125
STK35 Other Group Regulation of actin stress fibers 140901
Gene name NCBI Accession ID for Targeted Transcripts
siRNA
 
ID from 
Supplier1
Infection 
Rate2
Cell 
Proliferation3
Remaining 
mRNA4
MET NM_000245 242542; 242543 76,2 78,4 35,7
PRKCI NM_002740 311; 242360 130,2 98,1 18,0
PRKCZ NM_002744 103575; 242362 75,6 86,3 23,4
SGK2 NM_170693;NM_016276 1485; 1579; 1669 66,2 100,0 38,2
PRKWNK1 NM_018979 1269; 242540 74,2 103,7 15,7
STK35 NM_080836 1135; 103377; 103461 71,7 97,4 30,1
1Ambion, Applied Biosystems; 2number of EEFs normalised to confluency, shown as % of plate mean; 
3number of cell nuclei, shown as % of plate mean; 4% relative to negative control.
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Table 1 | Host kinases and related genes identified as important
 
for Huh7
 
 
infection by P. berghei
 
sporozoites.
The NCBI gene accession number and accession ID for targeted transcripts, as well as 
the kinome
 
group and main described function are provided for the genes identified 
in the RNAi screen. In addition the infection rate (corresponding to the number of 
EEFs normalized to confluency, shown as % of plate mean), cell proliferation
 
 
(number of cell nuclei, shown as % of plate mean) and remaining mRNA (% relative 
to negative control) data from Pass 3 are also shown. The values
 
correspond to the 
average of the data of the siRNAs yielding a phenotype change for each gene.

Prudêncio et al. , Supplementary Table 1
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
ABL1 25 1241 1336 1431
ABL2 27 1478 1662 103346 103346 242409 242410
ACVR1 90 76 77 78 76 242344 242345
ACVR1B 91 1331 103589 111240
ACVR2 92 143 144 103568
ACVR2B 93 79 80 81
ACVRL1 94 11 12 13
ADK 132 1474 1568 1658
ADRBK1 156 147 103304 103391
ADRBK2 157 628 629 630
AK1 203 65 66 110741
AK2 204 41652 41815 147152
AK3 205 915 916 917 916 242490 242491
AKT1 207 632 42811 118270
AKT2 208 149 150 103305
ALK 238 499 500 501
AMHR2 269 1044 1045 1046
ARAF1 369 151 152 153
ATM 472 111194 118231 118232
ATR 545 82 83 103302
AXL 558 1218 1313 1408
BCR 613 1237 1332 110844
BLK 640 154 155 156
BMPR1A 657 502 503 504
BMPR1B 658 85 87 103565
BMPR2 659 1438 1623 110763
BMX 660 157 158 159
BRAF 673 506 507 110846
BRDT 676 160 161 162
BTK 695 14 15 16
BUB1 699 508 509 510
BUB1B 699 88 89 90
DDR1 780 1221 1316 1411
CALM1 801 146695 146696 146697
CALM2 805 145935 145936 145937
CALM3 808 634 636 111245
CAMK4 814 163 164 165
Gene Information Pass 1 Pass 3Pass 2
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
CAMK2A 815 1484 1578 1668
CAMK2B 816 9477 9571 9662
CAMK2D 817 91 93 118256
CAMK2G 818 40536 40631 40719
CDC2 983 1625 42819 103821
CDC2L1 984 41656 214537 214538 41656 214537 214538 41656 214537 214538
CDK2 1017 1314 1409 42820
CDK3 1018 94 95 96
CDK4 1019 44756 44852 213350
CDK5 1020 1466 1560 1650
CDK6 1021 98 99 42822
CDK7 1022 166 167 168
CDK8 1024 100 101 102
CDK9 1025 103 104 103567
CDKN1A 1026 1436 1531 1621 1436 242474 242475
CDKN1B 1027 118712 118713 118714 118712 242378 242379 118712 242378
CDKN1C 1028 2789 118537 119424 119424 242331 242332
CDKN2A 1029 118858 119508 119509
CDKN2B 1030 118739 118740 118741
CDKN2C 1031 118622 118623 119531
CDKN2D 1032 118644 118645 118646
CDKN3 1033 637 45016 45105
CHEK1 1111 106 107 108
CHKA 1119 109 110 111 109 242492 242493
CHKB 1120 202425 202426 202427
CHUK 1147 112 113 114
CKB 1152 170 118235 118236
CKM 1158 172 173 110772
CKMT1 1159 1178 1273 1368
CKMT2 1160 175 176 177
CLK1 1195 479 480 110837
CLK2 1196 43833 43929 44017
CLK3 1198 1233 1328 1423
PLK3 1263 103318 103806 103809 103809 242380 242381
MAP3K8 1326 118272 118273 118274
MAPK14 1432 1217 1312 111198
CSF1R 1436 641 642 643
CSK 1445 511 512 513
CSNK1A1 1452 178 179 180
Gene Information Pass 1 Pass 2 Pass 3
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
CSNK1D 1453 1220 1315 1410
CSNK1E 1454 1441 1536 1626
CSNK1G2 1455 115 117 118258
CSNK1G3 1456 103320 103404 103486
CSNK2A1 1457 1146 1242 1337
CSNK2A2 1459 181 183 103306
CSNK2B 1460 9710 9806 9896
DGKA 1606 118 119 120
DGKB 1607 1235 1330 1425
DGKG 1608 121 122 123
DGKQ 1609 124 125 126
DAPK1 1612 598 599 600
DAPK3 1613 129 103790 103795
DCK 1633 68 69 103564
DGUOK 1716 1514 1606 1695
DLG1 1739 146326 146327 146328
DLG3 1741 146766 146767 146768
DLG4 1742 145816 145817 145818
DMPK 1760 517 518 519
DOK1 1796 145825 145826 145827
DTYMK 1841 1152 45179 45274
DYRK1A 1859 1439 1534 1624
EGFR 1956 644 42833 110895
EPHA2 1969 520 521 110852 520 242384 242385 520 242384
MARK2 2011 1582 103359 103443 103359 103443 242440 242441 103359 103443
EPHA1 2041 647 648 649
EPHA3 2042 652 103330 103414 103330 103414 103330 103414
EPHA4 2043 523 524 525
EPHA5 2044 1460 1555 1645
EPHA7 2045 527 528 103321
EPHA8 2046 1041 1042 118289
EPHB1 2047 1149 1245 1340
EPHB2 2048 1487 1581 1671
EPHB3 2049 529 530 531
EPHB4 2050 533 103322 103406
EPHB6 2051 535 536 537
ERBB2 2064 42836 103546 103552
ERBB3 2065 184 185 186
Gene Information Pass 1 Pass 2 Pass 3
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
ERBB4 2066 103331 103415 103497
ERF 2077 3387 3483 115797
ERN1 2081 130 131 132
PTK2B 2185 484 103319 103403
FER 2241 657 658 103594
FES 2242 187 188 189
FGFR1 2260 1216 1311 118296
FGFR3 2261 103815 110725 110728
FGFR2 2263 1215 118291 118292
FGFR4 2264 103307 103394 103816
FGR 2268 1468 1562 1652
FLT1 2321 190 191 192
FLT3 2322 487 488 489
FLT3LG 2323 44790 44886 144682
FLT4 2324 193 194 195
FRK 2444 1147 1243 1338
FRAP1 2475 601 602 603 603 242386 242387
FYN 2534 1442 1537 1627
GAK 2580 661 103332 103416
GALK1 2584 20 21 22
GALK2 2585 198 103570 103624
GCK 2645 1507 1600 1690
GCKR 2646 144707 144708 144709
GK 2710 24 25 103562
GK2 2712 1200 1295 1390
GRK4 2868 662 663 664
GRK5 2869 666 667 110898
GRK6 2870 199 200 201
MKNK2 2872 1157 1252 1347
GSK3A 2931 1492 1586 1676
GSK3B 2932 202 203 204
GUCY2C 2984 604 605 606
GUCY2F 2986 133 134 135
GUK1 2987 71 72 103786 71 72 242335 242336 71 72
GUCY2D 3000 26 27 28
HCK 3055 205 206 207 205 206 207 205 207
HK1 3098 1506 1599 1689
HK2 3099 1433 1528 1618
HK3 3101 208 209 210
Gene Information Pass 1 Pass 2 Pass 3
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
IGF1R 3480 74 103301 110754
IKBKB 3551 147120 147121 147122
ILK 3611 1461 1556 1646
INSR 3643 103297 103384 103467
INSRR 3645 103722 103730 103738
IRAK1 3654 136 137 138
IRAK2 3656 139 140 141
ITK 3702 701 702 703
ITPK1 3705 921 922 923
ITPKA 3706 211 212 213
ITPKB 3707 214 215 216
JAK1 3716 217 218 219
JAK2 3717 607 608 609
JAK3 3718 32 33 34
KDR 3791 220 221 222
KHK 3795 103298 103385 103468
KIT 3815 35 36 37
LCK 3932 668 669 670
LIMK1 3984 1223 1318 1413
LIMK2 3984 1469 1563 1653
LTK 4058 223 224 111201
LYN 4067 226 227 103571
MARCKS 4082 11454 143479 143480
MAK 4117 734 735 736
MARK1 4139 1173 1268 1363
MARK3 4140 229 230 231
MATK 4145 1443 1538 1628
MAP3K1 4214 202512 202513 202514
MAP3K3 4215 234 103572 103626
MAP3K4 4216 1470 1564 1654
MAP3K5 4217 737 738 739
MET 4233 42825 242542 242543 242542 242543 242544 242542 242543
SCGB2A1 4246 44821 143538 143539 143539 242352 242353 143539 242352 242353
MAP3K9 4293 202330 202394 202395
MAP3K10 4294 1444 1539 1629
MAP3K11 4296 235 236 103787
MOS 4342 671 672 673 672 242388 242389
MST1R 4486 237 103308 103395
Pass 2 Pass 3Gene Information Pass 1
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
MUSK 4593 704 705 706
MVK 4598 56 57 58
MYLK 4638 1603 1692 103376
NEK1 4750 147471 147472 147473
NEK2 4751 240 241 242 240 242354 242355
NEK3 4752 1445 1540 1630 1540 1630 242356 242357
NME1 4830 41 42 43
NME2 4831 244 245 111203
NME3 4832 42872 42968 118241
NME4 4833 610 612 110871
NPR1 4881 1437 1532 1622
NPR2 4882 1234 1424 110833 110833 242337 242338
NRGN 4900 17411 17506 144200
NTRK1 4914 42873 42969 43056
NTRK2 4915 752 753 754
NTRK3 4916 246 247 248
ROR1 4919 613 614 615
ROR2 4920 541 542 543
DDR2 4921 757 118276 118277
PAK1 5058 249 250 251
PAK2 5062 252 110776 110779
PAK3 5063 255 256 257 255 242358 242359
PCM1 5108 144220 144221 144222
PCTK1 5127 1472 1566 1656
PCTK2 5128 258 259 260
PCTK3 5129 202294 202295 202296
PDGFRA 5156 758 759 760
PDGFRB 5159 1446 1541 1631
PDK1 5163 261 103573 103627
PDK2 5164 264 265 266
PDK3 5165 674 675 676
PDK4 5166 267 268 269
PDPK1 5170 270 271 272
PFKFB1 5207 273 274 275
PFKFB2 5208 761 762 763
PFKFB3 5209 103323 103407 103489
PFKFB4 5210 547 548 549
PFKL 5211 276 277 278
PFKM 5213 44 46 103563
Gene Information Pass 1 Pass 2 Pass 3
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
PFKP 5214 279 280 281
PFTK1 5218 118282 118283 118284
PGK1 5230 48 103299 110731
PGK2 5232 1204 1299 1394
PHKA1 5255 143791 143792 143793
PHKA2 5256 143277 143278 143279
PHKB 5257 143280 143281 143282
PHKG1 5260 764 765 766 765 242394 242395
PHKG2 5261 110737 118254 118293
PIK3C2A 5286 143796 143797 143798
PIK3C2B 5287 143799 143800 143801
PIK3C2G 5288 143925 143926 143927
PIK3C3 5289 143802 143803 143804
PIK3CA 5290 144250 144251 144252
PIK3CB 5291 144253 144254 144255
PIM1 5292 1447 1542 1632
PIK3CD 5293 143975 143976 143977
PIK3CG 5294 143807 143808 143809
PIK3R1 5295 118085 118086 118087
PIK3R2 5296 143978 143979 143980
PIK4CA 5297 1511 1604 1693
PIK4CB 5298 282 283 284
PIP5K2A 5305 616 617 618
PKLR 5313 53 54 55
PKM2 5315 285 286 287
PLK1 5347 1341 42856 103548
PRKAA1 5562 767 768 769 767 242396 242397
PRKAA2 5563 772 103599 103652
PRKAB1 5564 142927 142928 142929
PRKAB2 5565 142837 142838 142839
PRKACA 5566 292 293 103574
PRKACB 5567 294 295 118253
PRKACG 5568 297 298 299
PKIA 5569 143005 143006 143007
PKIB 5570 34178 34263 143137
PRKAG1 5571 11916 12010 12098
PRKAR1A 5573 42857 44836 44930
PRKAR1B 5575 142277 142278 142279
PRKAR2A 5576 490 491 492
Gene Information Pass 1 Pass 2 Pass 3
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
PRKAR2B 5577 142280 142281 142282
PRKCA 5578 300 301 302
PRKCB1 5579 304 103309 103396
PRKCD 5580 774 775 103600
PRKCE 5581 677 678 679
PRKCG 5582 306 307 308
PRKCH 5583 777 778 103822
PRKCI 5584 309 311 110781 309 311 242360 242361 311 242360
PKN1 5585 312 314 111207
PKN2 5586 779 780 781
PRKCM 5587 103310 103397 103479
PRKCQ 5588 782 783 784
PRKCSH 5589 11918 12012 12100
PRKCZ 5590 103575 103629 103679 103575 242362 242363 103575 242362
PRKDC 5591 842 844 103604
PRKG1 5592 785 786 787
PRKG2 5593 790 103337 103421
MAPK1 5594 1449 1544 1634
MAPK3 5595 142304 142305 202320
MAPK4 5596 318 319 320
MAPK6 5597 1450 1545 1635 1545 242364 242365
MAPK7 5598 1414 110787 110792
MAPK8 5599 1225 1320 1415
MAPK11 5600 103311 103807 103810
MAPK9 5601 1452 1547 1637
MAPK10 5602 1517 1608 103378
MAPK13 5603 321 322 323
MAP2K1 5604 324 325 326
MAP2K2 5605 1080 1081 1082
MAP2K3 5606 1518 1609 1698
MAP2K5 5607 1519 1699 118252
MAP2K6 5608 1226 1321 103576
MAP2K7 5609 103744 103745 103746
PRKR 5610 328 329 42855
PRKRIR 5612 142801 142802 142803
PRKX 5613 1151 1247 1342
PRKY 5616 332 103312 103805
PRPS1 5631 335 111211 118242
PRPS2 5634 336 337 338
Gene Information Pass 1 Pass 2 Pass 3
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
PSKH1 5681 1476 1570 1660
PTK2 5747 708 103596 103649
PTK6 5753 740 741 742 740 741 742
PTK7 5754 339 340 341
PTK9 5756 342 343 344
ALDH18A1 5832 345 346 347
MAP4K2 5871 550 103590 103643
RAGE 5891 924 925 926 924 242421 242422
RAF1 5894 1548 1638 42858
RET 5979 1435 1530 1620
GRK1 6011 349 111213 111215 349 111215 242366 242367
RNASEL 6041 1179 1274 1369
BRD2 6046 118266 118267 118268
ROCK1 6093 680 681 682
ROS1 6098 353 110795 110797
RPS6KA1 6195 354 355 356
RPS6KA2 6196 1053 1054 1055
RPS6KA3 6197 553 554 555
RPS6KB1 6198 1454 1639 110802
RPS6KB2 6199 469 470 471
RYK 6259 357 358 103579
MAPK12 6300 360 44843 44935
MAP2K4 6416 363 103580 103634
SGK 6446 711 103597 103650
SKIV2L 6499 143038 143039 143040
SKP2 6502 142899 142900 142901
SRC 6714 683 684 103333
SRMS 6725 1131 1132 1133
SRPK1 6732 365 366 367
SRPK2 6733 103743 103749 103752
NEK4 6787 371 373 103581
STK3 6788 791 792 103601
STK4 6789 794 795 103602 794 795 242398 242399
STK6 6790 425 426 427
CDKL5 6792 374 375 376
STK10 6793 743 744 745
STK11 6794 59 60 61
AURKC 6795 378 379 111219
Gene Information Pass 1 Pass 2 Pass 3
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
SYK 6850 380 381 382
TAF1 6872 103547 103553 103559
MAP3K7 6885 1522 1613 1702
TEC 7006 383 384 385
TEK 7010 64 103300 103387
TESK1 7016 797 798 799 799 242400 242401
TGFBR1 7046 556 557 103324
TGFBR2 7048 386 387 388
TIE 7075 686 687 688
TK1 7083 389 390 391
TK2 7084 559 560 561
TRIO 7204 849 103343 103427
TTK 7272 392 393 394
TTN 7273 1515 1607 1696 1696 242370 242371
TXK 7294 395 396 397
TYK2 7297 398 399 400
TYRO3 7301 800 801 802
UGP2 7360 830 831 832
UCK2 7371 893 894 895
VRK1 7443 401 402 403
VRK2 7444 803 804 805 805 242402 242403
WEE1 7465 405 103582 103636
YES1 7525 690 103334 103418
ZAP70 7535 103736 110756 110759
MAP3K12 7786 103338 103422 103503
MAPKAPK3 7867 562 563 564
BRD3 8019 869 111249 111251 111249 242411 242412 111249 242412
MLL2 8085 107160 107161 115436
AKAP1 8165 139096 139097 139098
TRRAP 8295 408 103314 103399 103314 242374 242375
CDC7 8317 410 411 412
NME5 8382 13281 13442 139132
PIP5K1A 8394 415 103583 118245
PIP5K1B 8395 139134 139135 139136
PIP5K2B 8396 1227 1322 110806
ULK1 8408 118259 118260 118261 118261 242376 242377
STK24 8428 419 420 421
DYRK3 8444 424 103315 103400
DYRK2 8445 103339 103423 103504
Gene Information Pass 1 Pass 2 Pass 3
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
CDC42BPA 8476 430 22066 103791 430 22066 103791 242428 242429
MAP4K3 8491 1455 1550 1640
PIK3R3 8503 139246 139247 139248
IKBKG 8517 139260 139261 139262
IKBKAP 8518 139263 139264 139265
DGKZ 8525 432 433 111093
DGKE 8526 434 435 436
DGKD 8527 1228 1323 1418
CAMK1 8536 437 438 439
MAPKAPK5 8550 1229 1419 103379
CDK10 8558 1420 111225 111229
PDXK 8566 440 441 442
MADD 8567 139308 139309 139310
MKNK1 8569 445 111234 111236
CASK 8573 446 447 448
PRKRA 8575 449 450 451
STK16 8576 1457 1552 103584 1457 242342 242343
CDC2L5 8621 1231 1326 1421
SCAP1 8631 139355 139356 139357
MAP2K1IP1 8649 138573 138574 138575 138573 242456 242457
TNK1 8711 477 110823 110827
RIPK1 8737 452 453 454
RIPK2 8767 455 456 103585
RIOK3 8780 1232 1327 1422
DYRK4 8798 43832 43928 44016
TIF1 8805 103317 103402 103484
CDKL1 8814 1459 1554 1644
CDK5R1 8851 459 46067 110814
AKAP4 8852 137315 137316 137317
STK19 8859 1504 1597 1687
SPHK1 8877 1181 1276 1371
PRPF4B 8899 460 461 462
RPS6KA4 8986 463 464 103586
CDKL2 8999 466 467 468
MAP3K14 9020 474 118262 118263
STK29 9024 13849 13942 14032
PAPSS2 9060 1463 1557 1647
PAPSS1 9061 693 694 103595
Gene Information Pass 1 Pass 2 Pass 3
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
MAP3K6 9064 1558 103325 103491
PKMYT1 9088 41898 41988 118297
LATS1 9113 565 566 567
HGS 9146 137616 137617 137618
DYRK1B 9149 1239 1334 1429
DGKI 9162 571 572 573
MAP3K13 9175 103327 103411 103493
DCAMKL1 9201 576 103591 110854
AURKB 9212 494 495 103587
RPS6KA5 9252 580 581 103592
MFHAS1 9258 14331 14426 14519
MAPKAPK2 9261 1598 1688 103613
STK17B 9262 498 103588 118265
STK17A 9263 585 110861 110863
TAO1 9344 118285 118286 118287
MAP4K4 9448 1240 1335 1430
EIF2AK3 9451 592 594 103593
PRKCABP 9463 138239 138240 138241
AKAP7 9465 138632 138633 138634
AKAP6 9472 137533 137534 137535
ROCK2 9475 595 596 110867
MAPK8IP1 9479 16356 16447 137929
AKAP5 9495 15339 137774 137775
CDC42BPB 9578 746 747 103598
AKAP12 9590 137856 137857 137858
IKBKE 9641 918 919 920 918 242417 242418
ULK2 9706 954 955 956 956 242427
SLK 9748 957 958 959
IHPK1 9807 1213 1308 1403
MELK 9833 960 961 103349
KIAA0626 9848 1180 1275 1370
TLK1 9874 884 885 886 884 242415 242416
ARK5 9891 964 103350 103843
MRC2 9902 749 750 751
XYLB 9942 103329 103413 103495
OSR1 9943 625 626 627
AKT3 10000 695 697 110901
GNE 10020 698 699 700
SGK2 10110 1485 1579 1669 1485 1579 1669 242482 242483 1485 1579 1669
Gene Information Pass 1 Pass 2 Pass 3
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
HIPK3 10114 713 714 715
AKAP9 10142 138647 138648 138649
TRIM28 10155 716 717 718
ACK1 10188 721 103335 103419
NME6 10201 722 723 724
TRIB1 10221 103365 103449 103529
CNKSR1 10256 122592 122593 122594
AKAP8 10270 135514 135515 135516
APEG1 10290 42121 42210 42274
BCKDK 10295 729 730 110905
PAK4 10298 731 732 733
TESK2 10420 852 853 110925 853 242408
MAP3K7IP1 10454 17476 17569 135631
MERTK 10461 809 810 811
STK25 10494 812 813 814
CIB2 10518 135730 135731 135732
AKAP3 10566 135788 135789 135790
ERN2 10595 1201 1296 1391
LIM 10611 126673 126674 126675 126674 242404 242405
CAMKK2 10645 815 816 110919
PMVK 10654 818 819 820
PLK4 10733 103348 103432 103512 103432 242423 242424
MAP3K2 10746 824 825 103340
PLK2 10769 827 828 829
NEK6 10783 939 940 941
FASTK 10922 44224 44317 44407
ASK 10926 126686 126687 126688
TLK2 11011 103342 103426 103507
RIPK3 11035 836 837 110923
PIM2 11040 839 840 841 841 242406 242407
CIT 11113 103721 103729 103737
TRAD 11139 845 846 847
PKIG 11142 19143 19235 136230
MAP4K5 11183 822 103603 103656
MAP4K1 11184 854 855 856
CHEK2 11200 1477 118278 118298
IRAK3 11213 857 858 859
AKAP11 11215 136937 136938 136939
AKAP10 11216 136307 136308 136309
Gene Information Pass 1 Pass 2 Pass 3
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
AKAP2 11217 202406 202407 202408
PACSIN2 11252 136338 136339 136340
PNKP 11284 860 861 103345
STK38 11329 863 864 865
PTK9L 11344 868 118279 118281
Ksr 16706 71029 71124 71216
AAK1 22848 103351 103435 103515
LMTK2 22853 969 970 971
ICK 22858 972 974 103352
SEPHS2 22928 881 882 883
SEPHS1 22929 878 879 880
STK38L 23012 1481 1575 1665
MAST3 23031 202506 202507 202508
KIAA0551 23043 202509 202510 202511
SMG1 23049 44241 44334 44424
CDK11 23097 103723 103731 103739 103723 103731 103739 214337
MAP3K7IP2 23118 136739 136740 136741
MAST2 23139 975 977 103353
MAPK8IP3 23162 136770 136771 136772
PASK 23178 978 103354 110953
SIK2 23235 122759 122760 122761
KIAA0999 23387 1591 1681 103611
PIP5K1C 23396 136520 136521 136522
BRD4 23476 1512 1605 1694
P101-PI3K 23533 140138 140139 140140
MAPK8IP2 23542 19889 19983 20076
OSRF 23548 126713 126714 126715
CCRK 23552 875 876 111072
DAPK2 23604 930 932 110948
PRKCBP1 23613 135457 135458 135459
STK22B 23617 46442 103793 103798
SGKL 23678 1479 1573 1663
PRKCN 23683 727 103336 103420
CARKL 23729 902 903 904
PRKD2 25865 1011 1013 111257
DKFZP586B1621 26007 981 982 983
FBXW3 26226 213333 213334 213335
AK5 26289 872 873 874
HSPB8 26353 933 934 935
Gene Information Pass 1 Pass 2 Pass 3
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
LATS2 26524 948 949 950
STK23 26576 936 937 938 938 242425 242426
RPS6KC1 26750 890 891 892
AKAP8L 26993 21328 21422 147522
TPK1 27010 1184 1279 1374
HRI 27102 942 943 944
STK36 27148 1482 1576 1666
RPS6KA6 27330 945 946 947
STK39 27347 896 897 898
TRIB2 28951 1061 103364 103448
HIPK2 28996 1375 116346 116347
TBK1 29110 899 900 901
PACSIN3 29763 24054 24241 134898
EEF2K 29904 905 906 907
NME7 29922 908 45196 45290
PKN3 29941 909 910 911
NRBP 29959 913 914 103605
PACSIN1 29993 1496 1589 1679
SH3KBP1 30011 135342 135343 135344
HUNK 30811 951 952 953
PIK3R4 30849 1480 1574 103606
MINK 50488 985 986 103382
AK3L1 50808 1002 1004 103356
TNNI3K 51086 987 988 989 988 242432 242433 988 242432
IRAK4 51135 993 994 995
VRK3 51231 1008 1009 1010
CRIM1 51232 135025 135026 135027
CDKL3 51265 1154 1249 1344 1154 242438 242439
JIK 51347 999 1000 1001
PRKAG2 51422 134877 134878 134879 134878 242434 242435
IHPK2 51447 134946 134947 134948
NIPA 51530 126921 126922 126923
TRIM33 51592 103355 103439 103519
NLK 51701 996 997 998
UMP-CMPK 51727 1005 1006 1007
CRK7 51755 1153 1248 1343 1248 242436 242437
MST4 51765 1155 1250 1345
ZAK 51776 1016 103358 110959
PANK1 53354 1614 1704 103380
Gene Information Pass 1 Pass 2 Pass 3
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
PRKAG3 53632 24967 25060 131929
MYO3A 53904 1486 1580 1670
CSNK1G1 53944 1062 1064 110992
RIPK4 54101 1177 1272 113613
TRPM7 54822 1490 103360 103444
SNRK 54861 1159 1349 103607
PXK 54899 1585 1675 110964
UCKL1 54963 1161 1256 1351
FLJ20574 54986 1257 103361 103445 103361 103445
AKIP 54998 25730 45342 123005
P15RS 55197 1164 1259 1354
ETNK2 55224 1165 1260 1355
PANK4 55229 132362 132363 132364
PI4K2B 55300 1167 1262 1357
RFK 55312 1168 1358 110971
STK32B 55351 1023 1024 1025
STYK1 55359 1169 1264 1359 1359 242448 242449
PI4KII 55361 1170 1265 1360
ALS2CR2 55437 1171 1266 1361
CaMKIINalpha 55450 123137 202303 202322
ETNK1 55500 1172 1267 103362
NAGK 55577 1156 1251 1346
BMP2K 55589 1489 1583 111088 111088 242488 242489
FLJ10074 55681 110966 110968 110969
FLJ10842 55750 1166 1261 1356 1166 242444 242445
RIOK2 55781 1022 110975 110977
TOPK 55872 1026 1027 1028
TEX14 56155 1086 1087 1088
STK31 56164 1594 1684 103369
SPHK2 56848 1587 1677 103792
PAK6 56924 1029 1030 1031
CDC42SE2 56990 42453 42532 127235
CABC1 56997 1032 1033 110979
CAMK1D 57118 1035 1036 1037
ADCK1 57143 1176 1271 103609
PAK7 57144 42902 42997 43083
PACE-1 57147 103780 103782 111074
CAMK1G 57172 103363 103447 103527
Gene Information Pass 1 Pass 2 Pass 3
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
CLK4 57396 1048 1049 110988 1048 1049 110988 212808
SCYL1 57410 1050 1051 1052
MIDORI 57538 1495 1588 1678
KIAA1446 57596 140672 140673 140674
TRIB3 57761 1056 1057 1058
MARK4 57787 1089 1090 111028
LY6G5B 58496 42389 42474 42549
TSKS 60385 125326 125327 125328
RBKS 64080 1182 1277 1372
FN3K 64122 1183 1278 1373
NJMU-R1 64149 140704 140705 140706 140706 242458 242459 140706 242458
C9orf12 64768 1186 1281 1376 1186 1281 242460 242461 1186 1281 242460
CERK 64781 110997 111000 111002
FLJ12476 64799 1188 1283 1378
PINK1 65018 1199 1294 103372
ALS2CR7 65061 1140 1141 1142
PRKWNK1 65125 1174 1269 1364 1269 242450 242451 1269 242450
FLJ13052 65220 1189 1284 1379
PRKWNK4 65266 1104 1105 1106
PRKWNK3 65267 103724 103732 103740
PRKWNK2 65268 130209 130210 130211
STK33 65975 1683 103367 103451
MGC8407 79012 1065 1066 1067
MAPKAP1 79109 130548 130549 130550
PANK3 79646 130622 130623 130624
FN3KRP 79672 1190 1285 1380
LRRK1 79705 1497 1590 1680
PIP5K2C 79837 1191 1286 1381
NEK11 79858 1192 1287 1382
ADCK4 79934 1068 1069 1070
PANK2 80025 131832 131833 131834
FLJ23074 80122 1071 1072 1073
LAK 80216 1075 1076 103610
ITPKC 80271 1193 1288 1383
GKAP1 80318 1384 127538 127539
T3JAM 80342 123566 123567 123568
COASY 80347 1195 1290 111026
CDADC1 81602 1196 1291 103612
STK22C 81629 1122 1123 1124
Pass 2 Pass 3Pass 1Gene Information
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
SNARK 81788 1083 1084 103368 1084 242464 242465
UCK1 83549 103370 103454 103534
RPS6KL1 83694 1198 1293 1388
RIOK1 83732 44297 44389 44477
GSG2 83903 1093 1094 103371 103371 242466 242467
MGC4796 83931 103725 103733 103741
STK22D 83942 1097 111259 118249
SSTK 83983 42598 42691 42768
FLJ23356 84197 1098 1099 1100
CAMKK1 84254 103383 103466 103544
KIAA1811 84446 1502 1595 1685
KIAA1804 84451 1503 103373 103457
MASTL 84930 1108 1109 111039
MYLK2 85366 103375 103459 103539 103459 242468 242469
KIAA1765 85443 202523 202524 202525
PSKH2 85481 1119 1120 1121
NYD-SP25 89882 1508 1601 1691
ADCK2 90956 1125 103614 103666
NEK9 91754 1113 1114 1115
LOC91807 91807 103772 103775 103778 103772 103778
LYK5 92335 42950 43040 43116
MGC16169 93627 1110 1111 103374
PRKCDBP 112464 45706 129307 129308
TP53RK 112858 1202 1297 1392
STK11IP 114790 128863 128864 128865
HAK 115701 1128 1130 111041 1130 242470 242471
IHPK3 117283 1203 1298 1393
CIB3 117286 147982 147983 147984
PIK3AP1 118788 129419 129420 129421
CSNK1A1L 122011 1520 1611 1700
AK7 122481 129427 129428 129429
FLJ25006 124923 1207 1397 103615
KIS 127933 1208 1303 1398 1398 242484 242485
ACVR1C 130399 1521 1612 1701
GRK7 131890 1206 1301 1396 1206 1301 1396
ASB10 136371 1513 45582 45672 1513 242476 242477
PIP5KL1 138429 40615 40705 46550
TAF1L 138474 40303 40394 40482
Gene Information Pass 1 Pass 2 Pass 3
Gene Name LocusLink ID siRNA-1 siRNA-2 siRNA-3 siRNA1 siRNA2 siRNA3 siRNA4 siRNA5 siRNA1 siRNA2 siRNA3
PNCK 139728 124469 202319 202347
MYO3B 140469 1137 1138 1139
NEK7 140609 45587 45677 103794
TRPM6 140803 1158 1253 1348
STK35 140901 1135 103377 103461 1135 103377 103461 1135 103377 103461
TTBK2 146057 40791 40887 40980
HIPK4 147746 1143 1144 1145
LOC149420 149420 1526 1616 1706 1706 242480 242481
SNF1LK 150094 40587 40679 40762
FLJ32685 152110 103550 103556 111053
MAGI1 154043 129762 129763 129764
C9orf98 158067 1525 1615 111057
AKAP28 158798 128414 202311 202312 128414 242340 242341
DGKH 160851 129947 129948 129949
MGC45428 166614 39203 39298 39391
MGC42105 167359 42951 43041 43117
FUK 197258 111047 111049 111051
FLJ34389 197259 42942 43032 43109
ADCK5 203054 43144 103781 103783
HIPK1 204851 39638 111081 111083
MGC26597 206426 103381 103808 103811
C6orf199 221264 1209 1304 1399
ERK8 225689 1205 1300 1395
IPMK 253430 38438 38524 148096
ANKK1 255239 103771 103774 103777
MAGI-3 260425 123257 123258 123259
STK32C 282974 40863 45762 45854
KSR2 283455 41069 41165 111068
C14orf20 283629 41401 41491 41571
LOC283846 283846 202497 202498 202499
NEK8 284086 103726 103734 103742
LOC375133 375133 202463 202630 202631
LOC375449 375449 202348 202364 202379
Pass 1 Pass 2 Pass 3Gene Information
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Supplementary Table 1 | siRNAs used throughout the RNAi screen to access the 
functional role of the corresponding target gene in Plasmodium infection.
List with all the siRNAs screened for each gene in the different
 
phases of the RNAi 
screen. Highlighted in red and green are the siRNAs for which an
 
increase or
 
 
decrease in Plasmodium
 
infection was observed, respectively.
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Results 
 
 
An obligatory first step of malaria is the asymptomatic invasion of host hepatocytes 
by Plasmodium sporozoites, which develop therein to form thousands of 
erythrocyte-infective merozoites. While host factors required for liver infection 
offer powerful prophylactic potential, they remain poorly understood. Having 
found that modified forms of LDL can competitively inhibit the infection of 
human hepatoma cells by P. berghei sporozoites, we have used RNAi to screen host 
lipoprotein pathway genes, identifying the class B, type I scavenger receptor              
(SR-BI) as crucially required for infection. Compound- or antibody-inhibition of 
SR-BI function in cultured Huh7 cells similarly reduced P. berghei infection. 
Importantly, in vivo RNAi silencing of liver SR-BI expression in adult mice, and 
inhibition of SR-BI activity in human primary hepatocytes also reduced infection 
by P. berghei and P. falciparum, respectively, thus supporting the patho-
physiological relevance of our findings. With detailed analyses further revealing 
the SR-BI requirement in both sporozoite invasion and development, our study 
offers important mechanistic insights into the processes underlying Plasmodium 
liver infection, while also opening a powerful new interventional strategy for the 
development of novel anti-malarial prophylactics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 199
Chapter 4 
Malaria, caused by the protozoan parasite Plasmodium, is a major health problem, 
mainly in Sub-Saharan Africa and in some parts of Asia and South America. Each 
year there are about 600 million new clinical cases and at least one million 
individuals, mostly children, die from malaria (Greenwood and Mutabingwa, 2002). 
Moreover, malaria presents a serious risk to the economic potential of many countries 
in the world. Various attempts at eradicating this disease have so far been 
unsuccessful and in fact within the last 10 to 15 years the burden of malaria has been 
increasing (Greenwood and Mutabingwa, 2002) mainly because of the emergence of 
P. falciparum variants that are resistant to the drugs in use (Marsh, 1998; White, 2004). 
These realities have compounded the urgency of finding novel treatment strategies 
that will be less vulnerable to the development of parasite resistance, a goal that 
necessarily requires a better understanding of the underlying parasite-host 
interactions. 
After the bite of an infected mosquito delivers Plasmodium sporozoites into a human 
host, the parasite first accumulates in the liver where it migrates through the 
cytoplasm of several hepatocytes before invading the one in which it will develop into 
an exoerythrocytic form (EEF) (Mota et al., 2001). During this asymptomatic liver 
infection the parasite proliferates and changes from a motile sporozoite into its next 
form, the merozoite, which will allow the symptomatic infection of red blood cells. In 
doing so, its exploitation of host liver resources represents an important and as-yet 
under-investigated vulnerability to prophylactic intervention. In our ongoing study of 
such host factors needed for the liver infection stage, we have herein followed-up on 
observations from earlier reports which suggested a link between host lipoprotein 
clearance pathways and Plasmodium sporozoite infection of the liver (Shakibaei and 
Frevert, 1996; Sinnis et al., 1996).  
 
Modified forms of LDL but not HDL inhibit Plasmodium infection of Huh7 
cells 
As an initial step, we examined whether different types of lipoprotein particles 
display differential effects on Plasmodium sporozoite infection of host liver cells. To 
test this, cultured human Huh7 hepatoma cells grown in medium containing 
lipoprotein-deficient serum (LPDS) were infected with isolated Plasmodium berghei 
sporozoites in the presence of defined amounts of human high density lipoprotein 
(HDL), low density lipoprotein (LDL), acetylated LDL (acLDL) or oxidized LDL 
(oxLDL). Throughout these and all subsequent infection experiments in the present 
study, Plasmodium sporozoites were used fresh on the same day after isolation from 
the salivary glands of infected female Anopheles stephensi mosquitoes. Infected cell 
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cultures were fixed 24 h after sporozoite addition, stained for nuclear DNA and 
immunolabeled for a Plasmodium EEF-specific antigen, as well as host cell actin. 
Infection rates were then quantified by fluorescence microscopy, using automated 
image analysis to count the number of stained EEFs that had developed inside the 
Huh7 cells, and normalizing these values to cell confluency, as determined by actin 
staining, to compensate for potential differences in total cell surface available for 
infection in each well. Both modified forms of LDL (modLDL) reproducibly reduced 
the infection levels (P < 0.01 and P < 0.001 for concentrations equal or higher than 100 
μg/ml of oxLDL and acLDL, respectively), whereas LDL or HDL did not (Figure 1a). 
In fact, HDL at low concentrations showed a mildly positive effect on EEF number 
counted after 24h (Figure 1a; P < 0.05). As such, these initial results are indeed 
consistent with the earlier proposed link between Plasmodium infection and 
lipoprotein pathways in the liver (Shakibaei and Frevert, 1996; Sinnis et al., 1996). 
We therefore continued by analyzing the specific impact of this lipoprotein-mediated 
inhibition on two major steps of liver infection: invasion and development. Under the 
conditions of our 24 h in vitro infection assay, >95% of invasion events take place over 
the first 2 h following addition of sporozoites to the cells, consistent with the transient 
traversing of neighbouring cells prior to productive invasion events, which we 
reported previously (Mota et al., 2001). The expected inhibition of infection was only 
observed when the added acLDL or oxLDL were present during the first 2 h after 
sporozoite addition to the cells, i.e. the invasion phase (Figure 1b, P < 0.001). When 
lipoproteins were only added after this phase, i.e. more than 2h after sporozoite 
addition, once >95% of invasion events have already occurred, no significant 
reduction in infection level was detected (Figure 1b). These results strongly suggest 
that elevated levels of modLDL reduce Plasmodium infection of hepatoma cells 
primarily by inhibiting the sporozoite invasion step.  
 
Host scavenger receptor BI (SR-BI) is required for P. berghei infection of 
Huh7 cells 
A possible explanation for the observed lipoprotein-mediated inhibition of invasion 
would be the competitive binding of lipoproteins and sporozoites to the same cell 
surface protein(s). We therefore sought to further analyze the role of lipoprotein 
pathway genes in the liver stage of Plasmodium infection by applying our in vitro assay 
in the context of a systematic RNAi-induced loss-of-function screen. To this end, we 
assembled a library of 206 siRNAs targeting 53 genes expressed in the liver and 
annotated as having validated or putative roles in lipoprotein assembly, binding or 
uptake (Supplementary Table 1). Each gene was targeted with at least 3 distinct 
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siRNA sequences, applying the experimental workflow outlined in Figure 2a. Briefly, 
each siRNA was transfected individually into Huh7 cells 24 h after seeding, and 48 h 
later, cells were either infected with P. berghei sporozoites, or lysed for quantitative 
RT-PCR (qRT-PCR) analysis of target mRNA knock-down levels at the onset of 
infection. Infected samples were subjected to the same microscopy-based assay 
procedure described above, including fixation 24 h post infection and subsequent 
staining for EEFs, host actin and nuclear DNA to yield the quantification of infection 
rates, also as described above.  
This library of siRNAs was screened in two independent runs, generating phenotypic 
loss-of-function data for all tested siRNAs and conclusive qRT-PCR analysis of 
remaining target mRNA levels for 155 siRNAs targeting 40 genes (see detailed data in 
Supplementary Table 1). The vast majority of siRNAs did not significantly affect 
viability of the Huh7 host cells, as determined by number of cell nuclei (Figure 2b, 
Supplementary Table 1). Although several genes exhibited a single siRNA showing a 
notable up- or down-regulation of the infection rate, the lack of confirmation from 
other siRNAs targeting those genes rendered their significance unclear without 
further analysis. This is readily illustrated by plotting the mean results from all 
siRNAs for each targeted gene (Figure 2c). Only one gene, scavenger receptor BI (SR-
BI), stood out from the rest by showing significant reductions in infection rates with 3 
distinct siRNA sequences (Figure 2b, d, P < 0.001). This effect on infection occurred 
without any detectable side effects on cell proliferation, as measured by nuclear 
counts (Figure 2b, Supplementary Table 1). Importantly, the multiplicity of siRNA 
sequences underlying this result argues strongly that the observed phenotype is 
indeed a specific consequence of down-regulating SR-BI expression, and is not arising 
through off-target effects [see (Echeverri et al., 2006)]. As further confirmation of 
specificity, the phenotypic severity (i.e. degree of inhibition of infection) was found to 
correlate closely with SR-BI knock-down, as quantified at the mRNA level by qRT-
PCR (Figure 2d), using 4 distinct SR-BI-targeting siRNA sequences in multiple 
independent experiments. The SR-BI knock-down was also confirmed at the protein 
level by quantitative Western blotting (Figure 2e). Together, these results strongly 
implicate host SR-BI expression as a key requirement for Plasmodium infection of liver 
cells. It should be noted that the present data does not rule out the possible 
involvement of other genes among those tested here, as negative results in RNAi 
screens are generally inconclusive [see (Echeverri et al., 2006)]. Indeed, the present 
analysis already suggests that two other genes, ApoA1BP and MSR1, which displayed 
more moderate effects, may also warrant further examination in the future (Figure 
2d). 
 202 
Results 
The above RNAi-based identification of SR-BI was further validated by testing the 
effects on infection of known SR-BI inhibitors, including a SR-BI blocking antibody 
(Silver, 2002) and several small synthetic molecules previously reported to inhibit the 
SR-BI-mediated selective uptake of lipids from HDL [termed “blockers of lipid 
transport”, or BLTs (Nieland et al., 2002)]. Addition of the SR-BI blocking antibody to 
cells 1 h prior to sporozoite addition led to a marked, dose-dependent decrease in 
infection rate as compared to control samples, measured by the in vitro microscopy-
based Huh7 infection assay described above (Figure 3a). Similar dose dependent 
decreases in P. berghei sporozoite infection rates were observed when cells were 
similarly incubated with either BLT-1, BLT-2 or BLT-4 throughout the 24 h infection 
period, showing IC50 values of 0.9, 5.2 and 19.9 µM respectively (Figure 3b-d). 
Interestingly, the relative efficiencies with which the different BLT compounds 
inhibited sporozoite infection closely mirrored their previously reported effects on the 
selective uptake of lipids, with BLT-1 being 5 and 20 times more efficient than BLT-2 
and BLT-4, respectively (Nieland et al., 2002), thus suggesting a close structural link 
between the two activities. Infection rates were not affected by pre-incubation of 
Plasmodium sporozoites with BLT-1 for 1 hour prior to addition to cells, showing that 
BLT-1 has no effect on sporozoite viability (data not shown). Altogether, these results 
using RNAi, blocking antibodies and synthetic inhibitors clearly demonstrate a 
critical role for SR-BI during P. berghei sporozoite infection of Huh7 cells. 
 
Patho-physiological relevance of host SR-BI is confirmed with in vivo mouse 
infection model and P. falciparum infection of primary human hepatocytes 
As the above experiments were all performed in vitro using the human hepatoma cell 
line Huh7, we sought to validate the requirement for SR-BI in Plasmodium infection 
under more physiologically relevant conditions. To this end, we first confirmed that 
silencing or inhibition of SR-BI also leads to a reduction in P. berghei infection of 
primary mouse hepatocytes (Supplementary Figure 1).  
Next, we also confirmed the relevance of these findings in vivo, using systemically-
delivered, liposome-formulated siRNAs to silence SR-BI expression in adult mice and 
subjecting these to infection by P. berghei sporozoites. Here, a qRT-PCR-based assay 
was used to quantify infection rates by measuring levels of Plasmodium 18S RNA 
found within extracts of liver samples harvested 40 h after intravenous (i.v.) 
sporozoite injection. In vivo RNAi treatments have previously yielded potent gene-
specific knock-downs in rodent livers using cholesterol-conjugated siRNAs 
(Soutschek et al., 2004) or in non-human primates after systemic administration of 
siRNAs encapsulated in stable lipid-nanoparticles (Zimmermann et al., 2006). In our 
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experiments, SR-BI expression was also reduced successfully in adult mouse livers 
using 3 distinct SR-BI-specific siRNAs, each of which yielded ~25-45% remaining SR-
BI mRNA, as measured by qRT-PCR of tissue extracts taken 76 h after a single i.v. 
injection and normalization to SR-BI mRNA levels in the livers of adult mice treated 
with control siRNA (Figure 4a, P < 0.001, grey bars). When compared to control 
siRNA treatment, this administration of SR-BI specific siRNAs resulted in a significant 
reduction of liver infection by P. berghei sporozoites that correlated proportionally 
with the SR-BI mRNA silencing levels, yielding 30-50% of control infection loads, as 
measured by qRT-PCR of P. berghei 18S rRNA in samples taken 40h after sporozoite 
injection (Figure 4a, P < 0.001, black bars). In a parallel experiment, mice treated with 
one of the SR-BI siRNAs also showed a reduction in the number of parasites reaching 
the blood stream, when compared to their controls (Figure 4b, P < 0.05). While by day 
4 after sporozoite injection, all mice in the control group were positive for blood 
stages, only 2 of 6 mice were positive in the group pre-treated with SR-BI siRNA. 
Finally, we note that all of the above experiments were carried out using P. berghei, 
whose natural preference for rodent hosts entails the possibility that its infection 
strategy may differ in certain respects from that of Plasmodium species such as P. 
falciparum, known to be pathogenic to humans. The role of SR-BI was therefore also 
tested for P. falciparum infection in primary human hepatocytes 72 h after sporozoite 
addition, using the same qRT-PCR-based assay of Plasmodium 18S RNA used above. 
Once again, BLT-1 treatment of human primary hepatocytes caused a significant and 
specific decrease of P. falciparum infection in these cells (Figure 4c, P < 0.001).  
Altogether, these data unequivocally confirm the requisite role of host SR-BI 
expression in the liver stage of Plasmodium infection not only in vitro but also in vivo, 
and not only for the rodent malaria parasite, P. berghei, but also for P. falciparum, the 
deadliest of human malarial pathogens.   
 
Host cell SR-BI is required for both invasion and development of 
Plasmodium inside the parasitophorous vacuole 
The responses observed with the different BLT compounds, in yielding such similar 
profiles for both their anti-malarial and anti-lipid uptake activities (Figure 3b-d) 
(Nieland et al., 2002), suggest that the role of SR-BI in Plasmodium infection is closely 
related to its normal function in selective uptake of lipids from HDL particles. In fact, 
SR-BI has been described not only as a key component of HDL metabolism, but also 
as an efficient receptor for LDL, oxLDL and acLDL (Gillotte-Taylor et al., 2001), all of 
which are apparently processed via separable extracellular subdomains (Gu et al., 
2000). This is of particular interest in view of our present observations that excess 
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amounts of oxLDL and acLDL, but not HDL or LDL, inhibit Plasmodium infection in 
Huh7 cells (Figure 1a and b). One direct interpretation of that data would be that 
during invasion, Plasmodium sporozoites are competing directly or indirectly with 
certain lipid particles for access to a common rate-limiting interaction site and/or 
biochemical activity, implying, therefore, that these could be on or from SR-BI. In 
order to probe this hypothesis, we conducted a more detailed phenotypic dissection 
of the effects of SR-BI inhibition on sporozoite infection in Huh7 cells, to determine 
whether this might be linked mechanistically to the observed lipoprotein-mediated 
inhibition.  
To this end, we first determined whether SR-BI silencing or inhibition affects a crucial 
step of sporozoite infection, i.e. invasion (Figure 5a), as was observed for the 
lipoproteins tested (Figure 1b). In order to quantify invaded cells prior to EEF 
development most accurately, we used a FACS-based assay. Briefly, Huh7 cells were 
infected with GFP-expressing P. berghei sporozoites in the presence of rhodamine 
dextran. Two hours after sporozoite addition, cells were harvested and analyzed by 
FACS. Cells which had previously been transiently traversed by sporozoites were 
identified as rhodamine-dextran positive but GFP negative, while cells successfully 
invaded by sporozoites were identified by the presence of GFP and the absence of 
rhodamine-dextran (Mota et al., 2001) (Supplementary Figure 2). Pre-treatments with 
three distinct SR-BI-targeting siRNAs, as characterized above, again yielded 
significant reductions in the proportion of Huh7 cells invaded by P. berghei 
sporozoites, as compared to controls (black bars in Figure 5a, P < 0.001). Similarly, 
treatment with BLT-1 also led to a dose-dependent decrease in invaded cells 
measured 2 h after sporozoite addition (grey bars in Figure 5a). These results reveal a 
critical role for SR-BI during the initial invasion step of sporozoite infection, mirroring 
that which we had observed with excess amounts of acLDL and oxLDL.  
We next examined whether SR-BI also has a role in the following step of sporozoite 
infection, i.e. development of the EEF within the parasitophorous vacuole. Pre-
treatments with SR-BI-specific siRNAs, or exposure to blocking antibody or small 
molecule inhibitors (BLTs) throughout the full 24h infection period of our in vitro 
microscopy assay all yielded marked decreases in EEF size, as measured using 
automated image analysis algorithms (Figure 5b, Supplementary Figure 3). The 
absence of larger EEF classes noted using this analysis in treated cells suggested a 
possible blockage of EEF development. Detailed FACS analysis of Huh7 cells infected 
with GFP-expressing P. berghei also suggested an effect of BLT-1 treatment on EEF 
development (Figure 5c). This analysis showed that, in addition to the marked 
decrease in number of infected cells already noted 2 h after sporozoite addition 
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(Figure 5a, grey bars), a significant decrease in GFP intensity becomes apparent 
within the infected cells at the 24 h time point (Figure 5c). These results are consistent 
with a defect in P. berghei development, resulting in decreased size and/or numbers 
of EEFs.  
However, since invasion was also affected under the above assay conditions, we 
conducted more precise tests to address the development stage more unambiguously. 
We investigated whether BLT-1 retains its inhibitory effect on infection when added 
only after completion of sporozoite invasion, i.e., 2 h after sporozoite addition to cells 
under our assay conditions. The resulting infected cells, when compared with 
negative controls 24 h after sporozoite addition using the same microscopy assay and 
analysis algorithms described above, still showed a clear and comparable downward 
shift in the size profile of EEFs (Figure 5d). This result was also confirmed by FACS 
analysis of equivalently-treated samples, which revealed a significant drop in GFP 
intensity among infected cells (data not shown), as had been seen with the full 24-h 
exposure to BLT-1 (Figure 5c). Together, these data indicate that host liver cell SR-BI 
function is required not only for sporozoite invasion but also for the subsequent 
development of EEFs within the parasitophorous vacuole. 
Finally, in view of the above findings, we examined whether SR-BI’s role in 
Plasmodium infection correlates with its being brought into close subcellular proximity 
with the parasite itself, as it develops within the parasitophorous vacuole. Using a 
polyclonal antibody directed against the extracellular domain of SR-BI, control 
uninfected Huh7 cells exhibited highly reproducible staining patterns defining a high 
density of discrete, fine granular or punctate structures suggestive of sub-micron-
sized vesicles, distributed very homogenously throughout the cytoplasm (Figure 5e). 
In Plasmodium-infected cells, SR-BI staining revealed a marked accumulation of the 
same vesicle-like structures around the immediate periphery of 79.5 ± 6.3 % of 
intracellular EEFs (Figure 5e). This suggests that SR-BI may be residing within the 
parasitophorous vacuole membrane itself or accumulating in membranous 
compartments around EEFs, presumably catalyzing the lipid transfer between these 
compartments and the parasitophorous membrane. While more detailed, higher 
resolution analyses will be required to further elucidate this question, the present 
evidence of a clear subcellular accumulation of SR-BI around EEFs is consistent with 
all of our present findings that, besides its role in invasion, SR-BI also fulfills a 
requisite function in Plasmodium development inside liver cells.  
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Discussion 
Together with our past studies, which revealed how Plasmodium sporozoites 
transiently traverse several hepatocytes before initiating a productive invasion event 
(Mota et al., 2001), the present study adds significant new insights into the host 
molecules and cellular processes underlying this parasite’s infection of the liver. In 
particular, our results confirm and extend earlier suggested links between liver 
infection and lipoprotein pathways (Shakibaei and Frevert, 1996; Sinnis et al., 1996). 
By using several types of inhibitors including RNAi both in vitro in cultured human 
cells and in vivo in a mouse model of infection, we have identified a major lipoprotein 
receptor, SR-BI, as being crucial for both sporozoite invasion and EEF development.  
Our data strongly suggest that the inhibition of parasite invasion that we observe 
with modified forms of LDL occurs via competition between the excess lipoproteins 
and the parasite for a common SR-BI binding site or activity. This observation 
supports the hypothesis that SR-BI may be fulfilling some or all functions of a liver 
receptor for Plasmodium sporozoites. Such a hypothesis would imply at least one of 
two activities: first a binding or docking activity, and second, an internalization 
activity. SR-BI has been characterized as an efficient receptor for HDL, as well as 
native and modified forms of LDL, including acLDL and oxLDL. Our results showing 
that only modified forms of LDL, but not HDL or LDL, inhibit sporozoite invasion, 
may yield at least two models of the molecular interactions underlying Plasmodium 
binding to hepatocytes: the “HDL-piggyback” model and the “modLDL-mimic” 
model. In the former, Plasmodium sporozoites interact directly with HDL particles and 
benefit from their high affinity binding to SR-BI. Interestingly, in this case, the 
sporozoite would not need to come into direct contact with any host cell components 
at all, as this direct interaction would be assured by the HDL particle on which it is 
“piggybacking”, thereby explaining HDL’s slight positive effect on invasion. Further 
posits of this model would be that the parasite cannot similarly “piggyback” on 
modified forms of LDL and that the latter’s interaction mode with SR-BI must overlap 
sufficiently with that of the HDL-sporozoite complex so as to result in the observed 
competition effect between the two. In the “modLDL-mimic” model, the parasite does 
interact directly with SR-BI, using a mode of binding that overlaps with that of 
modLDL forms, but not with that normally used by HDL, therefore explaining the 
observed competition effects. The fact that SR-BI shows distinct and separable binding 
activities for different lipoprotein ligands (Gu et al., 2000) is consistent with this 
notion.  
Beyond these models for initial “docking”, the next key step of Plasmodium invasion 
must necessarily be internalization of the bound parasite, leading to establishment of 
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the parasitophorous vacuole. Here, the best-characterized activity of SR-BI with 
respect to bound lipoproteins proves less supportive of a conventional receptor role. 
SR-BI is known to primarily mediate selective uptake of cholesteryl esters from bound 
HDL or LDL without triggering an endocytic or phagocytic event (Nieland et al., 
2005). While this main activity does not immediately suggest an obvious mechanism 
for facilitating internalization, some have nonetheless noted that HDL can enter 
HepG2 cells by endocytosis, followed by rapid recycling to the surface without 
reaching late endosomes or lysosomes (Wustner et al., 2004). It is also interesting to 
note that the SR-BII isoform, which arises through alternative splicing from the SR-BI 
gene, undergoes endocytosis by a clathrin-dependent, caveolae-independent 
mechanism (Eckhardt et al., 2006). Our finding that siRNA-mediated silencing of SR-
BII expression by >70% has no detectable effect on P. berghei infection in vitro 
(Supplementary Table 1), argues against its involvement here, though not 
conclusively. As a further alternative, it has been suggested that Plasmodium 
sporozoites might enter the host cell in an active process from the parasite side 
without the need of the host endocytic or phagocytic machinery (Sibley, 2004), as 
previously demonstrated for the Plasmodium related parasite Toxoplasma gondii 
(Dobrowolski and Sibley, 1996). In this case, the so-called receptor activity needed by 
the parasite would only be restricted to the docking role, as the parasite itself would 
take care of the subsequent internalization. Further work is now under way to test 
these models. 
In addition to the role of SR-BI in Plasmodium sporozoite invasion, our results also 
show that SR-BI is critical for EEF development. Inside hepatocytes, Plasmodium 
sporozoites undergo a major transformation, with each giving rise to thousands of 
merozoites. However, the sporozoite’s requirements and the strategies it has 
developed to survive and to be successful remain poorly understood [reviewed in 
(Prudencio et al., 2006)]. Regardless, the parasite’s extensive proliferation during this 
stage necessarily requires the availability of sufficient lipids for the synthesis of large 
amounts of additional membranes. It is therefore tempting to speculate that our 
observations reflect a direct involvement of the host cell SR-BI’s selective lipid uptake 
activity in “feeding” cholesteryl esters and other lipids to the parasite across the 
parasitophorous vacuole membrane. While all of our present data are consistent with 
this hypothesis, more detailed analyses will be required to further test its validity. It 
will be of particular interest in this context to further examine the functional 
contributions of other known SR-BI pathway components to Plasmodium infection in 
liver. 
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Finally, the present study establishes an important proof of principle for the use of 
non-essential host factors as novel prophylactic or therapeutic drug targets to combat 
malaria and other infectious diseases. So far, most anti-malarial drug development 
has focused on targeting the Plasmodium parasite itself. However, targeting host 
components offers major advantages including the inherently lower vulnerability of 
such drugs to the development of resistance by the parasite (Cunha-Rodrigues et al., 
2006), arguably the biggest problem faced in all infectious disease fields today. 
Indeed, one or two mutations within a parasite gene can render useless virtually any 
drug targeting its encoded protein. By contrast, the need for the parasite to 
significantly re-direct its entire infection strategy to compensate for a missing host 
factor is a much more difficult obstacle to overcome through natural selective 
variation. As a second key advantage, the host factor approach also offers 
significantly higher potential for accelerated drug discovery and development 
through synergies with ongoing output from other disease pipelines, including so-
called “mainstream” ones. Host factors needed for parasitic infections are more likely 
to have been the focus of previous or even ongoing therapeutic development work in 
other fields, thus opening the possibility of finding anti-infective activities as second 
medical uses for existing drugs. This potential emerges particularly well in the 
present case of SR-BI, which has recently been proposed to function as a receptor for 
several pathogens, including hepatitis C virus (HCV) (Scarselli et al., 2002; Cocquerel 
et al., 2006), mycobacteria (Philips et al., 2005) and bacteria (Vishnyakova et al., 2006). 
Interestingly, it has been proposed that HCV requires functional cooperation between 
the host′s SR-BI and tetraspanin CD81, the latter having also been implicated in 
Plasmodium sporozoite invasion (Silvie et al., 2003; Silvie et al., 2006; Silvie et al., 2007). 
Thus, our present evidence, implicating for the first time host SR-BI in malaria 
infection, may in fact help to advance our understanding of several other important 
infectious diseases. By further exploring the parallels between these infection 
pathways, one can now hope for increasing synergies between all of these fields for 
years to come.  
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Methods 
 
Cells and Parasites  
Huh7 cells, a human hepatoma cell line, were cultured in RPMI (Gibco/Invitrogen) 
medium supplemented with 10% fetal calf serum (FCS, Gibco/Invitrogen), 1% non-
essential amino acid (Gibco/Invitrogen), 1% penicillin/streptomycin (pen/strep, 
Gibco/Invitrogen), 1% glutamine (Gibco/Invitrogen) and 1% HEPES, pH 7 
(Gibco/Invitrogen) and maintained at 37°C with 5% CO2. 
Mouse primary hepatocytes were isolated by perfusion of mouse liver lobules with 
liver perfusion medium (Gibco/Invitrogen) and purified using a 1.12 g/ml; 1.08 g/ml 
and 1.06 g/ml Percoll gradient. Cells were cultured in William´s E medium 
containing 4% FCS, 1% pen/strep, 50 mg/ml epidermal growth factor (EGF), 10 
µg/ml transferrin, 1 µg/ml insulin and 3.5 µM hydrocortisone in 24 well plates coated 
with 0,2% Gelatine in PBS. Cells were maintained in culture at 37°C and 5% CO2.   
Human primary hepatocytes were isolated from the healthy parts of liver biopsies 
from patients undergoing a partial hepatectomy with informed consent provided, as 
previously described (Mazier et al., 1985). Freshly isolated human primary 
hepatocytes were cultured in Williams Medium E supplemented with 10% FCS, 1% 
glutamine, 1% insuline/transferrine/selenium (Invitrogen), 10-7 M dexamethasone 
(Sigma), 1% sodium piruvate, 2% pen/strep in 48 well plates coated with rat tail 
collagen, type I. Cells were maintained in culture at 37ºC and 5% CO2. Medium was 
supplemented with 2% DMSO after complete cell adherence (12-24h) and until 1 hour 
before infection. 
Green fluorescent protein (GFP)-expressing P. berghei (parasite line 259cl2) sporozoites 
(Franke-Fayard et al., 2004) or P. falciparum sporozoites (NF 54 strain) were obtained 
from dissection of infected female Anopheles stephensi mosquito salivary glands. 
 
Cell treatment with lipoproteins  
Human low density lipoprotein (LDL), oxidised LDL (oxLDL), acetylated LDL 
(acLDL) and high density lipoprotein (HDL) (Biomedical Technologies Inc., USA) 
solutions were prepared in medium containing 1% lipoprotein deficient serum (Sigma 
Aldrich, Germany). Huh7 cells were incubated with different concentrations of 
lipoproteins during the periods described in the text, measured relative to sporozoite 
addition (104 per well). 
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siRNA design, siRNA library and screening controls 
All siRNAs were purchased from Ambion’s Silencer genome wide library 
(Ambion/Applied Biosystems, Austin USA). The siRNA library screened included 
validated or putative lipoprotein receptors and genes involved in lipoprotein 
assembly. Each gene was targeted by at least 3 distinct siRNAs used individually in 
all cases. Negative control samples included untransfected cells, and cells transfected 
with a negative control siRNA not targeting any annotated genes in the human 
genome. A full list of gene names, siRNA ID numbers and sequences, and associated 
screening data are shown in Supplementary Table 1. 
 
High-throughput siRNA screening of Plasmodium infection 
Huh7 cells (4500 per well) were seeded in 100 µl complete RPMI medium in optical 
96-well plates (Costar) and incubated at 37ºC in 5% CO2. Twenty-four hours after 
seeding, cells were transfected with individual siRNAs in a final concentration of 100 
nM per lipofection. Each siRNA was transfected in triplicate. Briefly, for each well, 
cell supernatant was replaced by 80 µl of serum-free culture medium without 
antibiotics. One µl of 10 µM siRNA diluted in 16 µl of Opti-MEM (Invitrogen.) was 
complexed with 0.4 µl Oligofectamine (Invitrogen) diluted with 2.6 µl Opti-MEM and 
added onto the cells following the manufacturer′s protocol.  Four hours after addition 
of the complex, 50 µl of fresh RPMI medium, supplemented with 30% FCS, 3% 
pen/strep, 3% non-essential amino acid, 3% glutamine and 3% HEPES were added to 
the cells. Two days after siRNA transfection, cells were infected with 104 P. berghei 
sporozoites/well. Twenty-four hours after infection, cells were fixed with 4% 
paraformaldehyde (PFA) in PBS and permeabilized with 0.2% saponin in PBS. Cell 
nuclei were stained with Hoechst-33342 (Molecular Probes/Invitrogen), filamentous 
actin was stained with Phalloidin AlexaFluor488 (Molecular Probes/Invitrogen), EEFs 
were detected using the mouse monoclonal antibody 2E6 (Tsuji et al., 1994) and an 
AlexaFluor555 labeled goat anti-mouse secondary antibody (Molecular 
Probes/Invitrogen).  
 
Automated image acquisition and analysis 
Plates were acquired with a Discovery1 automated fluorescence microscope 
(Molecular Devices Corporation, CA, USA) using a 10x lens. In each well, cell nuclei, 
actin and EEFs were imaged in 9 fields covering a total area of 2.7 x 2.0 mm. Image 
data was analyzed using a custom MetaMorph (Molecular Devices Corporation, CA, 
USA) based algorithm extracting the following values for each imaged field: Cell 
 211
Chapter 4 
proliferation as measured by the number of nuclei per imaged field (Hoechst 
staining), cell confluency as measured by the percentage of the imaged field covered 
by actin staining and number of EEFs as number of compact, high contrast objects in a 
size range from 16 to 150 pixels. Within each field, the number of EEFs was 
normalized to the cell confluency. Normalized EEF numbers and number of nuclei 
were averaged between the 9 imaged fields within each well. Mean and standard 
deviations were calculated for each experimental triplicate. Final readouts included 
number of EEFs and number of nuclei, shown as a percentage of the plate mean. For 
size analysis of EEFs (Figure 5c and 5e, Supplementary Figure 3), EEF classes were 
classified as follows: class 1 (3 to 15 pixels), class 2 (16 to 28 pixels), class 3 (29 to 75 
pixels) and class 4 (76 to 150 pixels). 
 
Gene-specific expression and infection quantification by qRT-PCR 
For gene-specific expression in vitro, total RNA was isolated from Huh7 cells 48 h 
post-transfection (Invitek Invisorb 96-well plate kit) and converted into cDNA (ABI’s 
HighCapacity cDNA reagents) with random hexamers, following the manufacturer 
recommendations. qRT-PCR used the SybrGreen method with Quantace qPCR 
mastermix at 11 µl total reaction volume, containing 500 nM of the target-specific 
primers, and primers that were designed to specifically amplify a fragment of the 
selected genes. Real-time PCR reactions were performed on an ABI Prism 7900HT 
system. Relative amounts of remaining mRNA levels of RNAi targets were calculated 
against the level of RPL13A or 18S rRNA, as housekeeping genes. Remaining mRNA 
levels of RNAi-treated samples were compared with those of samples transfected 
with Negative unspecific siRNA. RPL13A-specific primer sequences were: 5’-CCT 
GGA GGA GAA GAG GAA AGA GA-3’ and 5’-TTG AGG ACC TCT GTG TAT TTG 
TCA A-3’. 18S rRNA-specific primer sequences were: 5’-CGG CTT AAT TTG ACT 
CAA CAC G-3’ and 5’-TTA GCA TGC CAG AGT CTC GTT C-3’. 
For infection determination in vivo or ex vivo, total RNA was isolated from livers or 
primary hepatocytes using Qiagen’s RNeasy Mini or Micro kits, respectively, 
following the manufacturer’s instructions. The determination of liver parasite load in 
vivo, was performed according to the method developed for P. yoelii infections (Bruna-
Romero et al., 2001). Livers were collected and homogenized in denaturing solution (4 
M guanidine thiocyanate; 25 mM sodium citrate pH 7, 0.5 % sarcosyl and 0.7 %                
β-Mercaptoethanol in DEPC-treated water), 40 h after sporozoite injection. Total RNA 
was extracted using Qiagen’s RNeasy Mini kit, following the manufacturer’s 
instructions. RNA for infection measurements was converted into cDNA using 
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Roche’s Transcriptor First Strand cDNA Synthesis kit, according to the 
manufacturer’s protocol. The qRT-PCR reactions used Applied Biosystems’ Power 
SYBR Green PCR Master Mix and were performed according to the maunufacturer’s 
instructions on an ABI Prism 7000 system (Applied Biosystems). Amplification 
reactions were carried out in a total reaction volume of 25 µl, containing 0,8 
pmoles/µl or 0,16 pmoles/µl  of the Plasmodium- or housekeeping gene-specific 
primers, respectively. Relative amounts of Plasmodium mRNA were calculated against 
the Hypoxanthine Guanine Phosphoribosyltransferase (HPRT) housekeeping gene. 
18S PbA- and mouse HPRT-specific primer sequences were 5’- AAG CAT TAA ATA 
AAG CGA ATA CAT CCT TAC – 3’ and 5’ - GGA GAT TGG TTT TGA CGT TTA 
TGT G – 3’and 5’ – GTA ATG ATC GTC GTC AAC GGG GGA – 3´ and 5’ – CCA 
GCA AGC TTG CAA CCT TAA CCA – 3’, respectively. 18S Pf- and human HPRT-
specific primer sequences were 5’- CTG GTT TGG GAA AAC CAA AT – 3’ and 5’ – 
CTC AAT CAT GAC TAC CCG TCT G – 3’and 5’ – TGC TCG AGA TGT GAT GAA 
GG – 3´ and 5’ – TCC CCT GTT GAC TGG TCA TT – 3’. For SR-BI mRNA level 
determination by qRT-PCT, SR-BI-specific primers were used, namely for mouse SR-
BI, 5’ – AAG CTG TTC TTG GTC TGA ACC C – 3’ and 5’ –ACT ACT GGC TCG ATC 
TTC CCT G – 3’ and human SR-BI, 5´- AGA ATA AGC CCA TGA CCC TGA A - 3’ 
and 5´- TGA GCT CAG CAA ATA ATC CGA A – 3´, respectively. 
 
Quantification of host SR-BI protein expression using Western blot 
Huh7 cells were seeded and transfected in optical 96-well plates as described above. 
After an additional 48 h of incubation at 37°C in 5% CO2, cells were harvested in RIPA 
buffer (150 mM NaCl; 20 mM Tris, pH 8.0; 2% Triton X100, 0.5% deoxycholic acid  and 
0.1% SDS) containing 50 U/ml Benzonase (Merck, Germany) and complete EDTA-free 
protease inhibitor cocktail (Roche, Germany). The cell lysate was incubated for 20 min 
on ice. After centrifugation, reducing buffer (NuPAGE LDS Sample Buffer and 
NuPAGE Sample Reducing Agent, Invitrogen) was added to the supernatant. 
Proteins were resolved on a NuPAGE 4-12% Bis-Tris gel (Invitrogen) and transferred 
on a semi-dry transfer cell (Bio-Rad, Germany) to a nitrocellulose blotting membrane 
(Invitrogen) at 100 mA per blot for 2 hours. The membrane was blocked for one hour 
at room temperature (RT) in PBS containing 0.05% Tween 20 and 3 % nonfat dried 
milk and incubated subsequently over night at 4°C with the primary antibody (rabbit 
anti-SR-BI or mouse anti-GAPDH, Acris Antibodies GmbH, Germany). Then, the 
membrane was incubated for 1 h at RT with horseradish peroxidase-conjugated 
secondary antibodies (Goat anti-rabbit or Donkey anti-mouse, Dianova, Germany and 
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Jackson ImmunoResearch, UK, respectively). The secondary antibody was detected by 
chemiluminescence with the ECL Western Blotting Analysis System, according to the 
manufacturer’s instructions (Amersham Bioscience, Germany) using the LAS-3000 
Luminescent Image Analyzer (Fujifilm). Protein quantification was performed with 
the program AIDA Image Analyzer (Raytest, USA). 
 
SR-BI blockage with anti-SR-BI antibody  
Freshly-prepared serial dilutions of anti-SR-BI antibody (NB 400-134 from Novus 
Biologicals, USA) were added to Huh7 cells 1 h before sporozoite addition. Infection 
level and EEF size were determined 24 after sporozoite addition (104 per well). As 
control, a dilution of 0.02% Na azide, matching that present in the most concentrated 
antibody preparation was used. Huh7 cells were incubated with anti-SR-BI antibody 
during the periods described in the text, measured relative to sporozoite addition. 
 
Effect of BLTs on infection of Huh7 cells 
Stock solutions at 50 mM of BLT-1, BLT-2 and BLT-4 (ChemBridge Corporation, San 
Diego, USA) were prepared in DMSO. One hour prior to sporozoite addition (1-3 × 
104 per well, depending on the experiment). Huh7 cells were incubated with serial 
dilutions of each compound in complete medium, all of which contained DMSO in a 
final concentration of 0.1%. Negative controls were treated with 0.1% DMSO in 
complete medium. Infection level and EEF size were determined 24 h after sporozoite 
addition. Huh7 cells were incubated with BLT-1 during the periods described in the 
text, measured relative to sporozoite addition.  
 
SR-BI silencing in mouse primary hepatocytes 
Mouse primary hepatocytes (10 × 104 per well) were seeded in 700 µl complete 
Williams E medium in 24-well plates and incubated at 37ºC in 5% CO2. Forty-eight 
hours after seeding, cells were transfected with individual SR-BI siRNAs. As control a 
negative siRNA was used. Each siRNA was transfected in triplicate. Briefly, the 
culture medium was replaced by 200 µl of serum-free culture medium without 
antibiotics. Four µl of 10 µM siRNA diluted in 37,5 µl Opti-MEM (Invitrogen.) were 
complexed with 1 µl Oligofectamine (Invitrogen) diluted with 6,5 µl Opti-MEM and 
added to the cells following the manufacturer′s recommended protocol.  Four hours 
after addition of the complex, 125 µl of fresh Williams E medium, supplemented with 
12 % FCS and 3% pen/strep, were added to the cells. Two days later, cells were 
infected with 5 × 104 P. berghei sporozoites per well. Forty-eight hours after infection, 
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cells were collected in 150 µl of RLT buffer (Qiagen) containing 0.1%              
β-mercaptoethanol for RNA extraction and infection measurement by qRT-PCR. 
 
Effect of BLT-1 on infection of mouse and human primary hepatocytes  
Mouse primary hepatocytes (10 × 104 per well) were incubated with 10 µM BLT-1 one 
hour prior to infection with 5 × 104 freshly extracted P. berghei sporozoites. Forty-eight 
hours after infection, cells were collected in 150 µl of RLT buffer (Qiagen) containing 
0.1% β-mercaptoethanol for RNA extraction and infection measurement by qRT-PCR. 
Human primary hepatocytes (10 × 104 cells per well) were incubated with 10 µM BLT-
1 one hour prior to infection with 10 × 104 freshly extracted P. falciparum sporozoites. 
Three days after infection, cells were collected in 150 µl of RLT buffer (Qiagen) 
containing 0.1% β-mercaptoethanol for RNA extraction and infection measurement by 
qRT-PCR. 
 
Fluorescence Activated Cell Sorting (FACS) analysis  
FACS analysis at 2 and 24 h after sporozoite addition was performed to determine the 
percentage of parasite-containing cells. For infection level measurement at 2 h, 2 
mg/ml Dextran tetramethylrhodamine 10000 MW, lysine fixable (fluoro-ruby) 
(Molecular Probes/ Invitrogen) were added to the cells immediately prior to 
sporozoite addition. Cell samples for FACS analysis were washed with 1 ml PBS, 
incubated with 150 µl trypsin for 5 min at 37ºC and collected in 400 µl 10% FCS in PBS 
at the selected time-points post-sporozoite addition. Cells were then centrifuged at 0.1 
g for 3 min at 4 ºC and ressuspended in 150 µl 2% FCS in PBS. Cells were analysed on 
a Becton Dickinson FACScalibur with the appropriate settings for the fluorophores 
used. Data acquisition and analysis were carried out using the CELLQuest (version 
3.2.1fl1, Becton Dickinson) and FlowJo (version 6.3.4, FlowJo) software packages, 
respectively. 
 
Host SR-BI staining  
Huh-7 cells were seeded on coverslips in a 24-well plate (4 × 104 cells per well) and 
incubated at 37ºC in 5% CO2 for 48 h. The medium was then replaced by fresh 
complete medium and incubated at 37ºC in 5% CO2 for 24h. Three days after seeding, 
cells were infected with 5 × 104 P. berghei sporozoites/well. Twenty-four hours after 
infection, cells were fixed with 4% PFA in PBS and permeabilized with 0.01% saponin 
in PBS. Cell nuclei were stained with Hoechst-33342 (Molecular Probes/Invitrogen), 
EEFs were detected using the mouse monoclonal  antibody 2E6 (Tsuji et al., 1994) and 
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an AlexaFluor 488-labeled goat anti-mouse secondary antibody (Molecular 
Probes/Invitrogen). Host SR-BI was stained using the rabbit polyclonal antibody anti-
SR-BI (GTX30467 from GeneTex) and an AlexaFluor 555-labeled donkey anti-rabbit 
secondary antibody (Molecular Probes/Invitrogen). Stained cells were imaged with 
an Olympus fluorescence microscope (BX61) using an oil immersion 100× lens. A total 
of 252 EEFs were randomly imaged from three independent coverslips using identical 
acquisition settings and classified by the presence and intensity of SR-BI staining in 
their vicinity.  
 
In vivo RNAi 
C57Bl/6 mice (male, 6-8 weeks) were treated with a single intravenous (i.v.) 
administration of 5 mg/kg of siRNA formulated in liposomal nanoparticles (Alnylam, 
Germany).  Three different modified siRNAs targeting SR-BI were used. A modified 
siRNA targeting luciferase was used as control. Thirty-six h after siRNA 
administration mice were infected by i.v. injection of 2 × 104 P. berghei sporozoites. 
Remaining SR-BI mRNA levels and parasite load in the livers of infected mice were 
determined by qRT-PCR 40 h after sporozoite injection, 76 h after siRNA 
administration. Infection of mice treated with one SR-BI siRNA was allowed to 
proceed onto the blood stage and parasitemia (% of infected red blood cells) was 
measured daily. 
 
Statistical analysis 
For samples in which n > 5, statistical analysis were performed using unpaired 
Student t or ANOVA parametric tests. Normal distributions were confirmed using the 
Kolmogorov-Smirnov test. For samples in which n < 5, statistical analysis were 
performed using Kruskall-Wallis or Wilcoxon non-parametric tests. P < 0.05 was 
considered significant, P < 0.001 was considered highly significant. 
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Figure 1 | Modified forms of LDL reduce P. berghei
 
sporozoite infection of Huh7 
cells. 
(a)
 
Effect of different concentrations of LDL, oxLDL, acLDL
 
and HDL on Huh7 cell 
infection by P. berghei
 
sporozoites. (b)
 
Quantification of infection of Huh7 cells 
incubated with acLDL
 
for various time periods relative to addition of P. berghei
 
sporozoites. All infections were measured 24 h after sporozoite addition. Results are 
expressed as the mean ± s.d. of 3 independent infections.
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Figure 2 | RNAi screen of lipoprotein pathway genes identifies host SR-BI as 
critical requirement for infection of Huh7 cells by P. berghei
 
sporozoites. 
(a) Schematic representation of experimental workflow for cell-based RNAi 
screening assay to probe role of lipoprotein pathway genes in P. berghei
 
sporozoite 
infection of Huh7 cells.
 
(b) Effects of 206 siRNA
 
treatments targeting 53 lipoprotein 
pathway genes on Huh7 cell proliferation (X axis) and infection by P. berghei
 
sporozoites (Y axis), both measured 24 h after sporozoite addition and 72 h after 
siRNA
 
transfection. Cell proliferation was estimated as the percentage of Huh7 
nuclei relative to the mean from all experimental wells on each plate. Infection rates 
were calculated for each sample well as number of EEFs/cell confluency
 
(as 
described in main text), also plotted here as a percentage relative to the mean from 
all experimental wells on each plate. For convenience, horizontal lines marking ± 2 
s.d. of the whole dataset are also shown. Each circle represents one siRNA
 
(mean of 
triplicate values, see also Supplementary Table 1 for exact values). Negative controls 
appear as blue and green circles, corresponding to untreated cells and cells 
transfected
 
with a non-specific control siRNA, respectively. Red circles correspond to 
siRNAs targeting SR-BI.
 
(c) Same dataset as shown in panel b, with each circle 
representing one of the 53 tested genes, and corresponding to the mean value from 
all siRNAs targeting each gene. Color attributions are the same as in panel b.             
(d)
 
Comparison of effects of siRNA
 
treatments on infection rate versus
 
remaining 
mRNA levels for genes showing at least one positive siRNA
 
(beyond 2 s.d. above or 
below mean infection rate for entire dataset), and for which the
 
relationship between 
infection rate and remaining mRNA supports a proportional dosage
 
effect. The 
horizontal grey lines represent 2 s.d. from the mean infection rate for entire dataset. 
Each circle represents one siRNA
 
(mean of triplicate values), with red, grey and black 
circles corresponding to siRNAs targeting SR-BI, ApoA1BP and MSR1, respectively.
 
(e) Effect of siRNA
 
treatments on SR-BI protein levels in Huh7 cells, measured by 
semi-quantitative Western blotting of extracts taken at the time of infection, i.e. 48 h 
after siRNA
 
transfection, from untransfected
 
cells (Unt. C), cells transfected
 
with a 
negative control non-specific siRNA
 
(Neg. C), or cells transfected
 
with human             
SR-BI-specific siRNAs (hSR-BI siRNAs). Results were normalized to Neg. C levels 
(100%).
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Figure 3 | Inhibition of host SR-BI protein function reduces P. berghei
 
sporozoite 
infection of Huh7 cells. 
(a) Effect of a serial dilution of a SR-BI blocking antibody on P. berghei
 
infection rate 
of Huh7 cells. “C”
 
indicates solvent-treated cells used as control.
 
(b-d) Effect of 
known chemical inhibitors of SR-BI (BLT-1, 2 and 4, respectively) used at different 
concentrations, as shown, on P. berghei
 
infection rate in Huh7 cells, as measured by 
quantification of the number of EEFs. “C”
 
indicates solvent-treated cells used as 
negative control.
 
(a-d) Antibody and all compounds were added to Huh7 cells 1 h 
before sporozoite addition,
 
and infection rates were measured 24 h after sporozoite 
addition, by quantification of the number of EEFs, as described in main text. Results 
are expressed as the mean ± s.d. of EEFs (%) in 3 independent infections. Red 
symbols and lines represent the mean levels of cell confluence based on automated 
analysis of actin staining, as measured for each set of triplicate samples.
229

Rodrigues
 
et al., Figure 4
231
c
mSR-BI siRNAs
a
C 1 2 3
R
em
ai
ni
ng
 S
R
-B
I m
R
N
A
(S
R
-B
I/H
P
R
T,
 %
 o
f c
on
tro
l)
Li
ve
r I
nf
ec
tio
n 
Lo
ad
(P
b
18
S
/H
P
R
T,
 %
 o
f c
on
tro
l)
0
20
40
60
80
100
120
140
20
40
60
80
100
120
140
0
40
100
120
BLT-1
10μM
C
80
In
fe
ct
io
n 
Lo
ad
(P
f 1
8S
/H
PR
T,
 %
 o
f c
on
tro
l)
60
20
b
Pa
ra
si
te
m
ia
(%
 iR
B
C
s)
0.25
0.2
0.15
0.05
0.1
0
C siRNA C siRNA
day 4 day 5
Figure 4 | Host SR-BI is crucial for P. berghei infection in adult mice
 
in vivo and P. 
falciparum
 
infection in primary human hepatocytes. 
(a-b) Effect of siRNA-mediated in vivo
 
knock-down of SR-BI on mouse liver stage
 
(a) 
and blood stage
 
(b) infection by P. berghei. Liver infection load (a, black bars) was 
measured by qRT-PCR analysis of P. berghei
 
18S rRNA
 
normalized to HPRT in liver 
extracts taken 40 h after sporozoite i.v. injection, and plotted as percentage of the 
mean of negative control samples (C). Grey bars in (a) represent
 
the remaining 
mRNA levels for the targeted mSR-BI gene in the same liver samples. Results are 
expressed as the mean ± s.d. of 5 mice per group. Effect on blood stage of treatment 
of one SR-BI siRNA
 
(b) was measured by parasitemia
 
quantification (percentage of 
infected red blood cells, iRBC) using FACS. Mice treated with a siRNA
 
targeting 
luciferase
 
were used as control.
 
(c) Effect of BLT-1 on P. falciparum
 
infection in
 
 
human primary hepatocytes, measured by qRT-PCR as described for (b) above. BLT-
 
1 was added to cells 1 h before sporozoite addition,
 
and infection load was measured 
in cell extracts taken 72 h after sporozoite addition, as described in main text. Results 
are expressed as the mean ± s.d. of triplicate samples..
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Figure 5 | Host SR-BI plays a role in both invasion and development of P. berghei
 
in Huh7 cells. 
(a) FACS analysis of effects of siRNA-mediated knock-down of SR-BI (black bars) or 
different concentrations of BLT-1 treatment  (grey bars) on invasion phase of 
infection in Huh7 cells, using GFP-expressing P. berghei sporozoites. As indicated in 
diagrams above bar chart, cells were harvested for flow cytometry
 
2 h after 
sporozoite addition, and invasion rate was measured as percentage of GFP+
 
cells 
compared to control values. For siRNA-treated samples, control samples (Neg. C) 
were treated with a non-specific siRNA. For BLT-1-treated samples, control (DMSO) 
was treated with drug dilution buffer containing same level of DMSO found in most 
concentrated drug treatment. Results are expressed as the mean ± s.d. of triplicate 
samples.
 
(b) Effect of serial dilutions of a SR-BI blocking antibody on P. berghei
 
development within host Huh7 cells, as determined by EEF size classification using 
automated analysis of microscopy images from cells fixed 24 h after sporozoite 
addition. Data shown are from same samples used for infection rate analysis in 
Figure 3a. Four classes of EEF sizes are represented as different grey levels used in 
bar fills, ranging from black for EEFs with smallest diameter, up to lightest grey tone 
for largest EEFs. Negative control (C) represents cells exposed to antibody dilution 
buffer containing same azide
 
concentration present in most concentrated antibody 
treatment. As indicated in diagram above bar chart, antibody was
 
added 1 h before 
sporozoite addition. Results are expressed as the mean of triplicate samples.
 
(c) Effect 
of BLT-1 treatment at different concentrations on P. berghei
 
development within host 
Huh7 cells, as measured by FACS in cells harvested 24 h after addition of GFP-
 
expressing sporozoites. Negative control (C) represents cells treated with drug 
dilution buffer containing same level of DMSO found in most concentrated drug 
treatment. As indicated in diagram above chart, drug was added 1
 
h before 
sporozoite addition. The graph represents a representative dataset of triplicate 
experimental samples.
 
(d) Effect of BLT-1 treatment at different concentrations added 
2 h after sporozoite addition on P. berghei EEF size, determined as described in (b) 
above, from cells fixed 24 h after sporozoite addition. Negative
 
control (C) is as 
described in (c) above. Results are expressed as the mean of triplicate samples.
 
(e) Immunofluorescence
 
analysis of SR-BI localization in infected Huh7 cells fixed 24 
h after addition of
 
P. berghei
 
sporozoites. The plot represents the quantification of the 
percentage of EEFs (green in images) with different levels of SR-BI (red in images) in 
immediate proximity, according to classification shown in small images (I, II, III). 
Results are expressed as the mean ± s.d. of EEFs (%) in 3 independent infections.
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Supplementary Figure 1
 
| SR-BI is crucial for mouse primary hepatocyte infection 
by P. berghei
 
sporozoites.
(a) Effect of SR-BI
 
siRNAs in mRNA-specific levels (grey bars) and P. berghei
 
infection 
(black bars), both measured 48 h after sporozoite addition by
 
qRT-PCR. (b)
 
Effect of 
BLT-1 on infection of mouse primary hepatocytes by P. berghei,
 
as measured 48 h 
after sporozoite addition by
 
qRT-PCR. 
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Supplementary Figure 2
 
| FACS assessment of sporozoite migration through cells 
and invasion during infection.
(a)
 
Cells not incubated with sporozoites (negative population). (b)
 
Traversal vs
 
invasion were assessed in cells incubated with PbGFP
 
sporozoites (1.5x104) for 2 
hours. The gates contain RD-positive (RD+, red gate), GFP-positive (GFP+, green gate) 
or double-positive cells (RD+GFP +, yellow gate).
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Figure 3
 
| SR-BI plays a role in P. berghei
 
EEF development inside Huh7 cells.
(a) Effect of siRNA-mediated knockdown of SR-BI on EEF size, determined 24 h after 
sporozoite addition. (b)
 
Effect of BLT-1 on EEF size, determined 24 h after sporozoite 
addition.
 
Results are expressed as the mean ? s.d. of triplicates. 
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Gene Name
NCBI 
Gene 
Accession 
Number
NCBI  
Accession ID 
for Targeted 
Transcripts 
siRNA ID 
from 
Supplier1 
Infection Rate2 
Cell 
Proliferation3
Remaining 
mRNA4
ABCA1 19 NM_005502 107729 95,9 97,2 38,4
ABCA1 19 NM_005502 107730 91,3 91,8 38,0
ABCA1 19 NM_005502 117341 95,6 96,3 27,8
ABCA1 19 NM_005502 117342 101,3 95,6 30,4
ABCA1 19 NM_005502 118165 102,5 98,0 27,6
ABCA1 19 NM_005502 212921 109,7 105,5 25,3
APOA1 335 NM_000039,XM_496536 122559 89,7 99,2 18,7
APOA1 335 NM_000039,XM_496536 2250 78,9 96,0 15,2
APOA1 335 NM_000039,XM_496536 2346 110,6 88,9 26,5
APOA1 335 NM_000039,XM_496536 2436 126,4 111,9 20,9
APOA1BP 128240 NM_144772 129257 137,4 114,2 17,9
APOA1BP 128240 NM_144772 129258 113,3 106,1 63,4
APOA1BP 128240 NM_144772 37558 143,7 101,7 16,8
APOA1BP 128240 NM_144772 37652 124,6 100,5 22,5
APOA2 336 NM_001643 10053 116,8 95,6 25,6
APOA2 336 NM_001643 10143 128,8 77,7 15,9
APOA2 336 NM_001643 10229 87,0 75,2 19,3
APOA5 116519 NM_052968 128930 77,8 96,8 37,7
APOA5 116519 NM_052968 35650 * 75,7 76,6 37,3
APOA5 116519 NM_052968 35746 * 89,9 94,1 71,5
APOA5 116519 NM_052968 35835 * 92,7 112,7 17,3
APOB 338 NM_000384 120962 86,0 99,3 58,2
APOB 338 NM_000384 120963 120,8 98,8 34,7
APOB 338 NM_000384 120964 92,8 115,2 50,8
APOB 338 NM_000384 2257 116,1 99,1 20,1
APOC1 341 NM_001645 10231 65,0 97,4 19,0
APOC1 341 NM_001645 10327 95,4 109,3 15,8
APOC1 341 NM_001645 10421 94,2 117,1 26,8
APOC1 341 NM_001645 147168 94,8 107,6 135,6
APOC2 344 NM_000483 8600 107,8 79,4 27,3
APOC2 344 NM_000483 8696 133,1 98,1 22,5
APOC2 344 NM_000483 8789 86,6 94,2 16,3
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Remaining 
mRNA4
APOC3 345 NM_000040,XM_496537 146890 120,7 100,1 11,7
APOC3 345 NM_000040,XM_496537 45917 117,6 112,8 10,4
APOC3 345 NM_000040,XM_496537 7767 104,4 107,0 7,0
APOC3 345 NM_000040,XM_496537 7862 112,0 119,1 3,6
APOC4 346 NM_001646 10232 127,7 95,7 inconc
APOC4 346 NM_001646 10328 115,7 97,3 inconc
APOC4 346 NM_001646 147169 102,9 97,7 inconc
APOC4 346 NM_001646 45988 90,7 114,7 inconc
APOE 348 NM_000041 146891 * 87,4 97,3 68,1
APOE 348 NM_000041 41598 110,1 118,6 47,1
APOE 348 NM_000041 41694 114,5 79,9 62,0
APOE 348 NM_000041 41775 95,2 128,1 13,9
APOF 319 NM_001638 147163 82,2 109,8 inconc
APOF 319 NM_001638 2322 110,8 105,0 inconc
APOF 319 NM_001638 2414 125,9 135,6 inconc
APOF 319 NM_001638 2500 68,6 110,8 inconc
APOH 350 NM_000042 146892 59,9 111,7 20,9
APOH 350 NM_000042 146893 115,4 126,1 32,0
APOH 350 NM_000042 146894 67,4 79,2 11,4
APOH 350 NM_000042 7768 101,9 119,4 8,1
APOL1 8542
NM_003661,
NM_145343,
NM_145344
6709 145,5 88,8 inconc
APOL1 8542
NM_003661,
NM_145343,
NM_145344
6800 88,5 103,2 inconc
APOL1 8542
NM_003661,
NM_145343,
NM_145344
6886 134,2 124,1 inconc
APOL2 23780 NM_030882,NM_145637 135325 133,6 124,5 42,3
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APOL2 23780 NM_030882,NM_145637 135326 141,6 130,1 19,7
APOL2 23780 NM_030882,NM_145637 135327 102,1 102,3 14,6
APOL2 23780 NM_030882,NM_145637 6179 89,0 97,4 34,0
APOL3 80833
NM_014349,
NM_030644,
NM_145639,
NM_145640,
NM_145641,
NM_145642
38103 104,0 99,4 inconc
APOL3 80833
NM_014349,
NM_030644,
NM_145639,
NM_145640,
NM_145641,
NM_145642
38196 57,5 108,6 inconc
APOL3 80833
NM_014349,
NM_030644,
NM_145639,
NM_145640,
NM_145641,
NM_145642
38278 105,4 102,8 inconc
APOM 55937 NM_019101 27747 * 91,6 113,5 19,4
APOM 55937 NM_019101 27840 * 81,7 122,4 33,1
APOM 55937 NM_019101 27926 * 145,0 98,5 87,1
ARH 26119 NM_015627 108752 90,0 108,2 43,7
ARH 26119 NM_015627 23202 101,7 91,8 59,1
ARH 26119 NM_015627 23298 86,7 113,9 101,7
ARH 26119 NM_015627 23391 69,0 113,3 58,1
CAV1 857 NM_001753 10297 90,5 110,6 48,1
CAV1 857 NM_001753 10392 93,5 104,8 20,1
CAV1 857 NM_001753 10479 116,2 131,3 69,4
CAV1 857 NM_001753 145951 * 83,7 74,9 29,9
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CAV2 858 NM_001233,NM_198212 145680 * 107,5 105,6 2,0
CAV2 858 NM_001233,NM_198212 145681 * 119,9 104,9 17,1
CAV2 858 NM_001233,NM_198212 9481 * 114,1 97,1 3,0
CAV2 858 NM_001233,NM_198212 9575 * 97,4 80,1 14,2
CD36 948
NM_000072,
NM_001001547,
NM_001001548
105939 132,5 83,5 68,3
CD36 948
NM_000072,
NM_001001547,
NM_001001548
110587 * 109,8 89,3 24,3
CD36 948
NM_000072,
NM_001001547,
NM_001001548
7788 95,0 79,0 33,4
CD36 948
NM_000072,
NM_001001547,
NM_001001548
7883 125,6 91,4 35,9
CD36 948
NM_000072,
NM_001001547,
NM_001001548
7974 110,0 95,3 51,8
CD5L 922 NM_005894 107864 108,8 109,2 inconc
CD5L 922 NM_005894 107865 72,5 102,2 inconc
CD5L 922 NM_005894 2589 98,9 101,3 inconc
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CD5L 922 NM_005894 2679 112,2 103,6 inconc
CETP 1071 NM_000078 120947 98,8 107,2 inconc
CETP 1071 NM_000078 120948 84,4 99,2 inconc
CETP 1071 NM_000078 120949 91,9 105,3 inconc
CETP 1071 NM_000078 2251 93,4 106,7 inconc
CXCL16 58191 NM_022059 121892 * 106,1 99,9 29,3
CXCL16 58191 NM_022059 121893 * 74,3 100,5 21,8
CXCL16 58191 NM_022059 29610 * 120,0 91,9 13,4
CXCL16 58191 NM_022059 29705 * 85,2 100,7 26,0
DKFZP434F0318 81575 NM_030817 123591 * 96,3 100,9 1,3
DKFZP434F0318 81575 NM_030817 32719 * 118,5 94,2 63,2
DKFZP434F0318 81575 NM_030817 32811 * 111,3 95,5 100,6
DKFZP434F0318 81575 NM_030817 32898 * 113,6 100,9 60,6
HDLBP 3069 NM_005336,NM_203346 145235 * 99,5 91,5 12,2
HDLBP 3069 NM_005336,NM_203346 145236 * 90,0 98,6 18,7
HDLBP 3069 NM_005336,NM_203346 2329 * 91,1 103,2 25,5
HDLBP 3069 NM_005336,NM_203346 2419 * 113,2 92,4 26,5
LCAT 3931 NM_000229 110616 124,5 121,4 inconc
LCAT 3931 NM_000229 110617 88,6 84,5 inconc
LCAT 3931 NM_000229 110618 105,6 102,7 inconc
LCAT 3931 NM_000229 8062 79,1 93,2 inconc
LDLR 3949 NM_000527 106132 134,0 88,9 inconc
LDLR 3949 NM_000527 106134 * 127,2 101,0 32,7
LDLR 3949 NM_000527 110672 * 110,2 97,9 29,8
LDLR 3949 NM_000527 110674 * 80,6 116,9 19,9
LIPC 3990 NM_000236 143213 * 86,9 112,0 7,0
LIPC 3990 NM_000236 8068 * 106,9 117,6 1,4
LIPC 3990 NM_000236 8161 * 93,1 95,1 45,6
LIPC 3990 NM_000236 8252 * 145,1 125,3 12,7
LIPG 9388 NM_006033 138162 * 99,2 107,6 42,0
LIPG 9388 NM_006033 17152 * 78,5 92,9 18,5
LIPG 9388 NM_006033 17246 * 148,7 113,3 36,1
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LIPG 9388 NM_006033 17336 * 124,3 117,0 28,0
LISCH7 51599
NM_015925,
NM_205834,
NM_205835
23479 * 85,2 105,6 83,9
LISCH7 51599
NM_015925,
NM_205834,
NM_205835
23575 * 105,1 72,3 14,9
LISCH7 51599
NM_015925,
NM_205834,
NM_205835
23670 * 123,0 89,1 26,5
LOC338328 338328
NM_015925,
NM_205834,
NM_205835
116788 89,2 85,3 inconc
LOC338328 338328 NM_178172 128376 123,1 104,0 inconc
LOC338328 338328 NM_178172 128377 111,3 91,7 inconc
LOC338328 338328 NM_178172 217244 93,1 104,4 inconc
LOC388633 388633 NM_001010978 254859 125,9 90,1 inconc
LOC388633 388633 NM_001010978 285064 100,6 108,9 inconc
LOC388633 388633 NM_001010978 285065 90,4 103,2 inconc
LOC401944 401944 NM_001013693 255653 139,7 97,5 inconc
LOC401944 401944 NM_001013693 255654 131,9 110,9 inconc
LOC401944 401944 NM_001013693 255655 86,2 104,1 inconc
LRP1 4035 NM_002332 106763 102,9 109,9 32,5
LRP1 4035 NM_002332 111141 91,1 103,2 44,9
LRP1 4035 NM_002332 111142 114,0 86,6 42,6
LRP1 4035 NM_002332 11437 113,5 102,9 27,6
LRP10 26020 NM_014045 108464 82,9 95,4 29,7
LRP10 26020 NM_014045 134173 105,7 88,7 36,1
LRP10 26020 NM_014045 134174 80,4 74,8 52,7
LRP10 26020 NM_014045 20779 97,4 103,5 52,2
Rodrigues et al. , Supplementary Table 1
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LRP11 84918 NM_032832 109824 126,2 96,3 29,1
LRP11 84918 NM_032832 34821 42,5 78,4 29,9
LRP11 84918 NM_032832 34917 95,3 115,8 35,9
LRP11 84918 NM_032832 35005 112,1 106,6 11,7
LRP4 4038 NM_002334 202503 87,2 96,3 29,8
LRP4 4038 NM_002334 213206 67,0 73,4 35,5
LRP4 4038 NM_002334 213207 123,6 105,9 36,1
LRP4 4038 NM_002334 213208 108,2 113,0 88,9
LRP5 4041 NM_002335 106765 66,7 88,2 88,7
LRP5 4041 NM_002335 111147 100,8 101,3 54,8
LRP5 4041 NM_002335 111149 76,0 102,7 49,2
LRP5 4041 NM_002335 11438 75,2 92,8 35,4
LRP6 4040 NM_002336 106766 109,1 113,5 30,6
LRP6 4040 NM_002336 106767 122,2 119,7 117,1
LRP6 4040 NM_002336 11345 122,8 108,8 31,8
LRP6 4040 NM_002336 11439 99,9 105,2 29,0
LRP8 7804
NM_001018054,
NM_004631,
NM_017522,
NM_033300
107482 84,7 113,3 60,0
LRP8 7804
NM_001018054,
NM_004631,
NM_017522,
NM_033300
111478 71,0 108,4 62,9
LRP8 7804
NM_001018054,
NM_004631,
NM_017522,
NM_033300
111480 70,5 92,2 105,9
LRP8 7804
NM_001018054,
NM_004631,
NM_017522,
NM_033300
6039 76,2 123,0 72,1
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LRPAP1 4043 NM_002337 11346 71,9 97,9 24,9
LRPAP1 4043 NM_002337 11440 101,1 80,9 19,6
LRPAP1 4043 NM_002337 11528 89,8 108,6 18,3
MGC45780 286133 NM_173833 128312 74,1 95,3 inconc
MGC45780 286133 NM_173833 43900 72,6 87,3 inconc
MGC45780 286133 NM_173833 43994 68,3 85,3 inconc
MGC45780 286133 NM_173833 44079 79,1 98,0 inconc
MSR1 4481
NM_002445,
NM_138715,
NM_138716
110010 84,2 92,3 inconc
MSR1 4481
NM_002445,
NM_138715,
NM_138716
110011 * 61,3 99,2 12,7
MSR1 4481
NM_002445,
NM_138715,
NM_138716
36772 * 57,3 94,1 4,2
MSR1 4481
NM_002445,
NM_138715,
NM_138716
36859 * 95,2 101,3 9,1
MTP 4547 NM_000253 143239 147,9 111,4 59,4
MTP 4547 NM_000253 8075 105,4 96,4 38,1
MTP 4547 NM_000253 8168 128,0 107,1 21,2
MTP 4547 NM_000253 8259 141,0 117,9 72,6
NPC1 4864 NM_000271 106017 * 135,2 110,4 56,6
NPC1 4864 NM_000271 114040 * 112,4 98,2 54,9
NPC1 4864 NM_000271 114041 * 124,9 110,3 76,3
NPC1 4864 NM_000271 8092 * 127,7 109,2 31,5
PLTP 5360 NM_006227,NM_182676 121016 116,5 98,3 32,7
PLTP 5360 NM_006227,NM_182676 121017 102,9 128,3 114,7
PLTP 5360 NM_006227,NM_182676 17445 65,6 89,0 43,2
PLTP 5360 NM_006227,NM_182676 17538 80,5 76,6 47,9
SR-BI 949 NM_005505 107731 57,9 104,0 43,1
Rodrigues et al. , Supplementary Table 1
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SR-BI 949 NM_005505 107732 88,1 114,8 65,6
SR-BI 949 NM_005505 111573 47,1 84,4 20,1
SR-BI 949 NM_005505 16481 42,0 113,2 22,7
SR-BII 950 NM_005506 107735 89,4 90,5 30,9
SR-BII 950 NM_005506 16297 102,2 99,0 11,1
SR-BII 950 NM_005506 16392 121,5 74,0 23,6
SR-BII 950 NM_005506 16482 85,1 94,0 17,8
SCARF1 8578
NM_003693,
NM_145349,
NM_145350,
NM_145351,
NM_145352
111342 111,9 101,8 inconc
SCARF1 8578
NM_003693,
NM_145349,
NM_145350,
NM_145351,
NM_145352
111343 113,4 96,3 inconc
SCARF1 8578
NM_003693,
NM_145349,
NM_145350,
NM_145351,
NM_145352
13507 95,3 98,1 inconc
SCARF1 8578
NM_003693,
NM_145349,
NM_145350,
NM_145351,
NM_145352
13603 109,6 86,9 inconc
STAB1 23166 NM_015136 136773 78,6 90,6 inconc
STAB1 23166 NM_015136 136774 114,3 92,9 inconc
STAB1 23166 NM_015136 22421 100,5 105,8 inconc
STAB1 23166 NM_015136 22517 104,0 95,9 inconc
TLR6 10333 NM_006068 107933 * 107,0 109,9 68,6
TLR6 10333 NM_006068 17169 * 139,4 110,2 40,0
TLR6 10333 NM_006068 17263 * 119,6 111,1 67,5
TLR6 10333 NM_006068 17353 105,1 106,4 inconc
Rodrigues et al. , Supplementary Table 1
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VLDLR 7436 NM_001018056,NM_003383 107087 * 83,4 100,8 86,0
VLDLR 7436 NM_001018056,NM_003383 107088 * 112,6 96,0 17,5
VLDLR 7436 NM_001018056,NM_003383 4545 * 93,9 91,8 40,6
VLDLR 7436 NM_001018056,NM_003383 4641 * 114,9 102,9 51,0
neg1 103860 89,3 99,8 na
untreated na  114,8 115,8 na
Notes:
* siRNAs with one single experimental triplicate
"inconc": qRT-PCR yielded inconclusive or uninterpretable results despite testing multiple primer pairs (most 
likely due to low expression of gene or undocumented splice variants)
1 (Ambion, Applied Biosystem)
2 (nb EEFs normalized to confluency, shown as % of plate mean)
3 (nb of cell nuclei, shown as % of plate mean)
4 (% relative to negative control)
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Supplementary Table 1 | The relevance of lipoprotein pathway genes for the liver 
stage of Plasmodium infection was addressed by RNAi. 
A library of 206 siRNAs targeting 53 genes expressed in the liver and annotated as 
having validated or putative roles in lipoprotein assembly, binding or uptake was 
assembled and screened by RNAi. For each gene
 
is provided relevant information, 
namely the gene name, the NCBI (National Center for Biotechnology Information, 
Entrez
 
Gene Database; http://www.ncbi.nlm.nih.gov/sites/entrez) gene accession 
number and NCBI accession ID for targeted transcript together with the data 
obtained. The siRNAs used [distinguished by the siRNA
 
ID from the supplier
 
 
(Ambion, Applied Biosystems)] and their respective infection rate (corresponding to 
the number of EEFs normalized to confluency, shown as the % of plate-specific 
negative controls), cell proliferation (number of cell nuclei expressed as % of plate 
mean) and remaining mRNA (% relative to negative control) are provided.
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General Discussion 
 
Malaria is one of the most prevalent infectious diseases worldwide with forty percent 
of the world’s population at risk of infection. As is the case for any parasitic disease, 
malaria infection depends upon the occurrence of interactions between the parasite 
and its host [see (Leiriao et al., 2004; Bano et al., 2007)]. Every stage of Plasmodium 
infection relies, to different extents, on the presence of host molecules that enable or 
facilitate its invasion, survival and multiplication [reviewed in (Prudêncio et al., 
2006a)]. As the development of Plasmodium sporozoites inside hepatocytes is an 
obligatory step before the onset of disease, understanding the parasite’s requirements 
during this stage not only offers a new perspective into mammalian cell biology but 
also contributes to the design of rational prophylactic approaches against malaria 
infection. Despite this fact, to date, not much is known about the host molecules that 
play a role in malaria liver infection, particularly in what concerns Plasmodium 
invasion and development within hepatocytes. The work developed in the present 
PhD thesis used RNAi and microarray approaches to identify novel host factors 
playing a role in the establishment of a malaria infection.  
Microarray technology has revolutionized the analysis of gene expression since it 
allows monitoring the RNA products of thousands of genes at the same time. This is 
possible through the use of arrays, which consist of an orderly arrangement of DNA 
samples that act as a probe for the specific gene. Thus, in a single experiment, it is 
possible to address the expression level of hundreds or thousands of genes within a 
cell by measuring the amount of mRNA (previously converted into cDNA) bound to 
each probe on the array. This amount of mRNA can be precisely measured and used 
to generate a profile of gene expression in the cell(s) (Alberts et al., 2002). Together 
with the use of model systems of infection, microarrays are particularly useful to 
analyze a pathogen's response to its host environment as well as to examine how a 
pathogen alters its gene expression profile in response to its host [reviewed in (Jenner 
and Young, 2005)].  
In chapter 2, entitled “Identification of host molecules involved in the liver stage of 
malaria infection using transcriptional profiling followed by RNAi analysis”, a 
microarray approach was used to obtain a comprehensive view of the changes in the 
host cell transcription throughout Plasmodium infection. An in vitro model of 
Plasmodium hepatocyte infection, the infection of the mouse hepatoma cell line   
Hepa1-6 with the murine P. berghei parasite, was employed to identify the host genes 
that are differentially expressed during infection. However, the information obtained 
cannot distinguish between the host genes that constitute just a host cell response to 
the parasite infection from the ones that play an important role for the infection 
outcome. To this end, an RNAi approach was applied to a group of genes, which 
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presented an interesting gene expression signature during Plasmodium infection of 
hepatocytes, as revealed by the microarray analysis.   
RNAi technology is based on a biological mechanism that consists on a sequence-
specific post-transcriptional gene silencing as a response to dsRNA. The discovery of 
RNAi as a biological response to dsRNA was first made in the nematode 
Caenorhabditis elegans, in which, through the injection of dsRNAs, it was possible to 
silence the genes with complementary sequences to the introduced dsRNAs (Fire et 
al., 1998). RNAi was characterized as an evolutionarily conserved mechanism as it 
was observed in different species, such as fungi (Cogoni and Macino, 1999), Drosophila 
(Kennerdell and Carthew, 1998; Hammond et al., 2000), plants (Waterhouse et al., 
1998; Hamilton and Baulcombe, 1999) and mammals (Caplen et al., 2001; Elbashir et 
al., 2001). The mechanisms behind this remarkable pathway have been extensively 
studied and are reviewed in (Hammond, 2005; Sontheimer, 2005; Tomari and Zamore, 
2005; Sen and Blau, 2006; Rana, 2007). Briefly, the dsRNA is processed into siRNAs by 
the RNase III enzyme Dicer. These siRNAs are incorporated into an effector complex 
called the RNA-induced silencing complex (RISC) that identifies and silences the 
complementary mRNA.  
RNAi was soon employed from small-scale experimentation to genome-wide scale 
screening in Caenorhabditis elegans using dsRNAs (Fraser et al., 2000; Gonczy et al., 
2000). Hopes were raised that this method might also be applicable in mammalian 
cells, providing a direct causal link between gene sequence and functional data in the 
form of targeted loss-of-function phenotypes. However, although this method quickly 
proved successful in cultured Drosophila melanogaster cells (Clemens et al., 2000), the 
use of long dsRNAs to trigger RNAi in mammalian cells was initially hampered by 
the observation that they elicit an innate antiviral immune response by inducing 
interferon-linked pathways. Long sequences of dsRNA induce the activation of a 
cellular dsRNA-dependent protein kinase (PKR) that causes nonspecific destruction 
of RNA and the inhibition of protein synthesis [see (Williams, 1999)]. Fundamental 
insights into mammalian RNAi came with the knowledge that target mRNA 
degradation was guided by the siRNAs resultant from the dsRNAs (Zamore et al., 
2000). This indicated that siRNAs induce RNAi in mammalian cells without eliciting a 
PKR response or inducing antiviral pathways. In fact it was later reported that 
siRNAs could be transfected into mammalian cells to efficiently induce sequence-
specific gene silencing (Caplen et al., 2001; Elbashir et al., 2001). Shortly after, RNAi 
became a standard laboratory procedure to study gene functions in mammalian 
systems since it enables the experimental knockdown of a specific gene and through 
the observation of the subsequent phenotype allows the inference of the function of 
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the targeted gene. RNAi has been widely used in high-throughput screens in both 
basic and applied biology [reviewed in (Carpenter and Sabatini, 2004; Friedman and 
Perrimon, 2004; Willingham et al., 2004; Moffat and Sabatini, 2006; Fuchs and 
Borkhardt, 2007)] and has also become an excellent method for development of 
therapeutic agents, from target discovery and validation to the analysis of the 
mechanisms of action of small molecules [see (Kramer and Cohen, 2004; Ricke et al., 
2006)].  
The work presented in this PhD thesis took advantage of RNAi and constitutes an 
additional example of how this technique can be used to address basic biology 
questions. Furthermore it represents, to our knowledge, the first time that this 
technology was used as a screening tool to identify factors that influence the outcome 
of a parasitic infection. 
The basic question behind this work was to identify hepatocyte host factors that 
modulate Plasmodium infection. To this end an RNAi approach was applied to in vitro 
Plasmodium infection models and the infection phenotype, as a consequence of gene 
loss-of-function, was evaluated. As mentioned above, chapter 2 describes the use of 
RNAi to address the functional relevance of a selection of genes found to be 
differentially expressed throughout Plasmodium infection, as revealed by a previous 
microarray analysis. In chapter 3, entitled “Kinome-wide RNAi screen identifies host 
PKCζ as a critical kinase for Plasmodium sporozoite infection”, RNAi was used to 
address the role of all the known proteins with putative kinase activity, as well as 
several kinase-interacting proteins, in P. berghei sporozoite infection of hepatocytes. In 
chapter 4, “SR-BI is a crucially required host factor with a dual role in the 
establishment of malaria liver infection”, RNAi was decisive to identify the 
requirement of the host SR-BI for Plasmodium infection.   
The extensive use of RNAi to identify host factors important for hepatocyte infection 
by Plasmodium was only successful by following certain guidelines. As with any 
experiment, the use of appropriate negative controls is, in the case of RNAi, extremely 
important. The negative controls used in the RNAi screens performed consisted of a 
negative siRNA, not targeting any annotated genes in the human genome, and of 
untransfected cells, in which no siRNA was used to transfect the cells. The negative 
siRNA control is quite valuable because, as it is processed intracellularly, it reflects 
the effects of using the cell's RNAi processing machinery in the read-out phenotype 
[see (Huppi et al., 2005)]. Both controls have allowed evaluating the success of each 
experiment and were essential during data analysis.  
Systematic RNAi screens typically comprise multiple passes to achieve an optimal 
balance between comprehensive coverage, minimization of false negatives and 
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elimination of false positives, all at acceptable costs and within reasonable timelines 
[reviewed in (Echeverri and Perrimon, 2006)]. In the first pass, all genes were targeted 
using at least 3 independent siRNAs and the positive hits, i.e., siRNAs that led to a 
detectable phenotype, were chosen to undergo a follow-up step. It is commonly 
accepted that the initial hits will probably include a significant number of false 
positives due to reagent-specific off-target effects [see (Echeverri et al., 2006; Echeverri 
and Perrimon, 2006)] and, therefore, the second screening pass is important to refine 
the relevance of the selected hits with respect to the biological process of interest. In 
the second pass of the screens all the candidate hit genes were re-tested using the hit 
siRNA(s) and new siRNA(s) in order to test again a total of 3 siRNAs per gene. At this 
stage only the genes for which a positive loss-of-function phenotype was confirmed 
with more than one siRNA were considered as hits. As the specific pattern of 
transcripts silenced with a given siRNA derives directly from its own nucleotide 
sequence, the likelyhood that several siRNAs with completely distinct sequences 
share the same sequence-dependent off-target effect(s) is very low. Therefore, 
confirmation of an observed phenotype with redundant siRNAs (at least 2), offers the 
most straightforward and compelling way of demonstrating RNAi target specificity in 
large-scale screens [see (Echeverri et al., 2006)]. Finally, genes confirmed as “true 
positives” in the second pass were subjected to a final pass. In the latter the functional 
phenotypic read-out was repeated in parallel with an assay to measure target gene 
silencing, namely qRT-PCR, therefore, allowing the confirmation of a direct link 
between the two.  
The success of RNAi screens depends on the overall quality of the final data set, 
which is associated with the degree to which all sources of variability affect the 
experimental reproducibility. These comprise factors such as the experimental design, 
technical implementation, data processing and intrinsic biological variability.  The 
latter was undoubtedly the most important and difficult to control, ranging from cell 
confluency at the time of transfection and infection to the number of sporozoites 
obtained from infected mosquitoes and quality of the infections (i.e., the parasite’s 
development within each experiment). In order to evaluate and minimize the data 
variability from these factors, when possible, the different screening passes were 
performed twice. 
Besides all the different aspects mentioned above there are still other intrinsic aspects 
of the technique that should be considered. The most basic limitation of all RNAi-
based screens is that negative results, that is, the absence of a detectably altered 
phenotype, cannot be conclusively interpreted. This is due to the fact that RNAi is 
inherently a knock-down rather than a knock-out technology. Therefore, although 
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algorithms are developed to design highly efficient siRNAs, the silencing level 
achieved is rarely of 100% and it is inevitable that these lead to varying loss-of-
function degrees. Consequently, some level of the target protein will remain and, 
depending on the type and turnover of the protein, this may help explain the 
observation of wild-type phenotypes. Indeed, the threshold (i.e., the degree of 
silencing) required for achieving a detectable loss-of-function phenotype differs 
markedly between proteins and depends also on the detection sensitivity of the assay 
[see (Sachse et al., 2005)]. Taking this into consideration it should be noted that it is 
possible that, among genes with negative results in the screens performed, there 
might be host genes that play a role in hepatocyte infection by Plasmodium and which 
we were not able to identify.  
On the other hand, while evaluating the positive results, one should keep in mind that 
it is possible that a stringent direct correlation between the infection phenotype and 
remaining mRNA is not observed. This might be due to the fact that the activity of 
some proteins is concentration-dependent and, thus, small differences in the degree of 
down regulation by different siRNAs against the same target may be sufficient to 
originate different phenotype levels [see (Huppi et al., 2005)]. Moreover, it is possible 
that these small differences in the degree of down regulation are not completely 
distinguished with qRT-PCR, due to biological and/or experimental variability.  
The topics presented here were considered while performing the analysis of the data 
from the different RNAi screens that led to the identification of host factors that seem 
to modulate hepatocyte infection by Plasmodium sporozoites. The work presented in 
chapter 2 has revealed the host genes Atf3 and c-Myc through the combined use of 
microarray and RNAi technologies applied to the in vitro infection model constituted 
by the mouse hepatoma cell line Hepa1-6 and P. berghei sporozoites. In chapter 3, an 
RNAi screen comprising a total of 727 human genes, encoding all the known proteins 
with putative kinase activity as well as several kinase-interacting proteins, was 
performed using the in vitro infection model of human hepatoma Huh7 cells infected 
with P. berghei sporozoites. In this screen six host kinases, specifically MET, PKCι, 
PKCζ, PRKWNK1, SGK2 and STK35, were identified as playing important roles 
during P. berghei sporozoite infection. Another host factor, SR-BI, was revealed by 
RNAi as crucially required for P. berghei sporozoite infection of Huh7 cells, as 
described in chapter 4.  
Therefore, in conclusion, the use of RNAi has enabled the identification of several 
host factors as being essential for hepatocyte infection by Plasmodium sporozoites. The 
study of their relevance and specific role during Plasmodium infection merits further 
attention. For instance to assess their relevance in the several steps that constitute a 
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successful hepatocyte infection by Plasmodium, namely cell traversal, hepatocyte 
invasion and intrahepatocyte parasite development would be extremely important. In 
fact, some of these questions can be rapidly and efficiently addressed in vitro through 
flow cytometry in conjunction with GFP-expressing Plasmodium sporozoites 
[(Prudêncio et al., 2007), for more details consult this publication, which is provided in 
Appendix].  
A previous study has shown that hepatocyte wounding by sporozoite migration 
induces the secretion of HGF, which renders hepatocytes susceptible to infection 
through the activation of MET, HGF’s receptor (Carrolo et al., 2003). The malaria 
parasite exploits MET not as a primary binding site, but as a mediator of signals. 
HGF/MET signaling induces rearrangements of the host cell actin cytoskeleton that 
are required for parasite early development within hepatocytes (Carrolo et al., 2003). 
Moreover, HGF/MET signaling is also essential for protection of Plasmodium-infected 
hepatocytes from apoptosis (Leiriao et al., 2005). This is in agreement with our 
observation that MET knock-down led to a decrease in infection. 
For all the other host factors identified by the RNAi screens, follow-up experiments 
have to be performed in order to validate and understand their involvement in 
Plasmodium infection. To date we have focused, to different extents, on Atf3, PKCζ 
and SR-BI and the results obtained support a role for these host factors in Plasmodium 
sporozoite infection of hepatocytes.  
Atf3’s relevance for in vivo infections was successfully proved and evidence suggests 
that hepatocytes may respond to P. berghei infection by increasing expression of Atf3, 
which, in turn, plays a role in countering infection. Atf3 is a transcription factor linked 
to several cellular functions, such as stress response, regulation of the cell cycle and 
apoptosis (Hartman et al., 2004; Yan et al., 2005; Lu et al., 2006; Lu et al., 2007). The 
exact role that Atf3 plays in Plasmodium infection has to be determined. Still, it is quite 
interesting that Atf3 has been demonstrated by several microarray studies as one of 
the host genes regulated by diverse microbe infections [reviewed in (Jenner and 
Young, 2005)].  
PKCζ’s involvement in Plasmodium sporozoite infection has been confirmed with two 
different approaches. The first consisted of treating cells with a PKCζ pseudo-
substrate inhibitor (PKCζInh), which led to a decrease in P. berghei infection, both in 
Hepa1-6 and Huh7 cells as well as mouse primary hepatocytes. Moreover, PKCζInh 
treatment of human primary hepatocytes also led to a decrease of P. falciparum 
infection in these cells. In addition, PKCζ’s relevance was also proved for in vivo 
Plasmodium infection, since PKCζ silencing in adult mice by RNAi significantly 
reduced liver infection by P. berghei sporozoites. PKCζ has been implicated in several 
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signal transduction pathways regulating differentiation, proliferation and apoptosis 
of mammalian cells [see (Hirai and Chida, 2003; Moscat et al., 2006)]. The specific 
function of PKCζ in the establishment of a malaria liver infection as well as the 
mechanism involved clearly merit further attention.  
Finally, SR-BI is another host factor identified by our work and for which follow-up 
experiments have already been performed in order to validate its role in Plasmodium 
infection. SR-BI’s requirement for P. berghei sporozoite infection of Huh7 cells was 
recognized originally by siRNAi-gene silencing and further validated through 
compound- and antibody-inhibition of its function. SR-BI in vitro silencing or 
inhibition had as outcome a decrease in Plasmodium infection. Moreover, SR-BI 
relevance for infection was proved by ex vivo and in vivo experiments. It was shown 
that SR-BI silencing or inhibition in mouse primary hepatocytes as well as SR-BI in 
vivo silencing leads to a decrease in P. berghei sporozoite infection. Furthermore, 
inhibition of SR-BI activity in human primary hepatocytes also reduced infection by 
the human parasite, P. falciparum. SR-BI involvement in infection was analyzed in 
detail and it was observed a role in both sporozoite invasion and subsequent EEF 
development within the parasitophorous vacuole inside hepatocytes.  
SR-BI is an 82-kDa membrane glycoprotein containing a large extracellular domain 
and two transmembrane domains with short cytoplasmic amino- and carboxy-
terminal domains [reviewed in (Krieger, 1999; Zannis et al., 2006)]. SR-BI functions as 
a multiligand receptor, able to bind with high affinity to a wide variety of apparently 
unrelated ligands. These include native (VLDL, LDL and HDL) and chemically 
modified lipoproteins (oxLDL and acLDL), maleylated bovine serum albumin, 
advanced glycation end-product modified proteins, liposomes containing anionic 
phospholipids and apoptotic cells [see (Trigatti et al., 2000; Trigatti et al., 2003)].  
SR-BI was initially identified as a binding receptor for acLDL, oxLDL and native LDL 
(Acton et al., 1994). Later, SR-BI was reported as the first molecularly well-defined and 
functionally active cell-surface HDL receptor capable of mediating selective lipid 
uptake (Acton et al., 1996). Interestingly, it has been shown that SR-BI interaction with 
HDL differs from that with LDL (Gu et al., 2000b). While HDL competes effectively 
for the binding of LDL to SR-BI, LDL can only partially compete for HDL binding to 
SR-BI. This phenomenon suggests that SR-BI possesses multiple binding sites with 
differing ligand binding properties [see (Krieger, 2001)]. 
The cellular uptake of cholesterol from the hydrophobic cores of lipoproteins by SR-BI 
occurs initially through the binding of the lipoprotein to the cell outer surface, as is 
the case for the classic LDLR. However, SR-BI’s mechanism of lipid uptake after 
lipoprotein binding differs markedly from that of LDLR. Whereas LDLR mediates 
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endocytosis of the intact lipoprotein particle via coated pits and vesicles and its 
subsequent hydrolysis in lysosomes [reviewed in (Hussain et al., 1999)], SR-BI 
mediates the selective uptake of HDL’s cholesteryl esters. During this selective uptake 
the lipid is efficiently transferred from the lipoprotein’s hydrophobic core to cells 
while the lipid-depleted apolipoprotein-containing shell is released to the 
extracellular space [see (Krieger, 2001)]. In addition to its role in the selective uptake 
of HDL cholesteryl esters, SR-BI stimulates the bi-directional flux of free cholesterol 
between cells and HDL and in fact the rate of cholesterol efflux from various cell 
types correlates with the expression of SR-BI (de la Llera-Moya et al., 1999; Gu et al., 
2000a; Yancey et al., 2000).  
SR-BI is highly conserved and, although expressed in various cells, its highest 
expression occurs in organs with critical roles in cholesterol metabolism (i.e. liver) and 
steroidogenesis (i.e. adrenal, ovary, testis) (Acton et al., 1994; Acton et al., 1996; Calvo 
et al., 1997). Studies using Chinese hamster ovary cells (CHO) have shown that SR-BI 
localizes to caveolae (Babitt et al., 1997; Graf et al., 1999), which are cholesterol- and 
sphingomyelin-rich microdomains in the plasma membrane [see (Parton and Simons, 
2007)]. Surprisingly, in mouse hepatocyte couplets, SR-BI has been localized on both 
canalicular (apical) and sinusoidal (basolateral) membranes but, also in juxtanuclear 
compartments, which were identified as the endosomal recycling compartment (ERC) 
[(Silver et al., 2001) and reviewed in (Rhainds and Brissette, 2004)]. Moreover, 
evidence of SR-BI internalization has been provided, which suggests that SR-BI can 
undergo rapid endocytosis from the cell surface (Silver et al., 2001).  
SR-BI has been involved in several pathogen infections. Recently, a Drosophila RNAi 
screen aiming the identification of host factors required for uptake and growth of 
mycobacteria has shown that SR-BI mediates the uptake of Mycobacterium fortuitum, 
Escherichia coli and Staphylococcus aureus (Philips et al., 2005). In addition, a different 
study has provided evidence that SR-BI mediates E. coli K1 and K12, S. aureus, 
Salmonella typhimurium and Listeria monocytogenes bacterial adhesion and cytosolic 
invasion in mammalian cells (Vishnyakova et al., 2006).  
SR-BI was also identified as a novel receptor for the Hepatitis C Virus (HCV) (Scarselli 
et al., 2002). Several studies have tried to define the role of SR-BI in HCV cell entry 
[reviewed in (Tellinghuisen et al., 2007)]. It has been shown that antibodies against SR-
BI, BLT-2 and BLT-4, and siRNAs targeting SR-BI inhibit HCV infection (Bartosch et 
al., 2003b; Lavillette et al., 2005; Voisset et al., 2005) while SR-BI expression level in 
Huh7.5 cells modulates the level of HCV infection (Grove et al., 2007). Moreover, HDL 
and oxLDL, two natural ligands of SR-BI, were shown to modulate HCV infectivity in 
different ways. While HDL facilitates HCV entry into host cells in an SR-BI-dependent 
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manner (Bartosch et al., 2005; Voisset et al., 2005), oxLDL is a potent HCV entry 
inhibitor (von Hahn et al., 2006). In addition it has been observed that LDL and VLDL 
have no effect on HCV infection of host cells (Bartosch et al., 2005; Voisset et al., 2005).  
SR-BI has been shown to interact with HCV envelope glycoprotein E2 (Scarselli et al., 
2002), suggesting that it might be involved at some step of HCV’s entry into its host. 
However, the exact role of SR-BI in invasion by HCV is far from understood. Ectopic 
expression of this molecule in non-liver cell lines does not lead to HCV entry, which 
suggests that additional molecule(s) is/are required for HCV entry (Bartosch et al., 
2003b). Alternatively, it has been suggested that SR-BI may have the capacity to traffic 
HCV virions to low pH compartments where the fusion of HCV may occur or that  
SR-BI might modulate the lipid composition of the plasma membrane to render the 
membrane permissive to HCV entry [reviewed in (Cocquerel et al., 2006)]. 
Although its role is not fully understood, SR-BI’s importance for HCV infection has 
already been extensively addressed. Our work describes for the first time SR-BI’s 
involvement in Plasmodium infection. Our results show that, like for HCV, SR-BI 
silencing by RNAi or its blockage with specific antibodies or chemical inhibitors have 
an inhibitory effect on Plasmodium infection. Similarly, we have observed that HDL 
has a mild positive effect on infection while oxLDL or acLDL inhibit infection and 
LDL has no effect. Furthermore, we have shown that SR-BI plays a role not only in 
invasion but also on parasite development inside the hepatocyte. Its exact function(s) 
in these two steps still remain(s) to be elucidated.  
SR-BI’s role in both HCV and Plasmodium infection, two liver infectious agents, 
suggests that these pathogens have developed common strategies that allow them to 
infect their host cells. This notion is further supported by the fact that both 
Plasmodium sporozoites (Pancake et al., 1992; Frevert et al., 1993) and HCV (Barth et al., 
2003; Koutsoudakis et al., 2006) interact with heparan sulfate proteoglycans and also 
by the observation that another host molecule, the tetraspanin CD81, is involved in 
both HCV and Plasmodium infection.  
CD81 was identified as a candidate HCV receptor based on its ability to bind the virus 
envelope protein E2 (Pileri et al., 1998). Several studies have confirmed CD81’s 
involvement in HCV entry [see (Favre and Muellhaupt, 2005; Cocquerel et al., 2006)]. 
Indeed, it was observed that HCV presents a restricted tropism for human hepatic cell 
lines expressing CD81 (Bartosch et al., 2003a; Bartosch et al., 2003b; Hsu et al., 2003; 
Cormier et al., 2004; Zhang et al., 2004). Moreover, anti-CD81 mAbs inhibit the entry of 
HCV into hepatoma cell lines (Hsu et al., 2003; Cormier et al., 2004; Zhang et al., 2004; 
Lindenbach et al., 2005) and CD81 siRNA-silencing abolishes infection of Huh7 cells 
by HCV (Zhang et al., 2004). In addition, it has also been shown that the human 
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hepatoma cell line HepG2, which does not express CD81 and, therefore, is not 
infected by HCV, becomes susceptible to infection upon CD81 ectopic expression 
(Bartosch et al., 2003b; Cormier et al., 2004; Zhang et al., 2004; Lavillette et al., 2005; 
Lindenbach et al., 2005).   
The exact role of CD81 in HCV entry is also not well understood. Nevertheless, 
although its role in virus entry has been confirmed, CD81 ectopic expression in non-
hepatic cell lines does not lead to HCV entry, which again suggests that additional 
molecule(s) is/are needed for HCV entry (Bartosch et al., 2003b; Cormier et al., 2004). 
It has been proposed that CD81 may function as a post-attachment entry co-receptor, 
i.e., that CD81 might play a role after binding of the particle to a first receptor 
(Cormier et al., 2004). This hypothesis is supported by the fact that tetraspanins are 
able to form lateral associations with multiple partner proteins and with each other in 
a dynamic assembly, described as the “tetraspanin web” [see (Boucheix and 
Rubinstein, 2001)]. Additional experimental evidence is still needed to confirm such a 
role.  
CD81 was also identified as an important molecule required for hepatocyte invasion 
by the rodent P. yoelii and the human malaria P. falciparum parasites (Silvie et al., 
2003). It was shown that P. yoelii sporozoites fail to infect CD81-deficient mouse 
hepatocytes and antibodies against human and mouse CD81 inhibit the hepatic 
development of P. falciparum and P. yoelii, respectively (Silvie et al., 2003). On the other 
hand, the rodent parasite P. berghei can use both CD81-dependent and -independent 
pathways to enter the hepatocyte (Silvie et al., 2003; Silvie et al., 2007). It has been 
shown that P. berghei sporozoites use a CD81-independent pathway to infect             
CD81-negative cells, such as HepG2 and CD81 KO mouse hepatocytes, as well as 
CD81-positive cells, such as Huh7 or HeLa, in which it was observed that CD81 
silencing or antibody-blockage does not alter P. berghei infection (Silvie et al., 2003; 
Silvie et al., 2007). Conversely, similarly to P. yoelii, P. berghei sporozoites use a CD81-
dependent pathway to infect Hepa1-6 cells, since in these cells infection is 
blocked/reduced by anti-CD81 antibody, CD81 siRNA and cholesterol depletion 
(Silvie et al., 2007). 
To date, the precise role of CD81 in P. yoelii and P. falciparum infection remains 
elusive. Tetraspanin-enriched microdomains, which depend on membrane 
cholesterol, have been shown to contribute to CD81-dependent infection by P. yoelii 
and P. falciparum sporozoites (Silvie et al., 2006a). In addition, attempts to identify a 
sporozoite ligand for CD81 have not yet revealed a binding partner for this protein 
(Silvie et al., 2003). Taking this into consideration, it has been proposed that within 
tetraspanin-enriched microdomains, CD81 may regulate the activity of a partner host 
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membrane molecule which plays an essential role during sporozoite invasion (Silvie 
et al., 2006a). Additionally, it has also been proposed that CD81 may play a role 
during the early stages of PV formation, since it was observed that the few P. yoelii 
sporozoites that do invade CD81-negative cells are found without a vacuole, 
developing in the nucleus (Silvie et al., 2006b). 
Thus, since SR-BI, HSPGs and CD81 have been revealed as important for HCV and 
Plasmodium infection, it is tempting to speculate that altogether these host factors 
might account for pathogen tissue tropism towards the liver and pathogenicity. A 
synergy between SR-BI and CD81 functions has already been described in HCV 
infection (Kapadia et al., 2007). It would be extremely important to address this issue 
in Plasmodium infection. In order to do so, CD81-dependent infection models would 
have to be used namely the P. yoelii and/or P. falciparum parasites. It would also be 
possible to use P. berghei but only in combination with Hepa1-6, since it has been 
shown that this infection model is CD81-dependent, contrary to Huh7 infection by P. 
berghei, which is CD81-independent. For example, this question could initially be 
addressed by cell treatment with specific antibodies against CD81 and SR-BI or by 
siRNA-gene silencing for both genes. 
It should also be considered that CD81 and SR-BI are probably not the only host cell 
factors important for HCV and Plasmodium infection. Actually, for Plasmodium 
infection, other host factors, namely HGF, L-FABP and ApoA1, have already been 
disclosed as playing important roles in this process. To reconcile their functions is 
quite challenging. 
Regarding SR-BI, the work that has already been developed and is presented in 
Chapter 4 provides strong evidence of its crucial role for Plasmodium infection. Still to 
complement the RNAi in vivo experiments, in which SR-BI was silenced and 
Plasmodium liver infection was determined, it would be extremely important to test if 
SR-BI-deficient mice are susceptible to Plasmodium liver infection. In fact, we have 
already observed a reduction in P. berghei liver infection in SR-BI heterozygous in 
comparison to wild-type mice (data not show). However, to test homozygous KO 
mice would be an appropriate strategy, but until now, this has not been possible due 
to difficulties in obtaining these mice. These difficulties are related to the fact that 
homozygous female SR-BI KO mice are infertile, therefore, homozygous vs. 
homozygous breedings are nonproductive (Miettinen et al., 2001). Moreover, 
intercrosses of SR-BI heterozygous mice on a mixed C57BL6/129 background result in 
a non-Mendelian transmission of the SR-BI KO allele and subsequently a low 
frequency of homozygous mice is obtained (Rigotti et al., 1997). An alternative option 
would be to test Plasmodium infection in vivo in PDZK1-deficient mice. PDZK1 is a 
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multi-PDZ domain containing adaptor protein, known to interact with SR-BI [see 
(Yesilaltay et al., 2005)]. It has been shown that PDZK1 controls in a tissue-specific and 
post-transcriptional fashion SR-BI in vivo expression. PDZK1-deficient mice have 
greatly diminished surface expression of SR-BI in the liver, i.e., a 85-95% reduction of 
SR-BI protein expression has been observed (Kocher et al., 2003). Recently, these mice 
have become commercially available through The Jackson Laboratory 
(http://www.jax.org/) and they will be tested earlier in the future. 
A different strategy to prove that SR-BI is essential for host cell infection by 
Plasmodium, already ongoing in our laboratory, consists on testing the effect of SR-BI 
overexpression in different cell lines. It can be expected that SR-BI overexpression in 
hepatic cells known to support Plasmodium sporozoite infection will lead to an 
infection increase, while SR-BI overexpression in non-hepatic cells that do not support 
sporozoite infection would turn them susceptible to infection. However, it is also 
possible that the latter assumption cannot be observed, which would suggest that, 
although SR-BI is important, additional host molecule(s) is/are needed for 
Plasmodium infection.  
As previously mentioned, SR-BI plays a dual role in Plasmodium infection, it is 
important for sporozoite invasion and also for parasite intracellular development. 
Therefore, understanding SR-BI’s exact function in these two steps of Plasmodium 
infection constitutes one of our next objectives.  
In terms of invasion one can speculate on a direct or on an indirect interaction 
between sporozoites and SR-BI. A direct interaction between sporozoites and SR-BI is 
supported by the observation that modLDL, in particular oxLDL and acLDL, inhibit 
sporozoite invasion. It is tempting to picture a “modLDL-mimic” model, in which the 
sporozoite would be interacting directly with SR-BI through a mode of binding 
similar with that of modLDL forms, but not with that normally used by HDL. This 
hypothesis can be ascertained by the observation of a direct binding between 
sporozoites and SR-BI and, furthermore, by the identification of the sporozoite 
molecule that interacts with SR-BI. An indirect interaction would imply that the 
sporozoites would interact directly with HDL particles and benefit from their high 
affinity binding to SR-BI. This “HDL-piggyback” model would be based on the 
sporozoite’s ability to associate with HDL and would explain HDL’s slightly positive 
effect on invasion. 
Besides how SR-BI and sporozoites interact, another important question is if and how 
does SR-BI contribute to sporozoite internalization? It is possible that SR-BI might not 
play an active role during sporozoite invasion and instead this host factor would only 
serve as a “docking” site. In this scenario the sporozoite would enter the host cell by 
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engaging an active process, as previously shown for Toxoplasma gondii (Dobrowolski 
and Sibley, 1996). If, on the other hand, SR-BI plays an active role during Plasmodium 
invasion, this must somehow be related with its mode of action. SR-BI has been 
mainly characterized to mediate the selective uptake of cholesteryl esters from bound 
HDL or LDL without triggering an endocytic or phagocytic event [see (Krieger, 
2001)]. Taking into consideration only this SR-BI mode of action it is not obvious how 
sporozoites would be able to enter the hepatocyte. However, it has also been shown 
that HDL is able to enter HepG2 cells by endocytosis (Wustner et al., 2004), therefore, 
it is possible and more logical that sporozoites could invade hepatocytes by 
endocytosis.  
Moreover, it is also possible that our observations are due to a side effect of 
interfering with SR-BI’s pathway, such as an alteration of the membrane composition 
(i.e. re-arrangement or destruction of lipid rafts) and, in fact, downstream signalling 
events and/or another receptor would be involved in Plasmodium invasion.  
Concerning SR-BI’s role in Plasmodium development within hepatocytes, it is tempting 
to speculate that SR-BI may participate in a mechanism that would provide 
cholesteryl esters and other lipids to the parasite across the PV membrane, since 
during this phase the parasite undergoes an amazing proliferation process. The 
knowledge that other cholesterol-related proteins, ApoA1 and L-FABP, are also 
important for Plasmodium infection supports this hypoyhesis.  
ApoA1 is the major structural apolipoprotein of HDL, and it has been observed to 
interact with the UIS4 sporozoite protein and co-localize in the PV 24 hours after 
sporozoite infection [Mueller and Matuschewski, unpublished data referenced in 
(Prudêncio et al., 2006b)]. Our observation of a subcellular accumulation of SR-BI 
around EEFs together with this knowledge of ApoA1 co-localization on PV supports 
the hypothesis that SR-BI would be “feeding” the parasite with cholesteryl esters and 
other lipids.  
L-FABP, is the main cytoplasmic carrier of fatty acids in hepatocytes. Down-
regulation of its expression in hepatocytes severely impairs parasite growth while its 
overexpression promotes growth. L-FABP has been shown to interact with the UIS3 
sporozoite protein through a two-hybrid system and, although no direct interaction 
has been shown in infected hepatocytes, it has been suggested that the UIS3 parasite 
association with L-FABP would allow the parasite to acquire fatty acids (Mikolajczak 
et al., 2007). Thus, this can represent a totally different alternative mechanism that the 
parasite has to access cholesterol or, instead it might be linked to SR-BI “feeding” 
mechanism. It is known that free cholesterol obtained from the SR-BI pathway 
normally reaches the endoplasmic reticulum, a cholesterol regulatory compartment, 
 269
Chapter 5  
through cholesterol diffusion into membranes. However, it is possible that 
intracellular transport proteins may help to deliver cholesterol to cell surface-remote 
compartments and, in hepatocytes, L-FABP would be a good candidate for this 
transport, since it binds fatty acids and cholesterol, both of which are products of 
cholesteryl ester hydrolysis [see (Rhainds and Brissette, 2004)]. This hypothesis is 
further supported by the observation that SR-BI overexpression in HepG2 cells 
increases L-FABP expression (Rhainds et al., 2004). 
In addition, it has recently been shown that Plasmodium preferentially develops in the 
host juxtanuclear region and its PV forms an association with the host endoplasmic 
reticulum (Bano et al., 2007). Moreover, it was reported that during intrahepatic 
development Plasmodium actively modifies the permeability of its vacuole to allow the 
transfer of a large variety of molecules from the host cytosol to the vacuolar space 
through open channels (Bano et al., 2007).  
Altogether the data presented and referenced strongly indicate that the parasite needs 
cholesterol and that it is able to acquire it through the manipulation of one or more 
pathways. In order to access if any of the hypothesis formulated are true it is 
important to explore the combined function of these cholesterol-related host factors 
during Plasmodium development. Although quite challenging, this approach will 
certainly reveal new insights into Plasmodium liver stage infection.  
In conclusion, we have identified a number of host factors that are important for 
hepatocyte infection by Plasmodium. This study provides a crucial basis for the more 
extensive studies that are required to understand the role of the now-revealed host 
molecules as well as to identify additional ones. The study of Plasmodium liver stage 
infection is extremely important to develop prophylactic strategies. In fact, if infection 
is blocked at this stage, there will be no pathology and consequently no disease. The 
major concerns regarding the prophylaxis strategies are drug resistance and toxicity if 
the drug target is parasite or host-derived, respectively. With increasing knowledge of 
the molecular mechanisms underlying parasite invasion and development in the liver, 
it might become possible to design drugs that do not interfere with normal liver 
functions but do prevent infection. 
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Summary
The study of the liver stage of malaria has been ham-
pered by limitations in the experimental approaches
required to effectively dissect and quantify hepatocyte
infection by Plasmodium. Here, we report on the use of
flow cytometry, in conjunction with GFP-expressing
Plasmodium sporozoites, to assess the various steps
that constitute a successful malaria liver infection: cell
traversal, hepatocyte invasion and intrahepatocyte
parasite development. We show that this rapid, effi-
cient and inexpensive method can be used to over-
come current limitations in the independent quantifi-
cation of those steps, facilitating routine or large-scale
studies of host–pathogen molecular interactions.
Introduction
The liver stage of the life cycle of Plasmodium is the first,
obligatory step in any natural malaria infection. During this
asymptomatic phase, the sporozoites injected into the
mammalian host through the bite of an infected mosquito
reach the liver, where they traverse several hepatocytes
before invading a final one with formation of a parasito-
phorous vacuole (PV) (Mota et al., 2001; Frevert et al.,
2005). Inside hepatocytes, the parasites develop and mul-
tiply, forming a so-called exoerythrocytic form (EEF).
During this process, which takes 5–7 days for the human
parasite Plasmodium falciparum and c. 42 h for the rodent
Plasmodium berghei parasite, the EEF grows in size and
eventually releases 20 000–30 000 merozoites into the
blood, where they will invade erythrocytes and cause the
symptoms of the disease (reviewed in Prudencio et al.,
2006).
Although the liver stage of malaria constitutes an ideal
target for prophylactic intervention, only recently have the
processes that take place during this stage begun to be
understood. This is largely due to practical issues ham-
pering the study of what goes on when sporozoites invade
and develop inside hepatic cells. In fact, unlike blood
stages that can be easily obtained from frozen-infected
blood, sporozoites need to be freshly extracted from the
salivary glands of infected mosquitoes, which poses con-
straints to their availability. Moreover, studies in human
volunteers or in endemic populations are not feasible due
to ethic constraints and to the fact that this stage of
disease is asymptomatic. This leaves researchers with a
few important tools to study liver stage malaria, namely, in
vivo animal models, ex vivo primary hepatocytes and in
vitro hepatoma cell lines. The latter constitute a valuable
resource to study the fundamental aspects of EEF forma-
tion and development and to evaluate drug candidates
that may interfere with these processes.
Recently, genetic manipulation of Plasmodium has
allowed the generation of parasites that express green
fluorescent protein (GFP) (Kadekoppala et al., 2001;
Natarajan et al., 2001; Franke-Fayard et al., 2004;
Tarun et al., 2006; Ono et al., 2007), which enables
cells infected with these parasites to be analysed by
fluorescence-activated cell sorting (FACS). This tech-
nique has been successfully used to separate infected
hepatocytes or hepatoma cells (Natarajan et al., 2001;
Tarun et al., 2006) as well as to monitor infection of red
blood cells in mice (Janse et al., 2006; Ono et al., 2007).
In this report we describe how flow cytometry can be
employed to obtain crucial quantitative information
regarding the hepatic stage of malaria. Our results show
that this technique can be used to determine the efficiency
of infection of a hepatoma cell line by the GFP-expressing
rodent malaria parasite P. berghei (PbGFP). In particular,
it enables the quantitative assessment of the cell traversal
process that precedes invasion, as well as of both the
invasion and development processes essential for the
establishment of a successful infection.
Results and discussion
Quantification of cell traversal by migrating sporozoites
When sporozoites traverse hepatocytes before the final
invasion, they disrupt the membrane of the host cell,
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which then quickly reseals (Mota et al., 2001). Cell tra-
versal can be monitored and quantified by fluorescence
microscopy by a cell wounding assay employing
rhodamine dextran (RD), which, if present in the medium
upon sporozoite addition, is trapped within the cell before
resealing occurs (Mota et al., 2001). Generally, such
quantification is laborious and time-consuming, as it
involves the visual inspection of RD-positive (RD+) cells
and their quantification. A very recent report uses FACS to
compare cell wounding by mutant and wild-type sporozoi-
tes but does not provide any controls to show that this
technique can be used to quantify cell traversal (Labaied
et al., 2007). We have sought to establish whether FACS
can be used to quantitatively assess cell traversal by
sporozoites. RD was added to the cells immediately prior
to sporozoite addition and cells were collected and analy-
sed by FACS 2 h later. Non-infected cells incubated with
RD during the same period as the infected ones and cells
that were mechanically disrupted in the presence of RD
were used as controls (Fig. 1A and B). The percentage of
RD+ cells in untreated cultures is minimal, when com-
pared with those in which cells were either incubated with
sporozoites or mechanically disrupted, showing that
membrane wounding by traversing sporozoites can be
detected by this approach (Fig. 1B). In order to determine
whether the technique can give quantitative information
about cell traversal, cells were incubated with different
amounts of sporozoites for 2 h (Fig. 1C and D). Cells
incubated with sporozoites treated with cytochalasin
(CCH), whose motility is impaired (Stewart et al., 1986),
and uninfected cells, were used as controls (Fig. 1C and
D). The results obtained show that the percentage of RD+
Fig. 1. FACS assessment of cell wounding during sporozoite traversal.
A. Cell wounding was assessed in a RD-based assay by fluorescence intensity. Dot plots represent undisrupted-uninfected cells (control),
mechanically disrupted cells and cells incubated with sporozoites (15 ¥ 103) for 2 h. The gate contains RD+ cells.
B. Bar plot represents the percentage of RD+ cells in the conditions in (A) (n = 3). Error bars represent SD.
C. Cell wounding by sporozoites was assessed in a RD-based assay by fluorescence intensity. Dot plots represent cells incubated for 2 h with
different numbers of sporozoites (spz), previously treated with cytochalasin (CCH) or not (Untreated). The gate contains RD+ cells.
Non-infected cells were used as control.
D. Bar plot represents the percentage of RD+ cells in the conditions in (C) (n = 3). NI corresponds to non-infected cells used as control. Error
bars represent SD.
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cells correlates with the number of sporozoites added to
cells (Fig. 1D). When cells are incubated with a fixed
number of sporozoites for periods of time between 15 min
and 2 h, the percentage of RD+ cells correlates with the
time of incubation (data not shown). These results show
that flow cytometry can indeed be used to successfully
quantify hepatocyte traversal by sporozoites.
Quantification of invasion
Invasion of hepatoma cells by sporozoites is usually
assumed to be complete within the first 2 h following
parasite addition to the cells (Mota et al., 2001). Thus, by
determining the extent of infection 2 h after sporozoite
addition, one can, conceivably, assess the efficiency of the
invasion process. Quantification of invasion by any of the
techniques traditionally employed to study hepatocyte
infection is difficult. Until now, it has relied on a parasite
surface molecule double immunostaining, performed
before and after cell permeabilization (Sinnis, 1998). This
method distinguishes between parasites attached to the
cells and invading ones, but it is a time-consuming proce-
dure requiring pre-labelled, parasite-specific antibodies.
Another approach that can be employed to determine
infection levels in vitro is quantitative real-time reverse
transcription polymerase chain reaction (qRT-PCR), using
primers specific for the parasite in parallel with primers for
a housekeeping gene to allow normalization of the results,
as described for the quantification of in vivo liver infections
(Bruna-Romero et al., 2001). However, quantification by
qRT-PCR is not only a time-consuming approach but also
an expensive one, rendering it unsuitable for large-scale or
routine studies. Now, we demonstrate that these limitations
can be overcome by using FACS to analyse cells 2 h after
sporozoite addition.
We infected Huh7 cells with fixed numbers of PbGFP
sporozoites and analysed them by FACS 2 h later. Non-
infected cells were used as control (Fig. 2A and B). Our
results show that the infected cell population can be
successfully quantified using this technique and that, as
expected, the percentage of PbGFP-containing cells
depends on the number of sporozoites added (Fig. 2B).
CCH treatment of sporozoites does not impair their ability
to attach to cells but renders them unable to invade
(Stewart et al., 1986). Cells incubated with CCH-treated
sporozoites for 2 h and then analysed by FACS show only
negligible amounts of GFP fluorescence, when compared
with that of cells incubated with untreated sporozoites and
similar to those displayed by non-infected cells (Fig. 2A
and B). This shows that tripsinization of cells prior to
FACS analysis ensures that all GFP-positive (GFP+)
events observed correspond to parasite-containing cells
and not to cells with sporozoites attached to their surface.
In a parallel experiment, we incubated cells with the
supernatant of infected cells, collected 2 h after parasite
addition. Two hours later, cells to which this supernatant
was added were collected and analysed by FACS, reveal-
ing only residual amounts of infected cells (data not
shown). This result is in agreement with the notion that
successful infection is accomplished within the first 2 h
that follows sporozoite addition.
The traversal and invasion processes can be simulta-
neously assessed in RD-treated cell samples infected
with PbGFP sporozoites (Fig. 2C and D). By carefully
gating the various cell populations, FACS can be used to
determine the percentage of cells whose membrane has
been disrupted (RD+) and of those containing a parasite at
the time of measurement (GFP+). Furthermore, a double-
positive population (RD+GFP+) consisting of cells either
that contain parasites ‘in transit’ or that were traversed
and subsequently invaded can be identified (Fig. 2D).
Approximately 50% of the GFP+ cell population is
RD-negative and therefore these cells have been
unequivocally invaded. On the other hand, invasion with
PV formation may or may not have occurred in the
remaining 50% of the GFP+ cell population, which corre-
sponds to RD+GFP+ cells. Hence, data from double-
fluorescence FACS measurements should be taken into
account when the estimation of the percentage of
invaded, non-traversed cells is of relevance.
Quantification of EEF development
By itself, flow cytometry information collected 2 h after
sporozoite addition is useful to evaluate the ability of
parasites to invade cells in culture, but provides little
insight into the extent of their intracellular development.
The latter can be assessed by quantifying infection at later
time points after sporozoite addition. Traditionally, this
was done by immunofluorescence staining of the parasite
and EEF quantification by microscopy. This is a time-
consuming approach, made easier by developments in
automatic image acquisition and treatment techniques,
but is still impractical for the assessment of the early
developmental stages of infection. As an alternative to
microscopy, qRT-PCR can be used to quantify the number
of parasite copies at specific times following sporozoite
addition. However, in addition to the disadvantages men-
tioned earlier, qRT-PCR has limitations regarding an
effective differentiation between the invasion and devel-
opment processes, if samples are analysed at a single
time point of EEF development. This can be circumvented
by analysing samples at different times after sporozoite
addition, but this further increases both the price and time
of data acquisition. In order to overcome these draw-
backs, we sought to determine whether FACS can be
used to reliably estimate the extent of intrahepatocyte
parasite development.
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We infected Huh7 cells with a fixed number of PbGFP
sporozoites and analysed them by FACS at various time
points post infection (Fig. 3A and B). As control, we used
radiation-attenuated PbGFP sporozoites (RASPbGFP),
which are known to retain their ability to invade cells but fail
to develop and multiply (Suhrbier et al., 1990). As
expected, the percentage of PbGFP-infected cells
decreases for later time points of infection, as a result of the
multiplication of cells in culture (Fig. 3A). When the FACS
data are plotted as a histogram, it becomes apparent that
the maximum fluorescence of the PbGFP-infected cells
increases as the infection is allowed to proceed for longer
(Fig. 3B). These data show that although the relative pro-
portion of PbGFP-infected cells is decreasing as the time
post infection increases, the fluorescence emitted by these
cells is increasing during the same period, as a result of
EEF development. When cells are infected with RASPb-
GFP sporozoites, the percentage of infected cells also
decreases with time (Fig. 3A). However, the maximum
fluorescence of RASPbGFP-infected cells does not
change significantly in the same period (Fig. 3B), in agree-
ment with the knowledge that development of irradiated
parasites is impaired (Suhrbier et al., 1990).
In order to determine whether there is a correlation
between the position of the GFP+ curve and the number of
copies of parasite at a given time post infection, we analy-
sed cells infected under similar conditions as those
described above by qRT-PCR (Fig. 3C). We observed that,
as expected, the number of parasite copies in PbGFP-
infected cells increases up until 36 h post infection and is
Fig. 2. FACS assessment of cell invasion.
A. Cell invasion was quantified by determining the proportion of GFP+ cells in Huh7 cells incubated with PbGFP sporozoites. Dot plots
represent non-infected cells and cells incubated for 2 h with different numbers of PbGFP sporozoites (spz), previously treated with
cytochalasin (CCH) or not (Untreated). The gate contains GFP+ cells.
B. Bar plot represents the percentage of GFP+ cells in the conditions in (A) (n = 3). NI corresponds to non-infected cells used as control. Error
bars represent SD.
C. Traversal versus invasion were assessed in cells incubated with PbGFP sporozoites (15 ¥ 103) for 2 h. The gates contain RD+ (red) GFP+
(green) or RD+GFP+ (yellow) cells.
D. Bar plot represents the percentages of RD+, GFP+ or RD+GFP+ cells (n = 3). Error bars represent SD.
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reduced at 48 h post infection. The number of parasite
copies in RASPbGFP-infected cells increases slightly
between 2 and 12 h post infection and then remains
roughly constant up until 48 h after sporozoite addition, a
result that is in agreement with previous observations
(Suhrbier et al., 1990). Our results also indicate that the
number of PbGFP copies decreases between 36 and 48 h
after infection, possibly due to detachment of infected cells
or release of merozoites (Sturm et al., 2006). This is not
observed for RASPbGFP-infected cells, suggesting that
Plasmodium release by the host cells is dependent on the
development of the parasites within them.
The correlation between the number of parasite copies
and the intensity of the GFP+ band in PbGFP-infected
cells was further established by plotting the former against
the latter (Fig. 3D). This shows that intracellular parasite
development takes place exponentially until parasite
release starts to occur. Moreover, it shows that the fluo-
rescence corresponding to the maximum of the GFP peak
in a FACS histogram correlates linearly with the number of
copies of parasite in the cells and can thus be used as a
quick and effective way of estimating the intracellular
development of the parasite.
Finally, we assessed parasite development in cells that
are either RD–GFP+ or RD+GFP+, by independently plot-
ting the histograms of each of these cell populations at
time points between 2 and 48 h following sporozoite
addition. Our results reveal that RD–GFP+ cells contain
EEFs that develop normally during this period, showing
that the parasites in these cells have undergone produtive
invasion with formation of a PV. On the contrary, parasites
in RD+GFP+ cells develop poorly if at all and their GFP
intensity decreases at the later time points assessed (data
not shown).
Fig. 3. Assessment of infection at various times after sporozoite (30 ¥ 103) addition to cells.
A. Proportion of infected cells was quantified during infection with PbGFP (black bars) or RASPbGFP (white bars) (n = 3).
B. EEF development was assessed by fluorescence intensity of GFP+ cells. The graphs show one representative data set of triplicate
samples.
C. Infection was quantified by parasite-specific qRT-PCR 2, 12, 24, 36 and 44 h post infection with PbGFP or RASPbGFP (n = 3). Infection is
expressed as percentage of control (2 h time point of cells infected with RASPbGFP). Error bars represent SD.
D. Positive correlation (R2 = 0.98) between the parasite load measured by qRT-PCR and the maximum intensity of the GFP+ band in the
FACS histograms.
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The method presented in this report has various
important applications as it constitutes an efficient way
of assessing Plasmodium infection of hepatocytes under
different experimental conditions. Compared with other
available methods to address this, it presents advan-
tages both in terms of speed of data acquisition and in
terms of cost-effectiveness. Furthermore, it distinguishes
between invasion and developmental stages of Plasmo-
dium within a hepatocyte, overcoming limitations pre-
sented by other available techniques in this respect. The
method can, for instance, be used to address the effec-
tiveness of a given drug in impairing the invasion and/or
the development of the parasite in the liver. It can also
serve to study the role of specific host genes in Plas-
modium invasion and/or development, either by employ-
ing genetically modified cell lines or by using RNA
interference to down-modulate the expression of the
gene(s) of interest. Finally, the method provides a quick
way to address the potential invasion and/or develop-
mental consequences of introducing specific gene muta-
tions or deletions in the parasite. The methodology
described here greatly extends the potential of combin-
ing GFP-expressing pathogens with flow cytometry to
address host–pathogen interactions.
Experimental procedures
Cell, parasites and infection
Huh7 cells, a human hepatoma cell line, were cultured in RPMI
(Gibco/Invitrogen) medium supplemented with 10% fetal calf
serum (FCS) (Gibco/Invitrogen), 1% non-essential amino acids
(Gibco/Invitrogen), 1% penicillin/streptomycin (Gibco/Invitrogen),
1% glutamine (Gibco/Invitrogen) and 10 mM Hepes, pH 7 (Gibco/
Invitrogen) and maintained at 37°C with 5% CO2. GFP-
expressing P. berghei (parasite line 259 cL2) sporozoites were
obtained by disruption of the salivary glands of freshly dissected
infected female Anopheles stephensi mosquitoes, bred at the
Insectary of the Instituto de Medicina Molecular. Radiation-
attenuated sporozoites were obtained by irradiation of sporo-
zoites with 160 Gy on a Compagnie Oris Industrie IBL 437C
irradiator, at room temperature, for approximately 80 min. Non-
irradiated sporozoites used in development experiments were left
at room temperature during the same period. Sporozoite motility
was impaired by incubation with 10 mM cytochalasin (Calbio-
chem) for 10 min at room temperature prior to addition to cells.
Non-treated sporozoites used in these experiments were left at
room temperature during the same period. Cells (17.5 ¥ 104 per
well) were seeded on 24-well plates the day before infection.
Cells were infected by addition of specific numbers of sporozoi-
tes, followed by centrifugation at 1700 g for 7 min at 37°C. For
membrane disruption assessment, 2 mg ml-1 Dextran tetrameth-
ylrhodamine 10 000 MW, lysine fixable (fluoro-ruby) (Molecular
Probes/Invitrogen) were added to the cells immediately prior to
sporozoite addition. Cells used as positive controls for the mem-
brane disruption assay were mechanically disrupted by passage
through a 27 G syringe five times, in the presence of 2 mg ml-1
Dextran.
Fluorescence-activated cell sorting (FACS)
Cell samples for FACS analysis were washed with 1 ml of PBS,
incubated with 150 ml of trypsin for 5 min at 37°C and collected in
400 ml of 10% FCS in PBS at the selected time points post
sporozoite addition. Cells were then centrifuged at 0.1 g for 3 min
at 4°C and re-suspended in 150 ml of 2% FCS in PBS. Cells were
analysed on a Becton Dickinson FACScalibur with the appropri-
ate settings for the fluorophores used. Data acquisition and
analysis were carried out using the CELLQuest (version 3.2.1fl1,
Becton Dickinson) and FlowJo (version 6.3.4, FlowJo) software
packages respectively.
Quantification of parasite copy numbers by qRT-PCR
Cells were washed with 1 ml of PBS and collected at the selected
time points in 150 ml of RLT buffer (Qiagen) containing 1%
b-mercaptoethanol and immediately stored at -80°C until further
processing. Total RNA was isolated from Huh7 cells with
Qiagen’s Micro RNeasy kit, following the manufacturer’s instruc-
tions, and converted into cDNA using Roche’s Transcriptor First
Strand cDNA Synthesis kit, according to the manufacturer’s
protocol. The qRT-PCR reactions used Applied Biosystems’
Power SYBR Green PCR Master Mix and were performed
according to the manufacturer’s instructions on an ABI Prism
7000 system (Applied Biosystems). Amplification reactions were
carried out in a total reaction volume of 25 ml, containing
0.8 pmoles ml-1 or 0.16 pmoles ml-1 of the PbA- or housekeeping
gene-specific primers respectively. Relative amounts of PbA
mRNA were calculated against the Hypoxanthine Guanine
Phosphoribosyltransferase (HPRT) housekeeping gene. PbA-
and HPRT-specific primer sequences were 5′-AAG CAT TAA ATA
AAG CGAATA CAT CCT TAC-3′ and 5′-GGA GAT TGG TTT TGA
CGT TTA TGT G-3′, and 5′-TGC TCG AGA TGT GAT GAA GG-3′
and 5′-TCC CCT GTT GAC TGG TCA TT-3′ respectively.
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Heme oxygenase-1 and carbon monoxide suppress the
pathogenesis of experimental cerebral malaria
Ana Pamplona1,2, Ana Ferreira1, Jo´zsef Balla3, Vikto´ria Jeney3, Gyo¨rgy Balla3, Sabrina Epiphanio1,2,
Aˆngelo Chora1, Cristina D Rodrigues1,2, Isabel Pombo Gregoire1, Margarida Cunha-Rodrigues1,2,
Silvia Portugal1,2, Miguel P Soares1,4 & Maria M Mota1,2,4
Cerebral malaria claims more than 1 million lives per year. We report that heme oxygenase-1 (HO-1, encoded by Hmox1) prevents
the development of experimental cerebral malaria (ECM). BALB/c mice infected with Plasmodium berghei ANKA upregulated HO-1
expression and activity and did not develop ECM. Deletion of Hmox1 and inhibition of HO activity increased ECM incidence to
83% and 78%, respectively. HO-1 upregulation was lower in infected C57BL/6 compared to BALB/c mice, and all infected
C57BL/6 mice developed ECM (100% incidence). Pharmacological induction of HO-1 and exposure to the end-product of HO-1
activity, carbon monoxide (CO), reduced ECM incidence in C57BL/6 mice to 10% and 0%, respectively. Whereas neither HO-1
nor CO affected parasitemia, both prevented blood-brain barrier (BBB) disruption, brain microvasculature congestion and neuro-
inflammation, including CD8+ T-cell brain sequestration. These effects were mediated by the binding of CO to hemoglobin,
preventing hemoglobin oxidation and the generation of free heme, a molecule that triggers ECM pathogenesis.
Plasmodium, the causative agent of malaria, causes extensive hemolysis.
About 40% of the hemoglobin contained within each infected red
blood cell can be released and readily oxidized1. This leads to the
generation of free heme (reviewed in ref. 2), a molecule cytotoxic to
the parasite when generated within red blood cells3 and to the host
when released into the circulation4. Plasmodium has developed strate-
gies to cope with free heme generated within red blood cells, poly-
merizing it into hemozoin1. When exposed to free heme, host cells
(human or rodent) upregulate the expression of heme oxygenase-1
(HO-1), a stress-responsive enzyme that catabolizes heme into iron
(Fe), biliverdin and carbon monoxide (CO)5. As previously shown, CO
can limit the deleterious effects of inflammation (ref. 6, and reviewed
in ref. 7). We hypothesized that CO might counter the pathogenesis of
cerebral malaria, an inflammatory syndrome that can develop in the
course of malaria infection and lead to neurological disturbances
revealed clinically by abnormal behavior, impairment of consciousness,
seizures and irreversible coma, ultimately leading to death8.
C57BL/6 mice infected with P. berghei ANKA die within 6–12 d, due
to the development of a complex neurological syndrome consisting of
hemi- or paraplegia, head deviation, a tendency to roll over on
stimulation, ataxia and convulsions (reviewed in ref. 9). Given its
similarities to human cerebral malaria, this neurological syndrome is
referred to as experimental cerebral malaria (ECM). Certain mouse
strains, for example, BALB/c, are less likely to develop ECM when
infected with P. berghei ANKA; these strains, if not treated to control
parasitemia, die within 3 to 4 weeks of infection due to severe anemia
and hyperparasitemia but do not exhibit neurological symptoms
(reviewed in refs. 9,10).
RESULTS
HO-1 prevents the development of ECM in BALB/c mice
Infection of BALB/c mice with P. berghei ANKA led to the upregula-
tion of HO-1 in the brain, as assessed at the mRNA level by
quantitative RT-PCR (qRT-PCR) (P o 0.01 comparing day 6 versus
day 0; Fig. 1a), at the protein level by western blot (P o 0.05, days
9–12 versus day 0; Fig. 1b and Supplementary Fig. 1 online) and at a
functional level by assessment of HO enzymatic activity (P o 0.05,
day 6–12 versus day 0; Fig. 1c). Expression of Hmox1 mRNA reached
maximal levels 6 d after infection, decreasing thereafter until day 12,
the last day analyzed (Fig. 1a). HO-1 protein expression (Fig. 1b) and
HO activity (Fig. 1c) reached maximal levels 9 d after infection, and
the protein remained highly expressed and functional at day 12, the
last day analyzed. Expression of HO-2, the constitutive form of HO,
remained unchanged in the brains of infected mice, as assessed by
western blot (Fig. 1b and Supplementary Fig. 1). Hmox1 mRNA
expression in the liver and lungs increased steadily until day 12 after
infection (Supplementary Fig. 2 online).
Upregulation of HO-1 explains the low incidence of ECM in BALB/c
mice infected with P. berghei ANKA (ref. 11), as incidence of death with
ECM-like symptoms increased from 0% in wild-type (Hmox1+/+)
mice to 83.3% in HO-1 deficient (Hmox1/) BALB/c mice (P o
0.001; Fig. 1d). Heterozygous (Hmox1+/) and Hmox1+/+ BALB/c
Received 15 September 2006; accepted 9 April 2007; published online 13 May 2007; doi:10.1038/nm1586
1Instituto Gulbenkian de Cieˆncia, 2780-156 Oeiras, Portugal. 2Unidade de Mala´ria, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de
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mice behaved similarly in that neither group developed ECM. Despite
having increased ECM incidence, Hmox1/ mice did not have
increased parasitemia, as compared to Hmox1+/+ and Hmox1+/
mice (Fig. 1e). This suggests that the protective effect of HO-1 does
not rely on the modulation of parasitemia. We observed an apparent
decrease in parasitemia in two of six Hmox1/ mice that did not die
of ECM (Fig. 1e); however, this decrease was not statistically significant
(P 4 0.05) and therefore its importance is difficult to ascertain.
Pharmacologic inhibition of HO enzymatic activity by zinc proto-
porphyrin (ZnPPIX) resulted in the death of 77.5% of infected
Hmox1+/+ BALB/c mice, with symptoms consistent with the develop-
ment of ECM (Fig. 1f). ZnPPIX did not influence parasitemia
(Fig. 1g), suggesting again that the protective effect of HO-1 does
not rely on the inhibition of parasitemia. Infected mice treated with
cobalt protoporphyrin (CoPPIX), a protoporphyrin that induces
HO-1 expression and activity, did not develop ECM (0% incidence;
Fig. 1f). CoPPIX delayed parasitemia between days 9 and 11 after
infection (Po 0.05 versus PBS controls), an effect lost shortly after its
administration was discontinued (that is, on day 9 after infection;
Fig. 1g). As is the case with other non-iron porphyrins12, CoPPIX
might interfere with the ability of the parasite to polymerize heme into
hemozoin, thereby decreasing parasitemia.
HO-1 induction or exposure to CO prevent ECM onset
In contrast to BALB/c mice, C57BL/6 mice develop ECM when
infected with P. berghei ANKA, dying within 6 to 9 d after infection11.
ECM incidence was associated with lower levels of Hmox1 mRNA
expression in the brains of C57BL/6 mice, as compared to BALB/c
mice (P o 0.05; Fig. 2a). We hypothesized that lower HO-1 expres-
sion contributes in a critical manner to the incidence of ECM in
C57BL/6 mice infected with P. berghei ANKA. Pharmacologic induc-
tion of HO-1 using CoPPIX reduced the incidence of ECM and death
to 10%, from 100% in PBS- and ZnPPIX-treated controls (Fig. 2b).
Here too, CoPPIX led to a significant delay in parasitemia (P o 0.05
versus PBS-treated controls; Fig. 2c), which, as argued above, may
result from interference with parasite heme clearance12. As parasitemia
was not treated, infected mice that did not die due to ECM died later
due to the development of hyperparasitemia (460% infected red
blood cells; Fig. 2b,c).
CO (250 p.p.m.) given for 24 h (Fig. 2d) or 72 h (Supplementary
Fig. 3a online), starting at day 3 after infection, prevented death and
all ECM symptoms in C57BL/6 mice infected with P. berghei ANKA.
None of the C57BL/6 mice exposed to CO developed ECM (Fig. 2d).
This finding is in keeping with previous observations that inhaled CO
can mimic the protective effects of HO-1 in several experimental
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Figure 1 Expression of HO-1 prevents the pathogenesis of ECM in BALB/c mice
infected with P. berghei ANKA. (a) Hmox1 mRNA was quantified by qRT-PCR in
the brains of the infected mice. Results are shown as mean number ( 103) of
Hmox1 mRNA molecules per Hprt mRNA. n ¼ 3 mice per time point. (b) HO-1
and HO-2 protein expression in the brains of infected mice were semiquantified
by western blot. Results indicate the mean ratio of HO-1 or HO-2 expression to
a-tubulin expression. n ¼ 4–5 mice per time point. (c) HO activity was quantified
in the same samples as in b. Results indicate mean pmol of bilirubin per mg of
brain protein per hour. n ¼ 4–5 mice per time point. (d,e) Survival and mean
parasitemia of infected Hmox1+/+ mice (n ¼ 20), Hmox1+/ mice (n ¼ 14) and Hmox1/ mice (n ¼ 12). (f,g) Effects of HO inhibition by ZnPPIX (n ¼ 10)
and HO-1 induction by CoPPIX (n ¼ 10) on survival and mean parasitemia of infected mice. PBS-treated mice were used as a control. n ¼ 5 mice per
group. Error bars represent s.d.
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conditions (ref. 6, and reviewed in ref. 7). This protective effect was
still observed (80% reduction in ECM incidence) when CO was
administered at day 4 after infection, for 24 h (Supplementary
Fig. 3). CO administration starting at day 5 after infection was not
effective, even when given before the onset of ECM clinical symptoms
(data not shown). We observed no significant changes in parasitemia
upon CO exposure (Fig. 2e and Supplementary Fig. 3; P 4 0.05),
suggesting that, as with HO-1 induction, the protective effect of CO
does not rely on the inhibition of parasitemia. These data suggest that
at a dosage as low as 250 p.p.m., CO can be used therapeutically—that
is, treatment with CO following infection can prevent ECM even when
applied as late as 2 d before the expected time of death from ECM.
We assessed whether biliverdin, another end product of HO-1
activity, could mimic the protective effects of HO-1. In C57BL/6
mice infected with P. berghei ANKA, exogenous biliverdin did not
suppress the development of ECM when administered on day 2 after
infection and every 8 h thereafter until day 4 (a schedule that mimics
the protective effect of HO-1 in other inflammatory conditions,
ref. 13; Supplementary Fig. 3).
HO-1 and CO prevent BBB disruption and neuroinflammation
We confirmed ECM incidence under the different experimental
conditions described above by quantifying blood-brain barrier
(BBB) disruption, a hallmark of ECM as well as of cerebral malaria
in humans. We also performed histological examination of brain
tissue 6 to 12 d after infection.
In BALB/c mice, infection with P. berghei ANKA did not lead to
BBB disruption (Fig. 3a). In contrast, Hmox1 deletion led to BBB
disruption, as revealed by a 10- to 20-fold increase in Evans blue
accumulation in brain parenchyma of infected BALB/c mice, as
compared to infected wild-type controls (P o 0.0001; Fig. 3a).
Other major pathological features associated with ECM include
brain microvascular congestion with activated leukocytes and
red blood cells, and brain parenchymal hemorrhages. These
features were clearly detectable in Hmox1/ BALB/c mice infected
with P. berghei ANKA, but not in uninfected or infected wild-type
BALB/c controls (Fig. 3b and Supplementary Fig. 4 online).
In a similar manner to Hmox1 deletion, pharmacological inhibition
of HO activity by ZnPPIX also resulted in disruption of BBB
(Fig. 3c), brain microvascular congestion (Fig. 3d) and hemorrhage
(Supplementary Fig. 4) in infected BALB/c mice, but not in untreated
or CoPPIX-treated infected controls (Fig. 3c,d and Supplemen-
tary Fig. 4).
In C57BL/6 mice, P. berghei ANKA infection resulted in BBB
disruption: there was a 20- to 50-fold increase in Evans blue accu-
mulation in the brain parenchyma, as compared to that in uninfected
controls (Fig. 3e). HO-1 induction by CoPPIX reduced BBB disrup-
tion by 75.6 ± 4.2% (mean ± s.d.; Po 0.0001; Fig. 3e), and abolished
brain microvascular congestion (Fig. 3f) and hemorrhage (Supple-
mentary Fig. 4) associated with the onset of ECM; these effects were
not seen in untreated or ZnPPIX-treated controls (Fig. 3e,f and
Supplementary Fig. 4).
Likewise, exposure to CO reduced BBB disruption by 80.2 ± 8.1%
in infected C57BL/6 mice, as compared to air-treated controls (P o
0.0001; Fig. 3g and Supplementary Fig. 4), and abolished brain
microvascular congestion (Fig. 3h) and hemorrhage (Supplementary
Fig. 4). On the basis of previous results14,15, the inhibition of BBB
disruption, brain microvascular congestion and hemorrhage is likely
to have a major effect in suppressing the pathogenesis of ECM.
We carried out a more detailed histological analysis of the protective
effect of CO with regard to suppressing brain microvascular conges-
tion. Development of ECM in C57BL/6 mice was associated with
moderate to severe microvasculature occlusion in 58.4 ± 13.6% of
brain arterioles, capillaries or postcapillary venules. Up to 79.2 ±
10.3% of congested microvessels presented intraluminal accumulation
of both infected and uninfected red blood cells and leukocytes (91
vessels analyzed in 4 mice). Exposure to CO reduced the percentage of
occluded microvessels to 24 ± 8.3% (P o 0.001 versus air control).
Only 42.6 ± 10.8% of these microvessels contained infected red blood
cells and leukocytes (250 vessels analyzed in 10 mice). In uninfected
mice, 10.8 ± 12.5% of brain microvessels had low levels of red blood
cell intravascular congestion, and only 5.5 ± 6.8% of these vessels
contained leukocytes (56 vessels analyzed in 4 mice). Taken together,
these data suggest that both HO-1 induction and CO exposure
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Figure 3 HO-1 and CO prevent BBB disruption and brain microvascular congestion. BBB disruption was assessed by Evans blue (EB) quantification and
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infection). Evans blue quantification is shown as mean mg of Evans blue (EB) per g of brain tissue. n ¼ 5 mice per group. H&E staining of brain
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prevent microvascular congestion and hemorrhage in the brain, two
key pathologic features of ECM and cerebral malaria (ref. 11; and
reviewed in ref. 16).
We asked whether CO could modulate the expression of tumor
necrosis factor (TNF)17, lymphotoxin-a (LT-a)18 and interferon-g
(IFN-g)19, pro-inflammatory cytokines known to be upregulated
during the pathogenesis of ECM and to contribute to its onset
(reviewed in ref. 16). Expression of Tnf (Fig. 4a), Ifng (Fig. 4b) and
Lta (Fig. 4c) mRNAs were significantly upregulated in the brains of
C57BL/6 mice infected with P. berghei ANKA, as compared to
uninfected controls (Tnf, P o 0.001; Ifng, P o 0.005; and Lta,
P o 0.05; day 6 after infection). Exposure to CO reduced Tnf,
Ifng and Lta mRNA expression by 76 ± 13% (P o 0.002), 98 ± 1%
(Po 0.005) and 68 ± 20% (Po 0.005), respectively, as compared to
that in infected controls (Fig. 4a–c). Taking into consideration the
critical role of pro-inflammatory cytokines in the pathogenesis of
ECM (reviewed in ref. 16), it is likely that the protective effect of CO is
mediated at least in part through their inhibition.
Expression of intracellular adhesion molecule-1 (ICAM-1/CD54)14
and presumably that of vascular cell adhesion molecule-1 (VCAM-1/
CD106) promote the pathogenesis of ECM. Icam1 and Vcam1 mRNA
expression was increased in the brains of C57BL/6 mice showing ECM
symptoms (P o 0.001 and P o 0.005, respectively: infected versus
uninfected mice; Fig. 4d,e). Exposure to CO led to a 71 ± 9% and a
41 ± 4% decrease in ICAM-1 and VCAM-1 expression (Po 0.001 and
P o 0.05, respectively, infected versus infected exposed to CO), as
assessed on day 6 after infection (Fig. 4d,e).
In addition, we assessed whether pharmacological induction of
HO-1 or exposure to CO inhibited the recruitment of CD8+ T cells
into the brain, another critical event in the pathogenesis of ECM (refs.
20,21). When backcrossed into the severe combined immunodefi-
ciency (SCID) background, Hmox1/ BALB/c mice infected with
P. berghei ANKA did not develop ECM symptoms, and all mice
survived (Fig. 4f). This demonstrates that HO-1 counters the deleter-
ious effects of B or T cells that lead to ECM. Further, depletion of
CD8+ T cells using a CD8-specific monoclonal antibody was sufficient
to prevent the onset of ECM in infected Hmox1/ BALB/c mice
(Fig. 4f). This result suggests that HO-1 prevents CD8+ T cells from
triggering ECM (refs. 20,21). Moreover, we assessed whether exposure
to CO (Fig. 4g) or the induction of HO-1 by CoPPIX (data not
shown) could suppress CD8+ T-cell sequestration in the brain. In
infected C57BL/6 mice, CO decreased the total number of
CD8+ T cells in the brain (including activated CD8+CD69+ and
IFN-g–secreting CD8+ T cells) by 65–75%, as compared to air-
treated controls (P o 0.05; Fig. 4g). CO also inhibited monocyte/
macrophage (CD45RBhighCD11b+) and polymorphonuclear (PMN;
CD45RBhighGR1+) recruitment into the brain (data not shown).
Induction of HO-1 by CoPPIX yielded similar results to CO inhala-
tion, whereas ZnPPIX had no effect (data not shown). These results
suggest that CO suppresses the sequestration of CD8+ T cells in brains
of mice infected with P. berghei ANKA, an effect that should
contribute to the suppression of ECM onset20,21.
CO inhibits heme release from oxidized hemoglobin
Malaria is associated with a severe hemolysis that generates extra-
cellular ferrous (Fe2+) hemoglobin, which in the presence of reactive
oxygen species (ROS) is readily oxidized into methemoglobin
(MetHb) (Fe3+). We asked whether CO could arrest this process.
Generation of carboxyHb (COHb; 100%) by exposure of purified
ferrous (Fe2+) hemoglobin to CO in vitro suppressed MetHb forma-
tion driven by either H2O2 or activated polymorphonuclear (PMN)
cells (485% inhibition versus that in air-treated controls, Po 0.0001;
Supplementary Fig. 5 online). These effects were dose dependent, as
increasing the percentage of COHb led to increased inhibition of
MetHb formation (Supplementary Fig. 5), and were not observed
when PMN were exposed to CO instead of Fe2+ hemoglobin (data not
shown). These results suggested that CO prevents hemoglobin oxida-
tion through a mechanism that relies on its binding to Fe2+
hemoglobin. To ascertain whether similar effects occur in vivo, we
measured MetHb concentration in whole blood from infected C57BL/
6 mice that had or had not been exposed to CO. MetHb concentration
increased significantly in infected versus uninfected mice (P o 0.05;
Fig. 5a). Exposure of the infected mice to CO (250 p.p.m.;
23 ± 6% COHb; Supplementary Fig. 6 online) decreased MetHb
concentration to basal levels (that is, to levels observed in uninfected
mice; Fig. 5a).
MetHb is highly unstable, releasing free heme22. The ability of H2O2
or activated PMN cells to release heme from Fe2+ hemoglobin was
suppressed when hemoglobin was exposed to CO before oxidation
(495% inhibition versus air-treated controls, P o 0.0001; Fig. 5b).
These data indicate that once bound to Fe2+ hemoglobin, CO
suppresses not only its oxidation but also the subsequent generation
of free heme. To assess whether a similar mechanism occurs in vivo, we
measured the concentration of extracellular (non-protein-bound)
heme in the circulation of infected C57BL/6 mice (Fig. 5c). Free
heme concentration increased significantly upon infection (Po 0.001;
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Figure 4 CO inhibits neuroinflammation and CD8+ T-cell brain sequestration.
Uninfected and P. berghei ANKA–infected mice (at day 6 after infection) were analyzed.
CO was supplied by inhalation. (a–e) mRNA expression in the brain was quantified by
qRT-PCR and is shown as the mean number of mRNA molecules of the indicated gene
per Hprt mRNA ( 103). n ¼ 5 mice per group. UI, uninfected. Infected C57BL/6
mice were exposed to air (I) or to CO (I + CO). (f) Survival of Hmox1/ and Hmox1/
SCID BALB/c mice infected with P. berghei ANKA. A separate group of Hmox1/
BALB/c infected mice was treated with a CD8-specific depleting antibody. n ¼ 5 mice
per group. (g) Quantification of total CD8+, activated CD69+CD8+ and IFN-g+CD8+ T
cells in the brains of C57BL/6 mice. Error bars represent s.d.
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Fig. 5c). Both exposure to CO and the induction of HO-1 using
CoPPIX reduced plasma free heme concentration—by 88 ± 22% and
69 ± 31%, respectively—as compared to that in untreated infected
controls (P o 0.01; Fig. 5c). With ZnPPIX treatment, plasma free
heme concentration was not different than that in untreated infected
controls (Fig. 5c).
CO did not modulate red blood cell counts (data not shown), heme
red blood cell content, lactate dehydrogenase (LDH) levels or bilirubin
concentration in the circulation of infected C57BL/6 mice (Supple-
mentary Fig. 6). These results suggest that CO inhibits the accumula-
tion of free heme in the circulation of these mice by a process that
does not involve the inhibition of red blood cell lysis.
Free heme triggers ECM
We asked whether the accumulation of free heme in the circulation of
infected C57BL/6 mice was involved in the pathogenesis of ECM.
Heme administration 3 d after infection was sufficient to reverse the
protective effect of CO, causing death in 100% of infected mice, with
symptoms consistent with ECM, compared to 0% of vehicle-treated
mice (Fig. 5d). Heme had no deleterious effects when administered to
uninfected C57BL/6 mice at the same dose and on the same schedule
(data not shown). Heme administration reverted the protective effect
of CO and triggered BBB disruption, a key pathological feature of
ECM and cerebral malaria (Fig. 5e). These data reveal not only that
accumulation of free heme in the circulation of infected mice is a
central component in the pathogenesis of ECM, but also that CO
suppresses ECM by inhibiting this process, presumably by blocking
hemoglobin oxidation.
We tested whether the ability of different Plasmodium strains to
trigger ECM was functionally linked to the amount of free heme that
accumulates in the host circulation. Plasma free heme concentration
was reduced by 44 ± 19% (Po 0.001) in C57BL/6 mice infected with
P. berghei NK65 versus P. berghei ANKA. The former group did not
succumb, whereas the latter succumbed 6–7 d after infection, with
symptoms consistent with ECM (Supplementary Fig. 7 online). After
this time period, free heme concentrations remained constant in mice
infected with P. berghei ANKA NK65: at days 10 and 15 after infection,
concentrations were 33 ± 11% and 34 ± 19%, respectively, of those in
mice infected with P. berghei ANKA (P o 0.001; Supplementary
Fig. 7). Heme administration to C57BL/6 mice infected with P. berghei
ANKA NK65 (60 mg per kg body weight; at 6 d after infection) led to
death in 100% of mice, with symptoms consistent with ECM
(Supplementary Fig. 7). Heme administration to uninfected
C57BL/6 mice at the same dose and on the same schedule was not
lethal (data not shown).
We then asked whether the absence of ECM in P. berghei
ANKA–infected BALB/c mice compared to its occurrence in P. berghei
ANKA–infected C57BL/6 mice was also functionally linked to the
accumulation of circulating free heme. Plasma free heme concentra-
tion was reduced by 36 ± 9% (Po 0.001) in BALB/c versus C57BL/6
mice (Supplementary Fig. 7). At the time of development of ECM
symptoms, plasma free heme concentration in BALB/c mice was
reduced by 36 ± 9% and 28 ± 32% at days 10 and 15 after infection,
respectively, from the levels in infected C57BL/6 mice (P o 0.001;
Supplementary Fig. 7). Heme administration to BALB/c mice
infected with P. berghei ANKA (60 mg/kg; i.p.; 6 d after infection)
led to death in 100% of the mice, with symptoms consistent with
ECM (Supplementary Fig. 7). Heme administration to uninfected
BALB/c mice was not lethal (data not shown). Taken together, these
data support the notion that accumulation of free heme in the
circulation of a malaria-infected host plays a critical role in dictating
the host’s susceptibility to ECM.
We hypothesized that free heme might affect BBB tight-junction
function in a manner that would promote BBB disruption. We tested
this hypothesis using a well-established in vitro BBB model, in which
confluent bovine brain microvascular endothelial cells (bMVEC-B
cells) form functional tight junctions, revealed by the exclusion of a
fluorescent 10-kDa dextran tracer in a transwell assay (Fig. 5f). Tight-
junction functional integrity was not disrupted when bMVEC-B cells
were exposed to either H2O2 or heme alone. However, when bMVEC-B
cells were pre-exposed to heme, further addition of H2O2 caused loss
of functional tight-junction integrity, as revealed by a 2–5 fold increase
in fluorescent dextran tracer permeability. The effect of heme was dose
dependent, with higher concentrations leading to increased perme-
ability. We obtained similar results using Madin-Darby canine kidney
(MDCK) cells (data not shown), which also form tight junctions
Figure 5 HO-1 and CO prevent BBB disruption
and the development of ECM by inhibiting free
heme release from oxidized hemoglobin.
Uninfected (UI) and P. berghei ANKA–infected (I)
mice were analyzed. (a) Mean percentage of
methemoglobin (MetHb) in whole blood of
C57BL/6 mice. Measurements were performed
on day 6 after infection. n ¼ 5 mice per group.
(b) Hemoglobin (Hb, 200 mM) was exposed to air
or to CO (100% bubbled at a flow rate of 10 ml/
min for 10 s) to generate carboxyhemoglobin
(COHb) and then subjected to oxidation by
H2O2 (2 mM, 1 h, 37 1C) or by activated
polymorphonuclear (PMN) cells (4  107 per ml,
1 h). (), no addition. Free heme captured by
low density lipoprotein (LDL) is shown as mean
number of heme molecules per LDL particle.
n ¼ 3 independent experiments. (c) Mean free
heme concentration in protein-free plasma of
uninfected and infected C57BL/6 mice. Infected
mice were exposed to air () or CO, or treated with CoPPIX or ZnPPIX. Measurements were performed on day 6 after infection. n ¼ 4–7 mice per group.
(d) Survival of infected C57BL/6 mice exposed to CO and receiving heme or vehicle (PBS). (e) BBB disruption in uninfected versus P. infected C57BL/6
mice exposed to air (), CO or CO + heme. Evans blue (EB) quantification is shown as mean mg of Evans blue per g of brain tissue. n ¼ 4–5 mice per
group. (f) Permeability of confluent bMVEC-B cells to 10 kDa fluorescent dextran was quantified in a transwell chamber, after exposure to heme, H2O2 or
heme + H2O2. Results are shown as mean percentage of fluorescent tracer in the lower chamber. n ¼ 3. Error bars represent s.d.
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in vitro. These data suggest that in the presence of a ROS (that is,
H2O2), heme can disrupt BBB tight-junction function, which could
explain the BBB disruption associated with the pathogenesis of ECM.
By blocking the generation of free heme, CO may act to prevent
BBB disruption.
DISCUSSION
Understanding the pathogenesis of malaria infection is crucial for the
development of more efficient clinical interventions. Sequestration of
infected red blood cells and leukocytes (that is, CD8+ T cells in the
brain20,21,23), and the inflammatory response triggered by malaria
infection are thought to be the two key events in the pathogenesis of
cerebral malaria8. Our present data show that HO-1 expression and
enzymatic activity in the host counter the pathogenesis of ECM.
Moreover, we have demonstrated that the administration of exo-
genous CO via inhalation can be used therapeutically to suppress the
pathogenesis of ECM. The protective effects of CO administration
were associated with inhibition of BBB disruption, brain microvas-
cular congestion and hemorrhage, as well as with suppression of
neuroinflammation, including inhibition of adhesion molecule
expression in the brain microvasculature and the suppression of
activated CD8+ T cell sequestration in the brain.
The ability of CO to suppress the accumulation of free heme in the
circulation of the infected host seems critical for its protective effects.
Malaria infection is associated with severe hemolysis and therefore
with the oxidation of cell-free hemoglobin2, leading to the release of
free heme and its accumulation in plasma. We have shown that
circulating free heme is a central effector in the pathogenesis of
ECM, promoting BBB disruption by means of a mechanism targeting
the tight junctions that maintain BBB functional integrity. Binding of
CO to Fe2+ in the heme groups of ferrous hemoglobin prevents
hemoglobin oxidation, heme release from oxidized hemoglobin,
accumulation of free heme in the circulation, BBB disruption and,
consequently, the development of ECM.
Other researchers have shown that, as in other hemolytic diseases
(for example, sickle cell anemia24), scavenging of nitric oxide (NO) by
cell-free hemoglobin generated during malaria infection promotes the
onset of ECM (ref. 25). It is possible therefore that CO and NO might
interact functionally to suppress the pathogenesis of ECM. Once
bound to cell-free hemoglobin, CO may limit NO scavenging, an
effect that would increase NO bioavailability and thus suppress the
pathogenesis of ECM (ref. 25). According to this notion, the protective
effect of CO might be ‘NO dependent’. On the other hand, the
protective effect of NO might itself be ‘CO dependent’, as NO is a
potent inducer of HO expression26. NO might act in a protective
manner through the induction of HO-1 and the subsequent genera-
tion of CO, shown here to prevent the onset of ECM. These
hypotheses remain to be tested experimentally.
The proposed mechanism for the protective action of CO (Fig. 6)
may have important implications for understanding the pathogenesis
of cerebral malaria. Expression of HO-1 occurs during malaria
infection in humans27,28, suggesting that a similar protective mechan-
ism may operate to suppress the development of cerebral malaria.
Although ECM may not fully reflect human cerebral malaria, it allows
for the identification of genes that control both of these pathologic
processes, as shown for the involvement of TNF (refs. 29–32) and
ICAM1 (also known as CD54)33,34 in ECM and cerebral malaria
(reviewed in ref. 35). Thus, although our data do not allow to
conclude unequivocally that HMOX1 is a gene that determines
susceptibility to cerebral malaria, it is likely that variations in HO-1
expression, known to occur in human populations as a result of a
(GT)n microsatellite polymorphism in the promoter region of the
human HMOX1 gene (reviewed in ref. 36), can dictate susceptibility to
cerebral malaria.
Preliminary evidence suggests that the incidence of the homozygous
short GT(o28) polymorphism, which presumably affords a high level
of HO-1 induction during malaria infection, is markedly increased in
malaria patients who succumb to cerebral malaria37, a finding that is
in apparent discrepancy with the notion that HO-1 prevents the onset
of ECM. This might be explained by the observation that HO-1 is
highly induced in the liver during the initial liver stage of malaria
infection in mice, which occurs before the blood stage. Moreover, we
found that the liver stage of infection was reduced by 70–80% in
Hmox1/ mice (S.E. et al., unpublished data). These findings suggest
that a successful host-Plasmodium interaction leading to long-lasting
Invasion
Plasmodium
RBC cycle
Replication
Hemolysis
Hb (tetramers)
Hb (dimers)
ROS
MetHb CO
HO-1
CO
Free heme
BBB disruption
Experimental cerebral malaria
ROS
CD8+
T cells
Fe2+Fe2+
Fe2+Fe2+
Fe2+Fe2+
Fe2+Fe2+
Fe3+ Fe3+
Fe3+ Fe3+
Fe3+
Fe3+
Fe3+
Fe3+
Figure 6 Mechanism underlying the protective actions of HO-1 and CO.
Hemolysis is inherently associated with cycles of Plasmodium invasion,
replication and egress (hemolysis) in red blood cells (RBC). This process
leads to the release of hemoglobin into the circulation. Cell-free hemoglobin
dimerizes spontaneously and in the presence of ROS is readily oxidized into
MetHb. This process of hemoglobin oxidation readily leads to the release of
heme. In the presence of ROS, cell-free heme promotes BBB disruption;
activated CD8+ T cells can then promote the onset of ECM. Both heme and
ROS upregulate the expression of HO-1, a stress-responsive enzyme that
generates CO by degrading heme. CO binds cell-free hemoglobin dimers,
blocking their oxidation and thus the generation of circulating free heme.
In addition, CO prevents the recruitment of CD8+ T cells in the brain
microvasculature. These effects may together afford potent protection
against the development of ECM.
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infection in a viable host is quite complex and is dependent on the
regulated expression of HO-1 in different tissues at different stages of
the Plasmodium life cycle.
This study reveals that the pathogenesis of cerebral malaria might
be controlled through the expression of a so-called ‘protective gene’ in
the host38. We have shown this for HO-1 in the context of ECM, but
we do not exclude the possibility that other ‘protective genes’39 might
act in a similar manner to prevent the onset of cerebral malaria or
other forms of severe acute malaria in humans. These findings provide
new insights into the pathogenesis of ECM and may lead to new
therapeutic approaches to suppress the pathogenesis of human cere-
bral malaria based on the modulation of HO-1 expression or the
administration of CO.
METHODS
Mice. C57BL/6 and BALB/c mice were bred and housed in the pathogen-free
facilities of the Instituto de Gulbenkian de Cieˆncia. All protocols were approved
by the Animal Care Committee of the Instituto Gulbenkian de Cieˆncia. We
generated Hmox1/ mice by mating Hmox1+/ mice (backcrossed for ten
generations into the BALB/c background), as previously described40. We
backcrossed BALB/c Hmox1+/ mice into the severe combined immuno-
deficient (SCID) background (Jackson Laboratory). We isolated genomic
DNA from the tail and determined the Hmox genotype by PCR using the
following primers: 5¢-TCTTGACGAGTTCTTCTGAG-3¢ and 5¢-ACGAAGT
GACGCCATCTGT-3¢; 5¢-GGTGACAGAAGAGGCTAAG-3¢ and 5¢-CTGTAA
CTCCACCTCCAAC-3¢. We repeated each PCR reaction at least three times
before experiments on the mice were performed and once more afterward. As
controls, we used littermate Hmox1+/ and Hmox1+/+ mice.
Parasites, infection and disease assessment. In all experiments, we used red
blood cells infected with green fluorescent protein (GFP)-transgenic P. berghei
ANKA (ref. 41) or P. berghei NK65 to infect C57BL/6 or BALB/c mice. Mice
were infected by intraperitoneal (i.p.) inoculation of 105 infected red blood
cells, except in experiments using Hmox1-deficient mice, in which 104 infected
red blood cells were used. Infected mice were monitored twice daily for clinical
symptoms of ECM including hemi- or paraplegia, head deviation, tendency to
roll over on stimulation, ataxia and convulsions. We determined parasitemia by
flow cytometry for mice infected with GFP-transgenic P. berghei ANKA and by
Giemsa staining followed by microscopic counting for mice infected with
P. berghei NK65. These results are expressed as percentage of infected red blood
cells, as previously described41.
Protoporphyrins. Iron protoporphyrin-IX (FePPIX, hemin), zinc protopor-
phyrin-IX (ZnPPIX), cobalt protoporphyrin-IX (CoPPIX) and biliverdin
hydrochloride (BV) (Frontier Scientific Inc.), were dissolved in 0.2 M NaOH,
neutralized (to pH 7.2) with 1 M HCl, and adjusted to concentrations of 1 mg/
ml (ZnPPIX, CoPPIX) or 3.8 mg/ml (BV) with distilled water. Aliquots
were stored at –80 1C and protected from light until used. For BBB studies,
we treated mice with FePPIX (40 mg/kg body weight) every 12 h, starting
on day 3 after infection. For survival studies, we administered FePPIX
(60 mg/kg body weight) every 12 h, starting on day 5 after infection. CoPPIX
(5 mg/kg body weight per d) and ZnPPIX (5 mg/kg/d) were administered i.p.
and were started 2 d before infection and continued for 9 d thereafter.
We administered biliverdin every 8 h (35 mg/kg i.p.) between days 2 and 4
after infection.
CO exposure. Mice were placed in a gastight 60-liter capacity chamber and
exposed to CO for the times indicated in the figure legends, as described
elsewhere6,42. Briefly, 1% CO (Aga Linde) was mixed with air in a stainless steel
cylinder to obtain a final concentration of 250 p.p.m. CO was provided
continuously at a flow rate ofB12 liter/min, starting on day 3 after infection
and continuing for 72 h, unless otherwise stated. We monitored CO concen-
tration using a CO analyzer (Interscan Corporation). Controls were maintained
in a similar chamber without CO. We measured levels of COHb using a
portable CO-oximeter (AVOXImeter 4000, Avox Systems).
BBB permeability. We injected mice intravenously (i.v.) with 0.2 ml of 1–2%
Evans blue (Sigma) when clinical symptoms of ECM were observed (that is,
head deviation, convulsions, ataxia and paraplegia). Mice were killed 1 h
thereafter, and brains were weighed and placed in formamide (2 ml, 37 1C,
48 h; Merck) to extract Evans blue dye from the tissue, essentially as previously
described43. Absorbance was measured at l ¼ 620 nm (Bio Rad SmartSpec
3000). We calculated Evans blue concentration using a standard curve. Data are
expressed as mg of Evans blue per g of brain tissue.
CD8-specific antibody depletion. Hmox1/ BALB/c mice infected with
P. berghei ANKA received 0.8 mg of CD8-specific monoclonal antibody (clone
2.43, ATCC) on days 5 and 8 after infection, a protocol leading to CD8+ T-cell
depletion and suppression of ECM (ref. 20).
Heme quantification in vivo. Blood was drawn into heparinized tubes by heart
puncture and centrifuged (5 min, 4 1C, 1,100g). We collected red blood cells,
centrifuged the plasma (5 min, 4 1C, 1,100g) to remove contaminating red
blood cells and passed it through a Microcon YM-3 column (Millipore)(60 min
at 14 1C, 21,000g) to remove proteins (MW 4 3 kDa). We quantified heme
(that is, free heme) in protein-depleted plasma using a chromogenic assay
according to the manufacturer’s instructions (QuantiChrom heme assay kit,
Bioassay Systems). We washed red blood cells in a choline washing solution
(160 mM choline chloride, 10 mM glucose, 10 mM Tris.MOPS, pH 7.4); the
cells were incubated in washing solution for 5 min at 4 1C, then centrifuged at
1,100g, and this was repeated 4 times. We lysed the cells in H2O (1/100 vol) and
measured heme concentration using the same chromogenic assay as above.
Statistical analysis. For samples in which n 4 5, statistical analyses were
performed using the unpaired Student’s t-test or analysis of variance (ANOVA)
parametric tests. Normal distributions were confirmed using the Kolmogorov-
Smirnov test. For samples in which n o 5, statistical analyses were performed
using Kruskall-Wallis or Wilcoxon nonparametric tests. The log-rank test was
used for all experiments in which survival was assessed as an end point. P o
0.05 was considered significant; P o 0.001 was considered highly significant.
Note: Supplementary information is available on the Nature Medicine website.
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Preface
This book arose from a one-day symposium arranged as part of the Annual Meeting
of the Society for Experimental Biology (UK) in Barcelona in 2005 and takes up the
important question of how emerging genomic and proteomic technologies are
making significant contributions to global drug discovery programmes, and in partic-
ular the key role that comparative genomic and proteomic strategies play.
Rapid progress in our understanding of cellular and molecular biology has led to
the field of biomedical science undergoing a major revolution over the last 30 years or
so. Of particular note is the dramatic development of genomic and proteomic tech-
nologies and their associated application in biology and medicine.
Genomics is the study of an organism’s genome and involves isolation, identification
and mapping of genes along with associated functional dynamics and interaction. The
Human Genome Project has revealed that the human genome is composed of 20,000 to
25,000 genes. However, since each gene can be translated into a variety of different pro-
teins via a variety of cellular and molecular mechanisms, it is estimated that the human
proteome consists of approximately 1,000,000 differently modified proteins. This in
turn means that there are significantly more potential biomarkers or drug targets to be
discovered using proteomic approaches rather than genomic approaches. Expression of
these proteins is known to vary in response to environmental change and is related to
genetic history. Unlike variation in gene expression, any change in protein expression
usually results in alteration of function. Genomics and proteomics are thus considered
as being highly complementary approaches to the molecular study of disease. 
Written by widely respected authorities from both academic and pharmaceutical
backgrounds, this book is composed of seven concise chapters. In Chapter 1, Sara
Melville (Cambridge University, UK), introduces the use of comparative genomics in
drug discovery in one of the three main human pathogens associated with kinetoplas-
tids, the trypanosomatids, parasitic protozoa responsible for a wide range of diseases
including African sleeping sickness, Chagas disease and leishmaniasis. In Chapter 2,
Chris Peacock (Wellcome Trust Sanger Institute, UK) describes how comparative
genomics is being used to assist in developing treatments against the kinetoplastids, a
remarkable group of organisms that include major pathogens responsible for thou-
sands of deaths each year and serious illness to millions. Maria Mota (Universidade de
lisboa, Portugal) then considers the relevance of host genes in malaria (Chapter 3), a
devastating disease that affects extensive areas of Africa, Asia and South/Central
America causing up to 2.7 million deaths per year. In Chapter 4, David Sattelle
(University of Oxford, UK) describes how comparative genomics has contributed to
the study of nicotinic acetylcholine receptors as drug/chemical targets for a number
of conditions including genetic and autoimmune disorders. Chapter 5 (Jeff Clare,
GlaxoSmithKline, UK) discusses how genomic and proteomic strategies are being
used in gene family-based drug discovery projects aimed at isolating novel sodium
channel inhibitors. A sub-population of voltage-gated sodium channels are expressed
primarily in nerves involved in pain signalling; these are hence of major interest to the
pharmaceutical industry as potential targets for improved analgesics. In Chapter 6,
John Bilello (GlaxoSmithKline, USA) discusses how information resulting from
genomic and proteomic studies can be translated into disease understanding and
effective management of therapy. Finally, in Chapter 7, David Wishart (University of
Alberta, Canada) discusses how advances in genomic and information technology have
led to the possibility of in silico drug target discovery.
The purpose of this book is to provide an introduction to the concepts behind the
dynamic and powerful fields of comparative genomics and proteomics and their spe-
cific application in drug discovery. To some extent, the book assumes knowledge of
basic molecular biology and is targeted at students, researchers and academics in
related areas of biomedicine and pharmaceutics and to a more general readership
interested in specific applications of genomic and proteomic technologies. 
We would like to thank all of the contributing authors and the Society for
Experimental Biology (SEB, UK) for helping us to put this book together. We would
also like to extend our thanks to Elizabeth Owen and Kirsty Lyons at Taylor &
Francis for their extensive assistance in the final compilation of this book. 
Oxford, April 2006. John Parrington & Kevin Coward
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3The relevance of host genes
in malaria
Miguel Prudêncio, Cristina D. Rodrigues and 
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1 Introduction
Malaria is a devastating disease that affects extensive areas of Africa, Asia and South and
Central America, causing up to 2.7 million deaths per year, mainly children under the
age of five (Webster and Hill, 2003). The disease is caused by a protozoan parasite from
the genus Plasmodium and transmitted through the bite of the female Anopheles mos-
quito. When a mosquito infected with Plasmodium bites a mammalian host, it probes
for a blood source under the skin and, during this process, deposits saliva containing
sporozoites. These sporozoites reach the circulatory system and are transported to the
liver. Once there, they migrate through several hepatocytes by breaching their plasma
membranes before infecting a final cell with the formation of a parasitophorous vacuole.
After several days of development inside a hepatocyte, thousands of merozoites are
released into the bloodstream where they invade red blood cells (RBCs), initiating the
symptomatic erythrocytic stage of the disease (Figure 1).
Malaria infection depends upon the occurrence of interactions between the
Plasmodium parasite and the host. Every stage of an infection by Plasmodium relies, to
different extents, on the presence of host molecules that enable or facilitate its invasion,
survival and multiplication. Therefore, host genes play a crucial role in determining the
resistance or susceptibility to malaria and may constitute potential targets for preventive
or therapeutic intervention. Analysis of the genetic basis of susceptibility to major
infectious diseases is, arguably, the most complex area in the genetics of complex disease
(Hill, 2001). In this chapter, we will examine the progress made towards identifying
mammalian host molecules that play a role in the modulation of malaria infections.
2 The pre-erythrocytic stage: hepatocyte, liver and beyond
The hepatic stage of a Plasmodium infection constitutes an appealing target for the
development of an intervention strategy since this would act before the onset of pathol-
ogy, which only occurs during the blood stage of the parasite’s life cycle. In fact, until
now, the only demonstrably effective vaccine shown to confer a sterile and lasting pro-
tection both in mice (Nussenzweig et al., 1967) and in humans (Clyde et al., 1973;
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Rieckmann et al., 1974; Herrington et al., 1991) was the inoculation of γ-irradiation-
attenuated sporozoites, that are able to invade but not fully mature inside the hepato-
cyte (see Carvalho et al., 2002; Gruner et al., 2003; Bodescot et al., 2004; Todryk and
Walther, 2005; Waters et al., 2005).
Despite being symptomatically silent, the liver stage of a malaria infection is immuno-
logically very complex. Unlike RBCs, liver cells are able to promote cell-mediated immune
response mechanisms through expression of class I Major Histocompatibility Complex
(MHC) proteins. Class I MHC proteins present antigens to cytotoxic T lymphocytes
(CTLs) (Lowell, 1997), which are known to play an important role in the generation of
a protective immune response in many microbial infections (Esser et al., 2003). The acti-
vation of T cells by antigen-presenting cells (APCs) is required to initiate specific
immune responses. Different APCs have been shown to be important in this process,
including dendritic cells (DC) (Bruna-Romero and Rodriguez, 2001; Jung et al., 2002;
Leiriao et al., 2005) and Kupffer cells (Steers et al., 2005). 
Human leucocyte antigens (HLAs) are encoded by genes of the MHC, which are
known to be among the most polymorphic of all human genes (reviewed in Williams,
2001). Although most of the human MHC loci are relatively stable, the HLA-B locus
has been shown to undergo rapid changes, especially in isolated populations (McAdam
et al., 1994). HLA-B encodes an MHC class I heavy chain that is part of the HLA-B
antigen-presentation complex (Kwiatkowski, 2005). On the other hand, the HLA-DR
antigen-presenting complex includes an HLA class II β chain, which is encoded by
HLA-DRB1. HLA-DR is found in B lymphocytes, DC and macrophages where it
plays an essential role in the production of antibodies (Kwiatkowski, 2005). Both 
the HLA-B53 allele and the DRB1*1302-DQB1*0501 haplotype were shown to be
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Figure 1. The life cycle of Plasmodium in the mammalian and mosquito hosts.
associated with protection against severe malaria (SM) in The Gambia (Hill et al., 1991)
and the latter was also found to be associated with protection from malaria anaemia
and malarial reinfections in Gabonese children (May et al., 2001).
The analysis of the peptides from a vast range of malaria antigens that bind to
HLA-B53-restricted CTLs in malaria-immune Africans led to the identification of 
a single conserved peptide from liver-stage-specific antigen-1 (LSA-1) (Hill et al., 1992),
making LSA-1 an interesting malaria vaccine candidate (Migot-Nabias et al., 2001).
Of the four most prevalent allelic variants of the protein recognized by HLA-B53,
only two are indeed epitopes, binding this protein in vitro (Gilbert et al., 1998).
Moreover, these results suggest that cohabiting parasite strains, each of which being
an individually effective target for CTLs, may have the ability to use altered peptide
ligand (APL) antagonism mechanisms to suppress the CTL response to the other strain,
thereby increasing each other’s chances of survival. This observation has obvious impli-
cations in terms of vaccine development, since it suggests that including all allelic pep-
tide variants in a prospective vaccine might be counterproductive because one given
variant may antagonize immunity to other variants.
During Plasmodium sporozoite development inside hepatocytes there is an amazing
multiplication, with each parasite giving rise to 10,000–30,000 merozoites in 2–7 days
(depending on Plasmodium spp.). Moreover, there is a high level of specificity of
Plasmodium sporozoite development, which only occurs in certain types of cells. This
strongly suggests an important role for the host cell in supporting the full development
of the parasite. However, not much is known about Plasmodium requirements, strate-
gies developed to survive and be successful, or how much the host cell contributes to
this. An intriguing characteristic of Plasmodium sporozoites is their ability to migrate
through hepatocytes prior to invading a final one with the formation of a vacuole for
further development. Sporozoites breach the plasma membrane of the cell, traverse
through its cytosol and leave by wounding the membrane (Mota et al., 2001). This
unusual process is frequently observed in vitro, where sporozoites traverse mammalian
cells at a speed of approximately one cell per minute. Migration through host hepato-
cytes is also observed in vivo in the liver of mice infected with Plasmodium sporozoites
(Mota et al., 2001; Frevert et al., 2005). Wounding of host hepatocytes induces an
alteration in traversed cells which includes the secretion of host cell factor(s), which
render(s) neighbouring hepatocytes susceptible to infection. One such factor is hepato-
cyte growth factor (HGF), which, by activating its receptor MET, seems to be required
for the early development of parasites within host cells (Carrolo et al., 2003). These
results, however, appear to be contradicted by evidence provided by spect-deficient
sporozoites, which do not migrate through cells in vitro (Ishino et al., 2004). It would be
expected that spect-deficient sporozoites would not induce host cells to produce HGF
and, therefore, infection would be inhibited. However, these sporozoites efficiently
infect host cells in vitro (Ishino et al., 2004). This apparent discrepancy may be due to par-
ticular characteristics of the in vitro cell system used for infection (Mota and Rodriguez,
2004), or to alternative ways used by the parasite to fully develop inside host cells.
3 The erythrocytic stage and disease
The erythrocytic stage of Plasmodium’s life cycle corresponds to the symptomatic phase
of a malaria infection. During this phase, Plasmodium merozoites invade RBCs 
and degrade haemoglobin (Hb), releasing heme that is converted into haemozoin 
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(malarial pigment). The invading merozoites multiply in the RBCs and, upon ruptur-
ing the erythrocytic membrane, are eventually released into the blood where they
target new RBCs. The interaction between Plasmodium and the RBCs occurs in two
stages: first, the identification and binding of RBC surface molecules that will enable
invasion; subsequently, the intracellular interaction with Hb and the multiplication of
the parasite.
3.1 Erythrocyte invasion – P. vivax versus P. falciparum
The human malaria parasite, P. vivax, and the related monkey malaria, P. knowlesi,
use the Duffy blood group antigen as a receptor to invade human RBCs (Miller et al.,
1976). The Duffy antigen, encoded by the FY gene, is a chemokine receptor on the
surface of the RBCs. It belongs to the superfamily of G-protein coupled receptors
(GCRs) (Neote et al., 1994) and is also termed DARC (for Duffy antigen receptor for
chemokines). The Duffy blood group locus is polymorphic and has three main alleles
designated FY*A, FY*B and FY*O. The FY*A allele is very frequent in Asia and the
Pacific, whereas in Europe and the Americas the FY*A and FY*B alleles are at inter-
mediate frequencies. The FY*O allele is at or near fixation in most sub-Saharan
African populations, but is very rare outside Africa (Hamblin and Di Rienzo, 2000).
FY*O arises from a mutation at position -46 in the promoter of the FY*B allele, leading
to a Fy(a-b-) phenotype in which RBCs lack both Fya and Fyb antigens (Tournamille
et al., 1995). Fy(a-b-) RBCs resist invasion in vitro by P. knowlesi parasites and indi-
viduals homozygous for the FY*O allele are completely resistant to P. vivax malaria
(Miller et al., 1976). The correlation between the Duffy-negative serological pheno-
type and resistance to P. vivax malaria is now clear. P. vivax relies on a single path-
way to invade RBCs. The lack of redundancy in P. vivax invasion pathways may
explain the near absence of this parasite from West Africa, where almost 95% of the
population have the Duffy-negative phenotype and are resistant to P. vivax malaria
(Chitnis and Miller, 1994). The extreme degree of between-population differentiation of
allele frequency of the Duffy blood group gene shows evidence of human directional
selection by P. vivax (Hamblin et al., 2002). Furthermore, it has important implica-
tions in drug or vaccine design (Yazdani et al., 2004).
Unfortunately, things are a lot more complicated when it comes to the much more
deadly P. falciparum malaria parasite.
Contrary to P. vivax, P. falciparum displays the ability to invade RBCs following
multiple, alternative pathways, with significant redundancy. Research into the identifi-
cation of RBC receptors involved in merozoite invasion has made use of RBCs that lack
specific surface molecules or enzymes that modify protein and carbohydrate domains
on those molecules. The main enzymes used have been neuraminidase (which cleaves
sialic acid groups from surface glycoproteins and glycolipids) and trypsin (which
cleaves the peptide backbone of a number of surface proteins) (Baum et al., 2003).
These studies have revealed several surface receptors that are involved in invasion of
the RBC by P. falciparum merozoites. Three neuraminidase-sensitive molecules that
have received particular attention are glycophorin A (GYPA) (Pasvol et al., 1982),
glycophorin B (GYPB) (Dolan et al., 1994), and glycophorins C and D (GYPC/D)
(Mayer et al., 2001; Maier et al., 2003). GYPC and GYPD are encoded by the same
gene, but use alternative start codons. Deletion of exon 3 in the GYPC/D gene
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changes the serologic phenotype of the Gerbich (Ge) blood group system, resulting 
in Ge-negativity. Ge-negative RBCs exhibit a shortened GYPC and lack GYPD
(Mayer et al., 2001). This is of particular relevance if we consider that the Ge-negative
phenotype is found at high allele frequencies in some regions of Papua New Guinea,
which coincide with regions of malaria hyperendemicity. This strongly suggests that
selection of Ge-negativity in these populations confers at least partial protection
against P. falciparum malaria. It should be noted that this is in contrast to a study 
in which no correlation between the prevalence of P. falciparum infection and 
Ge-negativity in the Wosera region of Papua New Guinea was found (Patel et al.,
2001). More recently, the existence of yet another sialic acid-dependent receptor,
termed ‘Receptor Y’, has been demonstrated (Rayner et al., 2001). It would seem
apparent that P. falciparum shows a near-exclusive preference for sialic acid-depend-
ent (i.e. neuraminidase-sensitive) glycophorins for RBC invasion. This, however, is
now known not to be the case. Several reports have shown that alternative, sialic acid-
independent, invasion pathways are commonly used by P. falciparum (Mitchell et al.,
1986; Hadley et al., 1987; Dolan et al., 1994). Moreover, P. falciparum seems capable
not only of sialic acid-independent RBC invasion, but also of switching between sialic
acid-dependent and sialic acid-independent pathways (Dolan et al., 1990; Reed et al.,
2000; Duraisingh et al., 2003). Very recently, the molecular mechanism for this
switching process was elucidated (Stubbs et al., 2005).
As we have seen, the surface of the RBC presents various types of sialic acid-depend-
ent and sialic acid-independent receptors that can mediate P. falciparum invasion with
at least a certain degree of redundancy. Furthermore, it is clear that the relative impor-
tance of each receptor is strain-dependent (Rayner et al., 2001). These observations
have important implications for vaccine development. While the existence of a single
RBC invasion pathway for P. vivax yields good reasons to hope for a successful 
vaccine, this is clearly not the case for P. falciparum.
3.2 Intraerythrocytic stage – globin and non-globin genes
Following invasion of RBCs, Plasmodium parasites develop and multiply, leading to the
appearance of the symptoms of malaria infection. Almost 90% of the intraerythrocytic
space is taken up by Hb. Therefore, it is to be expected that Plasmodium will interact
closely with this molecule and be influenced by its overwhelming presence. Thus, it is
perfectly conceivable that Hb alterations will affect the development of the parasite, as
well as the parasitized RBC itself.
Normal Hbs are tetrameric proteins composed of two pairs of unlike globin
chains. After birth, the vast majority of Hb is composed of two α-globin and two 
β-globin chains (reviewed in Weatherall and Clegg, 2001; Richer and Chudley, 2005).
The molecular pathology of most of the haemoglobinopathies is well defined
(Weatherall and Clegg, 2001). The Hb disorders resulting from mutations in the α- or
β-globin gene clusters are the most common single-gene disorders in humans
(Weatherall, 2001). Inherited haemoglobinopathies can be divided into two main
groups: structural Hb variants, mostly resulting from single amino acid substitutions
in the α- or β-chains, and thalassaemias, arising due to the ineffective synthesis of the
α- and/or β-chains (reviewed in Weatherall and Clegg, 2001). These two classes of Hb
disorders constitute one of the most striking illustrations of why malaria is considered
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the strongest known selective pressure in the recent history of the human genome
(Kwiatkowski, 2005).
Structural Hb variants. Of the more than 700 structural Hb variants identified, only
those coding for ‘haemoglobin S’ (or ‘sickle haemoglobin’, HbS), ‘haemoglobin C’
(HbC) and ‘haemoglobin E’ (HbE) have reached polymorphic frequencies. Each of
the alleles HbS, HbC and HbE results from a single point mutation in the HBB gene.
Although often lethal in the homozygous state, the unusually high prevalence of these
alleles in areas of malaria endemicity has long been attributed to a selective pressure
exerted by Plasmodium on the human host genome (Min-Oo and Gros, 2005).
In HbS, the glutamate at position 6 of the β-globin chain is replaced by a valine
residue. The resulting protein contains ‘sickle’ β-globin (βS-globin) chains and tends to
polymerize at low oxygen concentrations, causing the RBC to acquire a sickle-like shape
(Brittenham et al., 1985). This results in a condition known as ‘sickle cell’ anaemia, an
autosomal recessive genetic disorder characterized by chronic anaemia and periodic
vaso-occlusive crises (Shiu et al., 2000). Although the homozygous state (HbSS) is
often lethal, the heterozygous state (HbAS) is referred to as sickle cell trait and is usu-
ally clinically silent. The HbAS state has been shown to confer significant protection
to malaria (reviewed in Kwiatkowski, 2005; see also Aidoo et al., 2002; Williams et al.,
2005a). The exact mechanisms through which HbAS protects against malaria are unclear.
A few possible explanations have, however, been put forward, including the enhanced
sickling of the infected RBCs (iRBCs) (Luzzatto et al., 1970), the suppression of parasite
growth in individuals with the sickling disorders (Pasvol et al., 1978) and increased
spleen clearance (Shear et al., 1993), enhanced phagocytosis (Ayi et al., 2004) and
enhanced acquisition of natural immunity to malaria, possibly due to the accelerated
acquisition of antibodies against altered host antigens expressed on the surface of the
infected RBCs (iRBCs) and/or against parasite-derived proteins (Williams et al., 2005b). 
In HbC, the glutamate at position 6 of the β-globin chain is replaced by a lysine
residue. The resulting condition is considerably less serious than sickle cell anaemia.
Even in the homozygous state (HbCC), only occasional pathologic developments are
observed whereas heterozygotes (HbAC) are asymptomatic (Agarwal et al., 2000;
Kwiatkowski, 2005). This Hb variant has been implicated in protection against
malaria in both the HbAC and the HbCC states (reviewed in Kwiatkowski, 2005;
Min-Oo and Gros, 2005), although contrasting results have been reported concerning
the heterozygous state (discussed in Modiano et al., 2001). Three recent reports pro-
pose complementary explanations for the protective effect of HbC against malaria, all
implying modifications that occur at the host cell surface (Tokumasu et al., 2005; Arie
et al., 2005; Fairhurst et al., 2005).
HbE results from a glutamate Æ lysine mutation at position 27 of the β-globin chain.
It is the most common structural variant of Hb and is innocuous both in its heterozygous
(HbEA) and homozygous (HbEE) states (Weatherall and Clegg, 2001). There is no
unequivocal proof that HbE protects against malaria but it has been suggested that an
alteration in the RBC membrane in HbEA cells renders the majority of the RBCs pop-
ulation relatively resistant to invasion by P. falciparum (Chotivanich et al., 2002).
Thalassaemias. The β- and α-thalassaemias are disorders of globin chain synthesis that
appear as a consequence of deletions or point mutations in the non-coding portion of
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the β- and α- globin genes, respectively (reviewed in Weatherall, 2001; Richer and
Chudley, 2005). Because the synthesis of the β-globin chain is determined by two
alleles of the HBB gene, whereas that of α-globin is encoded by the four 
alleles on the equivalent HBA1 and HBA2 genes, there is a wide range of possible 
thalassaemic genetic variants, with different clinical manifestations. In general,
homozygous thalassaemia is severe or even fatal, whereas the heterozygous state is
clinically benign. However, when either the HBA1 or the HBA2 gene, but not both,
is defective, a condition termed α-thalassaemia occurs, for which homozygous indi-
viduals show only mild anaemia (Kwiatkowski, 2005). Evidence for protection against
malaria by thalassaemia has been shown in different reports (reviewed in Min-Oo and
Gros, 2005; Williams et al., 2005a). The nature of protection against malaria by tha-
lassaemias is unclear. Again, several suggestions have been mentioned including
impaired parasite growth and increased susceptibility to phagocytosis (Yuthavong et al.,
1988, 1990), altered expression of parasite-induced surface neoantigens in β- and α-
thalassaemia allowing greater binding of specific antibody to iRBCs and their subse-
quent clearance (Luzzi et al., 1991a, 1991b) and enhanced phagocytosis of ring-stage
iRBCs of β- (but not α-) thalassaemia individuals (Ayi et al., 2004).
In addition to Hb, other RBC molecules also seem to play an important role in the
parasite’s development and in the host’s susceptibility to malaria.
G6PD deficiency. The haeme liberated in the process of intra-erythrocytic Hb degra-
dation by Plasmodium is polymerized to haemozoin or broken down non-enzymati-
cally. Non-enzymatic cleavage of haeme liberates iron and generates hydrogen
peroxide, a potential source of oxidative stress (Schwarzer et al., 2003). Glucose-6-
phosphate dehydrogenase (G6PD) catalyses the oxidation of glucose-6-phosphate to
6-phosphogluconate, while concomitantly reducing nicotinamide adenine dinu-
cleotide phosphate (NADP+ to NADPH). G6PD is the only erythrocytic enzyme
that produces NADPH, a compound that is crucial for the defence of the RBCs
against oxidative stress (Beutler, 1996). G6PD deficiency is the most common human
enzymopathy known, affecting over 400 million people (Beutler, 1990). There are
numerous variants of the G6PD gene and only those that significantly hamper
enzyme activity lead to haemolytic anaemia, a phenotype that is exacerbated under
oxidative stress conditions (Kwiatkowski, 2005). Evidence for the geographical corre-
lation between G6PD deficiency and protection against malaria comes from various
population-based studies and suggests evolutionary selection by the latter (reviewed
in Kwiatkowski, 2005; Min-Oo and Gros, 2005). Although reduced parasite replica-
tion in G6PD-deficient RBCs was initially proposed as the mechanism of protection
(Luzzatto et al., 1969), the invasion and maturation of the parasite seems not to be sig-
nificantly different between normal and G6PD-deficient RBCs (Cappadoro et al.,
1998). Instead, ring-stage iRBCs present on their surface a higher density of phago-
cytic removal markers than normal iRBCs and are, therefore, phagocytozed more
efficiently. This suggestion has been extended to explain the protective nature of other
erythrocytic defects against malaria (Ayi et al., 2004), as previously mentioned.
Band 3 protein. Band 3 protein, encoded by AE1, is a ~100 kDa membrane protein
that acts as an anion permeation channel, exchanging intracellular bicarbonate for
chloride through the RBC lipid bilayer (Rothstein et al., 1976; Alper et al., 2002). 
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A 27-base-pair deletion in the AE1 gene (known as Band3∆27), has been shown to
cause a condition known as South-East Asian ovalocytosis (SAO), characterized by
slightly oval or elliptical shaped RBCs, defective anion transport activity, increased
acidosis and haemolytic anaemia (Schofield et al., 1992). Whereas the homozygous
state is lethal, population-based studies have shown that the heterozygous state 
confers protection against cerebral malaria (CM), a condition characterized by 
progressing coma, unconsciousness, multiple convulsions and, often, death (Rasti et al.,
2004; Genton et al., 1995; Allen et al., 1999). Again, the mechanism of protection is
unknown but several hypothesis have arisen, such as membrane alterations in SAO
RBCs affecting parasite invasion (Kidson et al., 1981) and involvement of Band 3 pro-
tein in iRBC cytoadherence, a process described below (Winograd and Sherman,
1989; Winograd et al., 2005; Shimizu et al., 2005).
PK deficiency. RBCs do not have mitochondria and are, therefore, dependent on gly-
colysis for energy. Pyruvate kinase (PK) is a key enzyme in glucose metabolism,
catalysing the conversion of phosphoenolpyruvate into pyruvate, with simultaneous
production of ATP. Thus, PK-deficient RBCs have impaired glycolysis and difficulty
in maintaining normal levels of ATP and NAD. The degree of severity of PK-defi-
ciency depends on the mutation(s) in one or both genes coding for PK in the human
genome (Min-Oo and Gros, 2005). No formal evidence exists of a protective effect of
PK deficiency against malaria in humans (Min-Oo and Gros, 2005). However, such a
correlation is likely to exist, as suggested by recent studies carried out in mouse
models (Min-Oo et al., 2003, 2004).
3.3 Cytoadherence and sequestration – selective pressures and therapeutic value
P. falciparum is the most virulent of all four Plasmodium parasites that infect humans.
Two features are strongly suggested to contribute decisively to the outstanding path-
ogenicity of P. falciparum: its remarkable potential to multiply to high parasite bur-
dens and its unique ability to cause iRBCs to adhere to the linings of small blood
vessels. The latter process is termed cytoadherence and the ensuing sequestration of
iRBCs is frequently suggested to be a key feature in the pathogenesis of SM (see Ho
and White, 1999; Kyes et al., 2001; Miller et al., 2002 for reviews).
The most widely suggested justification for sequestration in P. falciparum malaria 
is that adhesion of iRBCs to the endothelium allows the parasite to escape peripheral
circulation and be cleared by the spleen. Another Plasmodium survival advantage is 
that sequestration in the deep tissue microvasculature provides the parasites with a
microaerophilic venous environment that promotes maturation and faster asexual
replication (Cranston et al., 1984). Alternative, but not necessarily exclusive, explana-
tions include sheltering of the iRBCs against destruction by the immune system of the
host, enhanced survival of the gametocyte and immunomodulation by inhibition of
the maturation and activation of DC (reviewed in Sherman et al., 2003).
It has been suggested that parasite accumulation in specific organs is an important
factor in malaria pathogenesis. Indeed, post-mortem examinations of people who
have died from P. falciparum malaria show sequestered iRBCs within the small 
vessels of several tissues. The best-documented situation regards the sequestration 
of iRBCs in the endothelium of small vessels of the brain, which can lead to CM
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(Kyes et al., 2001; Rasti et al., 2004). The proportion of iRBCs was higher in P. falci-
parum malaria patients dying with CM than in those that showed no CM symptoms
(MacPherson et al., 1985; Silamut et al., 1999; Taylor et al., 2004). The most prevalent
hypothesis to explain the clinical manifestations of CM seems to be that sequestration
obstructs blood flow, and, consequently, decreases the levels of oxygen and nutrients,
whilst increasing the accumulation of waste products in the brain (Miller et al., 1994).
A complementary hypothesis is that an inflammatory response to the infection 
activates leukocytes and promotes their adhesion to receptors in the endothelium
(Sun et al., 2003). Another organ where sequestration seems to play a particularly
important pathogenic role is the placenta. Maternal or placental malaria (PM) in 
P. falciparum-infected pregnant women is associated with disease and death of both
mother and child. The characteristic feature of infection during pregnancy is the selec-
tive accumulation of iRBCs in the intervillous blood spaces of the placenta, leading to
hypoxia, inflammatory reactions and intervillositis (reviewed in Beeson et al., 2001;
Andrews and Lanzer, 2002; Duffy and Fried, 2003).
Besides the cytoadherence of iRBCs to endothelial cells (sequestration), other dis-
tinctive patterns of iRBCs adherence can be distinguished at the cellular level. These
involve different types of interactions between iRBCs and other host cells, such as
RBCs (rosetting) (Udomsangpetch et al., 1989; 1992), platelets (‘platelet-mediated
clumping’, formerly known as autoagglutination) (Roberts et al., 1992; Pain et al.,
2001a) or DC (Urban et al., 1999, 2001). All these different types of interactions have
been suggested to have implications in the course of infection as well as in disease
severity (Udomsangpetch et al., 1989; Urban et al., 1999; Pain et al., 2001a).
Over the last few years, significant progress has been made towards the identifica-
tion of both parasite and host molecules that participate in these interactions. An array
of host molecules have been identified that mediate cytoadherence of the iRBCs to 
various host cells. Among the most important ones identified so far are CD36
(Barnwell et al., 1985), thrombospondin (TSP) (Roberts et al., 1985), intercellular
adhesion molecule-1 (ICAM-1) (Berendt et al., 1989), vascular cell adhesion molecule-
1 (VCAM-1) (Ockenhouse et al., 1992), E-selectin (endothelial leukocyte adhesion
molecule 1, ELAM-1) (Ockenhouse et al., 1992), chondroitin sulphate A (CSA)
(Rogerson et al., 1995), platelet/endothelial cell adhesion molecule-1 (PECAM-1/CD31)
(Treutiger et al., 1997), complement receptor 1 (CR1) (Rowe et al., 1997), hialuronic
acid (HA) (Beeson et al., 2002) and heparan sulphate (HS) (Vogt et al., 2003).
Nevertheless, the exact role of each of these molecules in pathogenesis remains largely
unclear. Whilst some host ligands appear to be nearly ubiquitous, others seem to be
organ- or cell-specific. This specificity has implications in terms of disease severity
and adhesion mechanisms. Moreover, sequestration in an organ is likely to involve
multiple receptors, and different combinations of specific receptors for adhesion may
determine the site at which parasites adhere and accumulate (Beeson and Brown, 2002).
Furthermore, receptors can act synergistically in mediating the adhesion of iRBCs
(McCormick et al., 1997; Yipp et al., 2000; Heddini et al., 2001b) and in vivo seques-
tration has been shown to involve a multi-step adhesive cascade of events where iRBCs
initially roll along the endothelial surface and are subsequently arrested (Ho et al., 2000).
CD36. CD36 (encoded by CD36), also known as GP88 or platelet glycoprotein IV, is
an 88 kDa cell surface class B scavenger receptor and is expressed in endothelial cells,
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monocytes, platelets and erythroblasts (Barnwell et al., 1989; Ho and White, 1999).
CD36 has been implicated in the interaction with a variety of natural ligands (reviewed
in Ho and White, 1999; Serghides et al., 2003) and it was identified in vitro as a receptor
for iRBCs (Barnwell et al., 1985, 1989). Since then, evidence for the involvement 
of CD36 in malarial cytoadherence became abundant and unequivocal, although its
implications in disease severity are not always clear-cut. Whilst some reports describe a
contribution of CD36 to malaria severity (Udomsangpetch et al., 1992; Pain et al.,
2001a; Urban et al., 2001; Prudhomme et al., 1996), others suggest that it might be
advantageous for host survival (Rogerson and Beeson, 1999; Serghides et al., 2003;
McGilvray et al., 2000; Traore et al., 2000). Several CD36 polymorphisms have been
identified. In Africa, the most common of these substitutions is a T1264G stop muta-
tion in exon 10 (Aitman et al., 2000). Studies of the effects of this polymorphism in dis-
ease severity have again yielded contradictory results and do not provide definitive
answers regarding a possible selective pressure by malaria in endemic areas (Aitman 
et al., 2000; Pain et al., 2001b; Omi et al., 2003).
The role of CD36 in the pathogenicity of malaria is still ambiguous. This has
important implications in terms of the development of therapies or vaccines that
target the interaction between PfEMP-1 and the CD36 receptor. The in vitro-based
assumption that adherence to CD36 contributes to disease severity, and results in
negative clinical outcomes, triggered research aimed towards interfering with this
interaction that did not always yield agreeing results (Barnwell et al., 1985; Baruch et al.,
1997; Cooke et al., 1998; Yipp et al., 2003). One way to try and circumvent this prob-
lem is by making use of appropriate animal, ideally rodent, models. The sequences of
human and rat CD36 differ in a single amino acid (His242 in humans is Tyr242 in rat)
and both are able to bind P. falciparum-infected RBCs (Serghides et al., 1998). It has
been shown that RBCs infected with the murine parasite P. chabaudi chabaudi AS
adhere in vitro to purified CD36 and are sequestered from circulation in an organ-
specific way in vivo (Mota et al., 2000). Recently, a novel system that enables real-
time in vivo imaging luciferase-expressing rodent malaria parasite P. berghei was used
to monitor sequestration (Franke-Fayard et al., 2005). Using CD36−/− mice, it was
shown that nearly all detectable iRBC sequestration depends on CD36 and that
murine CM pathology still develops in the absence of this receptor, implying that
CD36-mediated sequestration in nonerythroid organs does not constitute the molec-
ular basis of rodent CM. Despite the obvious advantages of using animal models 
to study sequestration, caution should be employed when extrapolating results to the
P. falciparum/human situation.
ICAM-1. Intercellular adhesion molecule-1 (ICAM-1), encoded by ICAM-1, is 
a surface glycoprotein member of the immunoglobulin superfamily. ICAM-1, also
known as CD54, plays a central role in immune response generation by functioning as
an endothelial and immune-cell ligand for integrin-expressing leukocytes (reviewed in
Ho and White, 1999; Kwiatkowski, 2005). ICAM-1 is widely distributed in endothe-
lial cells including, unlike CD36, those of the brain microvascular system (Adams et al.,
2000). Also unlike CD36, the expression of ICAM-1 can be up-regulated by a number
of factors, most notably pro-inflammatory cytokines such as tumour necrosis factor-α
(TNF-α), interleukin-1 (IL-1) and interferon-γ (IFN-γ) (reviewed in Dietrich, 2002),
which seem to correlate with disease severity.
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P. falciparum iRBCs have been shown to bind with different affinities to ICAM-1
in vitro (Berendt et al., 1989). Unequivocal in vivo evidence of the involvement of
ICAM-1 in sequestration, mainly in the brain, has been reported in both humans
(Turner et al., 1994) and mice models (Willimann et al., 1995; Kaul et al., 1998). 
The evidence gathered in these studies has led to the notion that ICAM-1 may play an
important role in CM by either sequestering iRBCs or adhering to activated leukocytes.
Furthermore, this receptor has also been shown to contribute to the cytoadherence of
iRBCs within the intervillous spaces of the P. falciparum-infected placenta, support-
ing a possible role of ICAM-1 in PM (Sugiyama et al., 2001), as previously suggested
(Sartelet et al., 2000). Moreover, ICAM-1 can synergize with CD36 to promote iRBC
adhesion under flow conditions (McCormick et al., 1997, Ho et al., 2000; Yipp et al.,
2000). For these reasons, it is generally accepted that ICAM-1 plays a role in iRBC
sequestration and in the severity of disease.
A high-frequency coding polymorphism in the ICAM-1 gene of individuals from
Kilifi (Kenya), an area of high malaria endemicity, has been identified (Fernandez-
Reyes et al., 1997). The mutant protein, termed ICAM-1Kilifi, contains a lysine Æ
methionine replacement at position 29 (Fernandez-Reyes et al., 1997). Intuitively, one
would be led to think that the prevalence of this polymorphism in malaria-endemic
regions would be associated with protection against severe forms of disease.
However, studies attempting to correlate this polymorphism with malaria severity,
yielded surprising and contradictory results (Fernandez-Reyes et al., 1997; Kun et al.,
1999; Bellamy et al., 1998; Ohashi et al., 2001; Amodu et al., 2005). The obvious dif-
ficulties that arise when attempting to reconcile those results constitute an illustration
of the extreme complexity of malaria pathogenesis and suggest that different biologi-
cal selective forces might simultaneously be at play in the studied populations (Craig
et al., 2000). In a very recent report, an ICAM-1 exon 6 polymorphism (lysine Æ
glutamate replacement at position 469 in the protein) was seen to positively correlate
with an increased risk of SM (Amodu et al., 2005).
PECAM-1/CD31. Platelet/endothelial cell adhesion molecule-1 (PECAM-1, also
known as CD31), encoded by PECAM-1, is a highly glycosylated transmembrane gly-
coprotein of the immunoglobulin superfamily (Newman et al., 1990). It is expressed
on endothelial cells and platelets, as well as on granulocytes, monocytes, neutrophils
and naïve T lymphocytes (Newman et al., 1990; Mannel and Grau, 1997).
The role of PECAM-1 as an endothelial receptor for adherence of P. falciparum-
infected RBCs was demonstrated in vitro by Treutiger et al. (1997). These authors
further demonstrated that binding could be blocked by monoclonal antibodies
(mAbs) specific for the N-terminus of PECAM-1 whereas it could be increased 
by IFN-γ, a proinflammatory cytokine associated with the development of CM. In
addition to serving as an endothelial receptor, the fact that PECAM-1 is expressed on
platelets raises the possibility that it may also be involved in platelet adhesion of
iRBCs, although no direct evidence exists for this. Platelets have been proposed as
important effectors of neurovascular injury in CM, both in mice and in humans (reviewed
in Mannel and Grau, 1997). Furthermore, the PECAM-1 receptor is quite commonly
recognized by wild P. falciparum isolates (Heddini et al., 2001a). In this particular study,
over 50% of the fresh patient-isolates tested recognized PECAM-1, a number that is not
matched by any other endothelial receptor, with the exception of CD36.
MIGUEL PRUDÊNCIO, CRISTINA D. RODRIGUES AND MARIA M. MOTA 57
A functional mutation in codon 125 of the PECAM-1 gene (leucine Æ valine
replacement in the protein) was analysed in terms of its possible influence on malaria
resistance (Casals-Pascual et al., 2001). This study, carried out in Madang (Papua
New Guinea) and Kilifi (Kenya) revealed no association between codon 125 poly-
morphism and disease severity in either of the populations. In another study, carried
out in Thailand, a PECAM-1 haplotype that is significantly associated with CM was
reported (Kikuchi et al., 2001).
It seems clear that our knowledge of the role of PECAM-1 in the pathogenicity of
malaria is, at present, quite limited. This may be partly explained by the fact that,
despite being an apparently high affinity receptor for iRBCs, PECAM-1 has been
identified as such more recently than, for example, CD36 and ICAM-1. The use of
appropriate animal models and larger-scale assessment of human PECAM-1
polymorphisms would be a welcome source of potentially valuable information 
concerning this molecule.
CR1. Complement receptor 1 (CR1; C3b/C4b receptor; CD35), encoded by CR1, is
a glycoprotein expressed on the surface of human RBCs and leukocytes (see Moulds
et al., 1991). CR1 was first implicated in malaria when its involvement in rosette for-
mation, a phenotype associated with disease severity, was shown (Rowe et al., 1997).
CR1-dependent rosette formation is common in P. falciparum field isolates and the
region of CR1 involved in rosetting was mapped (Rowe et al., 2000).
The common blood group antigens, Kn(a)/Kn(b) (Knops); McC(a)/McC(b)
(McCoy); Sl(a)/Vil (Swain-Langley/Villien) (now known as Sl:1/Sl:2); and Yk(a) (York)
have been shown to be expressed on CR1 and, thus, correspond to alleles that encode
polymorphisms in this receptor (Moulds et al., 1991, 2000, 2001). The null phenotypes
for the CR1-related blood group (also known as the Knops blood group) antigens are
associated with the expression of a low number of CR1 molecules on the erythrocytic
surface (Moulds et al., 1991). The Sl(a−) and the McC(b+) phenotypes had a significantly
higher prevalence in a Malian population when compared to other African and
European-American populations (Moulds et al., 2000). However, no correlation was
found between either the Sl(a−) or the McC(b+) phenotypes (or, in fact, the Sl:2/McC(b+)
allele) and protection against malaria in The Gambia (Zimmerman et al., 2003).
CR1 is also polymorphic with respect to molecular weight (Wilson and Pearson,
1986; Wong et al., 1989). A HindIII-RFLP (restriction fragment length polymor-
phism), was identified and shown to correlate with differential quantitative expression
of CR1 on RBCs in Caucasian populations (Wong et al., 1989). Homozygotes for a 
7.4 kilobase (kb) HindIII genomic fragment (the H allele) have high RBC CR1 density,
whereas homozygotes for a 6.9 kb HindIII genomic fragment (the L allele) have low
CR1 expression, with HL heterozygotes having intermediate CR1 levels (Wong et al.,
1989). Surprisingly, in a Thai population, malaria severity was most prevalent in 
individuals homozygous for the L allele, compared with heterozygous individuals and
individuals homozygous for the H allele (Nagayasu et al., 2001). However, a recent
study has found no correlation between the level of erythrocytic CR1 and the H and L
alleles in an African population (Rowe et al., 2002), raising doubts about the HindIII-
RFLP importance in determining CR1 density on RBCs. To add to the confusion, 
a recent report in Papua New Guinea showed that HH individuals were at most risk of
58 CH. 3. THE RELEVANCE OF HOST GENES IN MALARIA
developing SM whereas HL individuals were significantly protected and LL individuals
showed statistically insignificant, albeit reduced, odds (Cockburn et al., 2004).
It is clear that further studies are needed in order to fully understand the actual
role of CR1-mediated rosetting in determining malaria severity and in establishing a
clear correlation between CR1 polymorphisms and protection against severe disease.
Studies involving murine models are unlikely to provide any further insights into this
issue. In fact, although mouse leukocytes have been shown to contain CR1, it has
been shown that mouse RBCs are CR1-negative, in contrast to human RBCs
(Rabellino et al., 1978; Kinoshita et al., 1988). Moreover, recent work carried out with
the rodent malaria laboratory model P. chabaudi showed that rosetting does occur in
mice but suggested that the molecules involved may differ from those in human-
infecting parasite species (Mackinnon et al., 2002).
The results obtained when studying adhesion molecule polymorphisms in relation
to malaria severity were, in all cases described, ambiguous, if not contradictory. This
raises intriguing questions regarding Plasmodium-driven selection as well as important
issues of therapeutic relevance.
3.4 Host’s immune response
Any infectious disease is characterized, at the host level, by a complex reaction from
the host immune system. The counteraction of host invasion by replicating pathogens
demands a rapid response, generally provided by components of the innate immune
system, which develops promptly and precedes the time-consuming clonal expansion
of antigen-specific lymphocytes (Ismail et al., 2002). Recent research has collected
evidence of the importance of innate immunity in shaping the subsequent adaptive
immune response to malaria blood-stage infection. It is now known that during
blood-stage infection there is a ‘cross-talk’ between the parasite and cells of the innate
immune system, such as DC, monocytes/macrophages, natural killer (NK) cells,
NKT cells, and γ6 T cells. The activity of NK cells was found to be high in uncompli-
cated cases of malaria while in patients suffering CM there was a profound depression
of NK activity (Stach et al., 1986). Murine malaria studies also presented evidence that
NK cells play a role in providing protection against the early stages of P. berghei or 
P. chabaudi infections (Solomon et al., 1985; Mohan et al., 1997). Recently, using the
murine model P. berghei ANKA, it was shown that the natural killer complex (NKC)
regulates CM, pulmonary edema and severe anaemia, and influences acquired
immune responses to infection (Hansen et al., 2005).
Although several recent studies have partially elucidated the role of NK cells
during malaria infection (Orago and Facer, 1991; Artavanis-Tsakonas et al., 2003;
Artavanis-Tsakonas and Riley, 2002; Baratin et al., 2005), the ligands and receptors
responsible for NK-cell activation are still unknown. However, there are some data
suggesting an association between NK cell reactivity to P. falciparum-infected RBCs
and killer Ig-like receptors (KIR) genotype (Artavanis-Tsakonas et al., 2003). This
observation raises the fascinating possibility that genetic variation at the KIR locus
might explain heterogeneity of human NK cell responses to parasitized iRBCs and
that the parasite might express ligands to inhibit or activate KIR (Stevenson and Riley,
2004). Nonetheless, these findings highlight the need for large-scale population-based
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studies in order to address associations between KIR genotype, NK responses and
susceptibility to malaria.
The host’s immune response to a malaria infection involves not only molecules
from the rapid innate immune response but also molecules from a more specific
immune response.
IL4. Interleukin-4 (IL4) is a cytokine that regulates the differentiation of precursor T
helper cells into the TH2 subset, which enhance the antigen-presenting capacity of B
cells and specific antibody production (Romagnani, 1995). IL4 serves as an important
regulator in isotype switching from IgM/IgG to IgE. Several studies have pointed
towards IL-4 as an important factor in malaria resistance. A causal relationship
between the activation of IL4-producing T-cell subsets and production of the anti-
Pf155/RESA-specific antibodies in individuals with immunity induced by a 
natural malaria infection has been established (Troye-Blomberg et al., 1990). More
recently, it was shown that in the Fulani (Burkina Faso), known for having a lower
susceptibility to P. falciparum infection than their neighbours, the IL4-524T allele
(SNP C Æ T transition at position −524T from the transcription initiation site) was
associated with high IgG levels against malaria antigens (Luoni et al., 2001). However,
others did not find this association (Verra et al., 2004).
The possible association between three polymorphisms in the IL4 gene with SM in
Ghanaian children has been addressed (Gyan et al., 2004). One of these polymor-
phisms is located in the repeat region (intron3) of the IL4 gene while the other two are
in the promoter region (IL4+33T, SNP at position +33 relative to the transcription
initiation site and the previously mentioned IL4-589T). A significantly higher 
frequency for +33 and −589 loci (IL4+33T/-589T allele) was observed in patients with
CM and this was associated with elevated levels of total IgE.
Studies using the murine P. chabaudi and P. berghei models and IL4-deficient
mice failed to show any role for this molecule in parasitaemia control or resistance to
infection (von der Weid et al., 1994; Saeftel et al., 2004).
CD40L. CD40 ligand (CD40L) is a glycoprotein expressed in activated T cells. When
it binds to CD40 in B cells it regulates their proliferation, antigen-presenting activity
and IgG class switching (Durie et al., 1994). CD40L is encoded by the gene TNFSF5.
The study of CD40L-726 (C/T mutation in the promoter region) and CD40L+220
(C/T mutation in exon 1) polymorphisms association with resistance to SM in P. fal-
ciparum infections led to the observation that Gambian males with the CD40L-726C
allele were protected from CM and severe anaemia (Sabeti et al., 2002). This observa-
tion provides evidence to implicate CD40L as a factor in immunity or pathogenesis of
malaria infections. The role of CD40L in the course of malaria infections was also
explored in P. berghei infection, a mouse model of SM (Piguet et al., 2001). CD40L-
deficient mice are protected from CM, which seems to occur because the
CD40/CD40L system is involved in the breakdown of the blood–brain barrier,
macrophage sequestration and platelet consumption.
Fc receptors. The Fc receptors (FcRs) are a family of cell-surface molecules that bind
the Fc portion of immunoglobulins. FcRs are widely distributed on cells of the immune
system and establish a crucial connection between the humoral and the cellular immune
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responses (Ravetch and Kinet, 1991). There are three families of FcγR (FcγRI, FcγRII
and FcγRIII) that contain multiple distinct genes and alternative splicing forms. Few
studies have focused on polymorphisms in different FcγRs. The FcγRIIA presents a
polymorphism at position 131 that consists of a single histidine Æ arginine amino acid
substitution (FcγRIIA-131H/R). It was shown that infants with the FcγRIIA-R/R
genotype were significantly less likely to be at risk from high-density P. falciparum
infection, compared with infants with the FcγRIIA-H/R. A later study focused on
this same polymorphism and on another receptor polymorphism, FcγRIIIB-NA1/
NA2, known to influence the phagocytic capacity of neutrophils (Omi et al., 2002).
This work, performed in northwest Thailand, has shown that malaria severity in this
area is not associated with the FcγRIIA-131H/R or the FcγRIIIB-NA1/NA2 poly-
morphisms individually. However, the FcγRIIIB-NA2 allele together with the geno-
type FcγRIIA-131H/H was shown to be associated with susceptibility to CM. It has
been also shown that in West Africa the polymorphism FcγRIIA-131H/R is related to
disease severity since the FcγRIIA-131H/H genotype is significantly associated with
increased susceptibility to SM (Cooke et al., 2003).
The importance of Fc receptors in a malaria infection was addressed using transgenic
mice in two different studies using P. yoelii yoelii and P. berghei XAT rodent models
that showed that host resistance is mediated by antibodies (Rotman et al., 1998;
Yoneto et al., 2001). Overall, the different studies indicate that Fc receptors have an
important role in malaria infections.
TNF-a. Tumour necrosis factor-α (TNF-α) is a pro-inflammatory cytokine, produced
by macrophages, NK cells and T cells, involved in local inflammation and endothelial
activation (Janeway, 2001). This cytokine plays a pivotal role in the modulation of
immune functions to infection and it was shown to limit the spread of pathogens
(reviewed in Beutler and Grau, 1993). In a malaria infection TNF-α production by
monocytes/macrophages mainly occurs during the blood stage when RBCs rupture
and the schizonts, together with parasite-soluble antigens, are released into the blood-
stream (Bate et al., 1988; Kwiatkowski et al., 1989; Taverne et al., 1990a, 1990b;
Pichyangkul et al., 1994; Kwiatkowski, 1995).
TNF-α’s role in malaria has been extensively studied and both a protective and 
a pathogenic role for this cytokine have been observed during infection. TNF-α’s
dual actions are related to its ability to activate endothelial cells, leading to the release
of pro-inflammatory cytokines (Pober and Cotran, 1990), to the impairment of the
blood–brain barrier (Sharief et al., 1992; Sharief and Thompson, 1992) and to the 
up-regulation of adhesion molecules (reviewed in Meager, 1999). Of all up-regulated
adhesion molecules, TNF-α’s interplay with ICAM-1 seems to be extremely impor-
tant to malaria pathogenesis (Dietrich, 2002; reviewed in Gimenez et al., 2003). TNF-
α also induces nitric oxide (NO) release by endothelial cells (Lamas et al., 1991;
Rockett et al., 1992) which seems to play an important role during malaria infections
(see NO section below). TNF-α was shown to play a beneficial role by inhibiting 
P. falciparum growth in vitro (Haidaris et al., 1983; Rockett et al., 1988). However,
this effect was not observed using recombinant TNF (Taverne et al., 1987). TNF was
also reported to inhibit infection in murine malaria in vivo (Clark et al., 1987; Taverne
et al., 1987). These and other later studies suggest that TNF is important in the control
of malarial parasites (Ferrante et al., 1990; Kumaratilake et al., 1997). Nevertheless,
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TNF-α has also an important role in SM pathogenesis (reviewed in Richards, 1997;
Mazier et al., 2000; Odeh, 2001; Gimenez et al., 2003; Clark et al., 2004). High TNF-
α levels and malaria severity have been associated in several clinical studies (Grau 
et al., 1989b; Kwiatkowski et al., 1990; el-Nashar et al., 2002; Esamai et al., 2003) and
the ratio of the antagonistic cytokines TNF-α and Interleukin-10 (IL-10) has been
shown to be important to the outcome of malaria infection (May et al., 2000) (see IL-10
section). It was shown that the balance between the protective and pathological
actions of TNF-α depends on several factors, namely the amount, timing, and dura-
tion of TNF-α production, as well as the organ-specific site of synthesis (Beutler and
Cerami, 1988; Jacobs et al., 1996b).
TNF-α’s unquestionable role in malaria pathogenesis has led to research focused on
TNF polymorphisms and their association with malaria severity. Several polymorphisms
in the TNF gene, with special emphasis for 2 promoter polymorphism, the TNF-308 
and TNF-238, located -308 and -238 nucleotides relative to the gene transcriptional 
start, have been shown to be important for infection severity (McGuire et al., 1994;
Wattavidanage et al., 1999; Aidoo et al., 2001; Wilson et al., 1997; Abraham and Kroeger,
1999; McGuire et al., 1999; Knight et al., 1999; Meyer et al., 2002; Mombo et al., 2003;
Flori et al., 2003). While many studies suggest a positive association between the men-
tioned TNF-α polymorphisms and malaria severity, other studies have failed to find
these associations (Ubalee et al., 2001; Stirnadel et al., 1999; Bayley et al., 2004).
However, most evidence supports the idea that TNF polymorphisms may be part of the
genetic determinants for human malaria resistance/susceptibility. More studies and func-
tional analysis need to be carried out in order to understand the mechanisms involved.
Nevertheless the TNF polymorphisms studies performed to date have provided more
biological evidence for the role of TNF-α in human malaria.
A different set of studies, following a more therapeutic approach, has assessed the
clinical outcome of SM using antibodies to neutralize TNF-α levels (Kwiatkowski 
et al., 1993; van Hensbroek et al., 1996; Looareesuwan et al., 1999; Jacobs et al.,
1996b; Hermsen et al., 1997; Grau et al., 1987) and pentoxifylline to inhibit TNF-α
(Sullivan et al., 1988; Strieter et al., 1988; Kremsner et al., 1991; Stoltenburg-
Didinger et al., 1993; Di Perri et al., 1995; Hemmer et al., 1997; Looareesuwan et al.,
1998; Das et al., 2003) both in human infections and rodent models of infection. A
recent report explores a new way to treat CM by inhibiting TNF-α through the use
of LMP-420, an anti-inflammatory drug (Wassmer et al., 2005). Data from this
report suggest that LMP-420, through the inhibition of endothelial activation, should
be considered as a potential way to treat CM. However, the experimental results were
based only on in vitro assays and further in vivo experiments are required to assess
LMP-420 as a new therapeutic treatment. 
While some observations suggest that TNF-α inhibition therapies would be of
great value for malaria pathology control, others show that they may not hold any
benefit. This lack of consensus may reflect the dual action that TNF-α seems to
have during malaria infection.
IFN-g. Interferon-γ (IFN-γ), mainly produced by NK cells and helper T cells is 
a pro-inflammatory cytokine involved in macrophage activation, Ig class switching,
increased expression of MHC molecules and antigen processing components (Mohan
et al., 1997; Janeway et al., 2001; Seixas et al., 2002). IFN-γ plays a central role in the
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immune response to several infectious diseases (Pfefferkorn and Guyre, 1984; Suzuki
et al., 1988; Rossi-Bergmann et al., 1993; van den Broek et al., 1995).
IFN-γ has been shown to be produced during malaria infections (Brake et al., 1988;
Meding et al., 1990; Waki et al., 1992; Mohan et al., 1997; Artavanis-Tsakonas et al., 2003;
Artavanis-Tsakonas and Riley, 2002; Hailu et al., 2004), and both a protective and 
a pathological function have been reported. Concerning its protective effect, it was
demonstrated that an early IFN-γ-driven Th1-type response is required for an effective
control of parasite multiplication in a primary blood-stage infection (Clark, 1987; Shear
et al., 1989; Stevenson et al., 1990b; Taylor-Robinson, 1995; Favre et al., 1997;
Choudhury et al., 2000; Kobayashi et al., 2000). During infection, IFN-γ activates mono-
cytes/macrophages (Bate et al., 1988) and neutrophils (Kumaratilake et al., 1991), which
were shown to be involved in the recognition and removal of either merozoites or iRBCs
(Khusmith et al., 1982; Kharazmi et al., 1984; Kharazmi and Jepsen, 1984; Ockenhouse
et al., 1984; Bouharoun-Tayoun et al., 1995). This protective effect is strongly supported
by several studies with rodent models using exogenous IFN-γ (Clark, 1987; Shear et al.,
1989) or an anti-IFN-γ mouse antibody (Kobayashi et al., 2000). Furthermore, others
have shown a correlation between IFN-γ production and a more positive outcome of
malaria infections in both P. chabaudi and P. yoelii (Shear et al., 1989; Stevenson et al.,
1990a). Endogenous IFN-γ has also been shown to play a role in the development of pro-
tective immunity using IFN-γ and IFN-γ receptor-deficient mice (van der Heyde et al.,
1997; Favre et al., 1997). Altogether, these studies with different mouse strains combined
with different Plasmodium spp. support a beneficial role for IFN-γ. Several human stud-
ies also point toward a protective role for IFN-γ in a malaria infection (Luty et al., 1999;
Torre et al., 2001, 2002).
Despite this, several studies have clearly linked IFN-γ to the onset of pathology in
mice as well as in humans. The detrimental effects of IFN-γ are thought to be due to its
ability to activate macrophages, which, in turn, produce TNF-α, IL-1 and IL-6, leading
to activation of an inflammatory cascade (Kern et al., 1989; Day et al., 1999). Grau et al.
(1989a) showed that treatment of P. berghei ANKA CBA infected mice with a neutral-
izing anti-IFN-γ mouse antibody prevented development of CM and was associated
with a significant decrease of TNF-α serum levels. This study supports the idea that there
may be a fine balance between the levels of IFN-γ and TNF-α and protective immunity
or pathological consequences. Furthermore, a synergy between IFN-γ and TNF-α, 
particularly with respect to the effects on endothelial cells, has also been observed (Pober
et al., 1986). Additional data correlating IFN-γ production with the susceptibility to CM
are provided by the observation that CM-susceptible mice exhibit a preferential expan-
sion of Th1-like clones characterized by a marked production of IFN-γ (de Kossodo and
Grau, 1993). In addition, IFN-γ receptor deficient mice are completely protected from
CM (Rudin et al., 1997; Amani et al., 2000). IFN-γ association with malaria pathology 
in humans is based on the fact that patients with acute P. falciparum malaria present 
high IFN-γ serum levels (Ringwald et al., 1991; Ho et al., 1995; Wenisch et al., 1995;
Nagamine et al., 2003) and individuals at risk for SM produce more IFN-γ in an antigen-
specific manner (Chizzolini et al., 1990; Riley et al., 1991).
IFN-γ and its receptor are encoded by the IFNG and IFNGR1 genes, respectively.
It was shown that in the Mandika, the predominant Gambian ethnic group, those 
that are heterozygous for IFNGR1-56 polymorphism (SNP at position -56 (TÆC) in
the promoter region), presented a two-fold protection against CM and a four-fold
MIGUEL PRUDÊNCIO, CRISTINA D. RODRIGUES AND MARIA M. MOTA 63
protection against death resulting from CM (Koch et al., 2002). Later, it was shown
that this polymorphic allele reduces IFNGR1 gene expression (Juliger et al., 2003).
Only recently has research focused on IFNG polymorphisms. SNPs in the region
of IFNG and the neighbouring IL22 and IL26 genes were analysed but no evidence
of a strong association between SM and IFNG markers was found (Koch et al., 2005).
Recently it was shown that in children from Mali the −183T allele is associated with 
a lower risk of CM (Cabantous et al., 2005). This allele is the polymorphic form of the
IFNG-183G/T (G replaced by a T) polymorphism located in the gene promoter
region and has been shown to create an AP1-binding site for a nuclear transcription
factor, leading to the increase of gene transcription (Bream et al., 2002; Chevillard 
et al., 2002). IFN-γ clearly plays an important role during malaria infection, which can
lead towards protection or pathology. The knowledge of IFN-γ exact involvement in
malaria is important for the understanding of infection progression and, consequently,
for the assessment of possible therapies against malaria.
NO. Nitric oxide (NO), a labile and highly reactive gas, results from the oxidative
deamination of L-arginine to produce L-citruline through a reaction catalysed by the
enzyme inducible nitric oxide synthase (iNOS) (Leone et al., 1991). NO has been
shown to inhibit the growth and function of diverse infectious agents, such as bacte-
ria, fungi and protozoan parasites, by inactivating some of their critical metabolic
pathways (reviewed in James, 1995). Increased NO production has been reported in
murine (Taylor-Robinson et al., 1993; Jacobs et al., 1995) and human infections
(Kremsner et al., 1996). NO is produced by macrophages (Ahvazi et al., 1995; Tachado
et al., 1996) but also by hepatocytes (Mellouk et al., 1991; Nussler et al., 1991) and
endothelial cells (Oswald et al., 1994; Tachado et al., 1996). Cytokines such as IFN-γ and
TNF-α are critical for the regulation of NO production (Jacobs et al., 1996a). Tachado
et al. (1996) demonstrated that glycosylphosphatidylinositols (GPI) induce NO
release in a time- and dose-dependent manner in macrophages and vascular endothelial
cells, and regulate iNOS expression in macrophages. In addition, it was shown that
another parasite metabolite, haemozoin, is able to increase IFN-γ-dependent NO pro-
duction by macrophages (Jaramillo et al., 2003).
Both beneficial and pathological roles have been assigned to NO during malaria
infection (Sobolewski et al., 2005a). It is generally accepted that NO kills intraery-
throcytic malarial parasites (Brunet, 2001; Clark and Cowden, 2003; Stevenson and
Riley, 2004). However, it has been recently proposed that the blood stages are virtu-
ally immune to the cytotoxic effects of NO and other reactive oxygen species as 
a consequence of Hb NO scavenging and reactive oxygen species (ROS) suppression
within RBCs (Sobolewski et al., 2005b). Excess of NO can also contribute to malar-
ial immunosuppression (Rockett et al., 1994; Ahvazi et al., 1995) as well as to CM
development in P. falciparum infections (Clark et al., 1991; Al Yaman et al., 1996). 
It was proposed that overproduction of NO in the brain might affect local neuronal
function by mimicking and exaggerating the physiological effects of endogenous NO
(Clark and Cowden, 2003; Clark et al., 1992). However, this hypothesis is not 
consensual as there is evidence suggesting that NO production may be limited in
malaria due to the presence of hypoargininaemia in patients (Lopansri et al., 2003).
Furthermore, both plasma and urine NOx levels, as well as the iNOS protein and
mRNA levels, correlate inversely with disease severity (Anstey et al., 1996; Boutlis 
et al., 2003; Perkins et al., 1999; Chiwakata et al., 2000).
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A genomic approach, based on the association of iNOS gene polymorphisms with
malaria infection has been applied to address NO role in malaria. Two SNPs, −954G
Æ C and −1173 C Æ T, and a pentanucleotide (CCTTT) polymorphism have been
studied in terms of malaria clinical outcome. However, reports show controversial
data regarding the association of these iNOS gene promoter polymorphisms with
severe P. falciparum malaria. Several reports show that NOS2A-954C allele is associ-
ated with protection from SM and resistance to reinfection both in Gabon and
Uganda (Kun et al., 1998, 2001; Parikh et al., 2004). However, data from The Gambia,
Tanzania and Ghana did not detect this association (Levesque et al., 1999; Burgner 
et al., 2003; Cramer et al., 2004). A protective role for the iNOS -1173 C Æ T poly-
morphism has been shown in Tanzania (Hobbs et al., 2002) but not in The Gambia
and Ghana (Burgner et al., 2003; Cramer et al., 2004). Both these SNPs were shown
to increase NO synthesis (Kun et al., 2001; Hobbs et al., 2002).
A pentanucleotide (CCTTT) microsatellite -2,5 kb of the transcription start site
has also been studied. Short microsatellites (<11) have been shown to occur more 
frequently in fatal CM in The Gambia (Burgner et al., 1998) while longer microsatel-
lite alleles (≥13) were shown to be associated with SM in Thailand and Ghana (Ohashi
et al., 2002; Cramer et al., 2004).
These contradictory results may be explained by the fact that the studies reported
were carried out in different regions and again by the dual effect that host some mol-
ecules seem to have during malaria infection.
IL-10. Interleukin-10 (IL-10) is an anti-inflammatory cytokine produced by 
T cells and macrophages (Janeway et al., 2001). Expression of IL-10 was shown to
increase in response to high TNF-α levels and to down-regulate the production of the
latter in vivo (Gerard et al., 1993; Howard et al., 1993), possibly representing an
attempt of the host to counteract excessive activity of pro-inflammatory cytokines
(van der Poll et al., 1994).
Evidence for a beneficial role of IL-10 in malaria stems from an array of different
population-based and animal model-based studies. IL-10-deficient mice infected with
the rodent model parasite P. chabaudi chabaudi have been shown to have higher 
disease severity and mortality than their wild-type counterparts (Li et al., 1999, 2003;
Sanni et al., 2004). The levels of both IL-10 and TNF-α are increased in patients with
SM (Day et al., 1999). Several studies have attempted to correlate the IL-10:TNF-α
ratio with disease severity (Kurtzhals et al., 1998; Day et al., 1999; Kurtzhals et al.,
1999; May et al., 2000; Nussenblatt et al., 2001). The general consensus seems to be
that ratios <1 constitute a risk factor for severe anaemia, suggesting that an imbalance
between the anti- and the pro-inflammatory responses may constitute a determinant
of mortality. Furthermore, a study involving the simian model parasites P. cynomolgi
and P. knowlesi, a role for IL-10 in controlling anaemia during primary infection has
been suggested (Praba-Egge et al., 2002).
The available evidence of a protective role for IL-10 against malaria would suggest
that strategies to increase the production of this cytokine might hold therapeutic
value. However, this may be less simple than it appears. Studies with rodent models
have shown that an early pro-inflammatory response may be required to enhance the
mechanisms that are essential for elimination of the parasites (Shear et al., 1989;
Stevenson et al., 1995; De Souza et al., 1997). In fact, a positive correlation between
the IL-10 levels and parasitaemia in P. falciparum-infected individuals before the start
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of anti-malarial treatment has been found (Luty et al., 2000). These results were
extended in a recent study that showed a clear association between IL-10 levels and
reduced parasite clearance ability in a Tanzanian population undergoing four differ-
ent treatment regimens with distinct parasite clearance rates (Hugosson et al., 2004).
In another study using the rodent parasite model P. yoelii yoelii, it was found that
mice injected with anti-IL-10 antibody had significantly prolonged survival, suggest-
ing that IL-10 is associated with disease exacerbation rather than protection. Taken
together, these observations indicate that enhancing the level of IL-10 might actually
be beneficial for the parasite since it could interfere with production of pro-inflam-
matory cytokines and enable Plasmodium to escape effective killing (Hugosson et al.,
2004).
Genetic factors substantially influence production of cytokines and may 
account for as much as 75% of inter-individual differences in IL-10 production
(Westendorp et al., 1997). Furthermore, a clear association exists between a variety of
IL-10 polymorphisms and susceptibility to several inflammatory diseases, such as
rheumatoid arthritis (Eskdale et al., 1998) and systemic lupus erythematosus (Gibson
et al., 2001). Thus, the possible correlation between five IL-10 polymorphisms (defining
six haplotypes) and malaria severity in a population in The Gambia was investigated
(Wilson et al., 2005). One of these haplotypes, termed HAP3, defined by three SNPs
at positions +4949, −1117 and −3585, showed a significant association with protection
against CM and severe anaemia. However, this case-control association between
malaria and HAP3 was not confirmed by a transmission disequilibrium test analysis
of the same population. No evidence was found of a correlation between disease
severity and any of the individual polymorphisms under study, suggesting that resist-
ance either depends on other SNPs not addressed in this study or on specific combi-
nations of IL10 polymorphisms (Wilson et al., 2005).
It seems clear that a certain level of IL-10 is required to balance the effect of pro-
inflammatory cytokines. Still, an early pro-inflammatory response may be required
to enhance the mechanisms that are essential for elimination of the parasites The bal-
ance between pro- and anti-inflammatory cytokines during a malaria infection is
clearly difficult to ascertain and has important consequences in terms of disease pro-
gression. If it is true that fine tuning the inflammatory responses during disease
appears as an attractive way to improve its outcome, it is nonetheless obvious that our
current knowledge of the complex immunological response that takes place during
infection needs to be improved before this can be done in a manner that ensures a
promising outcome.
4 Final remarks: exploring the host potential in the ‘post-omics era’
The contact between Plasmodium and its mammalian host involves a number of inter-
actions that result in a series of different scenarios that range from complete or partial
protection to infection and/or disease to SM leading to death. Both sides of this rela-
tionship are quite variable and many different possibilities of interaction may occur in
the same population. Still, the survival of the Plasmodium parasite depends not only
on its interaction with host molecules but also on efficiently coping with the host’s
immune responses. Thus, not only host-driven genetic selection acts on malaria para-
site populations, but also Plasmodium is likely to exert evolutionary pressure on
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human gene frequencies. In malaria endemic regions, we might guess that infection
contributes positively to the allele frequency of variants associated with protection.
The gene conferring the Duffy blood group is one of the most striking examples of
this selection pressure; people of this blood type are completely resistant to P. vivax
blood-stage infection, as they lack a RBC receptor required for P. vivax invasion
(Hamblin and Di Rienzo, 2000; Chitnis and Miller, 1994). Another striking example is
the sickle cell anaemia allele. While severely deleterious in the homozygous state, this
allele is associated with malaria protection in the heterozygous state, although the pro-
tection mechanisms involved are not fully understood (Aidoo et al., 2002). Importantly,
as one might expect, host components involved in the symptomatic phase of infection
(blood stage) do not seem to be the only ones implicated in determining the severity
of malaria infection. In fact, some alleles on the MHC Class I B53 loci are associated
with protective clinical responses in African populations, due to interactions occurring
during the silent liver stage of infection (Hill et al., 1991). Presumably this association
has contributed to the high frequency of MHC-B53 observed in populations living in
areas of high malaria endemicity. Moreover, one should keep in mind that the blood
and liver stages of infection can coexist in populations living in endemic areas.
Therefore, the final result observed in human populations should not be extrapolated
without taking into account possible interactions or common pathways that may
occur between the two infection stages.
The sequence of both mice (rodent models of malaria infection) and human
genomes can prove to be very useful. Moreover, the use of high-throughput tech-
nologies to determine the host molecules altered during the course of an infection,
already used for some systems with interesting results (Delahaye et al., 2006), together
with systems that allow functional genomics studies, such as RNA interference, will be
powerful tools to determine the role of these host molecules during the course of
malaria infections.
References
Abraham, L.J. & Kroeger, K.M. (1999) Impact of the -308 TNF promoter polymor-
phism on the transcriptional regulation of the TNF gene: relevance to disease. 
J Leukoc Bio, 66: 562–566.
Adams, S., Turner, G.D., Nash, G.B., Micklem, K., Newbold, C.I. & Craig, A.G.
(2000) Differential binding of clonal variants of Plasmodium falciparum to allelic
forms of intracellular adhesion molecule 1 determined by flow adhesion assay.
Infect Immun 68: 264–269.
Agarwal, A., Guindo, A., Cissoko, Y., Taylor, J.G., Coulibaly, D., Kone, A.,
Kayentao, K., Djimde, A., Plowe, C.V., Doumbo, O., Wellems, T.E. & Diallo, D.
(2000) Hemoglobin C associated with protection from severe malaria in the
Dogon of Mali, a West African population with a low prevalence of hemoglobin S.
Blood 96: 2358–2363.
Ahvazi, B.C., Jacobs, P. & Stevenson, M.M. (1995) Role of macrophage-derived
nitric oxide in suppression of lymphocyte proliferation during blood-stage
malaria. J Leukoc Biol 58: 23–31.
Aidoo, M., McElroy, P.D., Kolczak, M.S., Terlouw, D.J., Ter kuile, F.O., Nahlen, B.,
Lal, A.A. & Udhayakumar, V. (2001) Tumor necrosis factor-alpha promoter
MIGUEL PRUDÊNCIO, CRISTINA D. RODRIGUES AND MARIA M. MOTA 67
variant 2 (TNF2) is associated with pre-term delivery, infant mortality, and
malaria morbidity in western Kenya: Asembo Bay Cohort Project IX. Genet 
Epidemiol 21: 201–211.
Aidoo, M., Terlouw, D.J., Kolczak, M.S., McElroy, P.D., Ter kuile, F.O., 
Kariuki, S., Nahlen, B.L., Lal, A.A. & Udhayakumar, V. (2002) Protective
effects of the sickle cell gene against malaria morbidity and mortality. Lancet
359: 1311–1312.
Aitman, T.J., Cooper, L.D., Norsworthy, P.J., Wahid, F.N., Gray, J.K., 
Curtis, B.R., Mckeigue, P.M., Kwiatkowski, D., Greenwood, B.M., Snow, R.W.,
Hill, A.V. & Scott, J. (2000) Malaria susceptibility and CD36 mutation. Nature 405:
1015–1016.
Al yaman, F.M., Mokela, D., Genton, B., Rockett, K.A., Alpers, M.P. & Clark, I.A.
(1996) Association between serum levels of reactive nitrogen intermediates and
coma in children with cerebral malaria in Papua New Guinea. Trans R Soc Trop
Med Hyg 90: 270–273.
Allen, S.J., O’Donnell, A., Alexander, N.D., Mgone, C.S., Peto, T.E., Clegg, J.B.,
Alpers, M.P. & Weatherall, D.J. (1999) Prevention of cerebral malaria in children
in Papua New Guinea by southeast Asian ovalocytosis band 3. Am J Trop Med
Hyg 60: 1056–1060.
Alper, S.L., Darman, R.B., Chernova, M.N. & Dahl, N.K. (2002) The AE gene
family of Cl/HCO3- exchangers. J Nephrol 15: suppl 5, s41–s53.
Amani, V., Vigario, A.M., Belnoue, E., Marussig, M., Fonseca, L., Mazier, D. &
Renia, L. (2000) Involvement of IFN-gamma receptor-medicated signaling in
pathology and anti-malarial immunity induced by Plasmodium berghei infection.
Eur J Immunol 30: 1646–1655.
Amodu, O.K., Gbadegesin, R.A., Ralph, S.A., Adeyemo, A.A., Brenchley, P.E.,
Ayoola, O.O., Orimadegun, A.E., Akinsola, A.K., Olumese, P.E. & 
Omotade, O.O. (2005) Plasmodium falciparum malaria in south-west Nigerian
children: is the polymorphism of ICAM-1 and E-selectin genes contributing to
the clinical severity of malaria? Acta Trop 95: 248–255.
Andrews, K.T. & Lanzer, M. (2002) Maternal malaria: Plasmodium falciparum
sequestration in the placenta. Parasitol Res 88: 715–723.
Anstey, N.M., Weinberg, J.B., Hassanali, M.Y., Mwaikambo, E.D., Manyenga, D.,
Misukonis, M.A., Arnelle, D.R., Hollis, D., Mcdonald, M.I. & Granger, D.L.
(1996) Nitric oxide in Tanzanian children with malaria: inverse relationship
between malaria severity and nitric oxide production/nitric oxide synthase type 2
expression. J Exp Med 184: 557–567.
Arie, T., Fairhurst, R.M., Brittain, N.J., Wellems, T.E. & Dvorak, J.A. (2005)
Hemoglobin C modulates the surface topography of Plasmodium falciparum-
infected erythrocytes. J Struct Biol 150: 163–169.
Artavanis-Tsakonas, K. & Riley, E.M. (2002) Innate immune response to malaria:
rapid induction of IFN-gamma from human NK cells by live Plasmodium falci-
parum-infected erythrocytes. J Immunol 169: 2956–2963.
Artavanis-Tsakonas, K., Eleme, K., McQueen, K.L., Cheng, N.W., Parham, P.,
Davis, D.M. & Riley, E.M. (2003) Activation of a subset of human NK cells upon
contact with Plasmodium falciparum-infected erythrocytes. J Immunol 171:
5396–5405.
68 CH. 3. THE RELEVANCE OF HOST GENES IN MALARIA
Ayi, K., Turrini, F., Piga, A. & Arese, P. (2004) Enhanced phagocytosis of ring-
parasitized mutant erythrocytes: a common mechanism that may explain protec-
tion against falciparum malaria in sickle trait and beta-thalassemia trait. Blood 104:
3364–3371.
Baratin, M., Roetynck, S., Lepolard, C., Falk, C., Sawadogo, S., Uematsu, S.,
Akira, S., Ryffel, B., Tiraby, J.G., Alexopoulou, L., Kirschning, C.J., Gysin, J.,
Vivier, E. & Ugolini, S. (2005) Natural killer cell and macrophage cooperation in
MyD88-dependent innate responses to Plasmodium falciparum. Proc Natl Acad
Sci USA 102: 14747–14752.
Barnwell, J.W., Ockenhouse, C.F. & Knowles, D.M., 2nd (1985) Monoclonal 
antibody OKM5 inhibits the in vitro binding of Plasmodium falciparum-infected
erythrocytes to monocytes, endothelial, and C32 melanoma cells. J Immunol
135: 3494–3497.
Barnwell, J.W., Asch, A.S., Nachman, R.L., Yamaya, M., Aikawa, M. &
Ingravallo, P. (1989) A human 88-kD membrane glycoprotein (CD36) functions
in vitro as a receptor for a cytoadherence ligand on Plasmodium falciparum-
infected erythrocytes. J Clin Invest 84: 765–772.
Baruch, D.I., Ma, X.C., Singh, H.B., Bi, X, Pasloske, B.L. & Howard, R.J. (1997)
Identification of a region of PfEMP1 that mediates adherence of Plasmodium 
falciparum infected erythrocytes to CD36: conserved function with variant
sequence. Blood 90: 3766–3775.
Bate, C.A., Taverne, J. & Playfair, J.H. (1988) Malarial parasites induce TNF 
production by macrophages. Immunology 64: 227–231.
Baum, J., Pinder, M. & Conway, D.J. (2003) Erythrocyte invasion phenotypes of
Plasmodium falciparum in The Gambia. Infect Immun 71: 1856–1863.
Bayley, J.P., Ottenhoff, T.H. & Verweij, C.L. (2004) Is there a future for TNF 
promoter polymorphisms? Genes Immun 5: 315–329.
Beeson, J.G. & Brown, G.V. (2002) Pathogenesis of Plasmodium falciparum malaria:
the roles of parasite adhesion and antigenic variation. Cell Mol Life Sci 59: 258–271.
Beeson, J.G., Reeder, J.C., Rogerson, S.J. & Brown, G.V. (2001) Parasite adhesion
and immune evasion in placental malaria. Trends Parasitol 17: 331–337.
Beeson, J.G., Rogerson, S.J. & Brown, G.V. (2002) Evaluating specific adhesion of
Plasmodium falciparum-infected erythrocytes to immobilized hyaluronic acid
with comparison to binding of mammalian cells. Int J Parasitol 32: 1245–1252.
Bellamy, R., Kwiatkowski, D. & Hill, A.V. (1998) Absence of an association
between intercellular adhesion molecule 1, complement receptor 1 and interleukin
1 receptor antagonist gene polymorphisms and severe malaria in a West African
population. Trans R Soc Trop Med Hyg 92: 312–316.
Berendt, A.R., Simmons, D.L., Tansey, J., Newbold, C.I. & Marsh, K. (1989)
Intercellular adhesion molecule-1 is an endothelial cell adhesion receptor for
Plasmodium falciparum. Nature 341: 57–59.
Beutler, B. & Cerami, A. (1988) Tumor necrosis, cachexia, shock, and inflammation:
a common mediator. Annu Rev Biochem 57: 505–518.
Beutler, B. & Grau, G.E. (1993) Tumor necrosis factor in the pathogenesis of infec-
tious diseases. Crit Care Med 21: S423–S435.
Beutler, E. (1990) The genetics of glucose-6-phosphate dehydrogenase deficiency.
Semin Hematol 27: 137–164.
MIGUEL PRUDÊNCIO, CRISTINA D. RODRIGUES AND MARIA M. MOTA 69
Beutler, E. (1996) G6PD: population genetics and clinical manifestations. Blood Rev
10: 45–52.
Bodescot, M., Silvie, O., Siau, A., Refour, P., Pino, P., Franetich, J.F., Hannoun, L.,
Sauerwein, R. & Mazier, D. (2004) Transcription status of vaccine candidate
genes of Plasmodium falciparum during the hepatic phase of its life cycle. Parasitol
Res 92: 449–452.
Bouharoun-Tayoun, H., Oeuvray, C., Lunel, F. & Druilhe, P. (1995) Mechanisms
underlying the monocyte-mediated antibody-dependent killing of Plasmodium
falciparum asexual blood stages. J Exp Med 182: 409–418.
Boutlis, C.S., Tjitra, E., Maniboey, H., Misukonis, M.A., Saunders, J.R., Suprianto, S.,
Weinberg, J.B. & Anstey, N.M. (2003) Nitric oxide production and mononuclear
cell nitric oxide synthase activity in malaria-tolerant Papuan adults. Infect Immun
71: 3682–3689.
Brake, D.A., Long, C.A. & Weidanz, W.P. (1988) Adoptive protection against
Plasmodium chabaudi adami malaria in athymic nude mice by a cloned T cell line.
J Immunol 140: 1989–1993.
Bream, J.H., Ping, A., Zhang, X., Winkler, C. & Young, H.A. (2002) A single
nucleotide polymorphism in the proximal IFN-gamma promoter alters control of
gene transcription. Genes Immun 3: 165–169.
Brittenham, G.M., Schechter, A.N. & Noguchi, C.T. (1985) Hemoglobin S poly-
merization: primary determinant of the hemolytic and clinical severity of the sick-
ling syndromes. Blood 65: 183–189.
Bruna-Romero, O. & Rodriguez, A. (2001) Dendritic cells can initiate protective
immune responses against malaria. Infect Immun 69: 5173–5176.
Brunet, L.R. (2001) Nitric oxide in parasitic infections. Int Immunopharmacol 1:
1457–1467.
Burgner, D., Xu, W., Rockett, K., Gravenor, M., Charles, I.G., Hill, A.V. &
Kwiatkowski, D. (1998) Inducible nitric oxide synthase polymorphism and fatal
cerebral malaria. Lancet 352: 1193–1194.
Burgner, D., Usen, S., Rockett, K., Jallow, M., Ackerman, H., Cervino, A., Pinder, M.
& Kwiatkowski, D.P. (2003) Nucleotide and haplotypic diversity of the NOS2A
promoter region and its relationship to cerebral malaria. Hum Genet 112: 379–386.
Cabantous, S., Poudiougou, B., Traore, A., Keita, M., Cisse, M.B., Doumbo, O.,
Dessein, A.J. & Marquet, S. (2005) Evidence that interferon-gamma plays a pro-
tective role during cerebral malaria. J Infect Dis 192: 854–860.
Cappadoro, M., Giribaldi, G., O’Brien, E., Turrini, F., Mannu, F., Ulliers, D., Simula,
G., Luzzatto, L. & Arese, P. (1998) Early phagocytosis of glucose-6-phosphate
dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falci-
parum may explain malaria protection in G6PD deficiency. Blood 92: 2527–2534.
Carrolo, M., Giordano, S., Cabrita-Santos, L., Corso, S., Vigario, A.M., Silva, S.,
Leiriao, P., Carapau, D., Armas-Portela, R., Comoglio, P.M., Rodriguez, A. &
Mota, M.M. (2003) Hepatocyte growth factor and its receptor are required for
malaria infection. Nat Med 9: 1363–1369.
Carvalho, L.J., Daniel-Ribeiro, C.T. & Goto, H. (2002) Malaria vaccine: candidate
antigens, mechanisms, constraints and prospects. Scand J Immunol 56: 327–343.
Casals-Pascual, C., Allen, S., Allen, A., Kai, O., Lowe, B., Pain, A. & Roberts, D.J.
(2001) Short report: codon 125 polymorphism of CD31 and susceptibility to
malaria. Am J Trop Med Hyg 65: 736–737.
70 CH. 3. THE RELEVANCE OF HOST GENES IN MALARIA
Chevillard, C., Henri, S., Stefani, F., Parzy, D. & Dessein, A. (2002) Two new poly-
morphisms in the human interferon gamma (IFN-gamma) promoter. Eur J
Immunogenet 29: 53–56.
Chitnis, C.E. & Miller, L.H. (1994) Identification of the erythrocyte binding
domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in ery-
throcyte invasion. J Exp Med 180: 497–506.
Chiwakata, C.B., Hemmer, C.J. & Dietrich, M. (2000) High levels of inducible
nitric oxide synthase mRNA are associated with increased monocyte counts in
blood and have a beneficial role in Plasmodium falciparum malaria. Infect Immun
68: 394–399.
Chizzolini, C., Grau, G.E., Geinoz, A. & Schrijvers, D. (1990) T lymphocyte inter-
feron-gamma production induced by Plasmodium falciparum antigen is high in
recently infected non-immune and low in immune subjects. Clin Exp Immunol
79: 95–99.
Chotivanich, K., Udomsangpetch, R., Pattanapanyasat, K., Chierakul, W.,
Simpson, J., Looareesuwan, S. & White, N. (2002) Hemoglobin E: a balanced
polymorphism protective against high parasitemias and thus severe P. falciparum
malaria. Blood 100: 1172–1176.
Choudhury, H.R., Sheikh, N.A., Bancroft, G.J., Katz, D.R. & de Souza, J.B. (2000)
Early nonspecific immune responses and immunity to blood-stage nonlethal
Plasmodium yoelii malaria. Infect Immun 68: 6127–6132.
Clark, I.A. (1987) Cell-mediated immunity in protection and pathology of malaria.
Parasitol Today 3: 300–305.
Clark, I.A. & Cowden, W.B. (2003) The pathophysiology of falciparum malaria.
Pharmacol Ther 99: 221–260.
Clark, I.A., Hunt, N.H., Butcher, G.A. & Cowden, W.B. (1987) Inhibition of
murine malaria (Plasmodium chabaudi) in vivo by recombinant interferon-gamma
or tumor necrosis factor, and its enhancement by butylated hydroxyanisole. 
J Immunol 139: 3493–3496.
Clark, I.A., Rockett, K.A. & Cowden, W.B. (1991) Proposed link between
cytokines, nitric oxide and human cerebral malaria. Parasitol Today 7: 205–207.
Clark, I.A., Rockett, K.A. & Cowden, W.B. (1992) Possible central role of nitric
oxide in conditions clinically similar to cerebral malaria. Lancet 340: 894–896.
Clark, I.A., Alleva, L.M., Mills, A.C. & Cowden, W.B. (2004) Pathogenesis of
malaria and clinically similar conditions. Clin Microbiol Rev 17: 509–539, table of
contents.
Clyde, D.F., Most, H., McCarthy, V.C. & Vanderberg, J.P. (1973) Immunization of
man against sporozite-induced falciparum malaria. Am J Med Sci 266: 169–177.
Cockburn, I.A., MacKinnon, M.J., O’Donnell, A., Allen, S.J., Moulds, J.M., Baisor, M.,
Bockarie, M., Reeder, J.C. & Rowe, J.A. (2004) A human complement receptor 1
polymorphism that reduces Plasmodium falciparum rosetting confers protection
against severe malaria. Proc Natl Acad Sci USA 101: 272–277.
Cooke, B.M., Nicoll, C.L., Baruch, D.I. & Coppel, R.L. (1998) A recombinant pep-
tide based on PfEMP-1 blocks and reverses adhesion of malaria-infected red blood
cells to CD36 under flow. Mol Microbiol 30: 83–90.
Cooke, G.S., Aucan, C., Walley, A.J., Segal, S., Greenwood, B.M., Kwiatkowski,
D.P. & Hill, W.V. (2003) Association of Fcgamma receptor IIa (CD32) polymor-
phism with severe malaria in West Africa. Am J Trop Med Hyg 69: 565–568.
MIGUEL PRUDÊNCIO, CRISTINA D. RODRIGUES AND MARIA M. MOTA 71
Craig, A., Fernandez-Reyes, D., Mesri, M., McDowall, A., Altieri, D.C., Hogg, N.
& Newbold, C. (2000) A functional analysis of a natural variant of intercellular
adhesion molecule-1 (ICAM-1Kilifi). Hum Mol Genet 9: 525–530.
Cramer, J.P., Mockenhaupt, F.P., Ehrhardt, S., Burkhardt, J., Otchwemah, R.N.,
Dietz, E., Gellert, S. & Bienzle, U. (2004) iNOS promoter variants and severe
malaria in Ghanaian children. Trop Med Int Health 9: 1074–1080.
Cranston, H.A., Boylan, C.W., Carroll, G.L., Sutera, S.P., Williamson, J.R.,
Gluzman, I.Y. & Krogstad, D.J. (1984) Plasmodium falciparum maturation abol-
ishes physiologic red cell deformability. Science 223: 400–403.
Das, B.K., Mishra, S., Padhi, P.K., Manish, R., Tripathy, R., Sahoo, P.K. &
Ravindran, B. (2003) Pentoxifylline adjunct improves prognosis of human cere-
bral malaria in adults. Trop Med Int Health 8: 680–684.
Day, N.P., Hien, T.T., Schollaardt, T., Loc, P.P., Chuong, L.V., Chau, T.T., 
Mai, N.T., Phu, N.H., Sinh, D.X., White, N.J. & Ho, M. (1999) The prognostic
and pathophysiologic role of pro- and antiinflammatory cytokines in severe
malaria. J Infect Dis 180: 1288–1297.
De Kossodo, S. & Grau, G.E. (1993) Profiles of cytokine production in relation with
susceptibility to cerebral malaria. J Immunol 151: 4811–4820.
De Souza, J.B., Williamson, K.H., Otani, T. & Playfair, J.H. (1997) Early gamma
interferon responses in lethal and nonlethal murine blood-stage malaria. Infect
Immun 65: 1593–1598.
Delahaye, N.F., Coltel, N., Puthier, D., Flori, L., Houlgatte, R., Iraqi, F.A.,
Nguyen, C., Grau, G.E. & Rihet, P. (2006) Gene-expression profiling discrimi-
nates between cerebral malaria (CM)-susceptible mice and CM-resistant mice. 
J Infect Dis 193: 312–321.
Di perri, G., Di perri, I.G., Monteiro, G.B., Bonora, S., Hennig, C., Cassatella, M.,
Micciolo, R., Vento, S., Dusi, S., Bassetti, D. et al. (1995) Pentoxifylline as a 
supportive agent in the treatment of cerebral malaria in children. J Infect Dis 171:
1317–1322.
Dietrich, I.B. (2002) The adhesion molecule ICAM-1 and its regulation in relation
with the blood–brain barrier. J Neuroimmunol 128: 58–68.
Dolan, S.A., Miller, L.H. & Wellems, T.E. (1990) Evidence for a switching mechanism
in the invasion of erythrocytes by Plasmodium falciparum. J Clin Invest 86: 618–624.
Dolan, S.A., Proctor, J.L., Alling, D.W., Okubo, Y., Wellems, T.E. & Miller, L.H.
(1994) Glycophorin B as an EBA-175 independent Plasmodium falciparum recep-
tor of human erythrocytes. Mol Biochem Parasitol 64: 55–63.
Duffy, P.E. & Fried, M. (2003) Plasmodium falciparum adhesion in the placenta.
Curr Opin Microbiol 6: 371–376.
Duraisingh, M.T., Maier, A.G., Triglia, T. & Cowman, A.F. (2003) Erythrocyte-bind-
ing antigen 175 mediates invasion in Plasmodium falciparum utilizing sialic acid-
dependent and -independent pathways. Proc Natl Acad Sci USA 100: 4796–4801.
Durie, F.H., Foy, T.M., Masters, S.R., Laman, J.D. & Noelle, R.J. (1994) The role
of CD40 in the regulation of humoral and cell-mediated immunity. Immunol
Today 15: 406–411.
El-nashar, T.M., El-kholy, H.M., El-shiety, A.G. & Al-zahaby, A.A. (2002)
Correlation of plasma levels of tumor necrosis factor, interleukin-6 and nitric
oxide with the severity of human malaria. J Egypt Soc Parasitol 32: 525–535.
72 CH. 3. THE RELEVANCE OF HOST GENES IN MALARIA
Esamai, F., Ernerudh, J., Janols, H., Welin, S., Ekerfelt, C., Mining, S. & Forsberg, P.
(2003) Cerebral malaria in children: serum and cerebrospinal fluid TNF-alpha and
TGF-beta levels and their relationship to clinical outcome. J Trop Pediatr 49:
216–223.
Eskdale, J., McNicholl, J., Wordsworth, P., Jonas, B., Huizinga, T., Field, M. &
Gallagher, G. (1998) Interleukin-10 microsatellite polymorphisms and IL-10
locus alleles in rheumatoid arthritis susceptibility. Lancet 352: 1282–1283.
Esser, M.T., Marchese, R.D., Kierstead, L.S., Tussey, L.G., Wang, F., Chirmule, N.
& Washabaugh, M.W. (2003) Memory T cells and vaccines. Vaccine 21: 419–430.
Fairhurst, R.M., Baruch, D.I., Brittain, N.J., Ostera, G.R., Wallach, J.S., Hoang,
H.L., Hayton, K., Guindo, A., Makobongo, M.O., Schwartz, O.M., Tounkara,
A., Doumbo, O.K., Diallo, D.A., Fujioka, H., Ho, M. & Wellems, T.E. (2005)
Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may pro-
tect against malaria. Nature 435: 1117–1121.
Favre, N., Ryffel, B., Bordmann, G. & Rudin, W. (1997) The course of Plasmodium
chabaudi chabaudi infections in interferon-gamma receptor deficient mice.
Parasite Immunol 19: 375–383.
Fernandez-Reyes, D., Craig, A.G., Kyes, S.A., Peshu, N., Snow, R.W., Berendt,
A.R., Marsh, K. & Newbold, C.I. (1997) A high frequency African coding poly-
morphism in the N-terminal domain of ICAM-1 predisposing to cerebral malaria
in Kenya. Hum Mol Genet 6: 1357–1360.
Ferrante, A., Kumaratilake, L., Rzepczyk, C.M. & Dayer, J.M. (1990) Killing of
Plasmodium falciparum by cytokine activated effector cells (neutrophils and
macrophages). Immunol Lett 25: 179–187.
Flori, L., Sawadogo, S., Esnault, C., Delahaye, N.F., Fumoux, F. & Rihet, P. (2003)
Linkage of mild malaria to the major histocompatibility complex in families living
in Burkina Faso. Hum Mol Genet 12: 375–378.
Franke-Fayard, B., Janse, C.J., Cunha-Rodrigues, M., Ramesar, J., Buscher, P.,
Que, I., Lowik, C., Voshol, P.J., den Boer, M.A., van Duinen, S.G., Febbraio, M.,
Mota, M.M. & Waters, A.P. (2005) Murine malaria parasite sequestration: CD36
is the major receptor, but cerebral pathology is unlinked to sequestration. Proc
Natl Acad Sci USA 102: 11468–11473.
Frevert, U., Engelmann, S., Zougbede, S., Stange, J., Ng, B., Matuschewski, K.,
Liebes, L. & Yee, H. (2005) Intravital observation of Plasmodium berghei sporo-
zoite infection of the liver. Plos Biol 3: e192.
Genton, B., Al-yaman, F., Mgone, C.S., Alexander, N., Paniu, M.M., Alpers, M.P. &
Mokela, D. (1995) Ovalocytosis and cerebral malaria. Nature 378: 564–565.
Gerard, C., Bruyns, C., Marchant, A., Abramowicz, D., Vandenabeele, P.,
Delvaux, A., Fiers, W., Goldman, M. & Velu, T. (1993) Interleukin 10 reduces
the release of tumor necrosis factor and prevents lethality in experimental endo-
toxemia. J Exp Med 177: 547–550.
Gibson, A.W., Edberg, J.C., Wu, J., Westendorp, R.G., Huizinga, T.W. &
Kimberly, R.P. (2001) Novel single nucleotide polymorphisms in the distal IL-10
promoter affect IL-10 production and enhance the risk of systemic lupus erythe-
matosus. J Immunol 166: 3915–3922.
Gilbert, S.C., Plebanski, M., Gupta, S., Morris, J., Cox, M., Aidoo, M.,
Kwiatkowski, D., Greenwood, B.M., Whittle, H.C. & Hill, A.V. (1998)
MIGUEL PRUDÊNCIO, CRISTINA D. RODRIGUES AND MARIA M. MOTA 73
Association of malaria parasite population structure, HLA, and immunological
antagonism. Science 279: 1173–1177.
Gimenez, F., Barraud de Lagerie, S., Fernandez, C., Pino, P. & Mazier, D. (2003)
Tumor necrosis factor alpha in the pathogenesis of cerebral malaria. Cell Mol Life
Sci 60: 1623–1635.
Grau, G.E., Fajardo, L.F., Piguet, P.F., Allet, B., Lambert, P.H. & Vassalli, P.
(1987) Tumor necrosis factor (cachectin) as an essential mediator in murine cere-
bral malaria. Science 237: 1210–1212.
Grau, G.E., Heremans, H., Piguet, P.F., Pointaire, P., Lambert, P.H., Billiau, A. &
Vassalli, P. (1989a) Monoclonal antibody against interferon gamma can prevent
experimental cerebral malaria and its associated overproduction of tumor necrosis
factor. Proc Natl Acad Sci USA 86: 5572–5574.
Grau, G.E., Taylor, T.E., Molyneux, M.E., Wirima, J.J., Vassalli, P., Hommel, M.
& Lambert, P.H. (1989b) Tumor necrosis factor and disease severity in children
with falciparum malaria. N Engl J Med 320: 1586–1591.
Gruner, A.C., Snounou, G., Brahimi, K., Letourneur, F., Renia, L. & Druilhe, P.
(2003) Pre-erythrocytic antigens of Plasmodium falciparum: from rags to riches?
Trends Parasitol 19: 74–78.
Gyan, B.A., Goka, B., Cvetkovic, J.T., Kurtzhals, J.L., Adabayeri, V., Perlmann, H.,
Lefvert, A.K., Akanmori, B.D. & Troye-Blomberg, M. (2004) Allelic polymor-
phisms in the repeat and promoter regions of the interleukin-4 gene and malaria
severity in Ghanaian children. Clin Exp Immunol 138: 145–150.
Hadley, T.J., Klotz, F.W., Pasvol, G., Haynes, J.D., McGinniss, M.H., Okubo, Y. &
Miller, L.H. (1987) Falciparum malaria parasites invade erythrocytes that lack gly-
cophorin A and B (MkMk). Strain differences indicate receptor heterogeneity and
two pathways for invasion. J Clin Invest 80: 1190–1193.
Haidaris, C.G., Haynes, J.D., Meltzer, M.S. & Allison, A.C. (1983) Serum contain-
ing tumor necrosis factor is cytotoxic for the human malaria parasite Plasmodium
falciparum. Infect Immun 42: 385–393.
Hailu, A., van der Poll, T., Berhe, N. & Kager, P.A. (2004) Elevated plasma levels of
interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma
inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg 71:
561–567.
Hamblin, M.T. & Di Rienzo, A. (2000) Detection of the signature of natural selec-
tion in humans: evidence from the Duffy blood group locus. Am J Hum Genet 66:
1669–1679.
Hamblin, M.T., Thompson, E.E. & Di Rienzo, A. (2002) Complex signatures 
of natural selection at the Duffy blood group locus. Am J Hum Genet 70:
369–383.
Hansen, D.S., Evans, K.J., D’Ombrain, M.C., Bernard, N.J., Sexton, A.C.,
Buckingham, L., Scalzo, A.A. & Schofield, L. (2005) The natural killer complex
regulates severe malarial pathogenesis and influences acquired immune responses
to Plasmodium berghei ANKA. Infect Immun 73:2288–2297.
Heddini, A., Chen, Q., Obiero, J., Kai, O., Fernandez, V., Marsh, K., Muller, W.A.
& Wahlgren, M. (2001a) Binding of Plasmodium falciparum-infected erythro-
cytes to soluble platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31):
frequent recognition by clinical isolates. Am J Trop Med Hyg 65: 47–51.
74 CH. 3. THE RELEVANCE OF HOST GENES IN MALARIA
Heddini, A., Pettersson, F., Kai, O., Shafi, J., Obiero, J., Chen, Q., Barragan, A.,
Wahlgren, M. & Marsh, K. (2001b) Fresh isolates from children with severe
Plasmodium falciparum malaria bind to multiple receptors. Infect Immun 69:
5849–5856.
Hemmer, C.J., Hort, G., Chiwakata, C.B., Seitz, R., Egbring, R., Gaus, W., Hogel, J.,
Hassemer, M., Nawroth, P.P., Kern, P. & Dietrich, M. (1997) Supportive pen-
toxifylline in falciparum malaria: no effect on tumor necrosis factor alpha levels or
clinical outcome: a prospective, randomized, placebo-controlled study. Am J Trop
Med Hyg 56: 397–403.
Hermsen, C.C., Crommert, J.V., Fredix, H., Sauerwein, R.W. & Eling, W.M.
(1997) Circulating tumour necrosis factor alpha is not involved in the development
of cerebral malaria in Plasmodium berghei-infected c57bl mice. Parasite Immunol
19: 571–577.
Herrington, D., Davis, J., Nardin, E., Beier, M., Cortese, J., Eddy, H., Losonsky, G.,
Hollingdale, M., Sztein, M., Levine, M., et al. (1991) Successful immunization of
humans with irradiated malaria sporozoites: humoral and cellular responses of the
protected individuals. Am J Trop Med Hyg 45: 539–547.
Hill, A.V. (2001) The genomics and genetics of human infectious disease susceptibil-
ity. Annu Rev Genomics Hum Genet 2: 373–400.
Hill, A.V., Allsopp, C.E., Kwiatkowski, D., Anstey, N.M., Twumasi, P., Rowe, P.A.,
Bennett, S., Brewster, D., McMichael, A.J. & Greenwood, B.M. (1991) Common
West African HLA antigens are associated with protection from severe malaria.
Nature 352: 595–600.
Hill, A.V., Elvin, J., Willis, A.C., Aidoo, M., Allsopp, C.E., Gotch, F.M., Gao, X.M.,
Takiguchi, M., Greenwood, B.M., Townsend, A.R. et al. (1992) Molecular analy-
sis of the association of HLA-B53 and resistance to severe malaria. Nature 360:
434–439.
Ho, M. & White, N.J. (1999) Molecular mechanisms of cytoadherence in malaria. Am
J Physiol 276: c1231–c1242.
Ho, M., Sexton, M.M., Tongtawe, P., Looareesuwan, S., Suntharasamai, P. &
Webster, H.K. (1995) Interleukin-10 inhibits tumor necrosis factor production
but not antigen-specific lymphoproliferation in acute Plasmodium falciparum
malaria. J Infect Dis 172: 838–844.
Ho, M., Hickey, M.J., Murray, A.G., Andonegui, G. & Kubes, P. (2000)
Visualization of Plasmodium falciparum-endothelium interactions in human
microvasculature: mimicry of leukocyte recruitment. J Exp Med 192: 1205–1211.
Hobbs, M.R., Udhayakumar, V., Levesque, M.C., Booth, J., Roberts, J.M.,
Tkachuk, A.N., Pole, A., Coon, H., Kariuki, S., Nahlen, B.L., Mwaikambo, E.D.,
Lal, A.L., Granger, D.L., Anstey, N.M. & Weinberg, J.B. (2002) A new NOS2
promoter polymorphism associated with increased nitric oxide production and
protection from severe malaria in Tanzanian and Kenyan children. Lancet 360:
1468–1475.
Howard, M., Muchamuel, T., Andrade, S. & Menon, S. (1993) Interleukin 10 pro-
tects mice from lethal endotoxemia. J Exp Med 177: 1205–1208.
Hugosson, E., Montgomery, S.M., Premji, Z., Troye-Blomberg, M. & Bjorkman, A.
(2004) Higher IL-10 levels are associated with less effective clearance of
Plasmodium falciparum parasites. Parasite Immunol 26: 111–117.
MIGUEL PRUDÊNCIO, CRISTINA D. RODRIGUES AND MARIA M. MOTA 75
Ishino, T., Yano, K., Chinzei, Y. & Yuda, M. (2004) Cell-passage activity is required
for the malarial parasite to cross the liver sinusoidal cell layer. Plos Biol 2: e4.
Ismail, N., Olano, J.P., Feng, H.M. & Walker, D.H. (2002) Current status of
immune mechanisms of killing of intracellular microorganisms. Fems Microbiol
Lett 207: 111–120.
Jacobs, P., Radzioch, D. & Stevenson, M.M. (1995) Nitric oxide expression in the
spleen, but not in the liver, correlates with resistance to blood-stage malaria in
mice. J Immunol 155: 5306–5313.
Jacobs, P., Radzioch, D. & Stevenson, M.M. (1996a) In vivo regulation of nitric
oxide production by tumor necrosis factor alpha and gamma interferon, but not
by interleukin-4, during blood stage malaria in mice. Infect Immun 64: 44–49.
Jacobs, P., Radzioch, D. & Stevenson, M.M. (1996b) A Th1-associated increase in
tumor necrosis factor alpha expression in the spleen correlates with resistance to
blood-stage malaria in mice. Infect Immun 64: 535–541.
James, S.L. (1995) Role of nitric oxide in parasitic infections. Microbiol Rev 59:
533–547.
Janeway C.A, T.P., Walport M, Shlomchik M (2001) Cytokines and their receptors.
Immunobiology: The Immune System in Health and Disease, 5 edn. Garland
Science Textbooks, Taylor and Francis, New York and London.
Jaramillo, M., Gowda, D.C., Radzioch, D. & Olivier, M. (2003) Hemozoin
increases IFN-gamma-inducible macrophage nitric oxide generation through
extracellular signal-regulated kinase- and NF-kappa B-dependent pathways. 
J Immunol 171: 4243–4253.
Juliger, S., Bongartz, M., Luty, A.J., Kremsner, P.G. & Kun, J.F. (2003) Functional
analysis of a promoter variant of the gene encoding the interferon-gamma recep-
tor chain I. Immunogenetics 54: 675–680.
Jung, S., Unutmaz, D., Wong, P., Sano, G., De Los Santos, K., Sparwasser, T., Wu, S.,
Vuthoori, S., Ko, K., Zavala, F., Pamer, E.G., Littman, D.R. & Lang, R.A.
(2002) In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+)
t cells by exogenous cell-associated antigens. Immunity 17: 211–220.
Kaul, D.K., Liu, X.D., Nagel, R.L. & Shear, H.L. (1998) Microvascular hemody-
namics and in vivo evidence for the role of intercellular adhesion molecule-1 in the
sequestration of infected red blood cells in a mouse model of lethal malaria. Am 
J Trop Med Hyg 58: 240–247.
Kern, P., Hemmer, C.J., van Damme, J., Gruss, H.J. & Dietrich, M. (1989)
Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for
complicated Plasmodium falciparum malaria. Am J Med 87: 139–143.
Kharazmi, A. & Jepsen, S. (1984) Enhanced inhibition of in vitro multiplication of
Plasmodium falciparum by stimulated human polymorphonuclear leucocytes.
Clin Exp Immunol 57: 287–292.
Kharazmi, A., Jepsen, S. & Valerius, N.H. (1984) Polymorphonuclear leucocytes
defective in oxidative metabolism inhibit in vitro growth of Plasmodium falci-
parum. Evidence against an oxygen-dependent mechanism. Scand J Immunol 20:
93–96.
Khusmith, S., Druilhe, P. & Gentilini, M. (1982) Enhanced Plasmodium falciparum
merozoite phagocytosis by monocytes from immune individuals. Infect Immun
35: 874–879.
76 CH. 3. THE RELEVANCE OF HOST GENES IN MALARIA
Kidson, C., Lamont, G., Saul, A. & Nurse, G.T. (1981) Ovalocytic erythrocytes
from Melanesians are resistant to invasion by malaria parasites in culture. Proc
Natl Acad Sci USA 78: 5829–5832.
Kikuchi, M., Looareesuwan, S., Ubalee, R., Tasanor, O., Suzuki, F., Wattanagoon, Y.,
Na-Bangchang, K., Kimura, A., Aikawa, M. & Hirayama, K. (2001)
Association of adhesion molecule PECAM-1/CD31 polymorphism with suscep-
tibility to cerebral malaria in Thais. Parasitol Int 50: 235–239.
Kinoshita, T., Takeda, J., Hong, K., Kozono, H., Sakai, H. & Inoue, K. (1988)
Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in
a distribution study showing that mouse erythrocytes and platelets are CR1-
negative. J Immunol 140: 3066–3072.
Knight, J.C., Udalova, I., Hill, A.V., Greenwood, B.M., Peshu, N., Marsh, K. &
Kwiatkowski, D. (1999) A polymorphism that affects OCT-1 binding to the TNF
promoter region is associated with severe malaria. Nat Genet 22: 145–150.
Kobayashi, F., Ishida, H., Matsui, T. & Tsuji, M. (2000) Effects of in vivo adminis-
tration of anti-IL:-10 or anti-IFN-gamma monoclonal antibody on the host
defense mechanism against Plasmodium yoelii yoelii infection. J Vet Med Sci 62:
583–587.
Koch, O., Awomoyi, A., Usen, S., Jallow, M., Richardson, A., Hull, J., Pinder, M.,
Newport, M. & Kwiatkowski, D. (2002) IFNGR1 gene promoter polymorphisms
and susceptibility to cerebral malaria. J Infect Dis 185: 1684–1687.
Koch, O., Rockett, K., Jallow, M., Pinder, M., Sisay-Joof, F. & Kwiatkowski, D.
(2005) Investigation of malaria susceptibility determinants in the IFNG/IL26/IL22
genomic region. Genes Immun 6: 312–318.
Kremsner, P.G., Grundmann, H., Neifer, S., Sliwa, K., Sahlmuller, G.,
Hegenscheid, B. & Bienzle, U. (1991) Pentoxifylline prevents murine cerebral
malaria. J Infect Dis 164: 605–608.
Kremsner, P.G., Winkler, S., Wildling, E., Prada, J., Bienzle, U., Graninger, W. &
Nussler, A.K. (1996) High plasma levels of nitrogen oxides are associated with
severe disease and correlate with rapid parasitological and clinical cure in
Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 90: 44–47.
Kumaratilake, L.M., Ferrante, A., Jaeger, T. & Morris-Jones, S.D. (1997) The role
of complement, antibody, and tumor necrosis factor alpha in the killing of
Plasmodium falciparum by the monocytic cell line THP-1. Infect Immun 65:
5342–5345.
Kumaratilake, L.M., Ferrante, A. & Rzepczyk, C. (1991) The role of T lymphocytes
in immunity to Plasmodium falciparum. Enhancement of neutrophil-mediated
parasite killing by lymphotoxin and IFN-gamma: comparisons with tumor necrosis
factor effects. J Immunol 146: 762–767.
Kun, J.F., Mordmuller, B., Lell, B., Lehman, L.G., Luckner, D. & Kremsner, P.G.
(1998) Polymorphism in promoter region of inducible nitric oxide synthase gene
and protection against malaria. Lancet 351: 265–266.
Kun, J.F., Klabunde, J., Lell, B., Luckner, D., Alpers, M., May, J., Meyer, C. &
Kremsner, P.G. (1999) Association of the ICAM-1Kilifi mutation with protection
against severe malaria in Lambarene, Gabon. Am J Trop Med Hyg 61: 776–779.
Kun, J.F., Mordmuller, B., Perkins, D.J., May, J., Mercereau-Puijalon, O., Alpers, M.,
Weinberg, J.B. & Kremsner, P.G. (2001) Nitric oxide synthase 2(Lambarene) 
MIGUEL PRUDÊNCIO, CRISTINA D. RODRIGUES AND MARIA M. MOTA 77
(G-954C), increased nitric oxide production, and protection against malaria. 
J Infect Dis 184: 330–336.
Kurtzhals, J.A., Adabayeri, V., Goka, B.Q., Akanmori, B.D., Oliver-Commey, J.O.,
Nkrumah, F.K., Behr, C. & Hviid, L. (1998) Low plasma concentrations of inter-
leukin 10 in severe malarial anaemia compared with cerebral and uncomplicated
malaria. Lancet 351: 1768–1772.
Kurtzhals, J.A., Akanmori, B.D., Goka, B.Q., Adabayeri, V., Nkrumah, F.K.,
Behr, C. & Hviid, L. (1999) The cytokine balance in severe malarial anemia. 
J Infect Dis 180: 1753–1755.
Kwiatkowski, D. (1995) Malarial toxins and the regulation of parasite density.
Parasitol Today 11: 206–212.
Kwiatkowski, D., Cannon, J.G., Manogue, K.R., Cerami, A., Dinarello, C.A. &
Greenwood, B.M. (1989) Tumour necrosis factor production in falciparum
malaria and its association with schizont rupture. Clin Exp Immunol 77:
361–366.
Kwiatkowski, D., Hill, A.V., Sambou, I., Twumasi, P., Castracane, J., Manogue, K.R.,
Cerami, A., Brewster, D.R. & Greenwood, B.M. (1990) TNF concentration in
fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum
malaria. Lancet 336: 1201–1204.
Kwiatkowski, D., Molyneux, M.E., Stephens, S., Curtis, N., Klein, N., Pointaire, P.,
Smit, M., Allan, R., Brewster, D.R., Grau, G.E., et al. (1993) Anti-TNF therapy
inhibits fever in cerebral malaria. Q J Med 86: 91–98.
Kwiatkowski, D.P. (2005) How malaria has affected the human genome and what
human genetics can teach us about malaria. Am J Hum Genet 77: 171–192.
Kyes, S., Horrocks, P. & Newbold, C. (2001) Antigenic variation at the infected red
cell surface in malaria. Annu Rev Microbiol 55: 673–707.
Lamas, S., Michel, T., Brenner, B.M. & Marsden, P.A. (1991) Nitric oxide synthesis
in endothelial cells: evidence for a pathway inducible by TNF-alpha. Am 
J Physiol 261: c634–c641.
Leiriao, P., Mota, M.M. & Rodriguez, A. (2005) Apoptotic Plasmodium-infected
hepatocytes provide antigens to liver dendritic cells. J Infect Dis 191: 1576–1581.
Leone, A.M., Palmer, R.M., Knowles, R.G., Francis, P.L., Ashton, D.S. &
Moncada, S. (1991) Constitutive and inducible nitric oxide synthases 
incorporate molecular oxygen into both nitric oxide and citrulline. J Biol Chem
266: 23790–23795.
Levesque, M.C., Hobbs, M.R., Anstey, N.M., Vaughn, T.N., Chancellor, J.A.,
Pole, A., Perkins, D.J., Misukonis, M.A., Chanock, S.J., Granger, D.L. &
Weinberg, J.B. (1999) Nitric oxide synthase type 2 promoter polymorphisms,
nitric oxide production, and disease severity in Tanzanian children with malaria. 
J Infect Dis 180: 1994–2002.
Li, C., Corraliza, I. & Langhorne, J. (1999) A defect in interleukin-10 leads to
enhanced malarial disease in Plasmodium chabaudi chabaudi infection in mice.
Infect Immun 67: 4435–4442.
Li, C., Sanni, L.A., Omer, F., Riley, E. & Langhorne, J. (2003) Pathology of
Plasmodium chabaudi chabaudi infection and mortality in interleukin-10-deficient
mice are ameliorated by anti-tumor necrosis factor alpha and exacerbated by anti-
transforming growth factor beta antibodies. Infect Immun 71: 4850–4856.
78 CH. 3. THE RELEVANCE OF HOST GENES IN MALARIA
Looareesuwan, S., Wilairatana, P., Vannaphan, S., Wanaratana, V., Wenisch, C.,
Aikawa, M., Brittenham, G., Graninger, W. & Wernsdorfer, W.H. (1998)
Pentoxifylline as an ancillary treatment for severe falciparum malaria in Thailand.
Am J Trop Med Hyg 58: 348–353.
Looareesuwan, S., Sjostrom, L., Krudsood, S., Wilairatana, P., Porter, R.S., Hills, F.
& Warrell, D.A. (1999) Polyclonal anti-tumor necrosis factor-alpha Fab used as
an ancillary treatment for severe malaria. Am J Trop Med Hyg 61: 26–33.
Lopansri, B.K., Anstey, N.M., Weinberg, J.B., Stoddard, G.J., Hobbs, M.R.,
Levesque, M.C., Mwaikambo, E.D. & Granger, D.L. (2003) Low plasma arginine
concentrations in children with cerebral malaria and decreased nitric oxide 
production. Lancet 361: 676–678.
Lowell, C. (1997) Fundamentals of cell biology. In: Daniel P. Stites, A. I. T., Tristram G.
Parslow (eds) Medical Immunology, 9 edn. Prentice-Hall International Inc, New
Jersey.
Luoni, G., Verra, F., Arca, B., Sirima, B.S., Troye-Blomberg, M., Coluzzi, M.,
Kwiatkowski, D. & Modiano, D. (2001) Antimalarial antibody levels and IL4
polymorphism in the Fulani of West Africa. Genes Immun 2: 411–414.
Luty, A.J., Lell, B., Schmidt-Ott, R., Lehman, L.G., Luckner, D., Greve, B.,
Matousek, P., Herbich, K., Schmid, D., Migot-Nabias, F., Deloron, P.,
Nussenzweig, R.S. & Kremsner, P.G. (1999) Interferon-gamma responses are
associated with resistance to reinfection with Plasmodium falciparum in young
African children. J Infect Dis 179: 980–988.
Luty, A.J., Perkins, D.J., Lell, B., Schmidt-Ott, R., Lehman, L.G., Luckner, D.,
Greve, B., Matousek, P., Herbich, K., Schmid, D., Weinberg, J.B. & 
Kremsner, P.G. (2000) Low interleukin-12 activity in severe Plasmodium 
falciparum malaria. Infect Immun 68: 3909–3915.
Luzzatto, L., Usanga, F.A. & Reddy, S. (1969) Glucose-6-phosphate dehydrogenase
deficient red cells: resistance to infection by malarial parasites. Science 164: 839–842.
Luzzatto, L., Nwachuku-Jarrett, E.S. & Reddy, S. (1970) Increased sickling of para-
sitized erythrocytes as mechanism of resistance against malaria in the sickle-cell trait.
Lancet 1: 319–321.
Luzzi, G.A., Merry, A.H., Newbold, C.I., Marsh, K. & Pasvol, G. (1991a)
Protection by alpha-thalassaemia against Plasmodium falciparum malaria: modi-
fied surface antigen expression rather than impaired growth or cytoadherence.
Immunol Lett 30: 233–2340.
Luzzi, G.A., Merry, A.H., Newbold, C.I., Marsh, K., Pasvol, G. & Weatherall, D.J.
(1991b) Surface antigen expression on Plasmodium falciparum-infected erythrocytes
is modified in alpha- and beta-thalassemia. J Exp Med 173: 785–791.
MacKinnon, M.J., Walker, P.R. & Rowe, J.A. (2002) Plasmodium chabaudi: rosetting
in a rodent malaria model. Exp Parasitol 101: 121–128.
Macpherson, G.G., Warrell, M.J., White, N.J., Looareesuwan, S. & Warrell, D.A.
(1985) Human cerebral malaria. A quantitative ultrastructural analysis of para-
sitized erythrocyte sequestration. Am J Pathol 119: 385–401.
Maier, A.G., Duraisingh, M.T., Reeder, J.C., Patel, S.S., Kazura, J.W.,
Zimmerman, P.A. & Cowman, A.F. (2003) Plasmodium falciparum erythrocyte
invasion through glycophorin C and selection for Gerbich negativity in human
populations. Nat Med 9: 87–92.
MIGUEL PRUDÊNCIO, CRISTINA D. RODRIGUES AND MARIA M. MOTA 79

EMBO reports VOL 5 | NO 12 | 2004 ©2004 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION1142
reviewrevie
Survival of protozoan intracellular parasites 
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The most common human diseases are caused by pathogens.
Several of these microorganisms have developed efficient ways in
which to exploit host molecules, along with molecular pathways to
ensure their survival, differentiation and replication in host cells.
Although the contribution of the host cell to the development of
many intracellular pathogens (particularly viruses and bacteria)
has been unequivocally established, the study of host-cell require-
ments during the life cycle of protozoan parasites is still in its 
infancy. In this review, we aim to provide some insight into the
manipulation of the host cell by parasites through discussing the
hurdles that are faced by the latter during infection.
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Introduction
After entering the host, intracellular pathogens need to recognize
and exploit host-cell resources for their own benefit. Although this
might seem obvious, the importance of a detailed understanding of
the host-cell environment has only recently been generally
acknowledged in the parasitology research field. The extent of the
manipulation of host function by protozoan parasites can be seen,
for example, in the uncontrolled proliferation of cells that are infected
by Theileria (Dobbelaere & Kuenzi, 2004) and in the microarray
analysis of a Toxoplasma-infected cell versus a non-infected cell,
which highlighted important differences in several regulatory and
biosynthetic activities (Blader et al, 2001). Therefore, the host-cell
composition should no longer be considered as a ‘black box’; rather,
it should be seen as an ideal ‘milieu’ of molecular interactions in
which the parasite strives towards success.
Reaching and entering the host cell
To infect a host, parasites must reach and recognize their specific tar-
get cell, as most infect only one or a few cell types in their host. In
the phylum Apicomplexa, for example, Plasmodium invades hepa-
tocytes and erythrocytes, whereas Theileria and Babesia spp. infect
leukocytes. Toxoplasma spp. are an exception as they can survive in
all types of nucleated cell, which implies that they recognize target
molecules that are present on all cells and/or have developed many
redundant mechanisms of infection.
On the transmission of Plasmodium by anopheline mosqui-
toes, sporozoites (the stage injected by a mosquito bite) rapidly
reach the liver. Once there, they traverse several cells by breach-
ing their plasma membranes before they finally invade their tar-
get cell through the formation of a vacuole (Mota et al, 2001).
The migration of Plasmodium sporozoites through different cells
before infection might be an example of a parasite seeking its
required target cell. Migration has also been observed during the
sporozoite and ookinete (the stage that traverses the mosquito
gut after fertilization) stages of other apicomplexan parasites,
such as Toxoplasma and Eimeria, although no migration has been
seen during the merozoite and tachyzoite stages (the second and
third invasive stages in the vertebrate host; Mota & Rodriguez,
2001). Therefore, the sporozoite and ookinete stages are the
invasive forms that encounter, and must overcome, host cellular
barriers to reach their replication sites. Recently, mutant
Plasmodium parasites have been generated by disruption of the
gene that encodes sporozoite microneme protein essential for
cell traversal (spect). Although spect mutants are unable to
migrate through cells and are not infectious in vivo, they are still
able to infect hepatocytes in vitro (Ishino et al, 2004). The reason
for this behaviour is under investigation.
Once their target has been reached, different parasites have
developed distinct strategies for entering the host cell. Professional
phagocytic cells, such as neutrophils and macrophages, use
phagocytosis to internalize and destroy not only foreign objects
and apoptotic cells but also microbial pathogens. However, several
intracellular pathogens are able to subvert this defence mechanism
to gain access to the cells. The invasion of macrophages by
Leishmania parasites, for example, is mediated by classical phago-
cytic receptors that are coupled to the vigorous actin-driven
uptake machinery of these cells (Peters et al, 1995; Mosser &
Brittingham, 1997).This process is mediated by serum opsonins
that coat the parasite and requires the activation of Rho, Cdc42
and Rac1 in the macrophage. Leishmania parasites can also enter
host cells by a non-opsonic pathway through a phagocyte-like
actin-mediated process that does not involve Rac1 activation
(Morehead et al, 2002). Conversely, the invasion of Trypanosoma
cruzi is distinct from phagocytosis and is actually enhanced by
inhibitors of actin polymerization (Kipnis et al, 1979; Schenkman
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et al, 1991; Tardieux et al, 1992; Rodriguez et al, 1999). This para-
site uses a unique calcium-regulated microtubule-mediated path-
way that directs the recruitment and fusion of lysosomes to the
plasma membrane of host cells. The binding of T. cruzi to cells
causes a transient increase in intracellular calcium, which induces
actin disruption and the mobilization of lysosomes along micro-
tubules towards the site of parasite attachment by associated
kinesin motors. T. cruzi exploits this lysosomal-derived membrane
to form a parasitophorous vacuole inside the host cell (Fig 1A;
Schenkman et al, 1988; Rodriguez et al, 1996). Not surprisingly,
other parasites have also developed strategies for cell invasion that
are not dependent on particular components of the host cell. Some
apicomplexans, for example, use an actin–myosin motor that is
present in their own cytoskeleton to generate the motile force that
is necessary to actively propel themselves into cells. This move-
ment is known as gliding motility and is required for the active
process of invasion that is mediated by the parasite. In the best-
studied example—Toxoplasma invasion—the host cell has little or
no active role in uptake (Fig 1B). No change is detected in host
membrane ruffling, in the actin cytoskeleton or in the phosphory-
lation of host-cell proteins (Morisaki et al, 1995; Dobrowolski &
Sibley, 1996). Host-cell actin polymerization is necessary, how-
ever, for the invasion of some apicomplexan parasites, such as
Cryptosporidium parvum (Fayer & Hammond, 1967; Elliott &
Clark, 2000; Elliott et al, 2001). Recent work indicates that 
C. parvum invades target epithelia by activating a Cdc42 GTPase
signalling pathway that induces host-cell actin remodelling at the
attachment site (Chen et al, 2004).
Fig 1 | Recognition, entrance and survival: a schematic representation of some of the strategies adopted by pathogens. (A) Induced recruitment of lysosomes to fuse
with the host-cell plasma membrane to form the required vacuole for Trypanosoma cruzi. (B) A parasite, such as Toxoplasma, uses its own form of motility to propel
itself into the host cell. (C) Once inside, intracellular pathogens follow different routes: they either reside inside the vacuole (i), which sometimes fuses with the
exocytic/endocytic pathways (ii), or they reside in the host cytosol (iii). The same pathogen might use different strategies at different stages of development.
(D) Independent of the route taken, all pathogens face similar problems, which include how to ensure that the cell is alive or dead at the appropriate times, how to
acquire nutrients, how to avoid host-recognition systems and how to increase in size. Parasites and their proteins are shown in orange. E, endosomes; Ly, lysosomes.
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Plasmodium sporozoites invade hepatocytes, whereas the
merozoites invade erythrocytes. The effects of actin-depolymerizing
agents on Plasmodium invasion are difficult to interpret as they
affect not only the cytoskeleton of the host but also Plasmodium
motility, which is required for invasion. The invasion of red blood
cells by the merozoite begins with the initial attachment of the par-
asite and its subsequent reorientation such that its apical end is
directed towards the erythrocyte. A moving junction is formed and
the parasite pulls itself into the cell, where it stays inside a vacuole
that is formed by the host plasma membrane (Chitnis & Blackman,
2000). In all of the apicomplexan parasite examples discussed
here, parasite ligands for host-cell receptors are required for inva-
sion. However, many of these adhesins are not displayed statically
on the surface of the parasite; instead, they are stored in apically
located secretory organelles that are known as micronemes.
Constitutive secretion from these organelles is probably sufficient
for gliding motility. Nevertheless, enhanced microneme secretion
is probably required for invasion. This occurs when parasites con-
tact host cells or migrate through cells, for example, in the cases of
Toxoplasma tachyzoites and Plasmodium sporozoites, respectively
(Carruthers & Sibley, 1997; Gantt et al, 2000; Mota et al, 2002).
However, another exception in the Apicomplexa is the invasion of
Theileria, the invasive stages of which are non-motile with no
micronemes, and which require neither apical attachment to the
host cell nor apical organelle secretion for invasion. In addition,
invasion is neither dependent on the parasite actin cytoskeleton,
nor does it involve substantial remodelling of the host cell surface.
It has therefore been proposed that entry is accomplished by a
physical process of zippering, which seems to be sufficient to
cause internalization by a passive process (Webster et al, 1985;
Shaw, 1999, 2003).
Vacuole or cytoplasm?
Parasites can survive and replicate in a vacuole or a phagolysosome
inside the cell, or, less commonly, free in the host-cell cytosol (Fig 1C).
Inside a vacuole. The vacuolar compartment that is formed during
parasite entry has an acidic environment, which is poor in nutrients,
and undergoes progressive fusions with early endosomes, late endo-
somes and lysosomes. Parasites must therefore avoid, or modify,
these compartments to escape destruction. 
A general strategy that is used by pathogens to avoid the hostile
lysosomal environment is to arrest the process of vacuole matura-
tion at different stages. The maturation of vacuoles might be arrested
not only by the persistence but also by the exclusion of host pro-
teins that are known to regulate the endocytic/phagocytic pathway.
For example, in infections by Toxoplasma gondii, which resist typi-
cal phagosome–lysosome fusion ( Jones & Hirsch, 1972; Sibley 
et al, 1985), host-cell integral membrane proteins are largely
excluded from the parasitophorous vacuole, whereas those of the
parasite are incorporated (Sibley & Krahenbuhl, 1988; Beckers 
et al, 1994). This results in the formation of a membrane that is
unique in its biochemical and biophysical properties, and leads to
the creation of a non-fusogenic vacuole.
Conversely, some parasites survive in, and might even depend
on, the harsh acidic environment of the phagolysosome. Although
these pathogens must be resistant to acid hydrolases, the molecular
mechanisms of this protection have yet to be clarified. Leishmania
donovani is an interesting example, as it applies a dual strategy at
distinct stages of its life cycle. L. donovani promastigotes, which are
sensitive to acid, seem to inhibit phagosome–endosome fusion
through unique lipophosphoglycan molecules on their cell surface
(Miao et al, 1995; Descoteaux & Turco, 1999). After the amastigote
transformation occurs, this inhibition is lifted and L. donovani multi-
plies in the now acidic intracellular compartment. Indeed, the
amastigotes are metabolically most active when their environment is
acidic (Joshi et al, 1993).
Free in the host-cell cytoplasm. Intracellular parasites can avoid
the harsh environment that results from the fusion of their vacuole
with degradative endocytic compartments by escaping rapidly
from the nascent vacuole into the cytoplasm. Surprisingly, this
strategy is used by only a few parasites, including T. cruzi and
Theileria. Little is known about the molecular events that precede
vacuole lysis. The exit of T. cruzi from the vacuole involves a 
parasite-secreted molecule, Tc-TOX, which has membrane pore-
forming activity at acidic pHs (Andrews & Whitlow, 1989;
Andrews et al, 1990; Ley et al, 1990). In the case of Theileria,
escape into the cytoplasm coincides with the discharge of the par-
asite apical organelles, but their contents remain unknown (Shaw,
2003). Theileria also secretes proteins that contain AT-rich DNA-
binding domains (AT-hook motifs) and that localize to the host-
cell nucleus during infection (Swan et al, 1999, 2001, 2003).
Recently, it has been shown that transfection of an uninfected,
transformed bovine macrophage cell line with a plasmid that
encodes the AT-hook parasite protein modulates cellular mor-
phology and alters the expression pattern of a cytoskeletal
polypeptide in a manner similar to that observed during the infec-
tion of leukocytes by the parasite (Shiels et al, 2004). Putative
polypeptides that bear AT-hook motifs are present in the genomes
of other parasites, such as T. gondii (http://ToxoDB.org; accession
number TgTwinScan_4661) and several Plasmodium spp.
(http://PlasmoDB.org; accession numbers PFC0325c, PB001090,
Q7R873 and Q7RDC7). However, whether they are involved in
host-cell modulation remains to be determined.
Problems of an intracellular lifestyle
Once inside the host cell, intracellular pathogens are faced with sev-
eral obstacles and, in particular, must circumvent host defences,
acquire nutrients and either kill or maintain the host cell according
to their needs. 
Host-cell defences. Parasites rarely reside in the cytosol, so it might
be expected to contain many protective proteins or other antimicro-
bial agents. However, surprisingly, no cytosolic agents with direct
antimicrobial activity have yet been identified. Most antimicrobial
agents are either delivered into ‘infected’ vacuoles or are secreted
into the extracellular space. The only known example of a cytosolic
antimicrobial peptide is ubiquicidin, which is produced by the
post-translational processing of the Fau protein, and part of which is
very similar to ubiquitin. The peptide has strong antimicrobial activ-
ity against several bacteria, including Listeria monocytogenes
(Hiemstra et al, 1999). However, it is not known whether this peptide
is active against protozoan parasites.
Replication and growth. One of the problems faced by an intra-
cellular pathogen is how to create sufficient space for replication.
For this process to occur inside the vacuole, a considerable
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expansion of the compartment is required. Therefore, vacuoles
must acquire large amounts of additional membrane lipids. As the
cytoskeleton is involved in membrane transport events, modula-
tion of its structure and/or function is an obvious strategy through
which pathogens might alter vacuole formation and behaviour. A
mesh of microtubules has been described around Toxoplasma
vacuoles (Melo et al, 2001), but whether this provides a means for
vacuole expansion is not yet known. No other strategy has been
described for the enlargement of a parasitophorous vacuole by a
protozoan parasite.
Nutrient acquisition. Acquisition of nutrients is crucial for
pathogen survival. Although it provides protection from host
defences, the membrane of non-fusogenic vacuoles restricts the
access of the intravacuolar pathogens to the nutrient-rich cyto-
plasm. Therefore, pathogens must modify the vacuole membrane
to allow them to scavenge the necessary nutrients and metabo-
lites from the cytosol. During the blood stages of its life cycle,
Plasmodium is inside a cell in which haemoglobin is extremely
abundant, and this serves as the main source of amino acids for
the parasite. As the parasite matures, it develops a special
organelle, called the cytostome, for the uptake of host cytoplasm
(Goldberg, 1993). In addition, Plasmodium (in the erythrocytic
stages) and other apicomplexan parasites, such as Toxoplasma
and Eimeria, have been shown to render the parasitophorous
vacuole membrane freely permeable to small cytosolic mole-
cules through the introduction of high-capacity channels or
pores (Desai et al, 1993; Schwab et al, 1994; Desai & Rosenberg,
1997; Werner-Meier & Entzeroth, 1997). Conversely, results
obtained for Leishmania imply that such pores or channels are
not present in their vacuoles (Antoine et al, 1990). In the case of
Leishmania amastigotes, the vacuole fuses with lysosomes and
endosomes, which provides a relatively constant supply of nutri-
ents. However, in promastigotes, the vacuole membrane does
not fuse with vesicles of the endocytic or lysosomal compart-
ments (Heinzen et al, 1996). It has been proposed that the associ-
ation of vacuolar membranes with host-cell organelles, such as
mitochondria and the endoplasmic reticulum, might have a role
in nutrient acquisition in Toxoplasma ( Jones & Hirsch, 1972;
Sinai et al, 1997; Fig 1D).
Host-cell death and survival. Pathogens often kill cells and some-
times even the whole host organism, but at the same time they
are heavily dependent on living cells and many of their functions.
It is therefore not surprising that they have developed mecha-
nisms for both the promotion of, and protection against, cell
death. Although the apoptotic pathways that are regulated by
virus- and bacteria-derived molecules have been extensively
characterized at the molecular level, the details of these path-
ways in protozoan parasites are only just beginning to be
revealed (reviewed in Heussler et al, 2001; Luder et al, 2001).
The intracellular parasites T. parva, Toxoplasma and Leishmania
can all inhibit apoptosis of the infected host cell (Moore &
Matlashewski, 1994; Nash et al, 1998; Heussler et al, 1999). For
both T. parva and Toxoplasma, activation of the transcription fac-
tor nuclear factor-κB (NF-κB) seems to be crucial in protecting
infected cells against apoptosis (Heussler et al, 2002; Molestina
et al, 2003; Payne et al, 2003). In Theileria, NF-κB activation in
infected transformed cells is known to be mediated by the
recruitment of the multisubunit IκB kinase (IKK) into large activat-
ed foci on the surface of a specific parasite stage (Heussler et al,
2002). This indicates that the parasite seems to bypass the con-
ventional pathways that link surface-receptor stimulation to IKK
activation (Heussler et al, 2002). However, the precise mecha-
nism by which the parasite recruits IKK signalosomes remains
unknown. How Toxoplasma infection mediates NF-κB activation
is also poorly understood and, in fact, is an area of some contro-
versy (reviewed in Sinai et al, 2004). T. cruzi shows dual activity:
it inhibits apoptotic pathways in the infected cell while simulta-
neously inducing apoptosis in T cells (Lopes et al, 1995; Clark &
Kuhn, 1999; Nakajima-Shimada et al, 2000). It has been reported
that Cryptosporidium infections induce apoptosis in in vitro-
infected cell lines that were derived from primary hosts (Chen et al,
1999; McCole et al, 2000). More recently, and using a different in
vitro cell system, it has been shown that Cryptosporidium
induces non-apoptotic death in host cells as it leaves them (Elliott
& Clark, 2003). The relevance of each of these observations to the
outcome of the infection remains to be clarified. The erythrocytic
stages of a malaria infection are unusual, as Plasmodium para-
sitizes one of the few types of cell that is thought to have limited
ability to undergo apoptosis. However, apoptosis in erythrocytes
has been characterized (Bratosin et al, 2001), and erythrocytes
that are infected with mature stages of Plasmodium seem to con-
tain phosphatidylserine on their surface (Eda & Sherman, 2002).
This membrane phospholipid is present on the external surface of
cells that are undergoing apoptosis or oxidative stress. It is not yet
known whether, in this case, it is related to apoptosis. Conversely,
in the hepatic stages of infection, hepatocytes infected with
Plasmodium berghei and Plasmodium yoelii are protected 
against apoptosis, and this resistance seems to be triggered by
both host and parasite molecules (P.L., S.S.A. and M.M.M.,
unpublished data).
Escape from the host cell
A final important step in the intracellular life of pathogens is their
ability to exit the host cell after intracellular replication. The free
pathogens can then infect new cells in the same host, or can be
transmitted into a new host, depending on the life cycle of the
pathogen. Parasites that have replicated inside a vacuole need to
exit from both the vacuole and the cell, whereas those in the cyto-
plasm only need to escape from the cell itself. In Plasmodium
merozoites, distinct proteases are involved in leaving the vacuole
and the cell (Salmon et al, 2001; Wickham et al, 2003). Although
the signals that trigger pathogens to leave cells are not yet known,
in Toxoplasma, an increase in intraparasitic Ca2+ signalling occurs
before exit of the parasite (Moudy et al, 2001; Arrizabalaga &
Boothroyd, 2004).
Conclusions
Although the study of infectious diseases has spanned more than
100 years, we have only recently begun to appreciate the intricate
interactions and the delicate balance that occur between
pathogens and their host cells. Signalling pathways abound in
cells and represent potential mechanisms by which a pathogen
can cause profound effects in a host cell. Understanding these
intricate interactions not only offers a new perspective on mam-
malian cell biology, but also allows the design of rational
approaches to combat infectious diseases. 
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Now this is not the end.  
It is not even the beginning of the end.  
But it is, perhaps, the end of the beginning. 
Sir Winston Churchill 
 
 
 
  
 

